• Like

Loading…

Flash Player 9 (or above) is needed to view presentations.
We have detected that you do not have it on your computer. To install it, go here.

Annual Report 2006/2007 Department of Oncology

  • 4,157 views
Uploaded on

 

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
4,157
On Slideshare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
4
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Annual Report 2006/2007 Department of Oncology August 14, 2007. Chair: Gerald Batist, MD Prepared by Gayle A. Shinder, PhD
  • 2. Department of Oncology Annual Report 2006/2007 Message from the Chair The 2006/2007 academic year was a year of growth for the Department of Oncology as we welcomed several new faculty members: In July 2006 the Department welcomed Dr. Carmela Pepe (Assistant Professor, Medical Oncology), Dr. Polymnia Galiatsatos (Associate Member, Medical Oncology), Dr. Fabio Cury (Assistant Professor, Radiation Oncology) and Dr. Mary Ellen MacDonald (Faculty Lecturer, Psychosocial Oncology Program). Dr. MacDonald’s position has recently been converted to an Assistant Professor. November 2006 heralded the arrival of Dr. Esther Shirrmacher (Assistant Professor, Experimental Therapeutics & Pharmacology), Dr. Linda Ofiara (Associate Member, Medical Oncology) and Dr. Robert Turcotte (Associate Member, Surgical Oncology. Finally, in February 2007 Dr. Janusz Rak came on board as an Associate Member, Hematology/Oncology while in April Dr. Nada Jabado became an Associate Member, Pediatric Oncology. In June 2006, Dr. Antonis Koromilas was promoted to full professor, and Dr. Gerald Batist was renewed as Chair of the Department of Oncology for a second 5 year term. Also in 2006, Dr. Carmen Loiselle was appointed Director of the Oncology Nursing Program. The goals of this Program are: • To provide a platform for academic and professional activities and exchanges among nurse researchers, undergraduate and graduate students, nurse managers, clinical specialists and nursing staff. • To encourage trans-disciplinary collaboration across cancer-related fields such as epidemiology, medicine, nursing, psychology, occupational therapy, physiotherapy and social work. • To increase the visibility of oncology nursing at McGill University, its affiliated health centers and abroad. The academic year also saw the departures of Dr. Brian Leyland-Jones, former Oncology Chair, who became Director of the Winship Cancer Institute at Emory University in Atlanta, Dr. Wahbi Hammouda who joined Sunnybrook Health Sciences Centre in Toronto, and Dr. Julio Guerra who has retired. The Department of Oncology administrative offices have also undergone some changes. Following the departure of Anna Ciarciello (Accounts Administrator & Visiting Professor Program Coordinator), Joanne Miller temporarily took over that role along with her duties as RUIS Liaison. As of March 2007, Winie Celestin has taken over those duties as Joanne Miller has moved to the Faculty of Management. In November 2006 Christine Talbot relinquished her role in maintaining the Department of Oncology website so that she could focus her attention on completing her final year as an undergraduate student. Kingsley Cheung took over those duties until June 2007 when Christine Talbot resumed website maintenance for the summer months. 2
  • 3. Department of Oncology Annual Report 2006/2007 Several of the Department’s faculty members were the recipients of awards and honours: Dr. Paul Allison was the recipient of the Howard Katz Award for Excellence in Teaching; Dr. Dawn Anderson was the recipient of the Inaugural Hingston Grant for Development of Medical Leadership; Dr. Nicole Beauchemin and Dr. Philip Gordon each received the Faculty of Medicine “Faculty Honour List for Educational Excellence” 2007; Dr. Martin Chasen and Dr. Thierry Muanza were each recipients of the Simone & Morris Fast Award; Dr. Fabio Cury was given the MGH 175th Anniversary Award; Dr. Eduardo Franco was awarded the “Ambassadeur de Montréal”, a prize by the Montreal Congress Centre; the Phil Gold Chair in Medicine was established in November 2006; Dr. Stephen Liben received the Service Award – Commander Palliative Care Presentation from The Military & Hospitaller Order of St. Lazarus and was also awarded First Prize - Royal Society of Medicine Book Awards, for the Oxford Textbook of Palliative Care for Children (Goldman, Hain, Liben eds); Dr. Ervin Podgorsak was the recipient of the Coolidge Award from the American Association of Physicists in Medicine; Dr. Stephane Richard was awarded the Prix d’excellence en recherche from the Conseil des gouverneurs de l'Hôpital general juif; Dr. George Shenouda received The Olive Williamson Award and was placed on the Faculty of Medicine’s Honour List for Educational Excellence; Dr. Michel Tremblay was elected a Fellow of the Royal Society of Canada; and Dr. Te Vuong was awarded both the RVH centennial Research Grant Award as well as the Howard W Pillow memorial Research Award. This year’s FRSQ salary award recipients were Dr. Stephane Richard (Chercheur Nationaux) Dr. William Foulkes (Chercheur Nationaux) and Dr. Marc Tischkowitz (Chercheur-boursier clinicien Junior 1) while Dr. Te Vuong was the recipient of a CIHR salary award. Through the efforts of Dr. Lawrence Panasci, Bayer Canada Inc. has given the Department of Oncology $40,000/yr for two years to award a Bayer Fellowship in Oncology. The first recipient of this award is Dr. Cristiano Ferrario who is working on combining new agents with traditional chemotherapy and integrating translational research in search of predictors of response. The 2006 Oncology Summer Scholarship Program was awarded to 1. Michael Dunn under the direction of Dr. Raquel Aloyz, for the research "The expression of the DNA repair proteins XPD and Xrcc3 as indicators of platinum resistance in ovarian cancer" and 2. Wenyong Tong under the direction of Dr. Uri Saragovi, for the research "Structure and Activity relationship between Ganglioside CG2 and its ligands”. This year’s Dept. of Oncology Retreat was held November 16, 17, 2006 at Le Sporting Club du Sanctuaire. In addition to the many interesting presentations covering basic, clinical and psychosocial research in oncology, attendees were encouraged to exercise and de-stress by participating in a floor hockey tournament. The Red Team were the 3
  • 4. Department of Oncology Annual Report 2006/2007 winners of the “Oncology Cup” which is now displayed in the Board Room of the Gerald Bronfman Centre along with a photograph of the winners. The Montreal Centre for Experimental Therapeutics in Cancer (MCETC) held its Fourth Annual Meeting on October 26, 27, 2006. Over 150 researchers and students from across Quebec listened to presentations focusing on discoveries currently being tested in the clinic as well as those which are approaching clinical trials. The 16th International Congress on Care of the Terminally Ill took place at the Palais des Congrès September 26-29, 2006. Congress Chair, Dr. Anna Towers, and members of the Executive Committee, Program Committee, Program Advisors and the Congress Secretariat, worked diligently to put together a diverse program touching on such topics as pediatric palliative care, complementary and alternative therapies, spirituality and hospice and palliative care services. The committee is now hard at work organizing The 17th International Congress on Care of the Terminally Ill in 2008. After being on hiatus, the Palliative Care Research Newsletter resumed in Fall 2006 with a brand new look. Edited by Dr. Gayle A. Shinder, the newsletter featured the research studies being conducted by members of the group, in areas such as Quality of Life, Networking, Anorexia Cachexia, Pain, Lymphedema, Palliative Care Services, Family Caregiving and Pediatric Palliative Care, In addition, the newsletter featured sections on Honours and Awards, Teaching and Training and the Psychosocial Oncology Option. The Visiting Professors in Oncology Program has been very active this year with presentations covering areas such as adjuvant endocrine treatment of breast cancer, radiation therapy, palliative care, cardiac side effects from cancer treatment and psychosocial issues in oncology patients. Following the Programme Québecois de lutte contre le cancer evaluations of Sections A to F in the Spring of 2006, Department of Oncology clinicians in the various tumour groups worked with their respective hospital-based inter-disciplinary teams to draft Section G of the document in preparation for evaluation of Quebec Supraregional status. To date, several tumour site teams have already undergone the site visit. The process will be continuing into the Summer/Fall of 2007. The Table d’oncologie of RUIS McGill continued to meet on a monthly basis, tackling a range of policy and service issues related to the RUIS. Gerald Batist, MD 4
  • 5. Department of Oncology Annual Report 2006/2007 Ala-Eddin Al Moustafa 1. Research Grants (new and ongoing) 1- CIHR team grant in HPV infection and associated diseases Source: CIHR Dollars Awarded: $ 508,218 per annum Dates of Approved Project: Oct.07 – Oct. 12 Role: Co-Applicant 2- Regulation of Basic Helix-Loop-Helix Transcription Factors in Human Colorectal Carcinogenesis Source: The National Colorectal Cancer Campaign Dollars Awarded: $33,900 per annum Dates of Approved Project: Jan. 06 – Jan. 07 Role: P.I 3- HPV, ErbB-2 and D-type cyclin interactions in vivo and in vitro studies. Source: CIHR Dollars Awarded: $90,646 per annum Dates of Approved Project: Oct. 04 – Oct. 07 Role: P.I 2. Presentations April 14-18, 2007 – Poster Presentation: AACR Annual Meeting, Los Angeles, CA, USA Sept. 2-8, 2006 – Oral Presentation: 9th International Conference of Drug and Gene- based Therapeutics, island of Crete, Greece Aug. 3, 2006 – Oral Presentation: Centre for cell Biology & Cancer Research, Albany, New York, USA 3. Journal reviewer - Cancer research - Clinical Cancer Res. - Carcinogenesis - Molecular Cancer Therapeutics - International Journal of Cancer - The Lung Cancer Journal 5
  • 6. Department of Oncology Annual Report 2006/2007 - The European Journal of Oral Sciences - Future Medicine - Biotechniques 4. Provincial, National and International Committees and Panels 2006-2007 Member of Hong Kong University grants committee, China 5. Professional Societies 2007- Member, National Arab American Medical Association (NAAMA) Paul Allison 1. Summary of New and Ongoing Research During the last year I have continued with two major projects involving my principal area of interest – the psychosocial elements of head and neck cancer. The first is a randomised trial investigating the effect of a psycho-educational intervention on H&N cancer patients with medium of high levels of psychological distress. The second project is an investigation of the interaction of psychosocial and biological factors along the life course in the aetiology of H&N cancer. This latter project involves collaborating sites in Brazil, South Africa and India. With respect to the last country, we were awarded a MISRI grant by McGill to help our collaboration and piloting of the work in that country. 2. Research grants (new and ongoing) Principal Investigator: P.J.Allison Co-investigators: E.L.Franco, R.Fuhrer, G.Humphris, B.F.Nicolau, A.Sacker Granting organisation: Canadian Institutes of Health Research Dates: Oct 2004 – Sept 2007 Amount: $434,063 Project title: The life course approach to the aetiology of squamous cell carcinoma in the upper aerodigestive tract 6
  • 7. Department of Oncology Annual Report 2006/2007 Principal Investigator: P.J.Allison Co-investigators: L.J.Edgar, J.S.Feine, E.L.Franco, B.F.Nicolau, R.D.Rajan Granting organisation: Canadian Institutes of Health Research Dates: April 2005 – March 2009 Amount: $471,139 Project title: A randomised controlled trial of the effectiveness of a coping strategies intervention for people with head and neck cancer PI: B. Nicolau Co-investigators: P.J.Allison, R. Burk, F. Coutlée, E. Franco, G. Humphris, J. O’Loughlin, A. Sacker, N. Schlecht Granting organization: Canadian Institutes of Health Research Dates: October 2006 – September 2010 Amount: $476,000 Project title: The life course approach to studying the etiology of head and neck cancer: HeNCe life study PI: P.J.Allison Co-investigators: B. Nicolau, E.L Franco, V.I. Varghese & G. Netuveli Granting organization: McGill India Strategic Research Initiative Dates: October 2006 – October 2007 Amount: $16,396 Project title: International multi-centre study of the aetiology of upper aerodigestive tract cancer investigating environmental and social factors during the life span: the HeNCe Life Study 3. Research Training: undergraduate students, graduate students, postdocs/fellows Student: Katia Muller Degree: Postdoctoral student Dates: September 2006 – present 7
  • 8. Department of Oncology Annual Report 2006/2007 My role: Supervisor Project title: An investigation of nutrition in the natural history of pre-oral- cancerous lesions Sponsorship: Faculty of Dentistry scholarship Student: Larissa Vilela Degree: PhD Dates: January 2005 – present My role: Supervisor Project title: An investigation of the predictive value of sense of coherence on survival in people with head and neck cancer Sponsorship: CIHR research grant 4. Scientific Reviews: Editorial Boards and Journal Reviews Editorial Board - Journal of Dental research 5. Research Advisory Work for National and International Organizations NCIC operating grant review panel K – Supportive Care, Palliative Care and Psychosocial Issues (Oct 2005 – present day) National Institutes of Dental and Craniofacial Research, NIH, Special grant panel (June 2006 & May 2007) 6. Invited Presentations and Workshops (National and International) P.J.Allison: How to improve quality of life in head and neck cancer patients. Presented to the 5th International Workshop on Quality of Life in Heand & Neck Cancer, Liverpool, November 2006 Raquel Aloyz 1. Summary of New and Ongoing Research (Collaborations) Dr Sylvain Martel (Ecole Polythechnique de Montreal) Dr Lawrence Panasci (Department of Oncology, McGill) Dr Ester Schirrmacher (Department of Oncology, McGill University) Member of the CLL Canadian Network, funded in 2005. 8
  • 9. Department of Oncology Annual Report 2006/2007 Dr William Foulkes (Department of Human Genetics, McGill) Dr Sabine Mai (University of Manitoba, Winnipeg) Dr Minna Tanner (University of Tampere, Finland) 2. Research grants (new and ongoing) Grant Title: Mechanisms of Dasatinib sensitization to standard therapy in chronic lymphocytic leukemia Agency: CIHR Type: Operating Grant Period: 2007-2009 Role: Principal Investigator Co applicants: None Project Title: "Role of BRCA1 and BRCA2 in breast carcinogenesis" Agency: SDM- Jewish General Hospital Foundation. Weekend to End Breast Cancer Award Period: 2006-2007 Role:Principal Investigator Co applicants: None Grant Title: Towards the biological treatment of BRCA1-related breast cancer: EGF, EGFR and tyrosine kinase inhibitors Agency: Breast Cancer Research Alliance Type: Research Operating Grant Period: 2006-2009 Role: Co-Investigator Project Title: Inhibition of DNA-PK to sensitize CLL lymphocytes to chlorambucil. Agency: Leukemia & Lymphoma Society of America Type: Translational Research Grant Period: 2005-2008 Role: Co-Principal Investigator 9
  • 10. Department of Oncology Annual Report 2006/2007 3. Research Training: undergraduate students, graduate students, postdocs/fellows Graduate Students: Michael Dunn (Master Student) Tayma Khalil (Master Student, Co-Supervisor) Post Doctoral Fellow: Carolyn Annette Holmann 4. Invited Presentations and Workshops (National and International) Canadian CLL Symposium. “DNA Repair in Chronic Lymphocytic Leukemia” Inn at the Forks, Winnipeg, Manitoba, November 12 & 13, 2006 5. Peer-Reviewed Abstracts #3475 Determining the effect of estrogen metabolites on BRCA1-allelic imbalance in normal breast cells heterozygous for BRCA1 mutations . Revital Bar Sade-Bruchim, Tayma Khalil, Louise Quenneville, William Foulkes, George Chong, Raquel S. Aloyz. Lady Davis Inst. for Medical Research, Montréal, PQ, Canada Poster Session. Board#: 22. American Association For Cancer Research, Centennial Meeting, 14-18 April 2007 #4753 Dasatinib sensitizes chronic lymphocytic leukemia lymphocytes to chemotherapeutic agents Anne-Christine Goulet, Lilian Amrein, Michael Dunn, Raquel Aloyz, Lawrence C. Panasci. Jewish General Hospital, Montréal, PQ, Canada Board#: 6. American Association For Cancer Research, Centennial Meeting, 14-18 April 2007 The p75 neurotrophin receptor regulates activity-dependent axon competition by antagonizing TrkA-mediated Ras-Raf-MAPK signaling Singh K (Singh, K.), Kramer B (Kramer, B.), Lin D (Lin, D.), Aloyz R (Aloyz, R.), Kaplan D (Kaplan, D.), Miller F (Miller, F.) International Journal Of Developmental Neuroscience 24 (8): 578-579 DEC 2006 Inhibition of DNA repair vis-a-vis resistance in chronic lymphocytic leukemia Amrein L, Loignon M, Aloyz R, et al.. EJC SUPPLEMENTS 4 (12): 152-152 498 NOV 2006 10
  • 11. Department of Oncology Annual Report 2006/2007 6. Hospital Activities Raquel Aloyz is in charge of supervising the in vitro correlations in a clinical protocol sponsored by Novartis. Clinical protocol (A phase I-II trial of Gleevec in combination with chlorambucil in previously treated chronic lymphocytic leukemia (CLL) patients) sponsored by Novartis. Three hospitals participate in this trial (Jewish General Hospital, Hopital Notre-Dame, CHUM, Hopital Charles Lemoyne). Dawn Anderson 1. Summary of New and Ongoing Research 1. PI at the Ville Marie Breast clinic for the NEOCAN study, a multicentered Canadian research protocol utilizing neo-adjuvant Letrozole in breast cancer. 2. Co-Investigator at St. Mary’s for three research protocols involving analysis of hereditary breast cancer.(Dr. W Foulkes PI on all 3). 3. Co-Investigator at St. Mary’s for breast cancer stem cell project (Dr. Danuta Balicki PI) 2. Hospital Activities 1. Surgical Grand Rounds at SMH including advising the Chief resident on appropriate topics. 2. Recording secretary for the St. Mary’s Interdisciplinary Thyroid Rounds, where patients are presented pre and/or post operatively to a team made up from surgery, endocrinology, pathology, medical oncology and nuclear medicine. 3. Lower GI Tumor Board at the Montreal General Hospital. 4. St. Mary’s weekly Tumor Board. 5. Ville Marie Breast Cancer weekly Clinico-Pathology Rounds . 6. Postgraduate Surgical Education Coordinator for St. Mary’s Hospital- supervising, advising and evaluating the surgical residents, family medicine residents and surgical oncology fellows who rotate through the surgical service at SMH, as well as mentoring ICM students to review case reports and supervising residents and students who choose electives at SMH 7. Formal small group teaching to ICM students. 3. Involvement in continuing education activities 1. Member of the General Surgery Residency Committee. 11
  • 12. Department of Oncology Annual Report 2006/2007 2. Member of the Surgical Oncology Residency Training Committee Mark Basik 1. Summary of New and Ongoing Research All Ongoing i. Discovery and validation of amplicons in colon and breast cancer ii. Discovery of novel tumor suppressor genes in breast cancer iii. mechanisms of resistance to trastuzumab iv. Paracrine factors in stroma-tumor cell interactions v. clinical serum/plasma proteomics 2. Research grants (new and ongoing) i. Quebec Breast Cancer Foundation $ 138 000/year 2004-2007 « The Discovery of Novel Tumor Suppressor Genes in Breast Cancer ». Multi-investigator grant (total amount $1,500,000/3 years), PI : M. Basik; co-applicants : P. Tonin, S.Mader, C.Rancourt ii. Cancer Research Society $ 60000/year 2006-8 «DARPP32 in resistance to trastuzumab in breast cancer », PI : M. Basik, co-applicant : W. Miller. iii.Clinical Proteomics in breast cancer $ 70000/yr 2006-7. Weekend to end breast cancer 3. Research Training: undergraduate students, graduate students, postdocs/fellows Students: Saima Hassan, Adbel Hosein, Sophie Hamel Postdocs: Adriana Aguilar, Aline Mamo 4. Invited Presentations and Workshops (National and International) “Discovering and validating novel targets and markers in breast and colon cancer”. Seminar, Dept Anatomy and Cell Biology, McGill University. October 25, 2006 “ Breast cancer update: prevention, detection and treatment”, and “Workshop on genetic testing and counseling in breast cancer”. Presented at the Annual Refresher Course for Family Physicians, McGill University Faculty of Medicine, November 28th 2006, Hotel Bonaventure Hilton. “Cancers Héréditaires: sein et côlon”. Led workshop seminar at the Annual Congress of the Association Québécoise de Chirurgie. La Malbaie, Qc, May 31, 2007. 12
  • 13. Department of Oncology Annual Report 2006/2007 5. Peer-Reviewed Abstracts Hassan S., Salvucci O, Baccarelli A, Basik M. Stromal cell derived factor (SDF)-1: predictive marker of distant metastasis and poorer survival in breast cancer. Clinical and Investigative Medicine Vol. 29 (4), Aug 2006: 268. Mamo A., Cavallone L., Ferrario C., Rancourt C. and Basik M. Genomic alterations as a guide to the discovery of novel therapeutic targets in breast cancer. Presented at the 25th Congress of the International Association for Breast Cancer Research, Montreal, September 2006. Cavallone L., Mamo A., Basik M. and Tonin P.An integrated genomics approach towards the identification of tumor suppressor gene candidates through nonsense- mediated mRNA decay inhibition of breast cancer cell lines. Presented at the 25th Congress of the International Association for Breast Cancer Research, Montreal, September 2006. Hassan S., Salvucci O, Baccarelli A, Basik M. Stromal cell derived factor (SDF)-1: predictive marker of distant metastasis and poorer survival in breast cancer. Presented at the 25th Congress of the International Association for Breast Cancer Research, Montreal, September 2006. Aguilar-Mahecha A, Cantin C, Deneault JS, Wu M, Huneau MC, O'Connor-McCourt M, Nantel A, Basik M. Optimization of reverse phase protein microarrays for blood biomarker validation . Presented at 5th Annual World Congress Human Proteome Organization, Long Beach, CA, Oct 2006 Hamel S, Wu M, Basik M. Molecular determinants of resistance to trastuzumab in breast cancer. Abstract at the Annual Meeting of the American Association for Cancer Research, Los Angeles April 2007. 6. Hospital Activities Medical Director of the Breast Cancer Inter-Disciplinary Team, Segal Cancer Centre, Jewish General Hospital Co-Director of Surgical Grand Rounds, Jewish General Hospital 7. Involvement in the community Speaker at the Weekend to End Breast Cancer, August 2006 13
  • 14. Department of Oncology Annual Report 2006/2007 Gerald Batist 1. Research grants (new and ongoing) 2002-2008 Canadian Institutes of Health Research, partnership with FRSQ, Montreal Centre for Experimental Therapeutics in Cancer, Strategic Training Program, G. Batist - P.I., Co-Invs. W. Miller, M. Alaoui-Jamali, J. Galipeau, C. Rancourt, et al. 6yrs., average operating $262,500 (Total : $1,455,000+ $120,000 FRSQ) 2003-2006 Canadian Institutes of Health Research, Characterization of the active site in gamma-glutamylcysteine synthetase and development of its novel inhibitors through molecular modeling, site-directed mutagenesis and synthetic chemistry, Operating Grant, G. Batist-P.I., Co-Inv.- JH Wu, $109,220/yr, 3yrs. 2003-2007 Canadian Breast Cancer Research Alliance, P.I.-Ronal S.Foley, McMaster Univeristy, Co-Principals: Mark Levine, Jonathan Bramson, Gerald Batist et al, Therapeutic cell genetic immunization for breast cancer, CBCRA Translational Acceleration Research Grant, 4yr award/2003-2007, Total amount: $1,717,848 2005-2007 The Cancer Research Society, Operating grant, Functional analysis of novel potential chemopreventive agents. G. Batist-P.I., Co-Inv.- JH Wu, Total amount: $120,000 04/2006-03/2009 Canadian Institutes of Health Research, Regulation of glutathione and related enzymes: dissection of the Nrf-2 master regulator and generation of novel potential chemopreventive molecules (renewal) $100,655/yr 09/2006-08/2008 The Cancer Research Society, research grant, Cullin3 regulates the proliferation of breast cancer cells, a potential novel target for therapeutic intervention, Co-PI/ Weimin Miao, 2yrs - $60,000 per annum ($120,000) 08/2006-03/2007 Canadian Institutes of Health Research, GD2 gangliosides and Small Cell Lung Cancer, one year (Aug.1/06 to July 31/07). Partners: Mimetogen Pharmaceuticals Inc. $250,000(non-renewable) 07/2007-2010 Canadian Institutes of Health Research, EphB2, a novel target for gamma- secretase inhibitors (GSIs) in cancer therapy, P.I.- G. Batist, Co-PI: M. Kandouz, $150,000 per annum ($450,000) 2. Research Training: undergraduate students, graduate students, postdocs/fellows Andrew Bier, Ph.D. Student, 2001- Mustapha Kandouz, Ph.D. Student, 2001- Khadijia Haidara, Ph.D. Student, 2003- 3. Scientific Reviews: Editorial Boards and Journal Reviews -Associate Editor, J. Cellular Pharmacology, Springer-Verlag 14
  • 15. Department of Oncology Annual Report 2006/2007 -Editorial Board, Journal of Liposome Research, Marcel Dekker -Editorial Board, Molecular Cancer Therapeutics, AACR -Member, Montreal Gazette "Board of Contributors" -Ad hoc reviews for: Cancer Research, Journal of Biological Chemistry, Biochemical Pharmacology, Journal of Clinical Oncology, Cancer Chemotherapy and Pharmacology 4. Research Advisory Work for National and International Organizations -Scientific Advisory Committee, Israel Cancer Research Fund, 1991-Present -Investigational New Drug Committee, National Cancer Institute of Canada -Member, Scientific Advisory Board, Les Laboratoires Aeterna (Aeterna Zentaris). 1999- Present -Member, Scientific Advisory Board, Thallion Pharmaceuticals Inc(Ecopia) 2005-Present -Member, Scientific Advisory Board, Sopherion Therapeutics, 2004-Present -Member, Scientific Advisory Board, Immunotec Inc., 2006-Present 5. Invited Presentations and Workshops 2006 Toronto, Ontario Cancer Institute, Seminar- Title “Refining and enhancing our view of molecular targets in cancer therapeutics”. 2006 Atlanta, ASCO, presented poster, title “Developmental Therapeutics: Cytotoxic Chemotherpay” 2006 Montreal, Joint conference held by the Weizmann Institute of Science and the McGill Cancer Centre, McIntyre Bldg, Palmer Auditorium, invited speaker, title “New Therapeutics: The Long and Winding Road”. 2006 Montreal, Palais des Congres, SYM39 Special Symposium: Molecular targeted therapy for cancer, speaker, Talk: "Molecular diagnostics in the development and the use of novel cancer therapeutics". 2006 Como, Italy –"International Workshop on Anthracycline Cardiotoxicity", speaker, title: "Cardiac safety of liposomal anthracyclines" 2007 McGill - 1st Expert Care Plan Initiative Workshop, The McGill Educational Initiative on Interprofessional Collaboration: Partnerships for Patient and Family- centered Practice. March 24 2007 Hôtel du Lac Carling, Québec – 27ieme Session de Formation Continue de l’ABCQ, invited speaker, title “Cancer Biomarkers- a great hope not yet fulfilled”. May 18 15
  • 16. Department of Oncology Annual Report 2006/2007 2007 Chicago, ASCO, presented poster, abstract title: “Ratiometric dosing of irinotecan (IRI) and floxuridine (FLOX) in a phase I trial: A new approach for enhancing the activity of combination chemotherapy”. June 3 2007 Gananoque, ON – Queen’s University Cancer Research Inst. Annual Retreat, Invited speaker, title: “Chemoprevention and chemotherapy resistance: the importance of context”. June 11 6. Other Activities 2006 Chair, Search & selection committee, Eric Flanders Professor of Palliative Care Medicine Nicole Beauchemin 1. Summary of New and Ongoing Research Modifiers of colon cancer. Dr. Philippe Gros, Dept. of Biochemistry, McGill University. Induction of colon tumors in eIF4-BP3-deficient mice. Dr. Nahum Sonenberg. Dept. of Biochemistry, McGill University. Evaluation of colon cancer pathology in transgenic and knockout mice. Dr. Victoria Marcus, MUHC pathologist, McGill University. Investigation into the insulin resistance phenotype of Ceacam1-/- mice. Dr. Emile Lévy, Centre de Recherche, Hôpital Ste-Justine, Montréal. Investigations into the altered fat metabolism in Ceacam1-/- mice. Dr. Roland Savard. Dept. of Biologie, UQAM, Montréal. Immunology and infections with MHV of Ceacam1-/- mice. Dr. Lucie Lamontagne. Dept. of Biologie, UQAM, Montréal. The role in CEACAM1 in activated T lymphocytes. Dr. André Veillette, IRCM Montréal. The role of the tyrosine phosphatase SHP-1 in metabolism. Dr. André Marette, Centre de Recherche du CHUL. Ste-Foy Qué. Association of CEACAM1 with Tyrosine phosphatases. Dr. Bjorn Obrink, Dept. of Cell Biology, Karolinska Institute, Stockholm, Sweden. Development of an endothelial-specific transgenic mouse model for CEACAM1, Dr. Christoph Wagener, Dept. of Clinical Biochemistry, Univ. of Hamburg, Hamburg, Germany. Mice Resistant to mouse hepatitis viral infections. Dr. Kathryn V. Holmes, Dept. of Microbiology, Univ. of Colorado, Denver, CO. 16
  • 17. Department of Oncology Annual Report 2006/2007 Analyses of brain-tropism of MHV in Ceacam1-/- targeted mice. Dr. Susan Weiss, Department of Microbiology, Univ. of Pennsylvania School of Medicine, Philadelphia, USA. Development of a Humanized CEACAM1-targeted mouse. Dr. Scott Gray-Owen, Dept. of Microbiology, Univ. of Toronto, Toronto, Canada. The functions of CEACAM1 in platelets. Dr. Denise Jackson. Austin Research Institute. Melbourne Australia. The role of CEACAM1 in dendritic cells. Drs. Robert Kammerer and Wolfgang Zimmerman. Klinikum der Universität München. Munich Germany. The role of CEACAM1 in insulin receptor signaling. Dr. Sonia M. Najjar. Medical College of Ohio. Toledo Ohio. The role of CEACAM1 in graft versus host disease. Dr. Marcel R.M. van den Brink. Memorial Sloan-Kettering Cancer Center. New York. N.Y. The role of CEACAM1 in immune responses of M cells. Drs. H. Kiyono and O. Igarashi. Institute of Medical Science, The University of Tokyo. Tokyo, Japan. The role of CEACAM1 in lung tissue. Dr. Bob Scholte, Cell Biology Dept. Eramus University Medical Centre, Rotterdam, The Netherlands. 2. Research grants (new and ongoing) Canadian Institutes for Health Research, CEACAM1 signaling in epithelial cell adhesion and motility, 2003-2007, $128,664/yr PI: Nicole Beauchemin Cancer Research Society Inc., Involvement of mouse biliary glycoproteins (CEACAM1) in tumor development and metastasis, 2005-07, $60,000./yr, PI: Nicole Beauchemin National Cancer Institute of Canada, CEACAM1 in colon cancer progression, 2005-08, $113,050./yr, PI: Nicole Beauchemin Miriam and Saul Goldberg Innovative Research, Genetic control to susceptibility of carcinogen-induced colon cancer, 2007-08, $ 15,000./yr, PI: Philippe Gros, co-PI: Nicole Beauchemin Canadian Institutes for Health Research, Metabolic functions of the PTPase SHP-1 in insulin target tissues, $123,030./yr, 2007-2012, (co-PI Nicole Beauchemin with André Marette & Kathryn Siminovitch) National Cancer Institute of Canada, Genetic control to susceptibility of carcinogen- induced colon cancer, 2007-2010, $123,000./yr, PI: Philippe Gros, co-PI: Nicole Beauchemin Canadian Institutes for Health Research, CEACAM1 as a regulator of normal and tumor angiogenesis, 2007-2012, PI: Nicole Beauchemin, pending, 17
  • 18. Department of Oncology Annual Report 2006/2007 Cancer Research Society Inc., Involvement of mouse biliary glycoproteins (CEACAM1) in tumor development and metastasis, 2007-09, PI: Nicole Beauchemin, pending 3. Construction of major facilities or major equipment grants and their impact Renewal application for the McGill Cancer Centre infrastructure grant with Dr. Michel Tremblay, FRSQ, 2007-2011, $400,000./yr. This budget is the major source of funding of the Centre for its research operations. 4. Major University Committees Chairperson of the Cancer Centre Safety committee since Jan. 2004-2006. Member of the Cancer Centre Recruitment committee since 2004-2006. Chairperson of the McGill Cancer Centre Advisory Committee, since Jan. 2005. Member of an Ad Hoc Faculty Postgraduate Promotions Review committee, Faculty of Medicine, since November 2003-2006. Member of the Faculty Promotions Committee, Faculty of Medicine, 2 meetings per year since June 2003-2006. Member of the Dept. of Oncology Promotions Committee, 2 meetings per year since 2006. Member of the Faculty of Medicine Admissions committee, 1 week/year of interviews of potential Medicine students, 2007-. Member of MUHC Lutte Contre le Cancer (Colorectal) team (2006-..). Presentation at McGill University Grantsmanship meeting (2007-…). 5. Research Training: undergraduate students, graduate students, postdocs/fellows Undergraduate Students Atta Goudarzi (Biochemistry), Summer 2006 Sarah Leblanc (Biochemistry), Winter 2007 Graduate Students Nelly Leung (Biochemistry), 2000-present, Ph.D. (expected 2008) Renée Atallah (Biochemistry), 2003-2006, M. Sc. (2006) Anne-Marie Charbonneau-Allard (Biochemistry), 2005-present, M.Sc. (2007) 18
  • 19. Department of Oncology Annual Report 2006/2007 Sarah Leblanc 2007-present, M.Sc. (2009) Post-Doctoral Fellows Anne-Laure Nouvion, Ph.D. Institute de Chimie-Biologie, Lyon, 2006-2010 Graduate students on whose supervisory committees I currently serve. RAC Nelly Leung, Dept. of Biochemistry 2001- RAC Melanie Chagnon, Dept. of Biochemistry 2003- RAC Renée Atallah, Dept. of Biochemistry 2004-2006 RAC Anne-Marie Charbonneau-Allard, 2005-2007 RAC Patrick Fok, Montreal Neurological Institute, 2004-2006 RAC Valérie Hudon, Dept. of Biochemistry, 2004- RAC Ghada Kurban, Dept. Biochemistry, 2004- RAC for Charles Meunier, Dept. of Biochemistry, 2006- RAC Malika Oubaha, IRCM, 2007- RAC Kataryna Jesien, Dept. of Medicine, IRCM, 2007- GAC Shun Li, Royal Victoria Hospital, student of Dr. P. Brodt, 2007- GAC for Sami Bouahia, Dept. of Biochemistry, May 2007- GAC for David Grote, Dept. of Biochemistry, April 2007- GAC for Alana Nguyen, Dept. of Biochemistry, April 2007- Ph.D. Oral Defense for John Lee, Dept. of Biochemistry, Dec. 2006. Ph.D. Oral Defense of Josée Laganière, Dept. of Biochemistry, Feb. 13, 2007. Pro-Dean on Ph.D. Defense of Kristin Joy Stewart, Dept. of Physics, May 2007. 6. Scientific Reviews: Editorial Boards and Journal Reviews Journal Review Nature Reviews Immunology Oncogene X 4 7. Research Advisory Work for National and International Organizations Panel Member 19
  • 20. Department of Oncology Annual Report 2006/2007 Member of the “Prix de la Recherche” committee for ACFAS, 2004-06 Canadian Institutes for Health Research Palliative Care committee, 2005- National Cancer Institute of Canada, Panel J, 2006- Ad hoc reviews for grant panel Canadian Institutes for Health Research, 2006 NSERC , 2006, 2007 8. Conference Organization Organizer of the McGill Cancer Centre seminar series 2005- Co-organizer of the Angiogenesis-Metastasis Research Group 2006-: meeting once/month of 15-20 research groups from the Montreal region interested in these topics. 9. Invited Presentations and Workshops (National and International) La tyrosine phosphatase SHP-1 régule négativement l’homéostasie du glucose. 5e Symposium sur la physiopathologie du tube digestif. Sherbrooke Qc, June 2006. CEACAM1, more than a gut feeling. Weissman Institute-Cancer Centre first international meeting, Montreal, Qc. Sept. 2006. CEACAM1: Role in progression of colon cancer and its progression through angiogenesis. Dept. of Oncology Retreat, Montreal, Qc. Nov. 2006. CEACAM1: from progression of colon cancer to integrity of blood vessels. Invited talk in the Dept. of Microbiology, University of Colorado, Denver CO, USA, Dec. 15 2006. CEACAM1 as a regular of normal and tumor angiogenesis. Angiogenesis and Metastasis Research Group. January 2007. CEACAM1: entre l’adhésion cellulaire, le cancer du côlon et l’angiogénèse. Invited talk at the Centre de Recherches de l’Hotel Dieu, Québec, Qc, May 25 2007. 10. Peer-Reviewed Abstracts Novel CEACAM1 splice variants expressed by murine small intestinal epithelium. Kazutaka Terahara, Osamu Igarashi, Masato Yoshida, Tomonori Nochi, Yoshiyuki Gotoh, Fumihiro Taguchi, Nicole Beauchemin, Hiroshi Kiyono. IUBMB International Congress of Biochemistry and Molecular Biology. Dec. 2006, Kyoto, Japan. Detection of a novel locus on chromosome 3 responsible for susceptibility to colon cancer (CRC) in mice. Charles Meunier, Anny Fortin, Nicole Beauchemin and Philippe Gros. Canadian Genetic Disease Network meeting, St-Sauveur Qc, April 2007. 20
  • 21. Department of Oncology Annual Report 2006/2007 Hyperproliferative Corneal Epithelium Expresses Proinflammatory Molecules That Recruit Neutrophils to the Cornea of corn1 Mice. A. M. Verdoni, N. Beauchemin, A. Ikeda, S. Ikeda. AVRO meeting, April 2007. Detection of a novel locus on chromosome 3 responsible for susceptibility to colon cancer (CRC) in mice. Charles Meunier, Anny Fortin, Nicole Beauchemin and Philippe Gros. Human Genome meeting, Montreal, Qc. May 2007. CEACAM1 in tumor angiogenesis of genetically-modified mouse models. Anne-Laure Nouvion, Claire Turbide, Valérie Breton, Andrea Horst, Christoph Wagener, William J. Muller and Nicole Beauchemin. 17th Annual CEA Workshop, Los Angeles California, 2007. Ceacam1 and Apc Cooperate Through Wnt Signaling in Mouse Intestinal Tumor Progression. Nelly Leung, Claire Turbide, Brinda Balanchandra, Victoria Marcus, Nada Jabado and Nicole Beauchemin. 17th Annual CEA Workshop, Los Angeles California, 2007. 11. Involvement in the community Member of the Institutional Review Board at the Ville-Marie Breast Clinic. Meetings once/month for evaluation of clinical trial protocols. (2004-…). Actively involved in speaking engagements to volunteers of the Canadian Cancer Society. Sept. 26, 2006: meeting of volunteers and conference, Montreal. March 22, 2007: shooting of a 2 h video interview for publicity campaigns of CCS. March 29, 2007: conference at Place Desjardins for Daffodil Day. April 11, 2007: meeting the press for unveiling of Cancer Statistics. Performed 7 television interviews. April 18, 2007: conference for volunteers in Sherbrooke Qc. May 18, 2007: 1 h interview at Radio-Ville Marie, Montreal, Qc. Philip Branton 1. Summary of New and Ongoing Research Thomas Dobner (Hamburg) - adenovirus E4orf6 protein Jose Teodoro (MCC) - adenovirus E4orf4 protein 2. Research grants (new and ongoing) a. Mechanism of Oncogene Transformation by Human Adenoviruses (Main applicant), Canadian Institutes of Health Research (CIHR), from 04/2006 to 03/2009, $630,000 21
  • 22. Department of Oncology Annual Report 2006/2007 b. Mechanism of Action of the Adenovirus Death Protein E4orf4 (Main applicant), National Cancer Institute of Canada, from 04/2004 to 03/2009, $750,000 c. Mechanism of oncogenic transformation by human adenovirus of p53 (Main applicant), Canadian Institutes of Health Research (CIHR), from 04/2002 to 03/2008, $412,500 d. FRSQ special funds to support Quebec CIHR director, Fonds de la Recherche en Santé du Québec (FRSQ), from 04/2001 to 03/2008, $300,000 3. Research Training: undergraduate students, graduate students, postdocs/fellows 1. Mui, Melissa (PhD) 2. Cheng, Chi Ying (PhD) 3. Binda, Olivier (PhD awarded 2007) 4. Miron, Marie-Joelle (PhD awarded 2007) 5. Li, Suiyang (Post-doc) 6. Blanchette, Paola (Post-doc) 4. Scientific Reviews: Editorial Boards and Journal Reviews Ad hoc reviews for several journals 5. Research Advisory Work for National and International Organizations 1. 2006-present Chair, International Advisory Board, University Hospital Network, University of Toronto 2. 2006-present Member, Board of Directors, National Cancer Institute of Canada (NCIC) 3. 2005-present Vice Chair, Board of the Canadian Cancer Research Alliance 4. 2004-present Member, Alberta Cancer Board, Advisory Committee on Research 5. 2003-present Member, Board of the Canadian Tobacco Control Research Initiative (CTCRI) 6. 2002-present Chair, Research Action Group of the Canadian Strategy for Cancer Control 7. 2002-present Member, Governing Council, WHO-International Agency for Cancer Research (Lyon, France) 8. 2001-present Member, Advisory Committee on Research, Canadian Alliance of Provincial Cancer Agencies (CAPCA) 9. 2001-present Member, Board of the Canadian Breast Cancer Research Alliance (CBCRA) 10. 2006- present Consultant, Terry Fox Research Institute 22
  • 23. Department of Oncology Annual Report 2006/2007 6. Conference Organization Organizer and session chair, DNA Tumor Virus Meeting July 11-14, 2006. The Salk Institute, La Jolla CA 7. Invited Presentations and Workshops (National and International) BRANTON, P.E. 2006. Mechanism of action of the adenovirus death protein. FASEB Summer Research Conferences (Protein Phosphatases), Snowmass, CO, July 15-20. (plenary talk, p47). 8. Peer-Reviewed Abstracts 1. Binda, O., J.-S. Roy and P.E. Branton. 2006. RBP1 family proteins exhibit SUMOylation-dependent transcriptional repression and induce cell growth inhibition reminiscent of senescence. Signal Transduction Meeting, Banff Alberta, March 3-7, 2005. (poster presentation, p.8) 2. Roopchand, D.E., M. Mui, M. Gentry, R. Hallberg, J. Vogel and P. E. Branton. 2006. Human adenovirus E4orf4 protein induces premature mitotic arrest by a PP2A- dependent mechanism leading to cell death in Saccharomyces cerevisiae. Signal Transduction Meeting, Banff Alberta, March 3-7, 2005. (plenary talk). 3. Blanchette, P., P. Groitl, T. Dobner and P.E. Branton. 2006. The major functions of E4orf6bduring adenoviral infection are achieved through its associated E3 ligase activity. DNA Tumor Virus Meeting 2006. The Salk Institute, La Jolla CA. July 11-14. (plenary talk, p58). 4. Miron, M.-J, P. Blanchette, P. Groitl, T. Dobner and P.E. Branton. 2006. Localization and functions of adenovirus E4orf4 virus mutants. DNA Tumor Virus Meeting 2006. The Salk Institute, La Jolla CA. July 11-14. (plenary talk, p67). 5. Branton, P.E. 2006. Mechanism of action of the adenovirus death protein. FASEB Summer Research Conferences (Protein Phosphatases), Snowmass, CO, July 15-20. (plenary talk, p47). 9. Involvement in the community None other than science councils Terry Chow 1. Summary of New and Ongoing Research Molecular and Genetic Analysis of Avascular Necrosis - publication: Mohammad Amin Kerachian, Edward j Harvey, Denis Cournoyer, Terry Y.K. Chow, Chantal Seguin. Avascular Necrosis of the Femoral Head: Vascular hypotheses. 2006. Endothelium 13:237-244. 23
  • 24. Department of Oncology Annual Report 2006/2007 2. Scientific Reviews: Editorial Boards and Journal Reviews Journal Reviews Molecular Cancer Therapeutics International Journal of Cancer 3. Research Advisory Work for National and International Organizations INSERM (France) External Panel of Expert 2006 4. Involvement in the community Member of the Board of Directors, Montreal Chinese Hospital Member of the User's Committee, Montreal Chinese Hospital S. Robin Cohen 1. Research Grants Improving Quality of Life and Informing Social Policy in Palliative Care. Infrastructure Funding to form a National Palliative Care Research Team. Robin Cohen (PI), Co Investigators: Allard P, Band P, Blood P, Chochinov H, Courneya K, Daneault S, Deschamps M, Dumont S, Fiset V, Fournier L, Fyles G, Gagnon P, Graham I, Gratton J, Kristjanson L, Lawlor P, Leis A, Logan J, Marchand R, Neron S, Nikoletti S, Poirier L, Porock D, Poulson J, Viola R, Wilson K, and others. National Cancer Institute of Canada - #010281 01/2000–12/2002, $60,000/year Renewed, 01/2003 – 06/2007; $88,000/year; $88,000/year; $88,000/year Quality of Life for Palliative Care Patients and Their Family Caregivers Robin Cohen (PI), Co-investigators: Brown S, Fiset V, Fyles G, Kristjanson L, Leis A, Porterfield P, Viola R. National Cancer Institute of Canada - #012201 Renewal. 07/2001 – 06/2006 $555,659 Strategic Training Program in Palliative Care Cancer Research. Robin Cohen (PI), Co Investigators: M Aubin, S Dumont, L Fillion, D Blondeau, P Gagnon, P Allard, F Fothergill-Bourbonnais, P Hall, P Dobkin, N Mayo, K Wilson. Canadian Institutes of Health Research/National Cancer Institute of Canada - #STI-63286, 04/2003 – 03/2009, $1,800,000 Prognostic value of clinical correlates of cancer cachexia: A prospective multicenter, population-based study. A Vigano PI, Co-investigators: Baracos, V, S Robin Cohen, Dalzell MA, Franco E, Macdonald N, Morais J, Thirlwell M, Canadian Institutes of Health Research - #122338 06/2004 – 05/2007 $200,644 A multidisciplinary cancer pain research network to improve the classification, assessment, and management of difficult cancer pain problems. P.I.s: N.A. Hagen , R.L. Fainsinger, P.M. Brasher, Co-investigators: Pereira, JL, Moulin, D Cahill CM, Cohen SR, Cummings- OLinyk GG, Canadian Institutes of Health Research- # 129697, 2004 – 2009 $1,363,586 24
  • 25. Department of Oncology Annual Report 2006/2007 GRISIM: Groupe de recherche interuniversitaire en soins infirmiers de Montréal P.I.s: Celeste Johnston and Nicole Richard, Co-investigator Cohen SR and many others FRSQ/Newton Foundation/MSSS, 04/2004 – 03/2008, $2,000,000 Evaluation of group remedial exercises for chronic breast cancer related lymphedema. P.I. Diane St. Pierre, Co-Investigators: Towers A, Cohen SR, Collet JP, Dalzell M National Cancer Institute of Canada - CCS Feasibility Grant, 2005 – 2006 $34,380 Quality of life in cancer patients admitted to an acute palliative care unit and their caregivers: a prospective study of self-report and proxy-for-patient ratings P.I.: Jennifer Jones, Co-Investigators: Cohen SR, Rodin GM, Zimmerman C, McPherson CNational Cancer Institute of Canada – CCS Research Grant for New Investigators, 2005 – 2006, $55,371; 2006 – 2007, $56,956; 2007 – 2008, $62,614 Measuring the quality of end-of-life care provided in inpatient health care settings, P.I. Kelli Stajduhar, Co-investigator Cohen SR, others, Michael Smith Foundation for Health Research HSPRSN Research Operating Grant, 05/2006 – 04/2008, $99,796 An evaluation of Canada’s compassionate care benefit from a family caregiver’s perspective, Co- P.I.s: A Williams and V Crooks, Co-investigators Stajduhar K, Allan D, Cohen SR , Brazil K. Canadian Institutes of Health Research (CIHR) 09/2006 – 08/2009, $169,729 Safety in home care: Perspectives from clients, family members, caregivers, and providers. P.I: Lang A, Co-investigators: Cohen SR, Easty AC, Lachance JA, Germain D, Stajduhar KI, Williams AM Canadian Institutes of Health Research 04/2007- 03/2010, $53, 237/year Family caregiving at the end of life: A women’s health issue, PI Koop P, Co- investigators: deJong-Berg MA, Cohen SR, Williams A, Stadjuhar K, Allan D, Canadian Foundation for Women’s Health, 01/06/2006 –31/05/2007, $8,035 Réduire l'incidence de la morbidité du membre supérieur suite aux traitements pour le cancer du sein : développement et évaluation d'un projet pilote en kinésiologie, PI: Towers A, Co-investigators: Letellier M, St. Pierre D, Cohen SR, Fondation Québécoise du Cancer (no grant number), 06/2006 – 06/2007, $15,000 Family caregiving in palliative and end-of-life care: A new emerging team, Robin Cohen (Co-PI with Kelli I Stajduhar), Co-investigators: Chappell, N, Koop, P, Williams, A, Heyland, D. Canadian Institutes of Health Research- #129692, 2004 – 2009, $1,361,361 T.I.P.S: Tele-homecare in palliation study. Co-investigators: Larry Librach, Co- applicants: Cohen SR, Abernathy T, GoldSmith, C, Jadad, C, Kirshen, A, Librach L, Thabane L (P.I.: A. Stern, McMaster) Ontario Ministry of Health Primary Health Care Transition Fund 04/2004 – 04/2006, $933,900 25
  • 26. Department of Oncology Annual Report 2006/2007 2. Teaching and Research Training PhD Students and Postdocs Shuling Chen Spirituality & Palliative Care in Chinese Canadians, Education (Ph.D. Thesis Committee Member), Ph.D. in progress Oct. 2002 – present. Anita Mehta Family caregivers of palliative care patients at home: The pain management process, Nursing, Ph.D. in progress, Sept. 2003 – present. (Maternity leave July-Dec 2006), -NCIC Studentship Marianne Olivier- d’Avignon Development of a needs profile for siblings of terminally ill children, Social Work, U. Laval. Co- supervisor with Serge Dumont, Ph.D., May 2006- present Lisa Chan The experience of end-of life-care on an end-stage medical in-patient unit, Nursing, Ph.D., Sept.2005-present. Melissa Henry, Ph.D. (Psychology) Meaning Making Intervention for women with newly diagnosed advanced ovarian cancer, Oncology , Postdoctoral Fellowship, April 2006- present Mary Rykov, Ph.D. (Adult Education) The impact of music therapy on patients and families on palliative care units, Oncology, Postdoctoral Fellowship, July 2006- present, NCIC Postdoctoral Fellowship. Réjeanne Dupuis, Psychology,York University Co-supervisor with Paul Ritvo, Ph.D., Sept. 2006- present. Andreea Iancu, M.D. Palliative Medicine Fellow, Cancer Pain Classification System, Nov.2005-Oct.2006 McGill Courses Winter 2006 , NUR2 705 A required course for the interdisciplinary Psychosocial Oncology Option in the Faculty of Graduate Studies and Research, Palliative Care in Cancer. April 20, 2006, Oncology Interdisciplinary Journal Club, Staff member responsible for discussion of student presentation of RCT. 3. Scientific Reviews: Editorial Boards and Journal Reviews Editorial Boards Journal of Palliative Care, 2004- present American Journal of Hospice and Palliative Care, 2004- present Ad Hoc Reviews Journal of Palliative Care, 1996, 97, 98, 99, 2000, 2001, 2002, 2004, 2005, 2006 26
  • 27. Department of Oncology Annual Report 2006/2007 Palliative Medicine, 1996, 97, 98, 99, 2001, 2006 Journal of Pain and Symptom Management, 2001, 2002, 2006 Quality of Life Research, 2006, 2007 4. Research Advisory Work for National and International Organizations National Cancer Institute of Canada , Clinical Fellowships Peer Review Committee, July 1-2006-June 30-2007 Ad Hoc Reviewer: Fonds de recherche en santé du Québec 1997, 1998, 2006 Committees McGill Department of Oncology Clinical Trials Operations, Supportive Care Section, Member, 1999 –present Canadian Hospice Palliative Care Association, Research Advisor, March 2003 – present Wellness Centre, Jewish General Hospital, Research Advisory Board, Member, February 2005- present VON Canada-University of Ottawa Bereavement Think Tank, Member, April 2005- present 5. Congress and Workshop Organization 16th International Congress on Care of the Terminally Ill, Montreal, September 25-28, 2006, Executive and Organizing Committee: Determining Congress content and schedule Sole Organizer of Research Program. Chair of Research Abstract Review Committee. Chair all Research Fora 17th International Congress on Care of the Terminally Ill, Montreal, September 22-26, 2008, Executive and Organizing Committee: Determining Congress content and schedule Sole Organizer of Research Program. Chair of Research Abstract Review Committee. Chair all Research Fora 27
  • 28. Department of Oncology Annual Report 2006/2007 6. Invited Presentations and Workshops (National and International) and Peer Reviewed Abstracts Williams A, Crooks V, Stadjuhar K, Cohen SR, Allan D. Women's Caregiving Work at End-Of-Life: An Evaluation of Canada's Compassionate Care Benefit. Ontario Women's Health Council Conference "Enhancing Women's Health Research", April, 2006, Ottawa, Ont. Cohen SR, Brown KS, Fyles G, Lachance J, Leis A, Viola R, Porterfield, P. The Quality of Life of Family Caregivers of People with Cancer at the End of Life. Canadian Association of Psychosocial Oncology Annual Conference: Psychosocial Risks and Consequences Across the Lifespan, Montreal, May 3-6, 2006 Koop PM, deJong-Berg MA, Williams A, Cohen SR, Allan D, Stajduhar K. Defining Caregiver Respite in End-of-Life Care: A Systematic Literature Review: Canadian Association of Psychosocial Oncology Annual Conference: Psychosocial Risks and Consequences Across the Lifespan, Montreal, May 3-6, 2006. Koop PM, deJong-Berg MA, Williams A, Cohen SR, Allan D, Stajduhar K. Defining Caregiver Respite in End-of-Life Care: A Systematic Literature Review. UICC World Cancer Congress, Washington, DC, July 8-12, 2006. Allan,DE, Heyland DK, Homer S, Gafni A, Frank C, Stajduhar KI, and Cohen SR. Prognostic awareness, satisfaction with quality of care, and resource utilization at end of life. Canadian Association for Health Services and Policy Research, Vancouver, BC, September 17-19, 2006. Cohen SR, Fyles G, Leis A, Viola R, Porterfield P, Lachance J, Brown KS. Family care quality of life relationship to carer optimism, sense of self-efficacy, and sense of preparedness to provide care to terminally ill people with cancer International Psycho- Oncology Society Conference, Venice, Italy, Oct.18-22, 2006.Psycho-Oncology 2006, 15 (Supp2);S207 *Thibodeau-Jarry N, Cohen SR. Content validity and acceptability of patient and family caregiver quality of life: Instruments for an end stage medical population 16th International Congress on the Care of the Terminally Ill, Montreal, Quebec, Sept.26-29, 2006. Journal of Palliative Care 2006, 22; 247. *Taylor G, Carpentier S, Cohen SR. Quality of life assessment in palliative care: How do family caregivers interpret the items? 16th International Congress on the Care of the Terminally Ill, Montreal, Quebec, Sept.26-29, 2006, Journal of Palliative Care 2006, 22; 240. *Carpentier S, Taylor G, Cohen SR. Quality of life assessment in palliative care: How do patients interpret the items? 16th International Congress on the Care of the Terminally Ill, Montreal, Quebec, Sept.26-29, 2006, Journal of Palliative Care 2006, 22, 237. Rose PA, Cohen SR, Amsel R. Pressure ulcer (PU) risk assessment in the critically ill. National Pressure Ulcer Advisory Panel biennial conference, San Antonio, Texas, February 9-10, 2007. 28
  • 29. Department of Oncology Annual Report 2006/2007 7. Hospital Activities Encompassed within responsibilities with McGill. McGill Executive Committee, Palliative Care McGill, Member, 1995 – present Division of Palliative Care, Oncology, Research Director, April 1996 – present Palliative Care McGill Education Committee, Member, 1998 – present Oncology, Member, Interdisciplinary Postgraduate Training Committee, Sept. 2002 – present Oncology, Member, Psychosocial Oncology Program, Sept. 2002 – present School of Nursing, Student Standing and Promotions Committee, Member, Dec. 2002 – April 2004 Sept.2005-present School of Nursing, Ph.D. Supervisors Committee, Member, January 2001 – present MUHC Palliative Care Service Divisional Meeting, Member, January 2003 – present Cancer Nutrition and Rehabilitation Program Steering Committee , Member, June 2005- present Eric Flanders Professor in Palliative Care Medicine Selection Advisory Committee, Member, June 2005-present Faculty of Medicine Student Research and Summer Research Bursary Committee, Member, 2006, 2007 Justine Farley 1. Conference Organization Program Committee for the 2006 and 2008 International Congress on Care of the Terminally Il, Montreal Responsable de la « Rencontre avec Serge Daneault « Souffrance et médecine », le 12 mai 2007, à Dorval, organisé avec Le programme de soins palliatifs du CH de Verdun 2. Invited Presentations and Workshops (National and International) Comité de programmation, 16e congrès international sur les soins aux malades en phase terminale, 26 au 29 septembre 2006. Membre du comité organisateur, Euthanasie et suicide assisté, conférence Derouin- Renaud, Montréal, le 3 mai 2006. La sédation palliative, l’art et la science de la médecine, Hôpital Ste-Anne-de-Bellevue, le 5 mai 2006. 29
  • 30. Department of Oncology Annual Report 2006/2007 Présidente d’atelier, Soins palliatifs, Congrès international de droit médical, Toulouse, France, 7 août 2006. L’insuffisance cardiaque terminale, Symposium annuel, Société québécoise de l’insuffisance cardiaque, St-Sauveur, le 29 septembre 2006. Approches simples en soins palliatifs, 2e journée scientifique annuelle de l’établissement d’Argenteuil, le 27 octobre 2006. Chemotherapy at the End of Life, Therapeutic Issues Day, CH St.Mary, le 23 novembre 2006. Les soins palliatifs d’un milieu à l’autre, un défi d’arrimage. En collaboration avec Dr Geneviève Dechênes, Colloque de la direction de lutte contre le cancer, Montréal, le 1er décembre 2006. 3. Hospital Activities Full-time clinician in Palliative Care within the Oncology Department and the Family Medicine Departement Chef du service de soins palliatifs Présidente du comité d’évaluation du CMDP du CH de St.Mary, jusqu’au 31 décembre 2006 Membre invité à l’Exécutif du CMDP, jusqu’au 31 décembre 2006 Membre du Quality and Risk Management Coordinating Committee, jusqu’au 31 décembre 2006 Membre du comité de gestion du Cancer Care Program Membre du comité de gestion de la qualité du Cancer Care Program: préparation de la visite 2006 du Conseil canadien d’agrément des services de santé (CCHSA) Présidente du Comité des finances du Fond d’Oncologie 4. National and International Commitees Membre du comité de gestion du Cancer Care Program Membre du comité de gestion de la qualité du Cancer Care Program: préparation de la visite 2006 du Conseil canadien d’agrément des services de santé (CCHSA) Présidente du Comité des finances du Fond d’Oncologie Présidente du Réseau de soins palliatifs du Québec depuis avril 2006 Responsable de la journée de réflexion sur le Suicide assisté, journée pré-congrès du Réseau de soins palliatifs: le 23 avril 2006 30
  • 31. Department of Oncology Annual Report 2006/2007 Membre délégué au Conseil d’administration de l’Association canadienne de soins palliatifs Membre au Organizational Development Committee Membre du Best Practices and Quality Care Working Group, Canadian Strategy on Palliative and End-of-Life Care, Health Canada Membre du comité aviseur pour le Projet Hospice and End-of-life Care, du Conseil canadien d’agrément des services de santé Membre du Comité sur l’évaluation des médicaments anticancéreux, comité du Conseil du médicament, de mai 2005 à ce jour. Visiteur pour l’accréditation des centres d’oncologie par la Direction du programme de lutte contre le cancer, 2006 William Foulkes 1. Research grants (new and ongoing) Title of Grant: BRCA1 splice variants and the breast cancer risk: novel approaches using nanobiology Agency: Canadian Breast Cancer Research Alliance, IDEA grant Dollars Awarded: CDN $97,380 total Dates of Approved Project: July 1, 2006 through June 30, 2007 Name of P.I.: WD Foulkes The goal of this project is to determine whether currently undiscovered splice variants of BRCA1 could contribute to risk of breast cancer in the general population. Title of Grant: Toward the biological treatment of BRCA1-related breast cancer: EGF, EGFR and tyrosine kinase inhibitors Agency: Canadian Breast Cancer Research Alliance, Operating grant Dollars Awarded: CDN $423,000 total Dates of Approved Project: July 1, 2006 through June 30, 2009 Name of P.I.: WD Foulkes List of Co-Applicants: Tarek Bismar, Raquel Aloyz, Parviz Ghadirian 31
  • 32. Department of Oncology Annual Report 2006/2007 The major goal of this study is to determine if alterations in receptor tyrosine kinases play a role in hereditary breast cancer. Title of Grant: The 3D telomeric signature(s) of DCIS Agency: Susan G Komen BrCa Foundation, Operating grant Dollars Awarded: US$249,805 total Dates of Approved Project: May 1, 2006 through April 31, 2009 Name of P.I: Sabine Mai List of Co-Applicants: WD Foulkes In this project, we wish to find out whether telomere dysfunction is an early event in DCIS. Title of Grant: BRCA1, CDC4, Cyclin E, and Chromosomal Instability in Breast Cancer Agency: Canadian Breast Cancer Research Alliance, Operating grant Dollars Awarded: CDN$ 430,000 total Dates of Approved Project: April 1, 2005 through March 30, 2008 Name of P.I.: WD Foulkes List of Co-Applicants: Sabine Mai, Torsten Nielsen The major goal of this project is to explore the cyclin E axis in BRCA1-related breast cancer. Title of Grant: Defining aggressive phenotype of prostate cancer using a multiplex of 12 gene model Agency: Prostate Cancer Research Foundation of Canada (PCRFC), Operating grant Dollars Awarded: CDN$ 60,000 Dates of Approved Project: Mar 1, 2005 through Feb 28, 2007 Name of P.I.:Tarek Bismar List of Co-Applicants: WD Foulkes, M. A Rubin The major goal of this study is to investigate the value of 12 gene model expression in localized prostate cancer in predicting cancer recurrence and cancer specific death. The 12 gene model was identified through gene expression profile and proteomic study of more than 1500 different gene of the prostate gland. 32
  • 33. Department of Oncology Annual Report 2006/2007 Title of Grant: Risk factor analysis of hereditary breast and ovarian cancer Agency:Canadian Breast Cancer Research Alliance, Operating grant Dollars Awarded: CDN$ 1,250,000 Dates of Approved Project: July 1, 2004 through June 30, 2009 Name of P.I.: Steven Narod List of Co-Applicants: WD Foulkes (receives no funding on this grant), P Ghadirian, A Eisen The aim of this project is to identify and quantify the role of risk modifiers in BRCA1/2 mutation carriers. Title of Grant: Programme de recherché en appui aux politiques de santé en génétique dans un souci de qualité, d'efficience et de bien-être social Agency: Canadian Institutes of Health Research Dollars Awarded: CDN$ 1,000,000 Dates of Approved Project: Jan 1, 2003 through Dec 31, 2007 Name of P.I.: Renaldo N Batista List of Co-Applicants: WD Foulkes (receives no funding on this grant), I Blancquaert G Cleret de Langavant, D Gaudet, B Godard, N Laflamme, A Marcoux, F Rousseau The major goals of this project are the establishment of acknowledge network for the development of health policy in genetics from the academic world and clinical world, and governmental agencies. Title of Grant: The Genetic of Prostate Cancer: The ICPCG Study Agency: National Institutes of Health (NIH) Dollars Awarded: US$ 2,097,089 total Dates of Approved Project: Sept 1, 2002 through Aug 31, 2006 Name of P.I.: William B Isaacs List of Co-Applicants: WD Foulkes, J Epstein , A Partin, D Easton, R Eeles, L Maehle et al. The goal of this study includes combined epidemiological, mutation analysis and linkage studies of thousands of men with hereditary, familial or sporadic prostate cancer. 33
  • 34. Department of Oncology Annual Report 2006/2007 2. Research Training: undergraduate students, graduate students, postdocs/fellows Graduate Students Supervised Name: Tayma Khalil (Raquel Aloyz: co-supervisor) Department: Human Genetics Years: 2005- Degree: MSc Topic: CDC4 in hereditary breast cancer Postdoctoral Trainees Name: Ahmet Yilmaz Department: Human Genetics Years: 2006- current Topic: CHEK2 and breast and prostate cancer in Ashkenazi Jews Advisor, M.Sc. And Ph.D Graduate Supervisory Committees Name: Andrea Karin Lawrance, MSc Thesis: Diet, folate and polyps in models of murine intestinal cancer Supervisor: Dr. Rima Rozen (Department of Human Genetics) Date: May 2001-current 3. Research Advisory Work for National and International Organizations Scientific Advisory Committee, Breast Cancer Family Registry (NIH), 2006- Promotion review (to Associate Attending Physician), Memorial Sloan-Kettering Hospital, November 2006 Promotion review (to Associate Member), Memorial Sloan-Kettering Cancer Center, November 2006 Canadian Breast Cancer Research Initiative, IDEA grant panel, 2006 4. Conference Organization Second International Symposium on Hereditary Breast and Ovarian Cancer, Montreal Oct 17-19, 2007. (www.odon.ca/brca/). Co-sponsored by the Program in Cancer Genetics and the Hereditary Breast and Ovarian Cancer Foundation (www.hboc.ca). Role: Scientific Director of Conference. 34
  • 35. Department of Oncology Annual Report 2006/2007 5. Invited Presentations and Workshops (National and International) a) International August 16, 2006 Title: Recent advances in understanding of the inherited susceptibility to cancers of the prostate, pancreas, stomach and colorectum, Australian Ovarian Cancer Study and the Family Cancer Clinics of Australia, Couran Cove Island Resort, Stradbroke Island, Australia August 18, 2006 Title: Hereditary breast cancer: from pathology to treatment and beyond, Australian Ovarian Cancer Study and the Family Cancer Clinics of Australia, Couran Cove Island Resort, Stradbroke Island, Australia October 28, 2006 Title: Breakthrough treatments for BRCA1 and BRCA2 mutation carriers, 10th Annual Cincinnati Comprehensive Breast Cancer Conference, Cutting Edge Strategies in Breast Cancer: The next decade, Cincinnati, OH, USA November 9, 2006 Title: Hereditary breast cancer: from pathology to treatment and beyond, Cancer Colloquia IV: Cell and Molecular Biology of Breast Cancer, University of St-Andrews, St-Andrews, Scotland b) National June 15, 2006 Title: Genetics and Breast Cancer: An update, Toronto Breast Cancer Symposium 2006, Metro Toronto Convention Center, Toronto, Ontario 6. Hospital Activities Teaching Hereditary Breast Cancer (Surgical Residents) October 2006, (1 hour teaching session surgical residents, RVH) 35
  • 36. Department of Oncology Annual Report 2006/2007 Eduardo Franco 1. Summary of New and Ongoing Research As PI: • Antioxidant nutrients among a Brazilian population (A Giuliano, E Franco [co-Pis], J Marshall, D Roe, L Villa, N Craft) National Institutes of Health (NCI Grant # RO1CA81310, approx. $1.3 million [US$ 870,000], 2000-03; renewed 2004-07, approx. $1.2 million). • Biomarkers of cervical cancer risk (E Franco, F Coutlée, G Matlashewski, M. Pollak, M Roger) Canadian Institutes of Health Research (CIHR grant #MOP-42532, $418,119, 2000-04; renewed 2005-08, $313,587). • Efficacy trial of HPV versus Pap testing for screening cervical cancer precursors (E Franco, F Coutlée, S Ratnam, S Walter, E Duarte, I Rodrigues, R Rajan, M Steben). Canadian Institutes of Health Research (CIHR grant #MCT-54063, $1,071,837, 2002-07). • PAP Cytology Screening Failure: Influences of the Patient, Physician, and Laboratory (E Franco, E Duarte-Franco, F Coutlée, A Ferenczy, P Ghadirian, M Dawes, M Deschamps, P Drouin). Canadian Institutes of Health Research (grants # IHS-61108, $48,545, 2002-03 and MOP-64454 $312,945, 2003-07). • HPV infection and transmission among couples through heterosexual activity (the HITCH cohort) (E Franco, F Coutlée, J Hanley, P Tellier). Canadian Institutes of Health Research (grant# 68893, $546,544, 2004-09). • CIHR Team in HPV infection and associated diseases (E Franco, F Coutlée [co-PIs], M Roger, G Matlashewski, P Brassard, Z Rosberger, A Al-Moustafa, J Archambault, P Davies, B Duval, R Rajan). Canadian Institutes of Health Research (grant #83320, $2,546,941, 2007-13). As Co-investigator: • Characterization of the human papillomavirus infection among a population of Inuit women in Québec. (P Brassard, E Franco, F Coutlée, M Roger). Canadian Institutes of Health Research (CIHR grant #MOP57749, $496,752, 2002-07). • Economic evaluation of population screening for cervical cancer using HPV testing in Canada (R Rajan, E Franco, J Penrod). National Cancer Institute of Canada (grant # 014033, $186,139, 2003-07). • Development and validation of new statistical methods for modeling intermediate events in survival analysis (M Abrahamowicz, A Ciampi, A Benedetti, E Franco, M Klein, L Pilote, R Platt, J Siemiatycki) Canadian Institutes of Health Research (grant# ATF66665, $158,263, 2004-06; renewed $54,787, 2006-07). 36
  • 37. Department of Oncology Annual Report 2006/2007 • Prognostic value of clinical correlates of cancer cachexia: A prospective, multicenter, population-based study (A Vigano, V Baracos, S Cohen, MA Dalzell, E Franco, N Macdonald, S Thirlwell). Canadian Institutes of Health Research (grant# MOP- 67043, $211,925, 2004-07). • CIHR training program in applied Oral Health Research (J Feine, P Allison, E Franco, W Fraser, M Frenette, D Grenier, A Kolta, G Lavigne, J Lund, M Mckee). Canadian Institutes of Health Research (grant #QTA-68723, $1.76M, July 2004 – June 2010). • Molecular analysis of HPV infection in precancerous and cancerous lesions of the uterine cervix (F Coutlée, E Franco, G Matlashewski). Canadian Institutes of Health Research (grant# MOP-67155, $289,371, 2004-07). • The life course approach to the aetiology of squamous cell carcinoma in the upper aerodigestive tract (P Allison, E Franco, R Fuhrer, G Humphris, B Nicolau, A Sacker). Canadian Institutes of Health Research (grant #69062, $434,063, October 2004 – September 2007). • The psychosocial impact of Pap versus HPV testing on Canadian women screened for cervical cancer (Z Rosberger, P DiDio, E Duarte, E Franco, B Knauper, MH Mayrand). Canadian Institutes of Health Research (grant# pending, $160,000, 2005- 08). • A randomized controlled trial of the effectiveness of a coping strategies intervention for people with head and neck cancer (P Allison, LJ Edgar, J Feine, E Franco, B Nicolau, R Rajan). Canadian Institutes of Health Research (grant #MCT-75475, $471,139, April 2005 – March 2009). • A randomised controlled evaluation of HPV testing for cervical cancer screening (A Coldman, P Davies, R Martin, J Matsic, D Van Niekerk, G Ogilvie, T Ehlen, G Stuart, E Franco, S Peacock, M Krajden), Canadian Institutes of Health Research (grant #TBA, $6,268,935, 2006-13). • The life course approach to studying the etiology of head and neck cancer: HeNCe life study (B Nicolau, P Allison, R Burk, F Coutlée, E Franco, G Humphris, J O’Loughlin, A Sacker, N Schlecht), Canadian Institutes of Health Research (grant #TBA, $478,236, 2006-10). Industry support (non-peer-reviewed unrestricted grants) (amounts in Canadian dollars) • Support for the Canadian Cervical Cancer Screening Trial (Merck-Frosst Co., $75,000, 2004-07). • Support for the HPV infection and transmission among couples through heterosexual activity (the HITCH cohort) (Merck-Frosst Co., $472,072, 2006-09) 37
  • 38. Department of Oncology Annual Report 2006/2007 International Activities: • PI of the Ludwig-McGill Cohort Study of the Natural History of HPV Infection and Cervical Neoplasia. • Member, Nominating Committee, International Epidemiological Association (2005-) • Chair, World Congress Advisory Committee, International Epidemiological Association (2005-) 2. Research grants (new and ongoing) See above. 3. Research Training: undergraduate students, graduate students, postdocs/fellows • H Trottier. Epidemiology of cervical cancer. Postdoctoral fellow, Department of Oncology, McGill University, Montreal, 2004-07. • M-H Mayrand. Efficacy trial of HPV testing in cervical cancer screening. Ongoing PhD research, Department of Epidemiology & Biostatistics, McGill University, Montreal, 2002-06 (FRSQ and NCIC scholarships). • A Spence. Determinants of cervical cancer screening failure. Ongoing PhD research, Department of Epidemiology & Biostatistics, McGill University, Montreal, 2001-07. • T Dang-Tan. Childhood cancer surveillance. Ongoing PhD research, Department of Epidemiology & Biostatistics, McGill University, Montreal, 2002-06 (CIHR scholarship). • CV Atwood. Determinants of cervical cancer screening. MSc thesis, Department of Epidemiology & Biostatistics, McGill University, Montreal, 2002-06. • S Lau. Natural history of ASCUS cervical cytological abnormalities. Ongoing MSc research (part-time student), Department of Epidemiology & Biostatistics, McGill University, Montreal, 2002-07. • A. Burchell. Behavioural determinants of HPV transmissibility. Ongoing PhD research, Department of Epidemiology & Biostatistics, McGill University, Montreal, 2003-08 (Tomlinson and NCIC scholarships). • A De Pokomandy. Anal intraepithelial neoplasia in HIV-infected men. Ongoing MSc research, Department of Epidemiology & Biostatistics, McGill University, Montreal, 2005-07. 38
  • 39. Department of Oncology Annual Report 2006/2007 • L Tomita. Diet, serum micronutrients and risk of cervical neoplasia. Ongoing PhD research (jointly), Departamento de Nutrição, Faculdade de Saúde Pública, Universidade de São Paulo, Brazil, Summer 2006. 4. Scientific Reviews: Editorial Boards and Journal Reviews International peer-review journals • Cancer Detection and Prevention (Editorial Board, from February 2001) • Cancer Epidemiology, Biomarkers and Prevention (Editorial Board, 1995-2007) • Epidemiology (Editorial Board, 1993-2008) • Oral Diseases (Editorial Board, from March 2005) • Public Library of Science (PLoS) – Medicine (Editorial Board, 2004-) Other • HPV Today (Scientific Committee Member, 2002-) • Salud Pública de México (Editorial Board, 2004-) Manuscript reviews (total of 41 from June 1, 2006 to May 31, 2007) Canadian Journal of Public Health (1), Canadian Medical Association Journal (1), Cancer Causes and Control (1), Cancer Detection and Prevention (4), Cancer Epidemiology, Biomarkers and Prevention (4), Cancer Research (4), Epidemiology (2), Chronic Diseases in Canada (1), Epidemiology & Infection (1), Gynecologic Oncology (1), International Journal of Cancer (6), Journal of General Virology (1), Journal of Infectious Diseases (2), Journal of the National Cancer Institute (1), Lancet (1), Oral Diseases (3), Oral Oncology (1), Proceedings of the National Academy of Sciences (1), Public Library of Science-Medicine (2), Sexually Transmitted Diseases (1), Tissue Antigens (1), Virus Genes (1) Grant reviews (internal): 13 • RO1 grants for NIH: 9 • NIH Intramural proposals: 4 39
  • 40. Department of Oncology Annual Report 2006/2007 Faculty evaluations • Fred Hutchinson Cancer Research Center, Division of Public Health Sciences, Seattle, USA (2006). • National Cancer Institute, Division of Cancer Epidemiology and Genetics, National Institutes of Health, Rockville, USA (2007). • University of Arizona Prevention Center, Tucson, USA (2006). • University of Montreal, Departments of Nutrition and Microbiology and Immunology, Faculty of Medicine, Canada (2006). 5. Research Advisory Work for National and International Organizations National • National Cancer Institute of Canada, Toronto: Member, Awards-in-Excellence Committee (2005-07). • National Cancer Institute of Canada, Toronto: Member, Nominating Committee (2005-). • Member, Environment Cancer Fund Advisory Board, Cancer Research Society, Toronto, Canada (2006-) • Clinical Medicine and Basic Biology Working Group, National Cancer Institute of Canada’s Prevention Initiative, Toronto, Canada (2006-07) International • National Cancer Institute, National Institutes of Health, Bethesda, USA: Member (2006), Site Review Committees for the intramural research program of the Hormonal, Reproductive and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics. • National Institutes of Health, Epidemiology & Disease Control-2 Study Section (renamed Epidemiology of Cancer [EPIC] panel in 2003), Bethesda, USA: Member (2002-07). • Consultant, University of Arizona Male HPV Cohort Study, University of Arizona, Tucson, USA (2003-). • Clinical Medicine and Basic Biology Working Group, National Cancer Institute of Canada’s Prevention Initiative, Toronto, Canada (2006-07) • Member, Scientific Advisory Board, The HPV Foundation, New York, USA (2004-). 40
  • 41. Department of Oncology Annual Report 2006/2007 • Member, Ad hoc Meeting of experts on surveillance of HPV-associated disease in the Americas, Pan American Health Organization, Washington, USA (October 2006). • Member, External Advisory Committee, Cancer Control and Population Sciences, University of Puerto Rico Comprehensive Cancer Center, San Juan, USA (2007-). 6. Conference Organization • Member, Steering Committee, “1st Global Congress on World Religions after September 11”, Montreal, Canada (September 2006). • Member, International Scientific Committee, 24th International Papillomavirus Conference and Clinical Workshop (IPCCW) to be held in Beijing, China (November 2007). • Member, Candidacy Planning Committee, World Cancer Congress of the Union Internationale Contre le Cancer, Montreal, Canada (winning bid for 2012). • Member, Local Organizing Committee, International Papillomavirus Conference, Montreal, Canada (2010). • Member, 60th Anniversary Cancer Research Conference Program Committee, National Cancer Institute of Canada, Toronto (2007) 7. Invited Presentations and Workshops (National and International) National (18) • “Principles of Clinical Research in Oncology: Grand Rounds Lecture to the Oncology Training Program, McGill University Health Centre, Montreal General Hospital, Montreal, Canada (September 29, 2006). • “HPV Vaccination: A New Paradigm in Cervical Cancer Prevention” Seminar to the Department of Epidemiology & Biostatistics, McGill University, Montreal, Canada (October 16, 2006). • “Expected impact of HPV vaccination on cervical cancer screening practices” Seminar to the Merck-Frosst HPV Club, Montreal Museum of Fine Arts, Montreal, Canada (October 25, 2006). • Chair and Speaker “L’impact attendu de la vaccination contre le virus du papillome humain sur les pratiques de dépistage du cancer du col utérin” in the Symposium “Dépistage du cancer du col utérin: une approche en pleine mutation”, 10es Journées annuelles de santé publique, Montréal, Canada (October 27, 2006). 41
  • 42. Department of Oncology Annual Report 2006/2007 • Chair and Speaker, “Prevention of cervical cancer: New paradigms”, Lecture in Workshop “Human Papilloma Virus Vaccination - A New Cervical Cancer Control Strategy”, 6th World Congress on Vaccines and Immunization, Montreal, Canada (November 8, 2006). • "Molecular epidemiology of HPV infection and cervical cancer" Lecture at the Sainte-Justine Hospital, Montreal, Canada (November 10, 2006). • “Human Papillomavirus: Truth or Fiction”, Plenary lecture, Continuing Medical Education Conference “Eradicating Cervical Cancer”, Cancer Care Manitoba, Winnipeg, Canada (November 17, 2006). • “Marrying HPV vaccines to screening”, Plenary lecture, Continuing Medical Education Conference “Eradicating Cervical Cancer”, Cancer Care Manitoba, Winnipeg, Canada (November 17, 2006). • “Impact of HPV vaccination on screening practices” Lecture, HPV and Cervical Cancer Prevention Summit: New Opportunities for Partnerships and Prevention, Montreal, Canada (November 28, 2006). • “The expected impact of HPV vaccination on cervical cancer screening practices” Lecture to the Cervical Cancer Screening Management Staff, Cancer Care Ontario, Toronto, Canada (December 14, 2006). • “HPV Vaccination in Cervical Cancer Prevention: Evidence and Implications” Lecture at the Division of Preventive Oncology, Cancer Care Ontario, Toronto, Canada (December 14, 2006). • “Changing Landscapes in HPV and Cervical Cancer Prevention and Screening” Lecture at the CityWide Grand Rounds, Women's Hospital, University of Toronto, Toronto, Canada (December 15, 2006). • "HPV Vaccination in cervical cancer prevention: promises & perils" Lecture given in the Symposium Challenges in Obstetrics & Gynecology, Gelber Conference Centre, Montreal, Canada (March 16, 2007). • Co-Chair and Speaker, “Impact of Vaccination on Screening Programs: An Opportunity” Lecture in Session “Implementation of the HPV Vaccine: Gaps in Knowledge and Opportunities”, 7th Annual Continuing Professional Development Meeting, Society of Gynecologic Oncologists of Canada, Toronto, Canada (April 27, 2007). • “Epidemiology of Genital HPV Infection and Cancer of the Cervix”, Lecture, 2nd Annual Gynaecologic Cancer Update Day: “Emerging Trends in Cervical Cancer”, Stratford, Canada (May 11, 2007). 42
  • 43. Department of Oncology Annual Report 2006/2007 • “Issues in planning screening in the era of HPV vaccination” Lecture, 2nd Annual Gynaecologic Cancer Update Day: “Emerging Trends in Cervical Cancer”, Stratford, Canada (May 11, 2007). • “Changing Landscapes in HPV and Cervical Cancer Prevention and Screening” Lecture given to the Institut du Cancer de Montreal, Centre de Recherche du CHUM- Hôpital Notre-Dame, Montreal, Canada (May 16, 2007). • “The implications of a new paradigm in cervical cancer prevention” Plenary lecture, XXXII Réunion des Registres des pays de Langue Latine, Montreal, Canada (May 17, 2007). International (45) • “Inovação na Prevenção do Câncer Cervical” Plenary lecture and panel discussion, 6th Congresso Brasileiro de Citologia Clinica, Curitiba, Brazil (June 5, 2006). • “O uso do teste HPV no rastreamento do câncer de colo uterino: Promessas e obstáculos”, Plenary lecture, 6th Congresso Brasileiro de Citologia Clinica, Curitiba, Brazil (June 6, 2006). • “História Natural do HPV e do Câncer do Colo Uterino: O que resta a descobrir?” Plenary lecture, 6th Congresso Brasileiro de Citologia Clinica, Curitiba, Brazil (June 7, 2006). • Chair, Plenary session “Recognizing and Solving Public Health Problems with Epidemiology: The Example of Cervical Cancer Control”, lecture: “A timeline for public health research in cervical cancer etiology and prevention” Congress of Epidemiology 2006 (sponsored by 18 societies), Seattle, USA (June 22, 2006). • Chair, Contributed paper session “Innovation in Cancer Screening and Prevention” Congress of Epidemiology 2006 (sponsored by 18 societies), Seattle, USA (June 22, 2006). • Nominator’s Introduction during Awards Ceremony to introduce Dr. Nubia Muñoz as Outstanding Epidemiologist of 2006. Congress of Epidemiology 2006 (sponsored by 18 societies), Seattle, USA (June 23, 2006). • “Impacto das vacinas contra o HPV no rastreio do cancro cervico-uterino” Plenary lecture, Symposium “O Vírus HPV, as Vacinas e o Cancro”, Instituto Português de Oncologia do Porto, Porto, Portugal (June 27, 2006). • “Infeccões como agentes etiologicos no cancro: o papel das vacinas” Plenary lecture, Symposium “O Vírus HPV, as Vacinas e o Cancro”, Instituto Português de Oncologia do Porto, Porto, Portugal (June 27, 2006). 43
  • 44. Department of Oncology Annual Report 2006/2007 • “Vacinação Contra a Infecção pelo HPV: O novo Paradigma da Prevenção do Cancro do Colo do Útero” Plenary lecture, Symposium “O Vírus HPV, as Vacinas e o Cancro”, Instituto Nacional de Saúde, Lisbon, Portugal (June 29, 2006). • “O Impacto da Vacinação Contra o HPV no Rastreio do Cancro de Colo do Útero” Plenary lecture, Symposium “O Vírus HPV, as Vacinas e o Cancro”, Instituto Nacional de Saúde, Lisbon, Portugal (June 29, 2006). • Chair and Speaker, “Human Papillomavirus Infection and Cervical Cancer: Promises and Perils in Prevention Research” Symposium: “Infection And Cancer: Prospects For Prevention”, UICC World Cancer Congress, Washington, USA (July 9, 2006). • Chair and Speaker, “Global burden of cervical cancer and HPV-associated diseases”, Symposium " Advances With Vaccines for the Prevention of Cervical Cancer and Other HPV-Related Diseases", UICC World Cancer Congress, Washington, USA (July 10, 2006). • “New approaches in cervical cancer screening” Lecture in Session: “Cervical Cancer Screening: Strategies for Developing Countries”, UICC World Cancer Congress, Washington, USA (July 10, 2006). • “HPV vaccination as a promising new strategy for cervical cancer prevention”, 37th Annual Conference, New Zealand Society of Cytology, Napier, New Zealand (August 24, 2006). • “Efficacy of HPV testing in cervical cancer screening”, 37th Annual Conference, New Zealand Society of Cytology, Napier, New Zealand (August 24, 2006). • “The impact of HPV vaccination on cervical cancer screening”, 37th Annual Conference, New Zealand Society of Cytology, Napier, New Zealand (August 24, 2006). • “Assessing new cancer screening technologies: The tyranny of evidence-based medicine”, 37th Annual Conference, New Zealand Society of Cytology, Napier, New Zealand (August 25, 2006). • “Epidemiology of HPV and CIN” Plenary lecture, 23rd International Papillomavirus Conference and Clinical Workshop, Prague, Czech Republic (September 1, 2006). • Chairperson, Clinical Workshop Session 1, 23rd International Papillomavirus Conference and Clinical Workshop, Prague, Czech Republic (September 1, 2006). • Speaker, Session “Handling HPV vaccines and screening”, 23rd International Papillomavirus Conference and Clinical Workshop, Prague, Czech Republic (September 3, 2006). • Co-Chair, Session PS10 “Preventive vaccines: models”, 23rd International Papillomavirus Conference and Clinical Workshop, Prague, Czech Republic (September 4, 2006). 44
  • 45. Department of Oncology Annual Report 2006/2007 • Speaker, Meet the Experts Session: Putting Science into Practice, 23rd International Papillomavirus Conference and Clinical Workshop, Prague, Czech Republic (September 5, 2006). • “O Valor da Vacinação contra o HPV na Prevenção do Câncer de Colo do Útero” Opening keynote lecture, Congresso Internacional de Experts: Patologia do Trato Genital Inferior e Colposcopia, Porto Alegre, Brazil (October 4, 2006). • “Controle do Câncer de Colo do Útero na Prática Diária: O impacto da Vacinação contra o HPV” Plenary lecture, Congresso Internacional de Experts: Patologia do Trato Genital Inferior e Colposcopia, Porto Alegre, Brazil (October 5, 2006). • “Grau de Evidência no Diagnóstico de Lesões Cervicais” Roundtable presentation, Congresso Internacional de Experts: Patologia do Trato Genital Inferior e Colposcopia, Porto Alegre, Brazil (October 6, 2006). • “Historia natural de las infecciones por virus del papiloma humano”, Plenary lecture, 1st Congress of the Sociedad Mexicana del Virus del Papiloma, Mexico City, Mexico (November 3, 2006). • “Tendencias actuales para detección de VPH”, Plenary lecture, 1st Congress of the Sociedad Mexicana del Virus del Papiloma, Mexico City, Mexico (November 3, 2006). • Chair and Speaker, Session on Vaccines, “La eficacia de vacunas bivalentes”, 1st Congress of the Sociedad Mexicana del Virus del Papiloma, Mexico City, Mexico (November 4, 2006). • “Concluding Remarks: The Road Ahead”, Closing Plenary Lecture, 1st Congress of the Sociedad Mexicana del Virus del Papiloma, Mexico City, Mexico (November 4, 2006). • “Planning Cervical Cancer Screening in the Era of HPV Vaccines”, Symposium lecture, Frontiers in Cancer Prevention Research Conference, American Association for Cancer Research, Boston, USA (November 15, 2006). • “Epidemiologia da Infecção por HPV”, Plenary lecture, Conferencia sobre Patologia Cervical 2006, Sociedade Portuguesa de Ginecologia, Aveiro, Portugal (November, 24, 2006). • “Rastreio do Cancro do Colo do Útero na Era Pós-Vacina”, Plenary lecture, Conferencia sobre Patologia Cervical 2006, Sociedade Portuguesa de Ginecologia, Aveiro, Portugal (November, 24, 2006). • “Questões relacionadas com a implementação da vacina: O que sabemos?”, Plenary lecture, Conferencia sobre Patologia Cervical 2006, Sociedade Portuguesa de Ginecologia, Aveiro, Portugal (November, 24, 2006). 45
  • 46. Department of Oncology Annual Report 2006/2007 • “Molecular epidemiology of HPV infection: new approaches” Roundtable presentation, 1st International Symposium on Cancer Research: Integrating Basic Science, Clinical Practice, and Epidemiology. São Paulo, Brazil (November 30, 2006). • Co-Chair and Discussant, Session “Childhood cancer – HPV and retinoblastoma: is there a relationship?”, 1st International Symposium on Cancer Research: Integrating Basic Science, Clinical Practice, and Epidemiology. São Paulo, Brazil (December 1, 2006). • “Distal and proximal causal agents in cancer: Reconciling social and molecular epidemiology” Lecture, 1st International Symposium on Cancer Research: Integrating Basic Science, Clinical Practice, and Epidemiology. São Paulo, Brazil (December 1, 2006). • “Vacuna VPH 16 & 18: una estrategia viable para la prevención del Ca. Cu.” Plenary lecture, Congreso Internacional de Colposcopia en la Practica Medica, Mexico City, Mexico (March 30, 2007). • “Impacto esperado de la vacunacion sobre los programas de deteccion” Plenary lecture, Congreso Internacional de Colposcopia en la Practica Medica, Mexico City, Mexico (March 30, 2007). • “La vacuna candidata de GSK VPH 16 & 18 contra Ca. Cu. Preguntas y respuestas” Plenary lecture, Congreso Internacional de Colposcopia en la Practica Medica, Mexico City, Mexico (March 30, 2007). • “Promises and perils in the changing landscape of cervical cancer prevention” Lecture given to the Department of Obstetrics and Gynecology, School of Medicine, Universidad de Puerto Rico, San Juan, USA (May 8, 2007). • “New directions in epidemiologic research on HPV and cancer” Symposium lecture, 3rd Puerto Rican Conference of Public Health, San Juan, Puerto Rico, USA (May 9, 2007). • “Bivalent HPV prophylactic vaccine: Efficacy for the prevention of cervical cancer” Plenary Lecture, International HPV Clinical Training and Scientific Workshop, Medellin, Colombia (May 24, 2007). • “Gaps in knowledge and research priorities for the prevention of cervical cancer in Latin American countries” Plenary Lecture, International HPV Clinical Training and Scientific Workshop, Medellin, Colombia (May 25, 2007). • “Impact of HPV vaccination in cervical cancer screening programs” Plenary Lecture, International HPV Clinical Training and Scientific Workshop, Medellin, Colombia (May 26, 2007). 46
  • 47. Department of Oncology Annual Report 2006/2007 • “HPV vaccination and screening: The need for synergy in cervical cancer prevention strategies” Plenary lecture, Congress “Prevenzione hpv: dalla ricerca traslazionale al vaccini: Nuove strategie e nuovi paradigmi di prevenzione sul territorio regionale”, Rome, Italy (May 31, 2007). 8. Peer-Reviewed Abstracts • de Pokomandy A(§), Rouleau D, Ghattas G, Vézina S, Coté P, Macleod J, Allaire G, Franco EF, Coutlée F. HPV-16, 18, 31, 45 viral loads in anal intra-epithelial lesions in HIV-seropositive men. 15th Annual Canadian Conference on HIV/AIDS research, Ottawa, Canada, June 2006. • Gagnon S, Hankins C, Pourreaux K, Franco E, The Canadian Women’s HIV Study Group, Coutlée F. Polymorphism of the capsid L1 gene is not a determinant of persistence of HPV-52 infection in HIV-seropositive women. 15th Annual Canadian Conference on HIV/AIDS research, Ottawa, Canada, June 2006. • Mayrand MH(§), Mahmud SM, Franco EL, Hanley J. Design, ethical and statistical challenges when studying the performance of new screening tests for cervical cancer. 23rd International Biometric Conference, Montreal, Canada, July 2006. • Burchell AN(§), Hanley J, Richardson H, Mahmud SM, Trottier H, Tellier PP, Coutlée F, Franco EL. Use of stochastic computer simulation and maximum likelihood methods to estimate sexual transmissibility of human papillomavirus infection. 23rd International Biometric Conference, Montreal, Canada, July 2006. • Trottier H(§), Schaffer A, Koushik A, Duarte-Franco E, Coutlée F, Pollak M, Franco EL. Insulin-like growth factor-I and risk of high-grade cervical intraepithelial neoplasia. 23rd International Papillomavirus Conference, Prague, Czech Republic, September 2006. • Trottier H(§), Mahmud S, Prado J, Rohan TE, Villa LL, Franco EL. Duration of type- specific HPV infection: Results from the Ludwig-McGill cohort study. 23rd International Papillomavirus Conference, Prague, Czech Republic, September 2006. • Kohli M, Ferko N, Martin A, Franco EL, Jenkins D, Gallivan S, Sherlaw-Johnson C, Drummond M. Estimating the long-term impact of a prophylactic human papillomavirus (HPV) 16/18 vaccine on the burden of cervical disease in the UK. 23rd International Papillomavirus Conference, Prague, Czech Republic, September 2006. • Trevisan A, Schlecht NF, Ferreira S, Sichero L, Ferenczy A, Duarte-Franco E, Franco EL, Villa LL. Correlation between viral load measured by real-time and low- stringency PCR testing of cervical specimens. 23rd International Papillomavirus Conference, Prague, Czech Republic, September 2006. 47
  • 48. Department of Oncology Annual Report 2006/2007 • Sichero L, Ferreira S, Trottier H, Ferenczy A, Franco EL, Villa LL. High grade cervical lesions are caused preferentially by non-European variants of HPVs 16 and 18. 23rd International Papillomavirus Conference, Prague, Czech Republic, September 2006. • Sénécal M, Maunsell E, Ferenczy A, Franco EL, Ratnam S, Coutlée F, Palefsky JM, Foucart S, Brisson M, Mansi JA. Psychosocial impact of cervical screening and condyloma: an epidemiological study (pisces). 23rd International Papillomavirus Conference, Prague, Czech Republic, September 2006. • Mayrand MH(§), Duarte-Franco E, Rodrigues I, Walter SD, Coutlée F , Ratnam S, Franco EL. Comparison of Pap and hpv testing strategies for screening high-grade cervical cancer precursors: Results from the Canadian Cervical Cancer Screening Trial (CCCaST). 23rd International Papillomavirus Conference, Prague, Czech Republic, September 2006. • De Pokomandy A(§), Rouleau D, Ghattas G, Vézina S, Côté P, MacLeod J, Allaire G, Fontaine J, Trépanier JM, Franco EL, Coutlée F. Human Papillomavirus 16, 18, 31, 45 viral loads and grade of anal intraepithelial neoplasia in HIV-infected men. 23rd International Papillomavirus Conference, Prague, Czech Republic, September 2006. • Tomita LY(§), Carneiro LC, Villa LL, Franco EL, Cardoso MA. Serum micronutrients in relation to human papillomavirus infection in Brazilian women: Preliminary results. 1st World Congress of Public Health Nutrition, Barcelona, Spain, September 2006. • Tomita LY(§), D´Almeida V, Longatto-Filho A, Villa LL, Franco EL, Cardoso MA. Higher homocysteine and lower serum levels of alpha-tocopherol are risk factors for cervical dysplasia in women living in São Paulo, Brazil. Frontiers in Cancer Prevention Research Conference, American Association for Cancer Research, Boston, USA, November, 2006. • Mahmud S, Turner D, Franco E, Aprikian A. Meta-analysis of the effects of aspirin, NSAID and acetaminophen use on prostate cancer risk. Poster presentation. Canadian Society of Epidemiology and Biostatistics. Calgary, Canada, May 2007. 9. Involvement in continuing education activities (mostly during speaking engagements in various conferences, nationally and internationally). 10. Involvement in the community The following are in addition to activities outlined above: 48
  • 49. Department of Oncology Annual Report 2006/2007 Consultancies to the private sector: • Technical Advisory Committee, Glaxo SmithKline Pharmaceuticals, Brussels, Belgium: HPV vaccines (1998-). • Technical Advisory Committee, Innovus, Inc., Burlington, Canada: Economic models of the natural history of cervical cancer (2000-). • Consultant, Merck-Frosst, Canada: Burden of HPV-associated diseases (2004-). • Consultant, GenProbe Inc. USA: HPV diagnostics (2007) • Consultant, Roche Molecular Systems: cervical cancer screening (2007). University service (McGill University) • Member, Management Committee, Department of Oncology (2001-) • Member, Committee on Joint Residency Training in Oncology, Faculty of Medicine (1994-present). • Chair, Faculty Promotion Sub-committees, Department of Oncology (2003-present). • Chair, Student Funding Committee, Department of Epidemiology and Biostatistics (2005-). Carolyn Freeman 1. Summary of New and Ongoing Research Current Research Interests Clinical research in paediatric tumours especially brain tumours and in soft tissue sarcomas in adults. Use of radio-sensitising and biological agents in pediatric brain tumours. Development of new radiotherapy treatment techniques. Evaluation of new radiotherapy technologies. 2. Research grants (new and ongoing) 2001 – 2007, National Childhood Cancer Foundation (NCCF): Co-Chair CNS Strategy Committee, Children’s Oncology Group (N.H.) Salary award ~ $20,000.00/yr. National Cancer Institute of Canada (With Seuntjens, J. (PI), Verhaegen, F., Shenouda, G. and Podgorsak, E.) Monte Carlo-based modulated electron beam inverse treatment planning and delivery. $61,960/year operating grant 49
  • 50. Department of Oncology Annual Report 2006/2007 3. Construction of major facilities or major equipment grants As Head of Radiation Oncology at the MUHC, I have been responsible for the acquisition of major new equipment including cone beam imaging for brachytherapy and Tomotherapy. 4. Research Training: undergraduate students, graduate students, postdocs/fellows I have supervised research projects of medical students and trainees in Radiation Oncology at McGill and at the U of M. 5. Scientific Reviews: Editorial Boards and Journal Reviews Editorial Boards 1987 - present Associate Editor, International Journal of Radiation Oncology, Biology and Physics 1999 – 2006, Member, Editorial Board, Journal of Neuro-Oncology 2004 – present, Member, Editorial Board, Pediatric Blood and Cancer Ad hoc Reviews Frequent: (8-10 each /year) International Journal of Radiation Oncology Biology Physics Pediatric Blood and Cancer Occasional: (1-3 each/year) American Journal of Pediatric Hematology Oncology Cancer Clinical Oncology European Journal of Cancer Expert Opinion in Oncology International Journal of Pediatric Hematology-Oncology Journal of Clinical Oncology Journal of Neuro-Oncology Radiotherapy and Oncology Very occasional: (0-1 each /year) Annals of the RCPSC 50
  • 51. Department of Oncology Annual Report 2006/2007 Canadian Medical Association Journal Clinical and Investigative Medicine Expert Review of Neuro-therapeutics Journal of the Canadian Association of Radiologists Lancet Oncology Radiology GRANT REVIEWS Panel Member: 2007 Member, Clinical trial/companion studies panel. Ontario Institute for Cancer Research Ad Hoc Grant Reviews 2006 Ad hoc reviewer, National Cancer Institute of Canada 2006 Ad hoc reviewer, Cancer Research UK x 2 2006 Ad hoc reviewer, Pediatric Brain Tumor Consortium NIH 6. Invited Presentations and Workshops (National and International) “Radiotherapy for pediatric brainstem gliomas.” Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, MD, May 2006. Guest lecture. “The Children’s Oncology Group CNS studies: strategy, progress and plans for the future.” Annual meeting of the National Cancer Research Institute. Birmingham, England, October 2006. Canadian Radiation Oncology Resident review course. “Paediatric CNS Tumours.” Montreal, January 2007. 7. Hospital Activities Administrative work McGill 51
  • 52. Department of Oncology Annual Report 2006/2007 1979 – present, Chair, McGill University, Department of Radiation Oncology Hospital 1979 – present, Radiation Oncologist-in-Chief, Montreal General Hospital and Royal Victoria Hospital (now the McGill University Health Centre) 2000 – present, Co-Chair, Tumor Board, Montreal Children’s Hospital Member of Hospital Committees (1995 onwards) 1978 – present, Member, Tumor Board, Montreal Children's Hospital 1979 – present, Member, Radiation Safety Committee, Montreal General Hospital/McGill University Health Centre 1979 – present, Member, Medical/Clinical Advisory Committee, Montreal General Hospital/McGill University Health Centre 1995 – present, Member, Fast Bequest Advisory Committee, Montreal General Hospital 2002 – present, Member, Oncology Quality Improvement Committee, McGill University Health Centre 2003 – present, Member, Selection Committee for Head of Pediatric, Oncology, McGill University Health Centre 2004 – present, Member, Medical Advisory Committee, Cedars Cancer Institute 2006 – present Member, Search Committee for Head of Diagnostic Imaging, Montreal Children’s Hospital 8. National and International Committees Note that I am co-chair of the Children’s Oncology Group CNS Strategy Committee 2001 - present Co-Chair, Brain Tumor Strategy Committee, Children’s Oncology Group Member of the Board of Directors of the Quality Assurance Review Centre 2003 - present , Member, Board of Directors, Quality Assurance Review Centre, Rhode Island (NIH funded) Member of the Data Monitoring and Safety Committee of two international studies, SIOP PNET-4 and UKCCSG Study for LGG 2003 - present Member, Data Monitoring and Safety Committee, SIOP PNET - 4 2003 – present Member, Data Monitoring and Safety Committee, UKCCSG Study on Low Grade Gliomas 52
  • 53. Department of Oncology Annual Report 2006/2007 2005 – present Associate Editor, Perez: Principles and Practice of Radiation Oncology 5th edition Administrative responsibilities at McGill as Co-Chair of the McGill MUHC Tele- oncology Committee Work with government 1999 – 2006, Chair, Comité de radio-oncologie, Ministère de la Santé et des Services Sociaux 2003 – 2006, Membre, Comité des équipes interdisciplinaires de lutte contre le cancer 2005 – 2006, Membre, Comité de direction, Direction de la lutte contre le cancer, MSSS 2005 - present Membre, Groupe conseil de lutte contre le cancer, MSSS 2006 – present Membre, Comité d’évaluation de la mise en oeuvre des équipes interdisciplinaires de lutte contre le cancer, MSSS Involvement in activities of professional associations 2004 - present Member, Manpower Committee, Canadian Association of Radiation Oncologists 2005 – present, Member of Board of Directors, Pediatric Radiation Oncology Society 9. Involvement in continuing education activities “Radiotherapy in the treatment of sarcomas.” Oncology Level 2 course. McGill University Health Centre. January 2006. “Advances in radiotherapy: reducing the morbidity of treatment.” McGill Thursday Evening Lecture Series. February 2006. 10. Involvement in the community 2003 – present, Chair, Medical Advisory Board, Sarah Cook Fund 1979 – present, Chair, Radiotherapy Advisory Committee, Radiotherapy Technology Training Program, Dawson College Bruno Gagnon 1. Summary of New and Ongoing Research • 2001-present. Member, End-of-Life, Health Services National Research Group. • 1999-present. Member, Research Group on Cancer Pain Classification, NCIC, CTG, NCRN Supportive Care Project. 53
  • 54. Department of Oncology Annual Report 2006/2007 • 1998-present. Membre, Comité Oncologie-Soins Palliatifs, Axe clinique Réseau FRSQ de Recherche en Éthique Clinique. 2. Research grants (new and ongoing) • Étude de faisabilité pour le traitement du delirium hyperactif chez les patients atteints de cancer avancé par l’haloperidol à dose différentielle. PI: P. Gagnon, Co-Investigator : B. Gagnon, CIHR, 2007-present. $20,000. • Étude de faisabilité pour le traitement du delirium hypoactif: Metylphenidate ou Risperidone. PI: P. Gagnon, Co-Investigator: B. Gagnon, CIHR, 2007-present. $20,000. • A Phase II study of methadone as a first line agent in the treatment on neuropathic pain. PI: B. Gagnon, National Cancer Institute of Canada (NCIC) 2007-present. $120,000. • Patterns of care during the last six months of life of patients dying of cancer. PI: B. Gagnon, CIHR: Operating Grant, 2004-2008. $411,610. • Les différents profiles de soins reçus par les patients mourant du cancer durant les six derniers mois de vie : une étude basée sur des banques de données administratives. PI : B. Gagnon, Fonds de la recherche en santé du Québec (FRSQ) 2004-present. $30,000. • Characterizing cognitive failure, physical retardation and hypo-active delirium in advanced cancer patients: A Pilot Project. PI: B. Gagnon, CIHR: Palliative and End of Life Care: A Pilot Project. 2004-2007. $80,160. • Depression in acute-stroke survivors and their caregivers: Foundational work on prevalence, time course and impact on function and quality of life. PI: SB Miller, Co-Investigator: B. Gagnon, Heart and Stroke Foundation of Canada. 2004-2007. $240,260. • An International Multicentre Validation Study of a Pain Classification System for Advanced Cancer Patients. PI: R. Fainsinger, Co- Investigator: Bruno Gagnon, CIHR. 2004-2006. $96,553. • A multicomponent intervention to prevent delirium in terminally ill cancer patients. PI: P. Gagnon, Co-Investigator: B. Gagnon, ResearchGrants National Cancer Institute of Canada (NCIC) 2000- 2006. $57,543. 3. Scientific Reviews: Editorial Boards and Journal Reviews • Editorial Board Member, The Open Clinical Cancer Journal(March 2007 – present) • Member, Advisory Board of Medicina Paliativa (July 2005 – present) • Ad hoc review, European Journal of Cancer (March 2005 – present) 54
  • 55. Department of Oncology Annual Report 2006/2007 • Ad hoc review, Journal of Pain and Symptom Management (May 2004 – present) • Ad hoc review, Supportive Care Therapy (September 2004 - present) • Ad hoc review, Journal of Palliative Care (June 2001- present) • Ass. Editor, Palliative Care, Pain Research & Management (June 1999 - present) 4. Research Advisory Work for National and International Organizations: • Fonds de la recherche en santé Québec - Ad hoc review. • National Cancer Institute of Canada - Ad hoc review. • Canadian Institutes of Health research - Ad hoc review. 5. Peer-Reviewed Abstracts • MacDonald N, Kasymjanova G, Agulnik J, Pepe C, Kreisman H, Cohen V, Sharma R, Gagnon B, Small D. Influence of baseline inflammatory markers on the response to first line chemotherapy in advanced NSCLC. Submitted to ECCO Meeting in Barcelona, Spain. September 2007. 6. Hospital Activities • 1998-present. Attending Staff - Department of Medicine, Division of Medical Oncology and Palliative care service, and Division of Clinical Epidemiology (2003) - McGill University Health Center, Montreal, QC. • 1996-2007. Affiliated Physician Emergency Department - Jean Talon Hospital, Montreal, QC. 7. Involvement in continuing education activities • Continuing Medical Education program, The Next Step in Pain Management - sponsored through an educational grant from Paladin Labs. April/May 2007. • Souper-Conférence, Methadone en soins Palliatifs - Organisé par le comité d’éducation continue de La maison de soins palliatifs de la Rivière-du-Nord en association avec la compagnie Paladin. St. Jerome, Québec, 10 Mai, 2007. Jacques Galipeau 1. Research Dr. Galipeau’s laboratory has been very active in developing regenerative medicine on a Regional, National and International scope. From a regional perspective, Dr. Galipeau has consolidated a collaborative link with the CHU Mere-Enfant (Ste-Justine Hospital) 55
  • 56. Department of Oncology Annual Report 2006/2007 and the Université de Montreal school of Veterinary Medicine with a major FRSQ grant exploring the use of gene-engineered cells for therapy of haematological disorders: 2007-2010 Programme Hémovigilance FRSQ Regroupement stratégique québécois pour la recherche et le développement de la thérapie cellulaire et génique pour les maladies hémovasculaires. $900,000 over 3 years. Principal Investigator : J. Galipeau On a national perspective, Dr. Galipeau plays a major leadership role within the Canadian Stem Cell Network as therapeutics theme leader and he leads a major collaborative effort between McGill, UHN, UOttawa and UBC in Cardiovascular regenerative Medicine: 2004-2009 Regenerative Medicine and Nanomedicine: Innovative Approaches in Health Research - New Emerging Team Grant Program. (CIHR RMF 72553). Cardiovascular and Respiratory Stem Cell Plasticity – CARE project. $1,500,000 over 5 years. Principal Investigator: J. Galipeau. The LDI and UHN are participating in an industry-sponsored cell therapy study investigating the use of gene-engineered autologous endothelial progenitor cells for treatment of pulmonary hypertension. The first such patient treated outside of Toronto will be cared for at the JGH in May 2007. Our international outreach in cellular therapeutics takes place at the basic research level as highlighted by a recent major award from the Roche Foundation for Anemia Research: 2007-2010 Roche Foundation for Anemia Research - RoFAR Cell and Gene Therapy with Erythropoietin-Secreting Marrow Stem Cells for Kidney Repair. $750,000 over 3 years. Principal Investigator: Dr. N. Eliopoulos and J. Galipeau (co-applicant). Dr. Galipeau is also a lead organizer for the 1st Quebec/New Jersey Stem Cell Workshop (June 4-5 2007)to be hosted at the MNI and sponsored by McGill University and the Canadian Stem Cell Network. 2. Teaching activities McGill Graduate Courses - Lecturer Gene transfer to hematopoietic stem cells. Physiology of Blood graduate course: 516 B - Dept of Physiology, McGill University - Course Coordinator Premsyl Ponka, Ph.D. Cancer Gene Therapy. Graduate course – Experimental & Clinical Oncology Course 516-635D, Course Coordinator Wilson Miller. Cancer Gene Therapy. Graduate course – Cellular and Applied Immunology Course PHGY 513B, Course Coordinator Julie Desbarats. 2006 McGill Undergraduate Courses - Lecturer Gene Therapy. Undergraduate Medical School course (McGill University), Unit 8: Pathobiology, Prevention and Treatment of Disease - INDS 208A. Department of Medical Genetics 56
  • 57. Department of Oncology Annual Report 2006/2007 A Conceptual Approach to Hematological Malignancies. Undergraduate Medical School course (McGill University), Unit 5: Hematological and musculoskeletal systems – INDS 102. Department of Medicine Clinical Teaching Ward Attending, Clinical Teaching Unit (Internal Medicine): SMBD-JGH: 2 weeks in November 1998; 3 weeks June 2006. “Gammopathies” seminar given at the McGill Faculty of Medicine 57th Annual Refresher Course for Family Physicians (November 27th 2006) 3. Clinical activities 3 weeks CTU 1 clinic day a week Vincent Giguère 1. Summary of ongoing research Our group studies the roles played by members of the superfamily of nuclear receptors in physiology and diseases. We have four funded research programs dedicated to 1) understand the molecular mechanisms by which nuclear receptors control gene expression; 2) explore the action of nuclear receptors at the level of the genome using functional genomics as a tool; 3) study the role of the orphan nuclear receptor ERRα in breast cancer; 4) study the role of the retinoic acid receptor β in breast cancer. 2. Research grants Canadian Institutes for Health Research Molecular and genetic analysis of ERRα orphan nuclear receptor function in breast cancer P.I.: Dr. Vincent Giguère October 2006-September 2011 $1,030,015 (100%) Canadian Institutes for Health Research Transcriptional activities of orphan nuclear receptors ERR and ROR P.I.: Dr. Vincent Giguère October 2005-September 2010 57
  • 58. Department of Oncology Annual Report 2006/2007 $847,355 (100%) National Cancer Institute of Canada Terry Fox Foundation New Frontiers Program Project Grant Preclinical models and therapeutic targets for metastatic breast disease Program leader: Dr. Morag Park July 2006-June 2009 $3,090,778 (18%) Canadian Institutes for Health Research Genetic Analysis of Orphan Nuclear Receptors Functions P.I.: Dr. Vincent Giguère April 2002-March 2007 $998,020 (100%) 3. Construction of major facilities None, wrote a CFI with Drs. Batist and Richard, but was not funded. 4. Research Training Lillian Eichner M.Sc. Alexis Charest-Marcotte M.Sc. Josée Laganière Ph.D. Annie Tremblay Ph.D. Brian Wilson PDF 5. Scientific Reviews Editorial Boards Molecular Endocrinology American Journal of Physiology: Endocrinology and Metabolism Nuclear Receptors, a BioMedNet Central eJournal 58
  • 59. Department of Oncology Annual Report 2006/2007 Manuscripts reviewed for American Journal of Physiology Biochemica Biophysica Acta BMC Genomics Canadian Journal of Biochemistry and Cell Biology Cancer Research Endocrinology EMBO Journal EMBO Reports Genes & Development Gynecologic Oncology Journal of Clinical Endocrinology and Metabolism Molecular and Cellular Biology Molecular Cell Molecular Endocrinology Nature Genetics Oncogene PLoS Genetics Proceedings of the National Academy of Sciences of the USA Grant review Canadian Institute for Health Research Molecular and Cellular Biology of Cancer (MCC Panel) Member National Institutes of Health Study Section Molecular and Cellular Endocrinology (MCE) Invited Member 59
  • 60. Department of Oncology Annual Report 2006/2007 6. Research Advisory Work External scientific advisor to the National Institute of Health (NIH) for a Program Project entitled "Functional Atlas of Orphan Nuclear Receptors" directed by Drs. Bert O’Malley, Baylor College of Medicine, Houston TX, and Dr. Ronald M. Evans, The Salk Institute for Biological Studies, La Jolla, CA (2002-present). Member, subcommittee of the International Union of Pharmacology for the data base and nomenclature of the nuclear receptor family and associated proteins (2005-present). 7. Conference Organization Chair, Organizing Committee, Keystone Symposia on Nuclear Receptors: Orphan Brothers, Banff, Alberta, March 2006. 8. Invited presentations February 2006. Endocrine Grand Round, Jewish General Hospital, Montreal, Québec, Canada. March 2006. Chairman of the meeting and Speaker, Keystone Symposia on “Nuclear Receptors: Orphan Brothers”, Banff, Alberta, Canada. April 2006. Invited speaker, 9th Conference entitled Frontiers in Nuclear Receptor Action, Florida, USA. May 2006. Research Institute Seminars, Montreal Children’s Hospital, Montreal, Quebec, Canada. September 2006. Invited speaker, 25th International Association of Breast Cancer Research Congress, Montréal, Québec, Canada. September 2006. Invited speaker, 1st Annual Conference on Molecular Mechanisms of Tumorigenesis, McGill Cancer Centre/Weizmann Institute of Science, Montreal, Québec, Canada. 9. Hospital activities Member of Studentship/Fellowship Award Committee of the MUHC Phil Gold 1. Research Responsible for Office for Clinical Research, MUHC. 60
  • 61. Department of Oncology Annual Report 2006/2007 2. Committee Participation Advisory Editorial Board, Cancer Metastasis – Tumor Biology Deputy Editor, Current Oncology Grant Panels Chairman of the Board, Burroughs Wellcome Fund (2006 – present), 3. Invited Talks and Conference Presentations Numerous talks, invited and given inside and outside of Canada on medical research, clinical medicine and medical teaching. 4. Providing academic expertise to the Montreal/Quebec/Canadianand international communities: - CEGEPS and schools - general public and media - industry, professional and business communities -charitable and non-profit based organizations Philip Gordon 1. Summary of New and Ongoing Research Hereditary Colorectal Cancer: the French Canadian Mutation Spectrum. Underexpression of mineralocorticoid receptor in colorectal tumors: an early event in cancer progression. 2. Research Training: undergraduate students, graduate students, postdocs/fellows Francesco DiFabio 3. Scientific Reviews: Editorial Boards and Journal Reviews BUPA Foundation: The Medical Research Charity, Grant Reviewer – 2006 – present Canadian Institutes of Health Research, Grant Reviewer – 2007 61
  • 62. Department of Oncology Annual Report 2006/2007 4. Invited Presentations and Workshops (National and International) Invited Participant. 37ieme Congrès Annuel Association Quebécoise de Chirugie Panelist on Clinical case presentations. Gatineau Que. May 25-28, 2006. Invited Participant. Cours de chirugie colorectal par laparoscopy. Montreal, Quebec June 16-17, 2006. (1) Update in laparoscopic treatment of colorectal cancer (2) Complications during the learning curve Invited Participant as Chair. State of the Art lecture – Digestive Disease Week. Washington DC May 19-24, 2007 “Development of the Embryonic Gastrointestinal Tract” 5. Hospital Activities Surgical Policy Committee - 1988 - present Surgical Operating Room Committee - 1989 - present Finance Committee Department of Surgery 1995 - present Credentials Committee - 2000 – present Operating Room Renovation Committee - 2001 – present Comprehensive Cancer Center Screening Committee – 2001-present Director, Division of Colon and Rectal Surgery Director, Clinical Teacing Unit Vice Chairman, Department of Surgery 6. Involvement in the community CBC - TV Colossal Colon Colorectal Cancer Awareness Event to inform public of importance of disease - Sept 15, 2005 – Interviewer – Gerri Barrer Radio Shalom – Medical Minutes – Colorectal Cancer. What is it? And What Do We Do About It? – Nov 28, 2006 – Interviewer – Dr. David Sinclair Laugh Attack XM153 satellite radio – Foreign Bodies of the Rectum. Feb 5, 2007. Interviewer – Mike Bullard CKRK 103.7 FM Radio. The value of screening for colorectal cancer. Apr 8, 2007 Interviewer – Joseph Cross 62
  • 63. Department of Oncology Annual Report 2006/2007 Walter Gotlieb 1. Collaborative Research Projects Within or Outside of McGill Reverse-phase protein microarrays for the validation of novel tumor markers and post- translational modified proteins in serum and other biological fluids from cancer patients. Genome Quebec, Consortium Project. Pre-clinical evaluation of novel drug candidates targeting the Insulin like growth factor receptor pathway. Collaboration with Dr. M. Pollak. Intraperitoneal chemotherapy for patients with advanced ovarian cancer: A review of the evidence and standards for the delivery of care. Collaboration with the society of Gynecologic Oncologists of Canada HPV related vulvar intraepithelial neoplasia: outcome of different management modalities. Collaboration with pathology laboratory Insulin-like growth factor I and risk of high grade cervical intraepithelial neoplasia. Collaboration with Epidemiology Department McGill. A clinical trial to evaluate endometrial cancer biomarker changes following exposure to the Insulin Sensitizer Metformin in Collaboration with Dr. M. Pollak Sources of Distress in Women with Ovarian or Uterine Cancer and the Strategies that are Supportive to them in Coping with Newly Recurrent Disease. In collaboration with the school of nursing at McGill Hélène Deutsch, M.Sc. Meaning-Making intervention in people newly diagnosed with advanced ovarian cancer. In collaboration with Melissa Henry, Department of Psychology, McGill University Clinical research protocols as part of the McGill Oncology Women Cancer Group. International Activities Clinical outcome of cystectomy compared with unilateral salpingo-oophorectomy as fertility-sparing treatment of borderline ovarian tumors. Collaboration with Gynecologic Department Tel Aviv University Sheba Medical Center Doxorubicin levels in the serum and ascites following intravenous administration in patients with ovarian cancer. Collaboration with the Norvegian Karolinska Institute. Malignancies following bilateral salpingo-oophorectomy. Collaboration with Genetics Department at Tel Aviv University Sheba Medical Center Importance of accurate preoperative diagnosis in the management of aggressive angiomyxoma: report of three cases and review of the literature. Collaboration with Gynecologic Department Tel Aviv University Sheba Medical Center 63
  • 64. Department of Oncology Annual Report 2006/2007 2. Hospital Activities Clinical Activities Fellowship program in Gynecologic Oncology 3. Conferences Organized Organizing committee for the Regroupement des gynécologues oncologues du Québec meeting, St-Anne Québec, March 2007 Council member involved in the supervision for the annual meeting of the Society of Gynecologic Oncologists of Canada, Vancouver June 2006 and for the continuous medical education meeting of the Society of Gynecologic Oncologists of Canada, Toronto, April 2007. 4. Referee for International Journals Acta Cytologica Analytical and Quantitative Cytology and Histology Annals of Oncology Cytokine European Journal of Surgical Oncology Gynecologic Oncology International Journal of Gynecologic Cancer Journal of Reproductive Medicine Obstetrics and Gynecology 5. Involvement in Continuing Education Activities Fertility preserving surgery in tumors of low malignant potential, Society of Obstetrics and Gynecology, Vancouver June 2006 CIN and glandular lesions. Congrès Franco-Canadien de Cancérologie, Montreal September 2006 Ovarian tumors and treatment. Congrès Franco-Canadien de Cancérologie, Montreal September 2006 Symptom management and pathology of ovarian cancer. Multidisciplinary oncology residency education. Montreal Nov 2006 64
  • 65. Department of Oncology Annual Report 2006/2007 Cervical Cancer and HPV. Rural multimedia web presentation. Quebec Feb 2007 GOC membership survey, Continuous Professional Development meeting. Toronto April 2007 Lower genital dysplasias. Association des Obstetriciens Gynecologues du Quebec 41st Conference, Sherbrooke, May 2007 6. Committees Vice President Association des gynécologues oncologues du Québec Member of the Oncology Committee Association of Obstetricians and Gynecologists of Quebec NCIC McGill representative for gynecologic cancers Council member of the Society of Gynecologic Oncologists of Canada 7. Media reports July 2006: 7 jours journal : Un Médecin vous répond article Sept 2006: 7 jours journal : Un Médecin vous répond article Sept 2006 : Ovarian Cancer Canada Yearly Breakfast Session Sept 2006: National Ovarian Cancer Walk of Hope Address Oct 2006 : Turqwise event, Montreal Nov 2006 : It’s a girl Thing Brunch, Montreal Nov 2006 : CTV television interview Dec 2006: Pink Lady Fund, Women of Action Brunch, Montreal Dec 2006: 7 jours journal : Un Médecin vous répond article Feb 2007 : On S’en Parle, Montreal Annette Herscovics 1. Summary of New and Ongoing Research Dr. Nobuko Hosakawa, Institute for Frontier Medical Sciences, Kyoto University, Kyoto, Japan Dr. Lynne P. Howell, Hospital for Sick Children, Toronto Dr. Gerardo Lederkremer, Department of Cell Research and Immunology, George Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel 65
  • 66. Department of Oncology Annual Report 2006/2007 Dr. Albert Berghuis, Dept. of Biochemistry, McGill University 2. Research grants (new and ongoing) National Institutes of Health, US Public Health Service - A. Herscovics, P.I. Mannoprotein biosynthesis in Saccharomyces cerevisiae.- GM 31265-24: 04/01/06 – 03/31/07 USD 250,615 GM 31265-25 04/01/07 – 03/31/08 USD 250,505 CIHR - A. Herscovics, P.I. Mechanisms of glycoprotein biosynthesis – role of mammalian Class I mannosidases. Grant MOP-74714: 01/04/06 – 31/03/07 131,073 01/04/05 – 31/03/06 104,858 3. Research Training: undergraduate students, graduate students, postdocs/fellows Dmitry Rodionov, Graduate student, Department of Biochemistry 4. Scientific Reviews: Editorial Boards and Journal Reviews Member of Editorial Board, Glycobiology Reviewer for misc journals (I don’t keep track) 5. Research Advisory Work for National and International Organizations NIH, National Cancer Institute Special Emphasis Panel to review: “Alliance of Glycobiologists for Detection of Cancer and Cancer Risk” NIH, National Institute of General Medical Sciences Special Study Section to review glue grant: “The Consortium for Functional Glycomics” NIH, National Heart, Lung and Blood Institute, Special Study Section to review Program Project: “Genetic modulation of blood and vascular glycosylation” 6. Peer-Reviewed Abstracts Lobsanov, YD, Yoshida, T, Desmet, T, Nerinckx, W, Herscovics, A, Howell, P.L. Possible mechanism of regulation of activity in Class I α1,2-mannosidases : structure of a fungal a1,2-mannosidase in complex with a substrate analog. XXIIIrd International Carbohydrate Symposium. Whistler, Canada 2006. 66
  • 67. Department of Oncology Annual Report 2006/2007 Rodionov, D, Romero, PA and Herscovics, A. Production of recombinant yeast mannosyltransferase complex M-Pol I. Society for Glycobiology, Los Angeles 2006. 7. Involvement in the community Member of I Medici di McGill Vera Hirsch 1. Summary of New and Ongoing Research • Clinical research in metastatic NSCLC = many new trials, international 2. Research grants (new and ongoing) • Roche fund, $22,500, for locally-advanced NSCLC treatment (SAIL); • Amgen fund, $130,000, for pilot study on predictive markers (genetic) in NSCLC; • Sanofi-Aventis fund, $43,017.00, for study of efficacy and safety of AVE0005 (VEGF Trap); • Millennium fund, $174,000 for Tarceva vs. Tarceva/Velcade study in NSCLC; • Pfizer fund, $99,645 for PF 676 study, 1st line, in advanced NSCLC. 3. Research Training: undergraduate students, graduate students, postdocs/fellows • Two students studying for "Diploma in Clinical Research" Program 4. Scientific Reviews: Editorial Boards and Journal Reviews • Reviewer of following journals: Cancer, Lung Cancer, Clinical Lung Cancer, Canadian Medical Association Journal, Annals of Oncology, Therapy 5. Research Advisory Work for National and International Organizations • Advisory boards of: AstraZeneca, Roche, Eli-Lilly, Amgen, Abraxis 6. Conference Organization • Organizer, International Lung Cancer Forum (Australia), March 2007 7. Invited Presentations and Workshops (National and International) • Faculty member/speaker, 2nd International Meeting on Radical Treatment of Lung Cancer, London, UK (July 2006); 67
  • 68. Department of Oncology Annual Report 2006/2007 • Faculty member/speaker, 3rd International Conference on Molecular Targeted Therapy in Lung Cancer (IASLC), Taormina, Sicily (November 2006); • Faculty member/speaker, 7th Annual Targeted Therapies of the Treatment of Lung Cancer (IASLC), Santa Monica, California (February 2007); • Speaker, International Lung Cancer Forum - Improving Outcomes in the Management of Lung Cancer, Gold Coast, Brisbane, Australia (March 2007); • Faculty member/speaker, 8th International Lung Cancer Congress, Wailea, Maui, Hawaii (June 2007). 8. Peer-Reviewed Abstracts • Hirsh V, Duclos M, Souhami L, Del Vecchio P, Ofiara L, Faria S, Ayoub JP, Charpentier D, Portelance L, and Soulieres D: A Phase II Trial with Carboplatin/Gemcitabine Induction Chemotherapy Followed by Radiotherapy Concomitantly with Paclitaxel/Gemcitabine in Stage III Non Small Cell Lung Cancer (NSCLC). 42nd ASCO Annual Meeting, Atlanta, Georgia, June 2-6, 2006. POSTER Abstract # 7139. • Berruti A, Dogliotti L, Tampellini M, Lipton A, Hirsh V, Saad F, Liati P, Shirina N, and Cook R: Effect of Zoledronic Acid Treatment Based on Serum Parathyroid Hormone Levels in Patients with Malignant Bone Disease. 42nd ASCO Annual Meeting, Atlanta, Georgia, June 2-6, 2006. POSTER Abstract # 8610. • Matczak E, Hirsh V, Lipton A, Cook RJ, Langer C, Hei YJ, and Major P: Effects of Zoledronic Acid on Survival in Patients with Lung Cancer and High Baseline N-Telopeptide (NTX) levels: Stratified by Baseline Bone Alkaline Phosphatase (BALP). 42nd ASCO Annual Meeting, Atlanta, Georgia, June 2-6, 2006. POSTER Abstract # 7228. • Manegold C, von Pawel J, Zatloukal P, Ramlau R, Mezger J, Hirsh V, Leighl N, Gorbunova V, Archer V, Reck M, and the BO17704 Study Group: Randomized, Double-Blind, Multi-Centre Phase III Study of Bevacizumab in Combination with Cisplatin and Gemcitabine in Chemotherapy-Naïve Patients with Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer (NSCLC): BO17704. 43rd ASCO Annual Meeting, Chicago, Illinois, June 1-5, 2007. ORAL Abstract # LBA7514. • Lynch TJ, Fenton DW, Hirsh V, Bodkin DJ, Middleman E, Chiappori A, Halmos B, Liu H, Eton O, and Shepherd WF: Randomized Phase II Study of Erlotinib Alone and in Combination with Bortezomib in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC). 43rd ASCO Annual Meeting, Chicago, Illinois, June 1-5, 2007. POSTER Abstract # 7680. 68
  • 69. Department of Oncology Annual Report 2006/2007 • Major P, Hirsh V, Lipton A, Cook RJ, Langer C, and Shirina N: Zoledronic Acid May Improve Survival in Lung Cancer Patients with High Baseline Bone Marker Levels. 31st ESMO Congress, Istanbul, Turkey, September 29 – October 3, 2006. POSTER DISCUSSION Abstract # 739. • Saad F, Hirsh V, Rosen L, Aapro M, and Chen Y-M: Continuing Benefit of Zoledronic Acid in Patients With Bone Lesions From Multiple Myeloma, Breast Cancer, or Prostate Cancer Who Are At High Risk for Skeletal Complications. 6th International Meeting on Cancer Induced Bone Disease, San Antonio, Texas, December 10-14, 2006. POSTER Abstract # 130. • Saad F, Hirsh V, Rosen L, Aapro M, Chen Y-M: Continuing Benefit of Zoledronic Acid in Patients with Bone Lesions from Multiple Myeloma, Breast Cancer, or Prostate Cancer Who Are At High Risk for Skeletal Complications. 20th International Symposium of the Multinational Association of Supportive Care in Cancer (MASCC), St Gallen, Switzerland, Europe, June 28-30, 2007. POSTER Abstract # 97. 9. Hospital Activities • Lecturer, Radiation Oncology Rounds, MGH, (October 2006); • Teacher/Trainer, Preceptorship, Hoffman-LaRoche, MGH, (December 2006); • Teacher/Supervisor, Introduction to Clinical Medicine (ICM) students, RVH, (February 2007 to June 2007); • Teacher/Supervisor, Visitors Rotation Program, MGH, (September 2006 to June 2007); • Teacher/Supervisor, Radiation Oncology Residency/Fellowship Program, MGH, (September 2006 to June 2007); • Teacher/Supervisor, Introduction to Clinical Medicine (ICM) students, MGH, (February 2007 to June 2007); 10. Involvement in continuing education activities • Consultant , Development of CHESTMATE Program (Eli-Lilly); • Lecturer/Presenter, Lung Speaker Training Program (OrthoBiotech); • Lecturer/Presenter, Clinical & Experimental Oncology Ph.D. Course # 516- 635D, McGill Faculty of Medicine; • Lecturer/Presenter, Multidisciplinary Oncology Residents Education (MORE), McGill Department of Oncology; • Moderator/Chairperson, Safety Update of ESA’s (OrthoBiotech); • Participant/Consultant, New Evidence in Oncology, ASCO Newsletter; 69
  • 70. Department of Oncology Annual Report 2006/2007 • Participant, AZ Oncology Network of Experts (E-One), Online Forum Meeting & Discussion Sessions; 11. Involvement in the community • Media Training, PF-676 Vaccine, Pfizer Global (June 2007) • Media Training, CERA publication, Hoffman-Roche Global (February 2007) Thomas Hutchinson 1. Research Grants New and Ongoing Qualitative Study on "Living with end-stage renal disease (ESRD): multiple perspectives on patients’ suffering and healing." Allied Health Research Grant awarded by the Kidney Foundation of Canada, April 2006 ($85,000). Ongoing. PI: Dr. Tom Hutchinson; Co- applicants: Dawn Allen, Steve Jordan, Antonia Arnaert, Paul-Eugene Barré, Murray Vasilevsky, Mark Lipman, Johana Eid - $85,952 (July 2006-June 2008). 2. Education Activities Hutchinson. Introduction to Clinical Medicine, “Communication Skills”, May 2006. Hutchinson. One half-day teaching session to pastoral care students, July 2006. Hutchinson. MUHC Medical residents. Post-graduate Core Competencies. Small groups. September 12, 2006. Hutchinson. Lecture to Nursing Students (Dr. Arnaert’s Chronic Illness & Palliative Care class). “Healing, a Healthcare Revolution: Opportunities at the Bedside.” February 16, 2007. Hutchinson. Concordia University. Dr. P. O’Rourke’s Religion and Healing course. “Healing, a Healthcare Revolution: Opportunities at the Bedside.” February 26, 2007. Integration of material based on “Healing and the Art of Medicine” into Physician Apprenticeship Program for second year medical students. Hutchinson, Small group teaching re. palliative care to medical students, ongoing. Hutchinson, Small group teaching to medical students re. Physician Apprenticeship, ongoing. Hutchinson, Small group teaching to medical students re. ICM Communication Skills. Hutchinson T, Dobkin, P. Design of an 8-week program for health care professionals based on the Mindfulness Based Stress Reduction Program developed by Jon Kabat-Zinn and colleagues at the University of Massachusetts. First program offered to physicians April 20 – June 8, 2007. (Accredited for 20 CME hours) 70
  • 71. Department of Oncology Annual Report 2006/2007 Curricular Change Participation with Associate Dean Donald Boudreau in a Faculty of Medicine revision of curriculum. Design of “Physicianship IV” program for Med 3 students, to commence August 2007 (Hutchinson and McNamara). 3. Congress Organization Organization of a full-day seminar: Healing, a Healthcare Revolution: The Challenge, the Opportunities for Caregivers. (Affiliated with the 16th International Congress on Care of the Terminally Ill). Attendance: 330. Organizing Committee: 17th Annual Congress on Care of the Terminally Ill scheduled for September 2008. 4. Presentations Invited Presentations and Workshops (National and International) Hutchinson T. “Aequanimitas for the 21st Century.” McGill Pain Centre Rounds. MUHC. May 31, 2006. Hutchinson T. “Healing and the Practice of Medicine.” McGill Alumni Event, Toronto. June 9, 2006. Hutchinson T. “Healing, a Healthcare Revolution: The opportunities at the bedside.” September 26, 2006. Hutchinson T. Nephrology Rounds. “Palliative Care in the Dialysis Unit: An overview for the diehard nephrologist.” MUHC, March 23, 2007. Hutchinson T. McGill Seminars on Healing. “Longing for Virginia: Satir’s Genius for Healing.” April 27, 2007. 5. Hospital Activities Dr. Hutchinson continues to practice as a palliative care physician (50%) with the McGill University Health Centre. 6. Public Education McGill Seminars on Healing May 2, 2006. The Interconnectedness is Already There. Michael Kearney. September 25, 2006, Soul Pain, Fear and Healing at the End of Life. Michael Kearney. October 27, 2006, Humour in Medicine. Manuel Borod, MUHC. November 24, 2006, Whole Health: Making the Connections. Steve Sims, Padua Centre, Montreal. 71
  • 72. Department of Oncology Annual Report 2006/2007 December 15, 2006, Healing and the Artistic Process. Garry Beitel, Filmmaker (The Man Who Learned to Fall). January 26, 2007. Dr. Neil MacDonald and Dr. Martin Chasen. McGill’s Cancer Nutrition and Rehabilitation Program. February 23, 2007. Dr. David Kuhl. Physician Self-Care. April 27, 2007. Dr. Tom Hutchinson. Longing for Virginia: Satir’s Genius for Healing. May 25, 2007. Dr. Marc Laporta. Emotions and Empathy: Music as a Vehicle. Film Series May 2, 2006: ‘Ram Dass: Fierce Grace’ (Michael Kearney, physician) June 6, 2006: ‘How’s Your News?’ (Lisa Walsh, singer) September 19, 2006: Flight From Death (Bal Mount, physician) October 17, 2006: Bonjour, Shalom (Garry Beitel, filmmaker) November 28, 2006: To a Safer Place (Beverly Shaffer, filmmaker) December 12, 2006: Gap Toothed Women (Garry Beitel and Steve Sims) January 16, 2007. “Doing Time, Doing Vipassana.” With guest discussants Dr. John Seely and Dr. George Poland. February 13, 2007. “Joseph Guinta: A Silent Triumph.” With guest discussants Pepita Ferrari (filmmaker) and Dr. Howard Chertkow. March 6, 2007. “This Beggar’s Description.” With guest discussants, Philip and Pierre Tetrault. April 17, 2007. “Born Into Brothels.” With guest discussant: Twinkle Rudberg (Leave Out Violence) May 15, 2007. “Murderball.” Other Activities Organization of a Reflective Practice Seminar for physicians, June 13, 2006. Sharyn Andrews & Ron Smith. “Practicing Medicine Mindfully: Cultivating Imperturbability and Equanimity”. A one day workshop for physicians: An introduction to mindfulness in Medicine. Dr. Hutchinson & Dr. Dobkin. December 1, 2006. 18 physicians participated. “Practicing Medicine Mindfully: Cultivating Imperturbability and Equanimity”. A one day workshop for physicians. Dr. Hutchinson & Dr. Dobkin, March 2, 2007. 72
  • 73. Department of Oncology Annual Report 2006/2007 Participation with GWISH (George Washington University): GWish Canadian Advisory Board on Spirituality and Health in Medical Education (Tom Hutchinson). Attendance at MBSR Research Conference: Integrating Mindfulness-Based Interventions into Medicine, Health Care, and Society, Worcester, Mass. March 2007. (Tom Hutchinson & Dawn Allen). Participation in the MUHC non-cancer palliative care group, Drs. Hutchinson & Allen. Stephen Liben 1. Summary of New and Ongoing Research Caregiving Parents of Children with Life-Limiting Illnesses: Beyond Stress & Coping to Growth. 2. Research grants Caregiving Parents of Children with Life-Limiting Illnesses: Beyond Stress & Coping to Growth. Principal applicant: Susan Cadell. Co-Applicants: S. Liben, H Siden, E Davies, R Steele, L Straatman, D Hemsworth. CIHR, Year 1 $ 101,318, year 2 $102,618, year 3 $59,510; 2006-2008. 3. Education and Training Residents: Dr C Phe IACS/Palliative care 2 months; Dr Catherine Audet Heme- Onc/Palliative care 3 months; Dr. G Rizzo - Anaesthesia/Palliative care Observership Pediatric Palliative Care –1st year P&OT Students McGill University –1 hr/yr. Faculty of Medicine Osler Fellow for Class of 2009. Approx 4hrs/month = 36hrs/year Course Director (27 hours direct instruction/yr): 4th Year Students Medicine & Society Seminar Course #inds-406) :” The doctor patient relationship” 2000 - present Introduction to the Patient (ITP) – 1st-2nd year medical students; Decision Making at the end-of-life for children. 2hours/yr. 2001 - present Invited discussant: Faculty of Religious Studies. McGill University. Director Dr Norman Cornett. Oct 2004, 2005, 2006, 2007 3 hrs/yr. Introduction to Pediatrics Course – 3rd year medical students, Small Group Leader. 14 hours/yr, 2003 - present Introduction to Pediatrics Course – 3rd year medical students: Yearly Lecturer: 4 hours/yr Pediatric Fluids and Dehydration. 1997 - present Communications Plus - Seminar Course – Final year medical students. Small Group Leader – Talking to Children About Death, 5 hours/year April 1999 – present 73
  • 74. Department of Oncology Annual Report 2006/2007 Seminar in Palliative Medicine – 3rd and 4th year medical students, Yearly Lecturer: Pain Management in Children, 4 hours/yr – 1997 - present Pediatric Clinical Clerks (3rd year students), Bimonthly Lecturer: Approach to the Critically Ill Child, 1-hour/2 months = 6 hrs/yr – 1997 - present Pediatric Residents – Protected teaching time workshop – Pediatric Palliative Care 2004 – present 2-4 hrs/yr. 4. Scientific Reviews Current Ad-Hoc Manuscript Reviews 2006 Pediatrics -2 manuscripts J of Palliative Care-1 manuscript J Palliative Medicine-1 manuscript Editorial Board Member The American Journal of Hospice and Palliative Care 5. Conference Organization International Congress on Care of the Terminally Ill 6. Invited Presentations and Workshops 2006 International Congress on care of the Terminally Ill – One day symposium Organizer and Chair – Keynote Speaker: 3rd International Cardiff Conference Paediatric Palliative Care June 2006, Progress in Palliation: Intervention or Interference? Cardiff, United Kingdom 7. Peer-Reviewed Abstracts Nadeau, L.; Johnson-Lafleur, J.; Liben, S.; MacDonald, ME.; Rousseau, C.; Polychronakos, C.; Perrault, J.; Lands, L. Treatment-compliance in chronically ill adolescents from cultural minorities. CACAP 26th Annual Meeting: November 2006, Toronto 8. Hospital Activities Ward attending – Medical wards 2-3 months/year, (4-5 medical students & 4-5 residents) Palliative Care Consultant – full time 74
  • 75. Department of Oncology Annual Report 2006/2007 Emergency Room Physician – 1 shift per month Carmen Loiselle 1. Summary of New and Ongoing Research I have initiated 7 projects this year: (1) International research collaboration with Dr. Brindha Sitaram, Bangalore India. The main goal is to collaborate on training young researchers in the area of psychosocial oncology and oncology nursing. We have set up a research curriculum, drafted a memorandum of understanding between COPER and McGill and PORT. We have also initiated a research project on distress among patients with cancer. We have applied to CIHR and McGill for our international collaboration. (2) Cross-university collaboration on Complementary and Alternative Medicine in cancer care; with UBC we are conducting a national survey on patients, health care providers and informal caregivers on their attitudes, beliefs, knowledge of CAM. (3) Research project with a faculty member, Dr. Antonia Arneart on distance supportive care for individuals in late stages of cancer and their caregivers. We are exploring the needs, the infrastructure and optimal psychosocial interventions to provide through IT. We have applied to CIHR. (4) With Carleton University, we are developing a research protocol on psychological distress among women identified as high risk for breast cancer. The proposed study is innovative as it includes psychosocial and biological markers related to stress and perceived high risk status. A team of transdisciplinary researchers has been assembled, the protocol is completed and I will be applying as PI in the Fall (CIHR and NCIC). (5) Together with Dr. Linda Edgar, we are planning to undertake a project to support nurses in their oncology work. Based on the NUCare approach, an evidence-based manual, we plan to enrol nurses from across Canada to offer them support through means of optimal problem and emotion-focus coping skills. We have applied to NCIC. (6) With Rosana Faria, a psychooncologist at St-Mary’s hospital, we are putting together a research protocol to assess couple’s resources to deal with a new cancer diagnosis. We have received seed funding to pilot the project. I serve as consultant on this project. (7) Together with family medicine (Dr. Pierre Pluye), I have applied to CIHR to explore the impact of IT on health care providers’ practices. We were successful in the LOI and have now sent the full proposal to CIHR. I continue with enhanced collaborations through PORT within Quebec (I have approached Laval University to join in for PORT’s renewal), across Canada (I have approached U. Toronto also to join PORT) and internationally, I have secured the collaboration of COPER in Bangalore, India. I am also in the process of establishing closer links with Brazil through a Brazilian graduate student who is training here at the 75
  • 76. Department of Oncology Annual Report 2006/2007 MNI. I am also involved in various research collaborations across the country (see CV and above section for details). 2. Research grants (new and ongoing) Côté, J., Godin, G., Tremblay, C., Lalonde, R., Otis, J., Loiselle, C. G., Cox, J., Guéhéneuc, Y-G., & Ramirez, M.P. (2007-2010). Evaluation d'un programme d'interventions sur mesure "tailored" visant à optimiser l'adhésion à la prise des antirétroviraux auprès de personnes vivant avec le VIH. Amount: $241,491, CIHR Operating Grant Program – Health Services Research (HSI). Côté, J., Ramirez, P., Loiselle, C. G., Tremblay, C., Godin, G., & Guéhéneuc, Y.G. (2006-2007). Intervention infirmière virtuelle : Un soutien dans la gestion quotidienne de la thérapie. GRISIM (Groupe de recherche interuniversitaire en sciences infirmières de Montréal) (supported by FRSQ/MSSS/ Newton Foundation). Amount : $10,000. Loiselle, C. G., & McVey, L. (2005-2007). Impact of a nursing informational intervention on family coping in an intensive care unit. The Adler/Sheiner patient support program for the intensive care unit (ICU). SMBD Jewish General Hospital, Montreal. $192,000. Loiselle, C. G., Degner, L., Butler, L., Bottorff, J. (2003-2009). Comprehensive research training program in psychosocial oncology. ($1.8 million, CIHR Strategic Research Training Program). Rhéaume, J., Descoteaux, S., Cognet, M., Hohl, J., Jaccoud, M., Leduc, N., Loiselle, C., McAll, C. et al. (2001-2004). Services de santé et services sociaux en milieu pluriethnique : la dynamique des acteurs dans l’intervention. Subvention de fonctionnement d’équipe. CLSC Côte-des-Neiges. CQRS, $186, 000/year. Renewed (FRSCQ, 2005-2008). Co-Principal Investigators: C. Johnston & N. Ricard. Co-Investigators (alphabetical order): A. Arnaert, C. Chapados, R. Cohen, S. Cossette, J. Côté, D. Ducharme, F. Duhamel, H. Ezer, N. Feeley, A. Gagnon, S. Gendron, J. Goudreau, C. Goulet, S. Le May, H. Lefebvre, C. Loiselle, S. Noiseaux, M. Purden, J. Rennick, N. Ricard, L. Richard, J. Ritchie. Le fonds de la recherche en santé du Québec (FRSQ)/Newton Foundation. “Groupe de recherche interuniversitaire en sciences infirmières de Montréal (GRISIM)”. Period of Award: April, 2006 – 2008. Amount: $1,000,000. Infrastructure – renewal. Co-Principal Investigators: McLeod, D., & Dumont, S. Project Partners (more than forty partners): Loiselle, C. G., et al. (2006-2008). An innovative national distance education initiative for interprofessional practice in psychosocial oncology. Health Canada, Amount : $749,608. 76
  • 77. Department of Oncology Annual Report 2006/2007 3. Research Training: undergraduate students, graduate students, postdocs/fellows Lambert, Sylvie (Ph.D.) School Of Nursing: 2002-2006 (FRSQ/CIHR funded; Maysie MacSporan fellowship, PORT fellowship, GRISIM doctoral scholarship) Dubois, Sylvie (Ph.D.) School Of Nursing: 2002-2006 (CIHR/ONQ funded; GRISIM doctoral scholarship) Hadd, Valerie (Ph.D.) Co-direction. School of Human Kinetics, University of British Columbia: 2006 – (SSHRC funded) Biron, Alain (Ph.D.) School of Nursing: 2003-2007 (FRSQ/FERASI/MUHC funded) Matousek, Rosa (Ph.D.) Co-direction. Psychology: 2006 - (NCIC/PORT Fellow funded) Genest, Christine (Ph.D.) Member of the dissertation committee for Doctoral Candidate, University of Montreal Liu, Tianli (MA) External reviewer (Nov. 2006) - Masters' student in School of Physical and Occupational Therapy, McGill University. Title of thesis: Quality of life among the elderly Chinese people living in Montreal and its indicators. Sabbagh, Melanie (M.S.(A)). School Of Nursing: 2006-2007 4. Scientific Reviews: Editorial Boards and Journal Reviews 2007 - Journal reviewer, International Journal of Public Health (IJPH) 2006 - Journal reviewer, European Review of Applied Psychology 2006 - Journal reviewer, Transcultural Psychiatry 2005 - Journal reviewer, Education for Evidence-Based Practice 2005 - Journal reviewer, Perspective Infirmière 2004 - Journal reviewer, Cultural Diversity and Ethnic Minority Psychology (APA journal) 2002 - Journal referee, Ad hoc reviews, Journal of Advanced Nursing (JAN) 1999 - Journal referee, Ad hoc reviews, Canadian Journal of Nursing Research (CJNR) 5. Research Advisory Work for National and International Organizations 2007 – External Grant Reviewer – Operating Grant Proposals – UK Cancer Agency – January 06, 2007 2007 - Grant reviewer – Operating Grants – National Cancer Institute of Canada (NCIC), February, 5 & 6, 2007 2007 - Grant panel reviewer – Special competition: Access to Quality Cancer Care – CIHR, February, 14 & 15, 2007 77
  • 78. Department of Oncology Annual Report 2006/2007 6. Conference Organization Organized the third annual PORT (Psychosocial Oncology Research Training) meeting. Which took place at the Fort Garry Hotel in Winnipeg, Manitoba on May 8th & 9th, 2007. 7. Invited Presentations and Workshops (National and International) Loiselle, C. G. Local, national and international oncology nursing activities: An update. Presented at the Faculty Meeting of the School of Nursing. May 24, 2007. Loiselle, C. G. Is broader access to cancer information helping patients cope better with their disease? Saint Mary's Hospital Center: Community Cancer Care Program, Montreal, Quebec, May 16th, 2007. This event was an accredited group learning activity (Section 1) as defined by the maintenance of certification program of the Royal College of Physicians and Surgeons of Canada. Loiselle, C.G. PORT’s ongoing activities: Update and trainees’ research programs highlighted. Third Annual PORT (Psychosocial Oncology Research Training) Meeting. The Fort Garry Hotel, Winnipeg, Manitoba, May 8-9, 2007. Loiselle, C. G. Oncology nursing leading the way with a new network program at McGill University. MUHC Oncology Nursing Management Group Meeting, Montreal General Hospital, Montreal, Quebec, April 26, 2007. Loiselle, C.G. Oncology Nursing leading the way with an ongoing CIHR/NCIC-funded national research training program and a brand new network program at McGill. Presentation given at the annual McGill University oncology research retreat. Montreal, November 17, 2006. 8. Peer-Reviewed Abstracts Loiselle, C. G., & Edgar, L. (2007). The impact of an IT informational intervention on psychosocial adjustment to cancer and health care service use: Are women and men with cancer reacting differently? Invited Speaker at the 5th annual Cancer Patient Education Network (CPEN) Canada Conference: Reasons to Hope, Knowledge to Cope - Innovations in Cancer Patient Education. Montreal, Quebec, May 31 – June 2, 2007. Lambert, S., Dubois, S. & Loiselle, C. G. (2007). Complementary data collection strategies to enhance data richness: The case of information-seeking behaviour in cancer. Oral presentation given at the 22nd Annual Conference of the Canadian Association of Psychosocial Oncology (CAPO): Communication, Collaboration and Creativity. Winnipeg, Manitoba, May 9-11, 2007. Dubois, S., & Loiselle, C. G. (2007). Informational support and health care service use: A qualitative study among individuals newly diagnosed with cancer. Oral presentation given at the 22nd Annual Conference of the Canadian Association of Psychosocial Oncology (CAPO): Communication, Collaboration and Creativity. Winnipeg, Manitoba, May 9-11, 2007. 78
  • 79. Department of Oncology Annual Report 2006/2007 Saint-Arnaud, J., Côté, J., Chapados, C., Bourdeau, M., Loiselle, C. G., Bouchard, L., Verrier, P., Audet, M., Gagnon, J., & Dupuis, C. (2007). Les critères de sélection des candidats à la dialyse au Québec: Aspects éthiques. Oral presentation given at the Congrès annuel de la Société québécoise de nephrology. Quebec City, Quebec, April 26- 28, 2007. Loiselle, C.G., Dubois, S., & Edgar, L. (2006). The role of interactive health communication (IHC) in softening the blow of a cancer diagnosis and guiding the use of health care services: Are women and men reacting to IHC differently? Poster presentation given at the 8th World Congress of Psycho-Oncology. Multidisciplinary Psychosocial Oncology: Dialogue and Interaction. International Psycho-Oncology Society (IPOS). Venice, Italy, October 18-21, 2006. Loiselle, C.G. (2006). PORT- A Canadian exemplar of high quality, cutting-edge transdisciplinary research training in psychosocial oncology. Oral presentation given at the 8th World Congress of Psycho-Oncology. Multidisciplinary Psychosocial Oncology: Dialogue and Interaction. International Psycho-Oncology Society (IPOS). Venice, Italy, October 18-21, 2006. Biron, A., Loiselle, C., & Lavoie-Tremblay, M. (2006). The role of distractions and interruptions as contributors to medication administration errors. Oral presentation given at the 17th International Nursing Research Congress: Focusing on Evidence-Based Practice – Sigma Theta Tau International, Montreal, Quebec, Canada, July 19-22, 2006. 9. Hospital Activities Appointed this year as the new Director of the Oncology Nursing Division in the Department of Oncology in the Faculty of Medicine at McGill University. Senior Researcher at the Centre for Nursing Research, SMBD-Jewish General Hospital Member, Research Ethics Committee, SMBD Jewish General Hospital Loiselle, C. G. Is broader access to cancer information helping patients cope better with their disease? Saint Mary's Hospital Center: Community Cancer Care Program, Montreal, Quebec, May 16th, 2007. This event was an accredited group learning activity (Section 1) as defined by the maintenance of certification program of the Royal College of Physicians and Surgeons of Canada. Loiselle, C. G. Oncology nursing leading the way with a new network program at McGill University. MUHC Oncology Nursing Management Group Meeting, Montreal General Hospital, Montreal, Quebec, April 26, 2007. 10. Involvement in continuing education activities 2006: Faculty of Graduate Studies: Workshop on graduate supervision 79
  • 80. Department of Oncology Annual Report 2006/2007 2006: May 2006 Workshop on integrating innovation into research and teaching (PORT, Montreal) Mary-Ellen Macdonald 1. Summary of New and Ongoing Research I joined the following projects (grants were already awarded when I was asked to join): Patients’ Perspective on the Physician as Professional and Healer, JD Boudreau, J Jagosh, ME Macdonald, R Slee, Y Steinert, Montreal General Hospital Foundation, $110,000, 2005-2007. The relationship between culture and treatment-compliance in chronically ill adolescents from cultural minorities, L Nadeau, S Liben, ME Macdonald, Montreal Children’s Hospital Research Institute and Department of Psychiatry, $13 160, 2005-2007. Faculty Development: A Field of Dreams? Y Steinert, M Boillat, P McLeod, S Meterissian, ME Macdonald, Royal College of Physicians and Surgeons Faculty Development Grant, $5000, 2005- 2007. Teaching Medicine in the ER: a Problem Becomes an Opportunity, Peter McLeod, C Chalk, ME Macdonald, J Wiseman, P Zanell, McGill Teaching and Learning Services: Teaching Innovations Grant, $4200, 2006-2007. Transitions in Paediatric Palliative and End of Life Care, H Siden, S Cadell, E Davies, R Steele, L Straatman, Collaborator: ME Macdonald, CIHR New Emerging Team Grant, $1,348,575, 2004-2009. 2. Research grants (new and ongoing) Family Caregiving in Palliative and End-of-Life Care, K Stajduhar, SR Cohen, N Chappell, D Heyland, P Koop, A Williams, (New Investigator: ME Macdonald, 2006- 2009) CIHR New Emerging Team Grant, $1,363,586, 2004-2009. An Anthropology of Bereavement: A sociocultural understanding of parental grief and mourning, ME Macdonald, S Cadell, L Mitchell, P Stephenson, SSHRC, $75,000 (supplemental + in-kind 25,000), 2007 – 2010 Conference Grant: Ensuring Quality in Qualitative Research, ME Macdonald, Sociobehavioural Cancer Research Network (CPRPE), $900, 2007 Travel Grant: Geneva, International Congress on Pediatric Critical Care, ME Macdonald, Sociobehavioural Cancer Research Network (CPRPE), $1500, 2007 Promoting Cultural Awareness: A Faculty Development Cultural Competency Training Program, FA Carnevale, ME Macdonald, Y Steinert, S Razack, Faculty Development Grant, Royal College of Physicians and Surgeons, $5500, 2006-2007. 80
  • 81. Department of Oncology Annual Report 2006/2007 Parental and Professional Decision-Making Regarding Benefits and Burdens of Interventions for Children with Life-Limiting Conditions, H Sidden, M Bennett, R Adderleym, S Cadell, L D’Agincourt-Canning, ME Macdonald, T Northway, L Straatman, E Stephanson, British Columbia Child and Youth Health Research Network Grant, $4815, 2006. Tuberculosis among Urban Aboriginals in Montreal, P Brassard, ME Macdonald, R Menzies, K Schwartzman, Partnered with the Native Friendship Centre of Montreal, CIHR Strategic Initiative: Aboriginal Community-based Research Competition, $213 450, 2005-2008 3. Research Trainees CIHR-NCIC Strategic Training Program in Palliative Care Mary Rykov, Postdoctoral Student, McGill University (Oncology) Mentor, 2006 to present Topic: Music therapy and cancer care Nicolas Vonarx, Postdoctoral Student, Laval University (Ethics and Nursing) Mentor, 2006 to present Topic: Les figures du religieux dans les épisodes de maladie marqués par une souffrance existentielle: pour une meilleure lecture de ces figures dans le cadre des soins palliatifs Lisa Chan, Doctoral Student, McGill University (School of Nursing) Mentor, 2006 to present Topic: Ethnographic Study of End-Stage Illness on an Acute Medical Unit McGill University Dawn Allen, Postdoc, Whole Person Care Postdoctoral Supervision, 2007 (informal mentorship until funding secured) Lisa Chan, Doctoral Student, School of Nursing Doctoral Co-Supervisor, 2006 to present Topic: Ethnographic Study of End-Stage Illness on an Acute Medical Unit 81
  • 82. Department of Oncology Annual Report 2006/2007 Royal Victoria Hospital Ebba Oloffson, PhD Mentorship + RA Supervision, 2007 to present Supervision in research techniques, protocol writing, analysis 4. Scientific Reviews: Editorial Boards and Journal Reviews Manuscript Review 2007 to present: Journal of Aboriginal Health 2006 to present Pediatrics Canadian Medical Association Journal Journal of Child Health Care Journal of Hospice and Palliative Medicine Protocol Review 2007 to present Institutional Review Board, Faculty of Medicine, McGill University Operating Grant Review 2006 to present Indian and Northern Affairs, Government of Canada Nursing Scientific Review Committee, Nursing Research Funds for Nurses, McGill University Health Centre (Chair, Judith Ritchie, PhD) Scholarship Review 2006-Trainee Selection Committee, CIHR-NCIC Strategic Training Program in Palliative Care Research 5. Conference Organization 2007, McGill Qualitative Health Research Group Annual Conference: Ensuring Quality in Qualitative Research. Funded by NCIC-Sociobehavioural Cancer Research Network, 82
  • 83. Department of Oncology Annual Report 2006/2007 and Palliative Care Program, Montreal Children’s Hosital, April 5, 2007, Conference Organizer and Chair. 6. Invited Presentations and Workshops 2006, Macdonald, ME, A Clash of Cultures: When Family Culture Meets Professional Culture in an Intensive Care Unit. 16th International Congress on Care of the Terminally Ill, Montreal, September 26, 2006. McGill University, Faculty of Medicine, Centre for Medical Education IMEX Program, Guest Instructor, May 2007, IMEX scholars (Dalhousie University, McGill University, Utrecht University, Karolinska Institute) Topic: “Qualitative Research in Medical Education” Faculty of Medicine, School of Nursing, Guest Instructor, March 2007, Chronic Illness and Palliative Care (NUR1 322), Topic: An Anthropology of Bereavement McGill University, Faculty of Medicine, Faculty Development Office, Cultural Competency Workshop: Educating for Cultural Awareness: Avoiding Stereotypes, Assumptions and Other Traps, 2007, With S Razack, FA Carnevale, Y Steinert Royal College of Physicians and Surgeons, Caring for a Diverse Diversity: Reconciling Cultural, Socioeconomic and Sexual Difference in Medical Education, 2006, with S Razack, FA Carnevale, Y Steinert, PP Tellier 7. Peer-Reviewed Abstracts Macdonald, ME, Liben, S, Carnevale, FA, Rennick, JE, Cohen, SR. Office or Bedroom? A Disconnect Between Family Culture and Professional Culture in the PICU, 5th World Congress on Pediatric Critical Care, June 24-8, 2007, Geneva. To be published in Pediatric Critical Care Medicine McLeod, P, Chalk, C, Zanelli, P, Wiseman J, Macdonald, ME, A Problem Becomes an Opportunity: The Emergency Department Consult Service for Students in Internal Medicine, Conference of the Canadian Association of Medical Education, Victoria., May 4-9, 2007 Boudreau, JD, Jagosh, J, Slee, R, Macdonald, ME, Steinert, Y, Incorporating the Patient Perspective in Curricular Renewal, Conference of the Canadian Association of Medical Education, Victoria., May 4-9, 2007 Razack, S, Macdonald, ME, Steinert Y, Carnevale, FA. Training in Cultural Competence: What We Want to Learn vs. What We Ought to Learn. Conference of the Canadian Association of Medical Education, Victoria. May 4-9, 2007 Nadeau, L, Johnson-Lafleur, J, Liben, S, Macdonald, ME, Rousseau, C Polychronakos, C, Perrault, J, Lands, L. Treatment-compliance in chronically ill adolescents from 83
  • 84. Department of Oncology Annual Report 2006/2007 cultural minorities. Canadian Academy of Child and Adolescent Psychiatry 26th Annual Conference, Toronto, 2006 (Nov). Published in conference proceedings. Razack, S, Steinert Y, Macdonald, ME, Carnevale, FA, Tellier, PP (September, 2006) Caring for a diverse diversity; Reconciling cultural, socioeconomic, and sexual difference in medical education. Royal College/Canadian Society for clinical Investigation, Annual Conference, Ottawa. Clinical and Investigative Medicine 2006 29(4): 221-222 Neil MacDonald 1. Summary of New and Ongoing Research New Emerging Team Grant (CIHR) – studies on cachexia. McGill PI. A collaboration with the University of Alberta. Dr Vickie Baracos is the overall PI. Clinical Trials – PI study on dronabinol – effects on appetite, taste and smell. A collaboration with the University of Alberta. Co-investigator – AVR 118 in the management of cancer anorexia (Dr Chasen PI – study to start in late May - early June. Studies on the role of inflammation as reflected by ↑ CRP and a high white count in patients with NSCLC. Current studies include: A continuing analysis of overall prognosis Relationship of inflammation to chemotherapy response Impact of CRP on early dropout rate in clinical trials Relationship of PET intensity to inflammatory markers Other research activities include: Shared supervision of a Master’s student (Ms Swinton) and continuing interaction with physiotherapy colleagues who are studying the role of exercise activities in NSCLC patients 2. Scientific Reviews Editorial Boards Journal of Palliative Care Journal of Pain and Symptom Management Quaderni di Cure Palliative 84
  • 85. Department of Oncology Annual Report 2006/2007 Journal of Supportive Oncology Palliative and Supportive Care Oncology Exchange Reviewer Canadian Medical Association Journal Journal of Clinical Oncology Journal of Palliative Care Journal of Palliative Medicine Journal of Supportive Oncology Journal of Clinical Nutrition Journal of Pain and Symptom Management Cancer Journal of Applied Physiology, Nutrition and metabolism Journal of Palliative Care – Book Review CIHR Grant 3. Advisory Work for National and International Organizations Chair, WHO IAHPC Joint Program - Developing a List of Essential Medicines for Palliative and End-of-Life Care. Salzburg, Austria May 2006. 4. Invited Presentations and Workshops (National and International) “Cancer Cachexia: The Argument for Early Palliative Care Intervention”. The 16th Annual Ontario Provincial Conference on Palliative and End-of-Life Care. Toronto Ontario. April 23 and 24, 2006. “How to Identify and Approach the Malnourished Patient”. Issues in Palliative Care Conference. Antigonish, Nova Scotia. May 13, 2007. “Ethics and End-of-Life Care”. Issues in Palliative Care Conference. Antigonish, Nova Scotia. May 14, 2007. 5. Hospital Activities Royal Victoria Hospital, Montreal - Attending Staff 85
  • 86. Department of Oncology Annual Report 2006/2007 Montreal General Hospital, Montreal - Attending Staff Jewish General Hospital, Montreal – Associate St Mary’s Hospital, Montreal – Associate Markus Martin 1. Scientific Reviews: Editorial Boards and Journal Reviews Doctor's Review: Editorial Board 2. Conference Organization AOGQ-Annual conference May 24-26/2007-Sherbrooke, QC 3. Peer-Reviewed Abstracts Blood Markers in Crohn's Disease during Pregnancy-GI -Calgary 4. Hospital Activities DPS:CHSLD Eldercare 5. Involvement in continuing education activities Member of the McGill Centre for Medical Education 6. Involvement in the community Les Amis de l'Insectarium: Board RCPSC: Board CMQ: Board ACOG Dist I: Board AOGQ: Board Wilson Miller 1. Summary of New and Ongoing Research Basic Research Collaboration within McGill Dr. H. Schipper, Neurology, Jewish General Hospital. Dr. J. Hoffer, Endocrinology, Jewish General Hospital. Dr. D. Scott Bohle, Department of Chemistry, McGill University. Dr. J. White, Department of Physiology, McGill University. University, Dr. M. Basik, Surgery/Oncology, Jewish General Hospital. Basic Research Collaboration outside of McGill Dr. Sam Waxman, Mount Sinai Medical School, New York, New York. 86
  • 87. Department of Oncology Annual Report 2006/2007 Dr. Clara Nervi, University of Rome "La Sapienza", Rome, Italy. Dr. Sylvie Mader, University of Montreal/Institute for Research in Immunology and Cancer. Dr. Kathy Borden, University of Montreal/ Institute for Research in Immunology and Cancer. Dr. Albert Baldwin, University of North Carolina. Dr. Paul Fisher, Columbia University, New York. Dr. Philip Komarnitsky, Ziopharm Oncology, Inc. 2. Research grants (new and ongoing) Merck, Phase IIB multi-center clinical trial of oral SAHA in advanced cutaneous T cell lymphoma. Total award = $28,750 CAD, Principal Investigator: Dr. Wilson H. Miller Jr., Funding Period: 2004-2006 Methylgene Inc.,Canada, A phase I study of MGCD0103 given as a three-times weekly oral dose in patients with leukemia or myelodysplastic syndromes, Total award up to date = $ 18,914.75 CAD, Principal Investigator: Dr. Wilson H. Miller Jr., Funding Period: 2005- ongoing Kosan Bioscience, USA, A Phase II Study of KOS-862 (Epothilone D), Administered Intravenously Weekly for 3 Weeks Every 4 Weeks, in Patients with Metastatic Breast Carcinoma, Total award = $ 48,486.70 USD, Principal Investigator: Dr. Wilson H. Miller Jr., Funding Period: 2005-2006 Medarex Inc.,USA, A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A*0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma, Total award to date = $ 41,172.48 USD, Principal Investigator: Dr. Wilson H. Miller Jr., Funding Period: 2005-ongoing Chemokine Therapeutics, Canada, An Open Label Phase I/II Study of CTCE-9908 in Subjects with Advanced Refractory Neoplasms, Total award to date= $ 61,282.50 CAD, Principal Investigator: Dr. Wilson H. Miller Jr., Funding Period: 2006-ongoing Pfizer, Canada, A SU011248 expanded access protocol for patients with cytokine- refractory or cytokine-intolerant metastatic renal cell carcinoma who are ineligible for participation in other SU 011248 and may derive benefit from the treatment with SU011248, Total award to date= $ 35,664.09 CA, Principal Investigator: Dr. Wilson H. Miller Jr., Funding Period: 2006-ongoing Berlex Canada Inc., Canada, Phase 2 study to investigate the efficacy and safety of ZK- Epothilone (ZK-Epo; ZK-219477) in patients with metastatic breast cancer, Total award to date= $ 34,912.50 CAD, Principal Investigator: Dr. Wilson H. Miller Jr., Funding Period: 2006-ongoing 87
  • 88. Department of Oncology Annual Report 2006/2007 GlaxoSmithKline, Canada, A Randomized, Double-blind, Multicenter, Placebo- controlled Study of Adjuvant Lapatinib in Women with Early-Stage ErbB2 Overexpressing Breast Cancer, Total award to date= $ 18,528.18 CAD, Principal Investigator: Dr. Wilson H. Miller Jr., Funding Period: 2006-ongoing Bristol Myers Squib, USA, A Multi-center, Randomized, Double-blind, Two-Arm, Phase III Study in Patients with Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10mg/kg of Ipilimumab (MDX-010) vs. Dacarbazine With Placebo, Total award to date= $ $ 3,500.00 USD, Principal Investigator: Dr. Wilson H. Miller Jr., Funding Period: 2006-ongoing 3. Research Training: undergraduate students, graduate students, postdocs/fellows Koren Mann, post-doctoral fellow, 9/1999-. Transcriptional mechanisms of response and resistance to retinoids. Dr. Mann received a Fellowship award from the Leukemia Fund of Canada and the CIHR Training Program of the MCETC. Filippa Pettersson, post-doctoral fellow, 10/2000-. Molecular interactions among nuclear receptors in breast cancer. Dr. Pettersson has a US Army Breast Cancer Research Program Postdoctoral Training Award. Zuanel Diaz-Heredia, PhD student in Experimental Medicine, 9/2002-. Mechanisms of induction of apoptosis by arsenic. Ms. Diaz holds a Fellowship award from the CIHR Training Program to the McGill Cancer Centre. Suzan McNamara, PhD student in Experimental Medicine, 1/2003-. Mechanisms of response and resistance to transcriptional therapies in acute promyelocytic leukemia. Ms. McNamara holds a Fellowship award from the CIHR Training Program to the McGill Centre for Experimental Therapeutics in Cancer. Clair Trottier, PhD student in Microbiology and Immunology, 9/04-. Molecular mechanisms of suppression of measles virus by retinoic acid. Co-sponsored with Dr. Brian Ward. Anna Laurenzana, PDF 10/04-. Epigenetic approaches to overcome retinoid resistance in acute promyelocytic leukemia. Dr. Laurenzana holds a Fellowship award from the CIHR Training Program to the McGill Cancer Centre. Ms Marina Lagodich, Honours Immunology undergraduate research student, “Regulation of SXR by rexinoids”, 2005-2006. Sophie Marcoux, PhD student in Experimental Medicine, 9/2006-. Mechanisms of arsenic-induced apoptosis: the role of caspases and reactive oxygen species. Andy Petruccelli, PhD student in Experimental Medicine, 1/2007-. Potential therapies exploiting the synergy between histone diacetylase and DMNT inhibitors. Myranda Tomensen, Honours Immunology undergraduate research student, Defining novel mechanisms by which HDAC-inhibitors induce apoptosis in cancer cells, 2006- 2007. 88
  • 89. Department of Oncology Annual Report 2006/2007 4. Scientific Reviews: Editorial Boards and Journal Reviews Peer Review Panel Member, Basic Mechanisms of Cancer Therapeutics Study Section, National Institute of Health (US) Center for Scientific Review, June 22-23, 2006. Peer Review Panel Member, Basic Mechanisms of Cancer Therapeutics Study Section, National Institute of Health (US) Center for Scientific Review, October 12-13, 2006. Peer Review Panel Member, Basic Mechanisms of Cancer Therapeutics Study Section, National Institute of Health (US) Center for Scientific Review, January 29-30, 2007. Peer Review Panel Member, Fonds de la Recherche en santé Québec, chercheur-boursier senior award committee, Feb 15-16, 2007. Reviewer of journals: Blood 1993-, Leukemia 1995-, Cancer Research 1995-, JNCI 1995-, Annals of Oncology 1995-, Clinical Cancer Research 1996-, Biochimica et Biophysica Acta 1996-, J Clinical Oncology 1999-, Oncogene 2001-, Leukemia Research 2002-, Cancer Cell 2002-, Nature Reviews Cancer 2002-, Brit. J Pharm 2003-, The Hematology Journal 2003-, Mol Cell Biol. 2003-, Mol Ca Res 2003-, Cancer Letters 2004-, J Biol Chem 2004-, Free Radical Biology and Medicine 2004-, Science 2005-, J Cellular Bioch 2006-. 5. Conference Organization International Organizing Committee, The 12th International Conference on Differentiation Therapy, November 4-8, 2006. 6. Invited Presentations and Workshops (National and International) Member, International Organizing Committee, 11th International Conference on Differentiation Therapy and innovative Therapeutics in Oncology, Nov 6, 2006. Chair, Workshop on Apoptosis and Signaling, 11th International Conference on Differentiation Therapy and innovative Therapeutics in Oncology, Nov 6, 2006. Invited Speaker, “Effects of Trolox, a water soluble derivative of vitamin E, on arsenic- mediated toxicity and antitumor activity”, 11th International Conference on Differentiation Therapy and innovative Therapeutics in Oncology, Nov 6, 2006. Invited Speaker, John Hopkins Workshop on Clinical Targeting of Epigenetic Changes I Cancer Therapeutics, Phoenix AZ, “Epigenetic activations of TNF-Alpha Induced Monocytic Differentiation of AML Cells,” Jan 14, 2007. 7. Peer-Reviewed Abstracts P. E. Goss, I. N. Bondarenko, G. N. Manikhas, K. B. Pendergrass, W.H.Miller, for the 777 CLP-29 Study Group. Phase 3 study of atamestane + toremifene vs. letrozole in advanced breast cancer. Am Soc. Clin Oncol, 2006. 89
  • 90. Department of Oncology Annual Report 2006/2007 Agulnik JS, Cohen V, Jarry J, Batist G, Small D, Kreisman H, Tejada A, Chong G, Miller WH Jr. Use of Denaturing High Performance Liquid Chromatography (dHPLC) for Detection of EGFR Mutations in Patients with NSCLC. Am Soc. Clin Oncol, 2006. Guillermo Garcia-Manero, Mark Minden, Wilson Miller, Zeev Estrov, Srdan Verstovsek, Willie Newsome, Gregory Reid, Jeffrey Besterman, Zuomei Li, Laura Pearce and Robert Martell. A Phase I study of MGCD0103 given as a three-times weekly oral dose in patients with leukemia or myelodysplastic syndromes. Am Soc. Clin Oncol, 2006. 8. Hospital Activities Director, Clinical Research Unit, Jewish General Hospital, Montreal PQ, 12/1997-. Director, McGill University Department of Oncology Developmental Therapeutics Program, 9/2001-. Member, Management Committee, McGill University Department of Oncology, 9/2001-. Co-Director, Clinical Research Program, McGill University Department of Oncology, March 2002-. Director, Program Advisory Committee of the CIHR Training Program in Oncology, Montreal Centre for Experimental Therapeutics in Cancer 2002-2008. Member, NSABP Foundation Research Program Steering Committee, June 2005-June 2008. Alain Nepveu 1. Summary of New and Ongoing Research The role of CDP/Cux in myeloid leukemias. Collaborators: Dr. Alan Peterson, Molecular Oncology Group, McGill University, Montreal; Dr. Sylvie Fournier, Department of Microbiology and Immunology, McGill University, Montreal; Dr. Christian Bédard, Faculty of Veterinary Medicine, Université de Montréal; Dr. Barry Bedell, Department of Pathology, McGill University. The role of cathepsin L in cancer. Collaborators: Dr. Matthew Bogyo, Stanford University School of Medicine, USA. Dr. Ekkehart Weber, Institute of Physiological Chemistry, Martin Luther University, Germany, Dr. Shyam S. Chauhan, All India Institute of Medical Sciences, India. Cell cycle control in T cells. Collaborator: Dr. Jacques Bertoglio, Université de Paris X1, France. Role of caspases in cell proliferation. Collaborators: Dr. Guy S. Salvesen and Dr. Jean- Bernard Denault, The Burnham Institute, USA. 90
  • 91. Department of Oncology Annual Report 2006/2007 Signal transduction downstream of the PAR2 receptor. Collaborators: Dr. Morley D. Hollenberg and Dr. Nathalie Vergnolle, University of Calgary, Ca. Cooperation between CDP/Cux and ErbB2 in breast cancer. Collaborator: Dr. William Muller, Molecular Oncology Group, McGill University, Montreal, Ca. Transcriptional control of cell migration and invasion. Collaborator: Dr. Morag Park, Molecular Oncology Group, McGill University. Genome-wide location analysis of CDP/Cux binding sites. Collaborator: Dr. François Robert, Institut de Recherches Cliniques de Montréal, QC. 2. Research grants (new and ongoing) Canadian Institute of Health Research CIHR Team in Cancer Progression and Metastasis $99,814/year 2006-2011 Co-Applicant (total 8 Co-Applicants) PI: Morag Park Canadian Institute of Health Research Structure/function analysis of the mammalian CDP/Cux protein $154,408/year 2003-2008 National Cancer Institute of Canada Function and modulation of CDP/Cux in cell cycle progression $143,909/year 2003-2008 Canadian Breast Cancer Research Alliance $149,271/year 2003-2008 The role of nuclear Cathepsin L in cellular proliferation and cancer Genome Canada/Génome Québec $230,000/year 2003-2006 Regulatory Networks in Gene Expression: from the Genome to the Organism. Co-Applicant with 9 other investigators. I wrote the application together with the PI: Dr. Benoit Coulombe. 91
  • 92. Department of Oncology Annual Report 2006/2007 3. Construction of major facilities or major equipment grants As a co-applicant on a CFI application to establish mouse facilities at McGill Life Science complex. 4. Research Training: undergraduate students, graduate students, postdocs/fellows Marianne Santaguida Biochemistry 1998- 2006 Ph.D. Obtained Mary Truscott Biochemistry 1999- 2006 Ph.D. Obtained Rachel Dudley Biochemistry 2004- 2006 M.Sc. Obtained Laurent Sansregret Biochemistry 2002-present Ph.D. Expected Chantal Cadieux Biochemistry 2003-present M.Sc. Expected Charles Vadnais Biochemistry 2006-present M.Sc. Expected Laura Hulea Biochemistry 2006-present Ph.D. Expected Valérie Kedinger PDF 2006-present 5. Scientific Reviews: Editorial Boards and Journal Reviews Ad hoc reviews of manuscripts for the journals: Molecular and Cellular Biology, Cancer Research, Blood, Oncogene, Journal of Biological Chemistry, Gene, Carcinogenesis. 6. Research Advisory Work for National and International Organizations Panel Member, National Cancer Institute, February 2007 Virology & Molecular and Structural Biology Panel Member, Canadian Institute of Health Research, May 2007 Molecular and Cellular Biology of Cancer, 92
  • 93. Department of Oncology Annual Report 2006/2007 7. Invited Presentations and Workshops (National and International) October 2006 Invited speaker, Department of Anatomy and Cell Biology, University of Kansas Medical Center, Kansas City, USA. October 2006 Invited speaker, Department of Medicine, The Vascular Biology Center, University of Minnesota, Minneapolis, USA. Jan. 2007 Presenter, "Transcriptional targets of CDP/Cux in cancer cells", 4th Annual Barbados Bioinformatics Workshop: Breast Cancer, Bellairs Research Station, Holetown, Barbados February 2007 Invited speaker, Centre de Cancérologie de l'Université Laval, Quebec, Canada. 8. Peer-Reviewed Abstracts Truscott, M., R. Harada, C. Vadnais, and A. Nepveu. Cooperation of CDP/Cux with E2F in the Transcriptional Activation of Cell Cycle-Regulated Gene Promoters. Presented at the FASEB Transcriptional Regulation During Cell Growth, Differentiation & Development meeting August 12-17, 2006 Cadieux, C., Sansregret, L., Harada, R., Kedinger, V., Nepveu, A. Short CDP/Cux isoforms stimulate cell proliferation and invasion, and cause cancer in mice. Mechanisms and models of cancer, Cold Spring Harbor, New York, August 2006. Cadieux, C., Goulet, B., Sansregret, L. and Nepveu, A. The Role of Short CDP/Cux Isoforms in Cancer. International Association for Breast Cancer Research, Montreal, October 2006. 9. Hospital Activities Chair, Animal Facility Users Committee, Royal Victoria Hospital Jerry Pelletier 1. Summary of New and Ongoing Research Research Program on Anti-cancer Activity of Hippuristanol: Dr. Junichi Tanaka (University of Ryukyus, Okinawa, Japan) Dr. Gerhard Wagner (Harvard University, Boston) Dr. Pierre Deslongchamps (U. Sherbrooke) Dr. Patrick Cormier (Roscoff, France) Research Program on Anti-cancer Activity of Pateamine: Dr. Peter Northcote (Victoria University of Wellington, New Zealand) 93
  • 94. Department of Oncology Annual Report 2006/2007 Dr. Paul Teesdale-Spittle (Victoria University of Wellington, New Zealand) Research Program on Anti-cancer Activity of Rocaglamides: Dr. John Porco (Boston University, Boston) Research Program on Development of Anti-Cachexic Chemotherapeutics: Dr. Michel Tremblay (McGill University) Dr. Imed Gallouzi (McGill University) Research Program on the Role of Deregulated Translation in Cancer: Dr. Nahum Sonenberg (McGill University) Dr. Scott Lowe (Deputy Director, Cold Spring Harbor) Dr. Hans-Guido Wendel (Sloan Kettering Cancer Research Institute, NY) Research Program on Chemical Suppressors of miRNA: Dr. Carl Novina (Dana Farber Cancer Institute, Harvard) 2. Research grants (new and ongoing) Support Period: 2005-2008 Amount/yr: $170,640 Agency: NIH Title: High Throughput Assays Targeting Ribosome Recruitment. Investigator: M. Pollak (P.I), N. Sonenberg, G. Fantus, J. Brisson, J. Woodget, S. Dunn, J. Pelletier Support Period: 2005-2009 Amount/yr: $75,000 (my share) Agency: CBCRA Title: IGF and Insulin Signaling Pathways in Breast Cancer Support Period: 2005-2010 Amount/yr: $140,858 Agency: CIHR 94
  • 95. Department of Oncology Annual Report 2006/2007 Title: Translation initiation and cancer: role of the ribosome recruitment step. Support Period: 2006-2009 Amount/yr: $125,735 Agency: NCIC Title: Chemical Dissection of Translation Initiation Support Period: 2006-2011 Amount/yr: $141,000 Agency: CIHR Title: Linking Translation to Chemotherapy Support Period: 2006-2011 Amount/yr: $112,769 (My Share) Agency: CIHR Team Grant (N. Sonenberg – Team Leader) Title: Molecular Basis of Translational Control of Memory Formation: Drug Discovery to Enhance Learning and Memory 3. Construction of major facilities or major equipment grants Support Period: 2002-2007 Amount/yr: $250,000/yr Agency: FRSQ (Michel Tremblay, P.I.) Title: FRSQ Center Grant 4. Research Training: undergraduate students, graduate students, postdocs/fellows Abba Malina, 2002- Present Subject: Characterization of Novel Protein Synthesis Inhibitors. Marie-Eve Bordeleau, 2002-Present Subject: Inhibiting Translation Initiation as a Chemotherapeutic Approach John Mills 2003-Present. Subject: Molecular Genetics of Lymphomas. Lisa Lindqvist 2005-Present Subject: Chemical Dissection of Translation Initiation. Aaron Winterstein 2005-2006 95
  • 96. Department of Oncology Annual Report 2006/2007 Subject: Molecular Genetics of Lymphomas. Betty Lin 2004-Present Subject: Molecular Genetics of Lymphomas. Rami Sukharieh 2004 – Present (Co-supervised with N. Sonenberg). In Viro FRET Analysis of Translation Initiation Jason Chen 2006- Present Subject: Role of Tsc2 in Lymphomagenesis Post-Doctoral Training Francis Robert 2003-Present Subject: Role of Translation Initiation in Cancer Initiation and Progression. Regina Cencic 2005-Present Subject: Chemical Inhibitors of Translation Initiation. 5. Scientific Reviews: Editorial Boards and Journal Reviews MCB RNA JBC Science Nature Chemical Biology PNAS 6. Invited Presentations and Workshops (National and International) Invited Speaker: McGill Cancer Center Workshop, “Challenges in the Discovery and Development of Targeted Therapies in Cancer”, Nov. 1, 2006 Invited Speaker: AACR Annual Meeting 2007 (April14th-April 17th), “Therapeutic Potential of Translation Initiation Inhibitors” April 14th, 2007, Los Angeles, CA 7. Peer-Reviewed Abstracts Costa-Mattioli, M., Gobert, D., Stern, E., Pelletier, J., Kaufman, R., Rosenblum, K., Lacaille, J.-C., Nader, K., and Sonenberg, N. Enhanced synaptic plasticity and learning in 96
  • 97. Department of Oncology Annual Report 2006/2007 mutant mice with reduced phosphorylation of the translation factor eIF2 . Translational Control Cold Spring Harbor Laboratories, Cold Spring Harbor. New York. 2006. Cencic, R. and Pelletier, J. Screening for small molecule inhibitors of eIF4F activity. Translational Control Cold Spring Harbor Laboratories, Cold Spring Harbor. New York. 2006. Chaudhry, Y., Nayak, A., Bordeleau, M.-E., Tanaka, J., Pelletier, J., Belsham, G.J., Roberts, L.O., and Goodfellow, I.A. Calciviruses differ in their functional requirements fir eIF4A components. Translational Control Cold Spring Harbor Laboratories, Cold Spring Harbor. New York. 2006. Lindqvist, L., Lin, B., and Pelletier, J. Repositioning of factors involved in ribosome recruitment downstream of the cap structure. Translational Control Cold Spring Harbor Laboratories, Cold Spring Harbor. New York. 2006. Ervin Podgorsak 1. Research Training: undergraduate students, graduate students, postdocs/fellows Arman Sarfehnia (supervisors: E.B. Podgorsak and J.P. Seuntjens) The use of orthogonal bremsstrahlung beams for imaging in radiation therapy Medical Physics Unit, McGill University, degree granted in June 2006. Current employment: Ph.D. graduate student, McGill University Rong Ding Li (supervisors: E.B. Podgorsak and W. Abdel-Rahman) Dynamic electron arc therapy with a Clinac 21EX linear accelerator Medical Physics Unit, McGill University, degree granted in December 2006. Current employment: Clinical Physicist Phoenix, Arizona Eric Reynard (supervisors: M.D.C. Evans and E.B. Podgorsak) Rotational Total Skin Electron Irradiation with a 6 MeV Electron Linear Accelerator Medical Physics Unit, McGill University, degree granted in March 2007 Current employment: Clinical Physicist Sir M.B. Davis Jewish General Hospital, Montreal, Quebec 2. Research Advisory Work for National and International Organizations 97
  • 98. Department of Oncology Annual Report 2006/2007 Member 2005- Education Council, American Association of Physicists in Medicine (AAPM) Chairman 2005- Education and Training of Medical Physicists Committee, American Association of Physicists in Medicine (AAPM) Member 2005- Medal committee, Canadian Organization of Medical Physicists (COMP) Member 2006- Committee on Radiation Source Use and Replacement, The National Academies, Washington, D.C. 3. Invited Presentations and Workshops (National and International) E.B. Podgorsak, Absolute dosimetry with an extrapolation chamber, John R. Cameron Lecture, University of Wisconsin, Department of Medical Physics, Madison, Wisconsin, May 1, 2006. E.B. Podgorsak, Crisis in health care financing in the U.S. and Canada: A Medical Physicist’s Perspective, Medical Physics seminar, University of Wisconsin, Department of Medical Physics, Madison, Wisconsin, May 2, 2006. E.B. Podgorsak, Acceptance speech for the W.D. Coolidge Award, 48-th annual meeting of the American Association of Physicists in Medicine (AAPM), Orlando, Florida, July 31, 2006. W. Abdel-Rahman*, S. Devic, J.P. Seuntjens, E.B. Podgorsak, Accurate dosimetry in photon build-up region, 48-th annual meeting of the American Association of Physicists in Medicine (AAPM), Orlando, Florida, 31 July – 4 August, 2006. E.B. Podgorsak, High technology equipment used in modern radiotherapy, Presentation to the “Committee on Radiation source use and replacement”, National Academies, Washington, D.C., September 12, 2006. Ervin B. Podgorsak, Effects of target and flattening filter on the quality of linac beams, Medical Physics seminar, Graduate Programs in Medical Physics, University of Chicago, Chicago, Illinois, January 26, 2007. Ervin B. Podgorsak, Health Care: A basic human right or privilege? A medical physicist’s perspective, Rounds, Departments of Radiology and Radiation & Cellular Oncology, University of Chicago, Chicago, Illinois, January 26, 2007. E.B. Podgorsak, Medical Physics: Historical Perspective and Current Trends, 2nd International Saudi Symposium on Medical Physics and the Inaugural meeting of the Saudi Medical Physics Society (SMPS), Riyadh, Saudi Arabia, May 7 - 9, 2007. E.B. Podgorsak, Stereotactic Irradiation, 2nd International Saudi Symposium on Medical Physics and the Inaugural meeting of the Saudi Medical Physics Society (SMPS), Riyadh, Saudi Arabia, May 7 - 9, 2007. 98
  • 99. Department of Oncology Annual Report 2006/2007 E.B. Podgorsak, Medicinska fizika kot znanost in poklic (Medical Physics: A Science and Profession), Keynote Address, Fifth Congress of Slovenian Physicians from Slovenia and Abroad, Slovenian World Congress, Ljubljana, Slovenia, 31 May - 2 June, 2007. 4. Peer-Reviewed Abstracts A. Sarfehnia, K. Jabbari, J. Seuntjens, E. Podgorsak, Radiation quality in high contrast imaging with orthogonal bremsstrahlung beams, Med. Phys. 33, 1984 (2006). W. Parker, E. Poli, H. Patrocinio, L. Souhami, L. Lucente Campos, E.B, Podgorsak, Analysis of 10,327 Pre-treatment ultrasound localizations for 387 prostate cancer patients treated with conformal 3D external beam radiation therapy, Med. Phys. 33, 2026 (2006). S. Devic, T. Vuong, Me. Evans, E. Podgorsak, E. Poon, F. Verhaegen, HDR endorectal brachytherapy: quality assurance, Med. Phys. 33, 2105 (2006). M. Evans, M. Olivares, J. Seuntjens, W. Parker, S. Devic, E. Poli, C. Freeman, E. B. Podgorsak, Rotational total skin electron irradiation using a commercially available linear accelerator with a high dose rate total body electron mode, Med. Phys. 33, 2134- 2135 (2006). Y-Z. Wang, D. Lewis, E. Poon, F. Verhaegen, E. Podgorsak, S. Devic, Sensitivity of document scanners used for radiochromic film dosimetry, Med. Phys. 33, 2135 (2006). W. Parker, E. Poli, M. Evans, L. Lucente Campos, E. Podgorsak, The effect of target volume depth on surface dose for inverse planned IMRT treatments of head and neck cancers, Med. Phys. 33, 2142 (2006). N. Tomic, M. Gosselin, J. Wan, U. Saragovi, M. Evans, E.B. Podgorsak, S. Devic, Verification of cell irradiation dose deposition using radiochromic film, Med. Phys. 33, 2149 (2006). E. Sham, S. Devic, J. Seuntjens, E. Podgorsak, Dosimetry of very small (1.5 and 3 mm diameter) photon beams: Diode and film measurements versus Monte Carlo calculations, Med. Phys. 33, 2214 (2006). E. Sham, S. Devic, J. Seuntjens, E. Podgorsak, Focal source size measurement for Monte Carlo simulations of percentage depth doses in very small photon fields, Med. Phys. 33, 2284 (2006). S. Devic, J. Seuntjens, N. Tomic, T. Vuong, E.B. Podgorsak, Impact of absorption spectroscopy on 2D radiochromic film dosimetry, J. Europ. Soc. for Therap. Radiol. and Oncol., 78 (Suppl. 1), S78 (2006). A. Sarfehnia, K. Jabbari, J. Seuntjens, E.B. Podgorsak, High Contrast Imaging Using Orthogonal Brems-strahlung Beams: An Experimental Study of Radiation Quality, Med. Phys. 33, 2668 (2006). 99
  • 100. Department of Oncology Annual Report 2006/2007 M.D.C. Evans, M. Olivares, J. Seuntjens, W. Parker, S. Devic, E. Poli, C.R. Freeman, E.B. Podgorsak, A rotational total skin electron irradiation technique using a linear accelerator with a commercially available high dose rate total body electron mode, Med. Phys. 33, 2674 (2006). M.E. Ramos Poli, W. Parker, H. Patrocinio, L. Souhami, L. Campos, E.B. Podgorsak, Sources of uncertainty in the target localization based on statistical analysis of pre- treatment ultrasound for prostate cancer patients, Proceedings of the “World Congress on Medical Physics and Biomedical Engineering”, Seoul, Korea, August 27 – September 1, 2006, 14, 4548. 5. Involvement in continuing education activities Secretary, American College of Medical Physics (2006 - ) Michael Pollak 1. Summary of New and Ongoing Research We continue to have ongoing collaborations with investigators at Harvard, NIH, and MD Anderson related to IGF-I physiology and cancer. We also have established relationships with pharmaceutical companies including Pfizer and Oncogenix with respect to clinical trials. We have agency funding from Prostate Cancer Foundation (Los Angeles), NIH, NCIC, and CBCRA. 2. Research grants (new and ongoing) Bristow R (PI) 2001-2007 National Cancer Institute of Canada ~$3,000,000 Canadian Molecular and Micronutrient Prostate Cancer Research Network The goals of this study are to examine the cellular effects of micronutrients on prostate cancer prevention, to identify genes and proteins that promote the growth and spread of this cancer and to improve early disease therapy. Role: Management Committee Member, Co-PI Pollak M (PI) 2005-2009 Canadian Breast Cancer Research Alliance $3,000,000 IGF and Insulin signaling pathways in breast cancer The goal of this study is to conduct translational research regarding the signaling pathways of insulin like growth factor and insulin in breast cancer. Role: Program Leader, Component PI 100
  • 101. Department of Oncology Annual Report 2006/2007 Lippman SM (PI) 2005-2009 National Cancer Institute ~$18,000,000 Biology of the prostate cancer prevention trial The goal of this study is to conduct translational research concerning the biology of prostate cancer prevention Role : Leads one of six sections of the overall project. Fleshner N (PI) 2004-2009 Ontario Cancer Research Network ~$500,000 Translation Companion Study to PRP.1 The goal of this study is to conduct research related to IGF physiology in prostate cancer. Role: Collaborator Kaplan RC (PI) 2003-2009 National Institute of Health ~$1,000,000 Epidemiology of IGF and Cardiovascular Events The goal of this study is to conduct research related to IGF physiology and cardiovascular disease. Role: Collaborator McTiernan Anne (PI) 2005-2010 National Cancer Institute ~$50,000.00 Glycemic load and obesity: effects in cancer biomarkers The goal of this study is to conduct research related the effects of gylcemic load and obesity on cancer biomarkers. Role: Co-PI for a component. Pollak M (PI) 2007-2010 National Cancer Institute of Canada ~$350,000.00 Dietary factors influencing IGF signaling in prostate cancer The goal of this project is to define the role of macronutrients in influencing cancer growth rate via mechanisms involving insulin and IGF signaling. Role: PI 101
  • 102. Department of Oncology Annual Report 2006/2007 Award Funds Prostate Cancer Foundation ~$88,000.00 Mediators of the Adverse Impact of Obesity on Risk for High Grade Prostate Cancer 3. Research Training: undergraduate students, graduate students, postdocs/fellows Name Status Carolyn Algire Graduate student Matei Mireuta Graduate student Matthew Cunningham Postdoc Marie-Jose Blouin Postdoc Mahvash Zakikhani Postdoc 4. Conference Organization International conference on Milk and Health, Boston, October 2006 (a collaboration between Harvard Center for Cancer Prevention and McGill Center for Cancer Prevetion). 5. Invited Presentations and Workshops (National and International) 2006 Canadian Breast Cancer “Weekend to end breast cancer” workshop, Vancouver, June Invited Speaker ASCO meeting, Podium Presentation, Breast Cancer Session, Atlanta, June, Lecture MD Anderson Cancer Centre, Houston, June, Invited speaker Harvard University, Dept. of Nutrition, Boston, October, Invited Speaker Sanofi Aventis, Paris, October, Invited speaker Prostate Cancer Foundation (USA) , Arizona, October, Invited Speaker Harvard – McGill Milk symposium, Boston, October, Co- Organizor and speaker AACR Cancer Prevention Meeting, Boston, November, Invited Speaker Department of Endocrinology, University of Toronto, November, Invited Speaker Department of Endocrinology, UCLA, December, Invited Speaker 102
  • 103. Department of Oncology Annual Report 2006/2007 2007 Prostate Cancer Foundation of Canada, Hockley Valley, Ontario, January, Invited Speaker Gordon Research Conference, Ventura beach, California, March, Speaker 6. Peer-Reviewed Abstracts Multiple abstracts presented at AACR, ASCO and other meetings. 7. Hospital Activities Director, Cancer Prevention Centre, JGH Stephane Richard 1. Summary of New and Ongoing Research Breast Cancer project with Dr. William Muller McGill (Paper in press Oncogene) AIDS and methylation with Dr. Mark Wainberg Arginine methylation with Dr. Mark Bedford MD Anderson Myelination Dr. Guillermina Almazan (McGill) DNA damage and cancer Dr. Jean Yves Masson (Université Laval) Cytoskeleton Dr. Claire Brown (McGill) DNA damage Dr. Paola Marignani (Dalhousie) Splicing (Dr. Ben Blencowe U of Toronto) 2. Research grants (new and ongoing) SR is sole PI on all of these grants 2005-2007 Cancer Research Society Inc. - Characterization of the Breast Tumor Kinase, $60,000.00/ year 2006-2009 National Cancer Institute of Canada-$137,240/ yr 2006-2009 Multiple Sclerosis Society of Canada- The role of the quaking proteins in oligodendrocyte physiology 98,610.00/ yr 2007-2012 Canadian Institutes of Health Research, Role of the STAR protein Sam68 in cancer: regulation by tyrosine kinases $141, 186.00/year 2007-2012 Canadian Institutes of Health Research, The role of arginine methylation of MRE11 in mediating the DNA damage response. $123,893.00/year 103
  • 104. Department of Oncology Annual Report 2006/2007 2007-2012 National Cancer Institute of Canada, The role of the QUAKING RNA binding proteins in tumorigenesis $123,000.00/year 3. Construction of major facilities or major equipment grants. Writing a CFI -LOF retention on behalf of the LDI-JGH =(2007) I applied to a major LEF (10,000,000) that passed the Quebec government but did not get funded 4. Research Training: undergraduate students, graduate students, postdocs/fellows PDFs: Dr. Erique Lukong, Ying Hunag, Jonathan Levesques-Michaud, Yunling Wang, Marc-Etienne Huot, Frederick Mallet-Antone, Tong Guo PhD students: Carol-Anne Chenard, Kai-Wei Chang, Lu Liu, Christina Gavin Research Associates: Gillian Vogel and Melanie Morel 5. Scientific Reviews: Editorial Boards and Journal Reviews CIHR Cancer A panel member, CRS panel member Reviewer for many journals Journal of Immunology, Biochemistry and Cell Biology, Blood, Biotechnique, Cell Growth & Differentiation, FEBS letters, Gene, Genes & Development, Journal of Biological Chemistry, Journal of Cell Science, Molecular and Cellular Biology, Journal of Neuroscience, Journal of Neuroscience Research, Journal of Molecular Biology, Oncogene, PLOS Biology, Nature, Biochimica et Biophysica Acta, Molecular Cell, Mammalian Genome, The American Journal of Psychiatry, Diabetologia, Médécine Science 6. Conference Organization Annual research day of the LDI 7. Invited Presentations and Workshops (National and International) 2006 Taming Sam68 for breast cancer prevention. PI meetings. Lady Davis Institute, McGill University. 2006 Invited to give a seminar at Seventh Conference on Signalling in Normal and Cancer Cells, to be held in Banff, Canada, Invited by Dr. A. Veillette, Pawson and Robbins March 3-7, 2006. 104
  • 105. Department of Oncology Annual Report 2006/2007 2006 Rôles des protéines KH liant l'ARN dans le destin cellulaire: implications pour la sclérose en plaques, l'obésité et l'ostéoporose. Invité pour le symposium scientifique de biochimie. Départment de biochimie, Université de Sherbrooke. Invite par Dr. S. Labbé 2006 Cellular responses regulated by arginine methylation. Manitoba Institute of Cell Biology. Invited by Dr. G. Hicks 2006 The role of arginine methylation in the DNA damage response. Molecular Immunology Unit, Pasteur Institute, Paris, France. 01/06 invited by Dr. Oreste Acuto 2006 Arginine methylation regulates the DNA damage response. FASEB summer research conferences. Saxtons River, Vermont. Invited by Dr. Catherine Clarke, June 26- 29/ 06 2006 Chromatin mediated biological decisions from October 5th-10th, 2006 in Marburg, Germany. Invited by Dr. Martin Eilers. 2007 RNA binding proteins in cell fate determination: implications for multiple sclerosis, obesity and osteoporosis. IRIC. Université de Montréal. Invited by Dr. K Borden 2007 RNA binding proteins in cell fate determination: implications for multiple sclerosis, obesity and osteoporosis. Ste-Justine Hospital. Université de Montréal. Invited by Dr. A. Richter. 2007 RNA binding proteins in cell fate determination: implications for multiple sclerosis, obesity and osteoporosis. Indiana University, Indianapolis. Invited by Dr. Johnny He 8. Peer-Reviewed Abstracts Torabi N. and S. Richard 2006. Sam68 deficient mice are protected from dietary obesity and insulin resistance. Adipogenesis, obesity and inflammation. Keystone Meeting, Vancouver, BC. Huot M.E., Richard S. 2006. Sam68 Nuclear Bodies (SNBs) Dynamics. Eleventh annual meeting of the RNA Society. Seattle, Washington. Huot M.E., Richard S. 2006. Sam68 Nuclear Bodies (SNBs) Dynamics in cell proliferation and metastatic potential. 25th Congress of the International Association for Breast Cancer Research (IABCR). Montreal, Canada. 9. Hospital Activities Associate director of basic research, member of numerous search committees 105
  • 106. Department of Oncology Annual Report 2006/2007 George Shenouda 1. Summary of New and Ongoing Research Applied For CMPA Grant Program 2007: Development of a comprehensive system for classifying, recording and analysis radiation events. ($31,000). Principal Investigator: Dr. C. R. Freeman Co-investigators: Carole Gingras, RTT, Ervin Podgorsak, Ph.D, FCCPM, DABMP, Mark Daly, RRT, MA(Ed), George Shenouda, M.B.,B.Ch., Ph.D., FRCPC. 2. Research grants (new and ongoing) May 2006 - McGill Teaching & Learning Improvement Fund: Grant received for the development of a Web-Based teaching module on Head & Neck anatomy for the Radiation Therapy Residents. ($12,000) Principal Applicant: Dr. L. Portelance Co-applicant: Dr. Fleur Gallant, Dr. Khalil Sultanem, Dr. Te Vuong, Dr. George Shenouda. 3. Research Training: undergraduate students, graduate students, postdocs/fellows. Program Director – Radiation Oncology, McGill University. 4. Peer-Reviewed Abstracts O. Ballivy MD, W. Parker MSc, T. Vuong MD, G. Shenouda MD, and H. Patrocinio MSc. Impact of geometric uncertainties on dose distribution during intensity modulated radiotherapy of head-and-neck cancer: the need for a planning target volume and a planning organ-at-risk volume. Current Oncology, 13(3), May 2006. 5. Hospital Activities Member of Quality Assurance Committee, Radiation Oncology Member of Comité d’éthique de la Recherche – Centre Hospitalier de Gatineau. 106
  • 107. Department of Oncology Annual Report 2006/2007 Luis Souhami 1. Research Activities Combined chemotherapy and radiotherapy in cancer Stereotactic Radiosurgery Altered fractionation schedules in radiotherapy Gynecologic malignancies Central Nervous System malignancies Genito-Urinary Malignacies 2. Research Grants (new and ongoing) D Roberge, L Souhami, T Muanza, Schering-Plough, $ 20, 000 2005-2007, Stereotactic radiosurgery and temozolomide in recurrent brain metastases C Catton, H Lukka, P Warde, M Levine, J Julian, A Gafni, G Bauman, M Parliament, J Wu, T Pickles, L Souhami, JP Bahary., Canadian Institutes of Health Research $2, 209, 971, 2005-2012 A randomized trial of a shorter fractionation schedule for localized carcinoma of the prostate.(Reference # 200504MCT – 146207) J P Seutjens, L Souhami, E podgorsak, R Lisbona, C J Thompson, Canadian Institutes of Health Research, $138, 562, 2005-2008, 4D Monte Carlo planning, 4D PET/CT-based delineation and post-treatment evaluation of lung cancer radiotherapy treatments 3. Research Trainees Dr Fabio Cury. Astra-Zeneca Genito-Urinary fellow. March 2004-June 2006. Dr Chandra Martens. Pulmonary fellow. September 2005-September 2006. Dr. Bosede Joshua. Astra-Zeneca Genito-Urinary fellow. July 2006-December 2007. 4. Scientific Reviews Editorial Board Revista Brasileira de Cancerologia, 1982 - present Current Oncology, 1993 - present Journal of Radiosurgery, 1997 - 2000 International Journal of Radiation Oncology Biology Physics, 1998 – present 107
  • 108. Department of Oncology Annual Report 2006/2007 Technology in Cancer Research & Treatment, 2002 – present Applied Cancer Research, 2005 – present Our Voice, 2005 - present Ad Hoc Reviews Radiology International Journal of Gynecological Cancer Canadian Journal of Neurological Sciences Cancer The Canadian Journal of Oncology Journal of Palliative Care Canadian Journal of Urology Expert Review of Anticancer Therapy Gynecologic Oncology 5. Conference Organization Member, Organizing Committee:Annual Meeting of the Brazilian Society of Radiation Oncology. Buzios, Brazil, October 27-29, 2006 (Chairman Scientific Program) 6. Invited Presentations February 16, 2007 – EXMD 617 Workshop on Advanced Drug Development. The importance of phase II-III in clinical research. April 23, 2007 – Radiation Oncology Rounds. Montreal General Hospital. Is there a role for post-operative RT in NSCLC? May 11, 2007 – McGill University Radiation Sciences Research Retreat. Montreal General Hospital. Future directions for clinical radiation oncology research Souhami L. Patient selection, target definition, organ delineation. Technical Meeting on Evaluation on Intensity Modulated Therapy as a Clinical Treatment in Radiotherapy. Vienna, Austria, June 13-16, 2006. Souhami L. Difficulties, uncertainties and concerns of IMRT. Technical Meeting on Evaluation on Intensity Modulated Therapy as a Clinical Treatment in Radiotherapy. Vienna, Austria, June 13-16, 2006. 108
  • 109. Department of Oncology Annual Report 2006/2007 Souhami L. Brachyhterapy fractionation schedules. Workshop on Guidelines for the Treatment of Cervical Cancer in Developing Countries. Vienna, Austria, September 11- 14, 2006. Souhami L. Prostate cancer and radiotherapy. Prostate Cancer Support Group. Montreal, QC, October 5, 2006. Souhami L. The role of radiotherapy in non-small cell lung cancer. I International Oncology Course. Quito, Ecuador, October 12-14, 2006 Souhami L. The non-surgical treatment of cervix cancer. . I International Oncology Course. Quito, Ecuador, October 12-14, 2006 Souhami L. The treatment of central nervous system tumors. . I International Oncology Course. Quito, Ecuador, October 12-14, 2006 Souhami L. Prostate Cancer. VIII Congress of the Brazilian Society of Radiotherapy. Buzios, Brazil, October 26-28, 2006. Souhami L. Evaluation of IMRT as a treatment modality: recommendations of an IAEA expert panel. International Conference on Quality Assurance and New Techniques in Radiation Medicine. Vienna, Austria, November 13-15, 2006. Souhami L. Multimodality therapy for stage III non-small cell lung cancer. The role of radiotherapy. XVII Meeting of the Brazilian Cancer Society. Belo Horizonte, Brazil, November 22-25, 2006. Souhami L. Recent advances in the management of malignant gliomas. XVII Meeting of the Brazilian Cancer Society. Belo Horizonte, Brazil, November 22-25, 2006. Souhami L. Treatment of metastatic brain disease. What’s new? XVII Meeting of the Brazilian Cancer Society. Belo Horizonte, Brazil, November 22-25, 2006. Souhami L. Concomitant radiotherapy and hormonal therapy in prostate cancer. XVII Meeting of the Brazilian Cancer Society. Belo Horizonte, Brazil, November 22-25, 2006. Souhami L. Post-operative radiotherapy in prostate cancer. XVII Meeting of the Brazilian Cancer Society. Belo Horizonte, Brazil, November 22-25, 2006. Souhami L, Bayley A. IMRT in prostate cancer. GUROC meeting. Toronto, ON, January 12-13, 2007. Souhami L. Completely resected stage III NSCLC: the role of post-operative radiotherapy. Improving outcomes in the management of lung cancer. Gold Coast, Australia, March 8-10, 2007 Souhami L. Brain metastases in NSCLC. Role of new agents and preventive brain radiotherapy. Improving outcomes in the management of lung cancer. Gold Coast, Australia, March 8-10, 2007 Souhami L. The role of radiotherapy in post-prostatectomy patients. II Congresso Cearense de Cancerologia. Fortaleza, Brazil, April 28-30, 2007. 109
  • 110. Department of Oncology Annual Report 2006/2007 Souhami L. Brain metastases. State of the art. II Congresso Cearense de Cancerologia. Fortaleza, Brazil, April 28-30, 2007. Souhami L. Current management of brain metastases. Grand Rounds, Hospital do Cancer. Fortaleza, Brazil. May 4, 2007. 7. National and International Committees Site visit surveyor - NCI sponsored RTOG Quality Control Committee site visit of the Tom Baker Cancer Center, Calgary, Alberta, July 10-11, 2006. Site visit surveyor - NCI sponsored RTOG Quality Control Committee site visit of the H Lee Moffitt Cancer center, Tampa, Florida, April 16-17, 2007. Abstract reviewer, Annual Meeting of the American Society of Therapeutic Radiology and Oncology, 2006. Consultant, International Atomic Energy Agency (IAEA). Technical meeting on Evaluation of Intensity Modulated Therapy as a Clinical Treatment in Radiotherapy. Vienna, Austria, June 13-16, 2006. External Reviewer for promotion to Full Professor, Dr David Gaffney, 2006 (University of Utah). Consultant, International Atomic Energy Agency (IAEA) on Development of Guidelines for the Treatment of Cervix Cancer. Vienna, Austria, September 11-14, 2006. Moderator, Gynecological Cancer Oral Session, 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology. Philadelphia, PA, November 5-9, 2006. Member, Strategic Planning Working Group of NCIC CTG Gynecology Committee, 2006-2007 Abstract reviewer, Annual Meeting of the American Society of Therapeutic Radiology and Oncology, 2007. 8. University and Hospital Committees Associate Director, Department of Oncology, Division of Radiation Oncology - 1991 - present Principal Investigator, Radiation Therapy Oncology Group – 1991 - present Co-Chairman, Clinical Research Program – 2002 - 2007 110
  • 111. Department of Oncology Annual Report 2006/2007 9. Peer-Reviewed Abstracts Parker W, Poli ME, Patrocinio H, Souhami L, Campos LL, POdgorsak E. Analysis of 10,327 pre-treatment ultrasound localizations for 387 prostate cancer patients treated with conformal 3D external beam radiation therapy. Med Phys 33:2026, 2006. Stroian G, Souhami L, Martens C, Collins DL, Seuntjens J. Image registration-based tool for correlation studies of radiation-induced fibrosis and local dose-related parameters in conformal non-small cell lung cancer radiation therapy. Med Phys 33:2289, 2006. Martens C, Lisbona R, Devic S, Faria S, Seutjens J, Stroian G, Swan S, Souhami L. Integrating PET-CT scans and radiation treatment planning of non-small cell lung cancer. Radioth Oncol 80(supp 1):S6, 2006. Faria S, Menard S, Devic S, Lisbona R, C Sirois, Souhami L, Freeman C. The impact of FDG-PET on radiation therapy gross tumor volume (GTV) delineation in non-small cell lung cancer (NSCLC) may be smaller than predicted. Radioth Oncol 80(supp 1):S6, 2006. Parker W, Poli ME, Patrocinio H, Souhami L, Shenouda G, Campos LL, Podgorsak E. An assessment of inter-fraction prostate motion based on 10,327 pre-treatment ultrasound localizations for 387 prostate cancer patients treated with conformal 3D external beam radiation therapy. Radioth Oncol 80(supp 1):S9, 2006. Faria SL, Souhami L, Patrocinio HJ, Joshua B, DeBlois F, Duclos M, David M, Shenouda G. Late rectal toxicity after hypofractionated radiation therapy for prostate cancer: lack of correlation with recognized dose-volume guidelines. Radioth Oncol 80(supp 1):S11, 2006. Shenouda G, Roberge D, Kavan P, Muanza T, Lambert C, Leblanc R, Del Maestro R, Guiot M-C, Souhami L. A novel approach using accelerated hypofractionation IMRT and temozolomide in patients with glioblastoma multiforme. Radioth Oncol 80(supp 1):S13, 2006. Patone H, Portelance L, Parker W, Souhami L. A comparison of individualized treatment planning to a standardized template planning approach in high dose rate brachytherapy for cervix cancer. Radioth Oncol 80(supp 1):S39, 2006. Cury F, Duclos M, Aprikian A, Mansour M, Souhami L. Volumetric changes post single fraction high-dose rate btachytherapy as a boost to external beam radiation therapy in prostate cancer. Should it be considered an important factor for margin definition? Radioth Oncol 80(supp 1):S44, 2006. Faria S, Lisbona R, Stern J, Souhami L, Portelance L, Devic S, Freeman C. Pre- and post-treatment PET/CT to evaluate the response of non-small cell lung cancer treated with curative radiotherapy alone. Radioth Oncol 80(supp 1):S50, 2006. Verhaegen F, Marl C, Fraser D, Cury F, Chang A, DeBlois F, Duclos M, Souhami L, Shenouda G, Falco T. The use of 3D intra-modality ultrasound imaging for daily localization of the prostate in radiotherapy. Radioth Oncol 81:S230-231, 2006. 111
  • 112. Department of Oncology Annual Report 2006/2007 Martens C, Lisbona R, devic S, Stroian G, Seuntjens J, Faria S, Souhami L. PET-CT scan integration and co-registration for use in radiation treatment planning of non-small cell lung cancer. Radioth Oncol 81:S393, 2006. Faria S, Freeman CR, Lisbona R, Stern J, Souhami L, Devic S, Small D. Pre and post- treatment PET/CT to evaluate the response of non-small cell lung cancer treated with curative radiotherapy alone. Radioth Oncol 81:S393-394, 2006. Menard S, Faria SL, Lisbona R, Souhami L, Freeman CR, Devic S. The delineation of gross tumor volume in the radiation trteatment of non-small cell lung cancer with fused FDG-PET/CT: are we ready for the alterations? Radioth Oncol 81:S397, 2006. Joshua B, Faria S, Patrocinio H, DeBlois F, Duclos M, David M, Shenouda G, Souhami L. Lack of correlation between recognized dose-volume guidelines and late rectal toxicity after hypofractionated radiation therapy for prostate cancer. Radioth Oncol 81:S449, 2006. Patrocinio H, Bosed J, Souhami L, Faria SL, Shenouda G, David M, Freeman CR. The complexicity of reporting late toxicity after curative hypofractionated radiation treatment in localized prostate cancer. Radioth Oncol 81:S455-456, 2006. Choy H, Swan S, Nabid A, Stea B, Roa W, Souhami L, Curran W. Comparison of 5-year survival between RTOG 94-10 and a Phase 2 study of induction chemotherapy followed by efaproxiral + radiotherapy in patients with locally advanced NSCLC. Int J Radiat Oncol Biol Phys 66: S28, 2006. Suh JH, Mehta MP, Dagnault A, Chabot P, Chang AL, Fortin MA, Grecula JC, Nabid A, Souhami L, Renschler MF. Motexafin Gadolinium-based treatment planning MRI identifies occult brain metastases amenable to stereotactic radiosurgery: imaging results of a phase II trial of motexafin gadolinium and whole brain radiotherapy with stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 66: S193, 2006. Siker ML, Berkey BA, Nelson D, Curran WJ, Michalski J, Souhami L, Chakravarti A, Yung WA, DelRowe J, Mehta MP. Age as an independent prognostic factor in patients with glioblastoma: a Radiation Therapy Oncology Group analysis. Int J Radiat Oncol Biol Phys 66: S196, 2006. Patone H, Souhami L, Parker W, Cury F, Portelance L. A dosimetric comparison of two high-dose-rate planning systems in cervix cancer: individualized treatment planning versus standardized template planning. Int J Radiat Oncol Biol Phys 66: S400, 2006. Stroain G, Marten C, Souhami L, Seuntjens J. Correlation of radiation-induced fibrosis and local dose related parameters in conformal non small cell lung cancer radiation therapy. Int J Radiat Oncol Biol Phys 66: S494, 2006. Siker ML, Berkey B, Porter K, Nelson D, Curran W, Michalski J, Souhami L, Charkravarti A, Yung W, DelRowe J, Coughlin C, Mehta MP. Age as an independent prognostic factor in patients with glioblastoma: an RTOG and ACos national cancer base comparison. Neuro Oncol 8:408, 2006 112
  • 113. Department of Oncology Annual Report 2006/2007 Blumenthal DT, Berkey B, Nelson D, Curran W, Leibel S, Souhami L, Michalski J, Corn B, Chakravarti A, Rogers L, Mehta M. “Short” delay in initiation of radiotherapy may not affect the outcome of patients with GBM: a secondary analysis from the RTOG data base. Neuro Oncol 8:483, 2006. Shapiro WR, Mehta MP, Patchell RA, Glantz MJ, Recht L, Sur R, Fortin A, Ung Y, Souhami L, Phan S, Smith JA, Renschler MF. Motexafin gadolinium combined with whole-brain irradiation therapy prolongs time to neurologic progression in non-small cell lung cancer patients with brain metastases: pooled analysis of two randomized phase 3 trials. Neuro Oncol 8:489, 2006. Souhami L, Bae K. Pilepich MV, Sandler H. The impact of the duration of adjuvant hormonal therapy in patients with unfavorable prognosis prostate cancer treated with radiotherapy: secondary analysis of RTOG 85-31. J Clin Oncol 25 (18S):250s, 2007. Joshua BB, Faria S, Patrocinio H, DeBlois F, Duclos M, David M, Shenouda G, Souhami L. The impact of varying rectal contours on rectal dose in prostate cancer patients treated with hypofractionated radiation. J Clin Oncol 25 (18S):657s, 2007. Marc Tischkowitz 1. Summary of New and Ongoing Research Study of DNA repair genes in breast cancer predisposition (McGill) Immunohistochemical markers in basal-like breast cancer (McGill, UBC, Hôpital du Sacre -Coeur de Montréal, The Gade Institute, Haukeland University Hospital, Bergen, Norway) Analysis PALB2/FANCN breast cancer familes (Program in Cancer Genetics, McGill University, Departments of Oncology, Human Genetics and Pathology, McGill University, The Research Institute, McGill University Health Centre, McGill University and Genome Québec Innovation Centre, Dana-Farber Cancer Institute and Harvard Medical School, The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London UK, Division of Experimental Therapy, Netherlands Cancer Institute, Amsterdam, The Netherlands, Women's College Research Institute, Women's College Hospital, Toronto. Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancer (McGill; Memorial Sloan Kettering Cancer Center, NY; Genetic Susceptibility Group, IARC, Lyon, France; Public Health Sci. and Div. Human Biol, Fred Hutchinson Cancer Research Center, Seattle, WA; Inst. Systems Biology, Seattle; Univ. Toronto, Toronto, ON, Canada; Dept Int. Med.& Urol., Univ. Michigan, Ann Arbor, MI; Cancer Genetics Branch, NHGRI, Bethesda, MD; Johns Hopkins Medical Institutions, Baltimore, MD. Pathogenicity of a BRCA1 missense variant is determined by the disruption of the phosphopeptide binding pocket – a multi-modal approach Program in Cancer Genetics, McGill University, Departments of Oncology, Human Genetics, Pathology and 113
  • 114. Department of Oncology Annual Report 2006/2007 Medicine, The Research Institute, McGill University Health Centre McGill University, Department of Risk Assessment, Detection, and Intervention, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA, Centro Federal de Educação Tecnológica de Química, Rio de Janeiro, RJ 20270, Brazil; Molecular Medicine Laboratory and Macromolecular Crystallography Unit, Division of Experimental Medicine, Harvard Institutes of Medicine, Harvard Medical School, Department of Pathology/Division of Experimental Therapy, Netherlands Cancer Institute, Amsterdam, The Netherlands, Department of Hematology & Genetic Pathology, Flinders Medical Centre and Flinders University of South Australia, Kathleen Cuningham Consortium for Research into Familial Breast Cancer, Peter MacCallum Cancer Institute, St Andrews Place, East Melbourne, Australia; Department of Dermatology, University of Utah School of Medicine, Salt Lake City, USA, International Agency for Research on Cancer, World Health Organization, Lyon, France. 2. Research grants (new and ongoing) CFI grant for new lab equipment (Segal Center) (PI) awarded April 2006 $103, 795 Rethink Breast Cancer Career Development Award, $35,000 (June 1st 2006) 3. Construction of major facilities or major equipment grants CFI grant for new lab equipment (Segal Center) $103, 795 4. Research Training: undergraduate students, graduate students, postdocs/fellows Rachel Kyle May 2007 – summer student 5. Scientific Reviews: Editorial Boards and Journal Reviews Member of Editorial board, Clinical & Investigative Medicine 6. Hospital Activities Cancer Genetics service, Cancer Prevention Centre, Segal Cancer Centre. 7. Involvement in continuing education activities September 22nd, 2006, An update on Hereditary Breast Cancer, Hôpital Charles LeMoyne Oncology Rounds October 26th, 2006, What’s new in DNA Repair? Montreal Centre for Experimental Therapeutics in Cancer, 4th Annual Meeting 114
  • 115. Department of Oncology Annual Report 2006/2007 December 14th, 2006, Genetic factors in breast and ovarian cancer: a primer for family doctors, McGill Thursday Evening Lecture Series 26th February, 2007, Jewish General Hospital Medical Rounds (also presented at Montreal General Hospital and Royal Victoria Hospital), A stitch in time?” - management issues in hereditary gastric cancer 13th April 2007, PALB2/FANCN – another link between Fanconi Anemia and breast cancer, McGill University Hospitals Research Institute Genetics Axis and McGill Department of Human Genetics Seminar Series 8. Involvement in the community 16th May 2007, Genetics of Colorectal Cancer, “Lets Talk about Colorectal Cancer” - Free Public Forum: Chevra Kadisha B’nai Jacob - Beit Hazikaron and Colorectal Association of Canada 27th May 2007, Hereditary Predisposition to Breast Cancer, 30 minute interview, Radio 940, Montreal, and Cancer- Are you at risk? Can you prevent it? Public Seminar, Salon des Baby Boomers Plus, Palais des congrès, Montréal Patricia Tonin 1. Summary of New and Ongoing Research See web site for summary of main research activities: www.toninlab.mcgill.ca Ovarian cancer collaborators: Drs. Anne-Marie Mes-Masson and Diane Provencher (CHUM, Montreal). Breast cancer research collaborators: Drs. Morag Park (MUHC-RI) and Mark Basik (LDI) Hereditary Breast-ovarian cancer research collaborators: Drs. Christine Maguard, Diane Provencher, and Parviz Ghadirian (CHUM), and Will Foulkes (MUHC-RI). 2. Research grants Agency: Fonds de la Recherche en Santé du Québec: Reseau cancerologie Project: Banque de tissues et de données pour le cancer du sein et du l’ovaire Investigators: D Bachvarov, M Basik, G Batist, J Brisson, W Foulkes, P Ghadirian, W. Gotlieb, T Hudson, A-M Mes-Masson, C Maugard, M Park, G Poirier, D Provencher, C Rancourt, B. Tetu, PN Tonin Type: Infrastructure - Group Amount: $1,100,000/annum [Allocation TBA] 115
  • 116. Department of Oncology Annual Report 2006/2007 Duration: 5 year [TBA] Comment: Successful renewal of FRSQ Cancer Reseau/Network grant “Banque de tissues et de données pour le cancer du sein et du l’ovaire” Agency: Cancer Research Society, Inc Project: Contribution of TP53 and novel suspected cancer susceptibility genes in high risk breast and/or ovarian cancer families of French Canadian descent. Investigator: PN Tonin (PI) Type: Operating Amount: $60,000/annum Duration: September, 2006 – August, 2008 Agency: Canadian Institutes of Health Research Project: An integrated functional and genomics approach at elucidating the chromosome 3 genes important in ovarian cancer. Investigator: PN Tonin (PI) Collaborators: M Chevrette, A-M Mes-Masson , D Provencher, J Squire Type: Operating Amount: $98, 517/annum Duration: October 2006 – September, 2009 Agency: Cancer Research Society, Inc. Project: A model for modulating genetic and epigenetic events that influence the metastatic potential of ovarian cancer. Investigator: PN Tonin and A-M Mes-Masson (Co-PIs) Collaborators: M Chevrette, D Provencher Type: Strategic Grant Amount: $150,000/annum Duration: September 1, 2005 – August 31, 2007 116
  • 117. Department of Oncology Annual Report 2006/2007 Comment: Successful renewal of CRS-Strategic Grant “A model for modulating genetic and epigenetic events that influence the metastatic potential of ovarian cancer. Agency: Canadian Institutes of Health Research Project: Selection and validation of target genes implicated in the clinical and biological features of ovarian cancer Investigators: A-M Mes-Masson (PI), PN Tonin, D Provencher Type: operating Amount: $135,000/annum Duration: Oct 1, 2005– Sept 30, 2008 Comment: Successful renewal of CIHR grant “Selection and validation of target genes implicated in the clinical and biological features of ovarian cancer” Agency: Quebec Breast Cancer Foundation Project: The Discovery of Novel Tumor Suppressor Genes in Breast Cancer Investigators: M Basik (PI), S Mader, C Rancourt, PN Tonin Type: Group-operating Amount: $1,499,128 [Total] Duration: July 1, 2004– June 30, 2008 Agency: Fonds de la Recherche en Santé du Québec: Reseau cancerologie Project: Banque de tissues et de données pour le cancer du sein et du l’ovaire Investigators: L Alpert, D Bachvarov, M Basik, G Batist, J Brisson, W Foulkes, P Ghadirian, T Hudson, A-M Mes-Masson, M Park, G Poirier, D Provencher, C Rancourt, PN Tonin Type: Operating - Group Amount: $648,000/annum Duration: January 1, 2000 – March 31, 2007. Agency: Canadian Institutes of Health Research Project: Development of new therapeutic strategies for ovarian cancer Investigators: M-M Mes-Masson, M Filion (Industrial partner), PN Tonin, PD Provencher 117
  • 118. Department of Oncology Annual Report 2006/2007 Type: University-Industry Program- Operating Grants Amount: $113,792/annum Duration: October 10, 2004 – September 30, 2006 Agency: Valorisation-Recherche Québec (VRQ) Project: Plateformes structurantes du réseau cancer du FRSQ : modélisations, services d’analyses et banques de tissus et de données Investigators: L Alpert, D Bachvarov, M Basik, G Batist, J Brisson, P Chartrand (Project Leader), W Foulkes, P Ghadirian, T Hudson, A-M Mes- Masson, M Park, G Poirier, D Provencher, C Rancourt, PN Tonin Type: Operating, Group - Volet Structurants Amount: 408,000/annum Duration: July 1, 2002-June 30, 2006. Agency: Canadian Foundation for Innovation (CFI) Project: Expansion of genomics and proteomics infrastructure in Québec Investigators: J Bergeron, H Bussey, K Dewar, T Hudson (Project Leader), BM Knoppers, C Laberge, F Labrie, S Michnick, D Sinnett, PN Tonin Type: Infrastructure - Innovation Fund Amount: $12,800,000 (Total) Duration: July 1, 2002 –June 30, 2006 [extended to 2011] Agency: Montreal Breast Cancer Foundation Project: New modalities for breast cancer diagnosis and treatment Investigators: M Basik, J Brisson, P Chartand, D Fleiszer, W Foulkes, M Park (PI), G Poirier, PN Tonin Type: Group-operating Amount: $507,486/annum Duration: July 1, 2003 – June 30, 2006 118
  • 119. Department of Oncology Annual Report 2006/2007 3. Construction of major facilities or major equipment grants Agency: Canadian Foundation for Innovation (CFI) Project: Expansion of genomics and proteomics infrastructure in Québec Investigators: J Bergeron, H Bussey, K Dewar, T Hudson (Project Leader), BM Knoppers, C Laberge, F Labrie, S Michnick, D Sinnett, PN Tonin Type: Infrastructure - Innovation Fund Amount: $12,800,000 (Total) Duration: July 1, 2002 –June 30, 2006 [extended to 2011] Nominal impact – I got a RT-PCR machine. 4. Education and Training Undergraduate Courses In Medicine Back to basics: Unit 8 - Genetics in Everyday Medicine II Department: Medicine Coordinator: Feigi Kaplan Format: Small group sessions Title: The genetics of inherited adult onset cancer Role: Animator, coordinated sessions on hereditary cancer genetics Level: Second year medical students Time (hrs/yr): 7 hours Years: 2006 BOM: Unit 1- Molecules, cells and Tissues Department: Medicine Coordinator: Dr. George Shenouda Format: Small group session Title: Cancer and Oncogenes Role: Animator, coordinated sessions on cancer and oncogenes Level: First year medical students Time (hrs/yr): 2 hours Years: 2006 119
  • 120. Department of Oncology Annual Report 2006/2007 524-405B Genomic Medicine BACK TO BASICS SCIENCES “SEMINAR OPTION” Department: Medicine Coordinators: Drs. Nathalie LaMarsh-Vane and Fiona Bedford Format: Seminar Title: The Genetics of Breast and Ovarian Cancer Susceptibility Role: Lecturer Level: Fourth year medical students Time: 1 hour Year: 2006 *Formerly 524-405B Molecular biology Undergraduate Courses (Non-Medical) BIOL 568B* Topics on the Human Genome Department: Biology Coordinator: Dr. Christina Haston (Jan 2007-present) Dr. Rima Rozen (Jan 1997-2006) Format: Lecture Title : Genetics of human cancer Role: Lecturer Level: Graduating students, and graduate students Time (hr/yr): 4.5 hrs (three 1.5 hr lectures) Years: 2006 *Formerly 486B prior to 2003/2004 academic year. EXMD 504A Biology of Cancer Department: Medicine (Division of Experimental Medicine) Coordinator: Dr. David M.P. Thompson Format: Lecture 120
  • 121. Department of Oncology Annual Report 2006/2007 Title: Screening Breast Cancer Genes Role: Lecturer Level: Graduating students and graduate students Time (hr/yr): 1-2 hrs Years: 2006 (2 hrs) Graduate Courses (Non-Medical) EXMD 635D Experimental & Clinical Oncology Department: Medicine (Div. Experimental Medicine) Coordinator: Dr. Maria Zannis-Hadjopoulos Format: Lecture Title: Cancer Genetics/Prevention Role: Lecturer Level: Graduate students Time (hr/yr): 2 hrs Years: 2006 (Fall) HGEN 690B Inherited Cancer Syndromes Department: Human Genetics and Medicine (Div. Experimental Medicine) Coordinator: Dr. Patricia Tonin Format: Lecture Role: Coordinator and Lecturer Level: Graduate students (fundamental and genetic counseling), (open to residents as well) Time (hr/yr): 8 hrs Years: 2007 HGEN 692A/B Human Genetics Department: Human Genetics Coordinator: Dr. Aimee Ryan Format: Lecture & Discussion Group 121
  • 122. Department of Oncology Annual Report 2006/2007 Role: Lecturer & Animator Level: Graduate students (fundamental) Time (hr/yr): 1.5 hrs (lecture) & 1.5 hr (Discussion group) Years: 2007 (6 hrs) Residency Programs Friday Lecture and Seminar Series Host: Department of Human Genetics, McGill Topic: Review of Human Gene Structure and Function and other topics Audience: Genetics Residency Training Program Role: Lecture Date: August 25, 2006 (1 hr) 5. Scientific Reviews: Editorial Boards and Journal Reviews Grant Reviewer: Panel Membership Agency: Research Institute of the McGill University Health Centre Panel: Studentships and Postdoctoral Fellowships Years: 2006 (Spring), 2006 (Fall) Agency: Canadian Institutes of Health Research Panel: Cancer Progression and Therapeutics Panel (Formerly Cancer B) Years: 2006 (Fall), 2007 (Spring) Reviewed for BMC: Cancer (2006, 2007) Breast Cancer Research (2007) Cancer Detection and Prevention (2007) Clinical Genetics (2006) Genetics in Medicine (2006) Nature Reviews Cancer (2007) 122
  • 123. Department of Oncology Annual Report 2006/2007 6. Conference Organization 25th Congress of the International Association for Breast Cancer Research (IABCR), Montreal (Quebec), September 15-18, 2006 7. Invited Presentations and Workshops (National and International) Place: Cancer Research Laboratory Program London Regional Cancer Program, London Health Sciences Centre, London Ontario Topic: Integrating genomic, gene expression and functional complementation strategies to identify genes implicated in ovarian cancer Date: March 20, 2007 8. Peer-Reviewed Abstracts Host: HUGO : The Human Genome Organization Topic: Heterogeneity of BRCA1/2 mutations in hereditary breast and/or ovarian cancer French Canadian families from Quebec, Canada Occasion: Human Genome Meeting 2007, Montreal, Quebec Date: May 21-24, 2007 9. Involvement in the community College Stage Students (2007) Colleen Marcotte, Marianopolis college student, joined my research group for 2 weeks to gain hands-on experience of genetic testing techniques. Lower Canada College (2007) Breast Cancer Awareness Evening, April 4. The evening was dedicated to raising awareness of all forms of breast cancer. I provided information with a focus on inherited predisposition to breast and ovarian cancer. Anna Towers 1. Summary of New and Ongoing Research The research studies in which I am involved are in the area of cancer rehabilitation and arm morbidity following breast cancer treatment. Although my primary interest is in lymphedema, our research to date shows that there are functional problems as well as 123
  • 124. Department of Oncology Annual Report 2006/2007 issues with pain and social problems following breast cancer treatment, all of which need to be addressed. The first and largest study is a CIHR funded Canadian-wide study of which McGill is one of four sites. The PI is at the University of Saskatchewan and I am the McGill collaborator and co-ordinator. This study investigates arm morbidity following breast cancer in prospective fashion. At the end of the study, we hope to be able to identify the frequency of arm morbidity for female survivors of Stage I to III breast cancer treatment, the course of this impairment, possible triggers of the morbidity, its psychosocial impacts, and how care and treatment varies from region to region. For this I have a full- time research assistant and we have so far recruited 260 patients. We are putting in a renewal grant to CIHR for March 2007 and hope to recruit 400 participants at the McGill site and 1000 across Canada. The second study, funded by NCIC, investigates the effectiveness of exercise interventions for breast cancer related lymphedema. In this study I am co-PI with the Director of Graduate Studies at the McGill School of Physical and Occupational Therapy. The patients are being recruited from my clinic and we are in the intervention stage. The third project, of which I am PI, is funded by Fondation Québecoise du Cancer. We are in the intervention development phase of this study that looks at educational interventions to help improve quality of life and prevent arm morbidity following breast cancer treatment. Summary of research activities 2006-2007 In the last year I have completed a research study on the psychosocial effects of lymphedema. I supervised a full-time research assistant and continued to recruit for a Canadian CIHR-funded study on arm morbidity following breast cancer. I attended a co- investigators meeting in Saskatoon in August 2006 to plan for a grant renewal application that will be submitted to CIHR in March 2007. I helped refine the intervention on an NCIC funded study on the effect of exercise interventions for lymphedema, added another site to this study (Charles Lemoyne Hospital) and helped train the therapists who will give this intervention. Data gathering began in January 2007. I applied for and received new research funding from the Fondation Québecoise du Cancer to investigate educational interventions to reduce arm morbidity following breast cancer. I wrote a chapter on lymphedema for a Palliative Care textbook. This was accepted for publication in 2007. I gave and/or was involved in the preparation of 13 research presentations between June 2005 and December 2006. 124
  • 125. Department of Oncology Annual Report 2006/2007 2. Research Grants (new and ongoing) Congress Chair, Support for 16th International Congress on the Care of the Terminally Ill, CIHR: $15,000; NCIC: $10,000 2006. Réduire L’incidence de la morbidité du membre supérieur suite aux traitements pour le cancer du sein: développement et évaluation d’un projet pilote en kinésiologie. Towers A, Cohen SR, Letellier ME. Fondation québécoise du cancer. Programme de recherche portant sur la qualité de vie des patients atteints de cancer, $15,000, 2006-2007. Evaluation of group remedial exercises for chronic breast cancer related lymphedema. St. Pierre D, Towers A (co-PI), Cohen SR, Collet JP., Canadian Cancer Society Feasibility Grant no. 016221, $34,380, 2005-2007 Towers A, St. Pierre D, Cohen SR, Collet JP. Evaluation of group remedial exercises for chronic breast cancer related lymphedema, Ahepa Ladies Senior Auxiliary Penelope Meandros Chapter 168, $7000, 2005-2006 Charting the course of arm morbidity following breast cancer treatment: a prospective follow-up study. Thomas-MacLean R, , Kwan W, Hack T, Miedema B, Tatemichi S Towers, A. CIHR MOP 68883. $438,336 (My share $75,000 per annum), 2004-2007. 500 out of the 1000 subjects to be recruited for this multisite Canadian study will come from the McGill University Health Centre and the Jewish General Hospital IMN 1207 versus casein in the prevention of wasting over six months in colorectal or non small cell lung cancer: a multicentre randomized double-blind study. Gagnon B, MacDonald N, Towers A et al. IMMUNOTEC phase II trial 1207-003, 2004-2006. 3. Education and Training Postgraduate Teaching McGill Medical Postgraduate Residency Programs, Oncology, Geriatrics, Internal Medicine Postgraduate Programs, 1993-present Undergraduate Teaching Faculty of Medicine, Physician Apprenticeship, 2005 to present Faculty of Medicine, ICMB-Seminars on Symptom Control Issues and Ethical Issues in Palliative Care, 1993 to present Faculty of Medicine, ICMB- Seminars on communication , 2000 to present Faculty of Medicine, ITP Palliative Care Seminar, 1994 to present Clinical Teaching 125
  • 126. Department of Oncology Annual Report 2006/2007 Oncology, Medicine, Family Medicine, Division of Palliative Medicine, Royal Victoria Hospital,, Montreal General Hospital, MUHC, Palliative Medicine residents, Rotating Residents from other Departments, International Trainees, 1993-present Research Trainees Supervised 2006-2007, Marie-Ève Letellier- A kinesiology intervention for patients treated for breast cancer, McGill University Kinesiology, PhD qualifying course work 4. Scientific Reviews International Advisory and Editorial Boards International Consensus Group on Best Practice Guidelines for the Management of Lymphoedema , 2006 Scientific Manuscript Reviewer Canadian Family Physician, 1989 - present McGill-Queen’s University Press, 1999 to present Journal of Palliative Care, 1996 – to present Oxford University Press, 1999 to present Journal of Lymphedema, 2006 to present Grant Reviewer Internal reviewer CIHR 2006 Ad-hoc reviewer: NCIC (2003-present) CIHR (2001- present) Social Sciences and Humanities Research Council (1997- present) MUHC Research Institute (1999 to present) 5. Conference organization Congress organization I chaired the 16th International Congress on the Care of the Terminally Ill that took place September 23-26 2006. The Congress attracted 1500 participants from 40 countries and had a large research component. 126
  • 127. Department of Oncology Annual Report 2006/2007 Within the last few months we have started to organize the 17th International Congress on the Care of the Terminally Ill that will be held in September 2008, and of which I am Chair. We are looking at the evaluations of the September 2006 Congress, which I also chaired, to guide us in programme development for 2008. The programme will be in place and preliminary announcements will be sent in September 2007. We will be reviewing abstracts from February through March 2008. Our next Congress will be more focussed on international advocacy issues and will involve my travelling to the European Congress in Budapest in June 2007, to the African Palliative Congress in Nairobi in September 2007, and to the Latin American Palliative Care Congress in Lima in March 2008. There I will be meeting with colleagues to not only finalize the programme for our Congress but also to initiate joint collaborations with the aim of enhancing palliative care development worldwide. Chair, 17th International Congress for the Care of the Terminally Ill, Montreal, Sept 21- 25, 2008 Chair, 16th International Congress for the Care of the Terminally Ill, Montreal, Sept 25- 29, 2006 6. Invited Presentations and Session Leadership Towers A. « La gestion du lympoedème relié au cancer : qui s’en occupe? » Le département de médecine générale du Centre Hospitalier et Centre de Santé et services sociaux du Suroît. Québec Kwan W, Thomas-MacLean R, , Tilley A, , Miedema B, Tatemichi S, Hack T, Towers A “Arm morbidity following breast cancer treatment”, Poster presentation, Annual BC Cancer Day Nov 23-25 2006 Klove J, Langevin N, Letellier, ME, Towers A. Living with Lymphedema; Prevention, Treatment and Working Together to Advocate for our Patients, Poster presentation, 16th Congress on the Care of the Terminally illl, Montreal, (and Abstract), September 2006 Preventing and Managing Lymphedema, Public Lecture Jewish General Hospital Hope and Cope, June 8, 2006 Le lymphoedème relié aux traitements pour le cancer. Oncology Rounds Centre Hospitalier Université de Montréal, June 1, 2006 Lymphedema Risk Factors and Prevention Public Lecture, CanSupport, Montreal April 3, 2006 Oncologic and Palliative Management of Advanced Leukemia (AML) patients, combined Hematology-oncology and palliative Care rounds- McGill University Health Centre March 29, 2006 127
  • 128. Department of Oncology Annual Report 2006/2007 7. Abstracts Winkle Kwan, Roanne Thomas-MacLean, Thomas Hack, Anna Towers, Bo Miedema, Sue Tatemichi and Andrea Tilley. Charting the Course of Arm Morbidity after Breast Cancer Treatment: A Prospective, Longitudinal Follow-up Study. British Columbia Cancer Agency Annual Cancer Conference, November 23-25,2006 Vancouver, BC, pp. 71. Roanne Thomas-MacLean, Andrea Tilley, Anna Towers, Bo Miedema, Sue Tatemichi, Winkle Kwan and Thomas Hack, 2006. "Lymphedema After Breast Cancer: Symptoms, Disability and Access to Treatment." Published abstract, 7th National Lymphedema Network International Conference, (NLN), November 1-5, Nashville, TN, pp. 9. Klove J, Towers A, Langevin N, Letellier ME. Living with Lymphedema: Prevention, Treatment and Working Together to Advocate for Our Patients.”, Journal of Palliative Care 22(3):241, 2006 Thomas-MacLean R, Miedema B, Tatemichi S, Tilley A, Towers A, Hack T and Kwan W, 2006. “Arm Morbidity and Breast Cancer: Mapping New Terrain.” Published Abstract, Reasons for Hope, 4th Scientific Conference, May 6-8, Montreal, PQ, pp. 248. Thomas-MacLean R, Hack T, Miedema B, Tatemichi S, Tilley A, Kwan W and Towers A, 2006. “Sociological and Psychological Consequences of Arm Morbidity after Breast Cancer.” Published Abstract, Psychosocial Risks and Consequences across the Lifespan, Canadian Association of Psychosocial Oncology (CAPO), May 3-6, Montreal, PQ, pp. 90. 8. Committees National Member of the Board, Canadian Association of Palliative Care Physicians, 2006 to present Réseau des Soins Palliatifs, Association Québecoise des Soins Palliatifs (organization regrouping 1900 palliative care professionals and volunteers, Member of the Board, 2005-present Provincial Réseau Universitaire Québecois des Soins Palliatifs (RUQSP) – regrouping palliative care chiefs from the four Quebec medical schools), Founder and Chairperson, 2001 to present Scientific Advisor, Lymphedema Association of Quebec, Scientific Advisor and Member of the Board, 1999 to present Clinical Advisory Council, ProCure Alliance, Member, 2003 to present 128
  • 129. Department of Oncology Annual Report 2006/2007 McGill network commitees RUIS Table d’Oncologie, Member, 2005- present Executive Committee, MUHC Department of Family Medicine, Member, 2003-present Executive Committee, MUHC Non-Cancer End of Life Care Interest Group, Co-Chair, 2005 to present Scientific and Research Advisory Board, Hope and Cope Wellness Center, JGH, Member, 2005-present Executive Committee, Department of Oncology, Member, 1999-present Women’s Cancer Section, Clinical trials Committee, Department of Oncology, Member, 2005 to present Council on Palliative Care, Member, 1999- present Education Committee, Palliative Medicine McGill, 1999-2003 (Chair), 2003 to present (Member) Executive Committee MUHC Division of Palliative Care, Chair, 1999- present 9. Other Publications and Media Communications Other non peer-reviewed publications: Towers, Anna, "Touch Their Hand Gently" in Selected Journals of Successful Hospice Palliative Care from the 16th International Congress on Care of the Terminally Ill, September 26-29, 2006 in Montreal, Canada. Toronto: Legacies Inc., 2006 Media communications Regarding lymphedema access to treatments: Since 2003 I have been giving national and provincial television and radio media interviews several times yearly, in English and in French to advocate for access to lymphedema treatments under Medicare. I have also participated and facilitated many provincial, municipal and community newspaper reports on this topic. Regarding access to palliative care: Since 2000 I have been giving regular interviews to advocate for access to treatment in Canada and in Quebec. Antonio Vigano 1. Research Grants (ongoing) Laboratory for correlative and interdisciplinary research on cancer nutrition and rehabilitation; Amount $ 303,582.00; Agency: Canadian Foundation for Innovation. 129
  • 130. Department of Oncology Annual Report 2006/2007 (Support period; 11/2004 to 11/2009) McGill Nutrition and Performance Laboratory recruited first patient on December 11, 2006. Official opening April 2007. Patients recruited to date (May 18, 2007): 48 Prognostic value of clinical correlates of cancer cachexia: a prospective, multicenter, population-based study; Amount $ 211,925.00; Agency: Canadian Institutes for Health Research. (Support period; 06/2004 to 05/2007) Patients accrued: 240 (target: 300) 2. Invited speaker Vigano A. McDonald N, Swinton N, Dalzell MA, Falconer W, Gombos M, Chasen Assessing and Managing Cancer Cachexia: What’s up. M, 16th International Congress on Care of the Terminally Ill, Montreal, Canada, September, 2006. A. A. Vigano. Three sessions. a) The science of prognosis: Snapshot – Tools in use: PaP. b) The science of prognosis: how can it be improved: Symptom distress. c) Have we discovered anything new? International Workshop on prognosis in palliative care. May 25-27, 2007. Surrey, British Columbia, Canada. 3. Peer-reviewed accepted/published abstracts Angiotensin-converting enzyme gene polymorphism (ACEGP) and cancer cachexia (CC): is there a link? A. A. Vigano1, N. Hamel2, J. Morais3, W. Foulkes2, R. Kilgour4, R. Bond1, B. Trutschnigg1, S. Brar1, J. Theberge5, M. Tremblay5; Poster presentation/discussion for the American Society of Clinical Oncology at the 43rd ASCO Annual Meeting, in Chicago, Illinois, June 1-5 2007. Body composition changes in advanced cancer associated with Angiotensin-Converting Enzyme (ACE) gene polymorphism: preliminary results. Vigano Antonio1, Trutschnigg Barbara1, Bond Rachel1, Brar Seema1, Hamel Nancy2, Theberge Jean-Francois3, Foulkes William2, Morais Jose4; Poster presentation for the European Association for Palliative Care at the 10th EAPC Congress in Budapest, Hungary, June 7-9 2007. Taxonomy for cancer cachexia: usefulness of blood counts, albumin and C-reactive protein. A. A. Vigano1, B. Trutschnigg1, R. Bond1, L. Hornby1, J. Morais1,2, R. Kilgour1,2; Poster presentation for the Multinational Association of Supportive Care in Cancer at the Supportive Care Cancer Research 20th International Anniversary Symposium in St. Gallen, Switzerland, 27-30 June 2007. Te Vuong 1. Summary of New and Ongoing Research 1) The role of IMRT for patients with unresectable rectal cancer (PI). 130
  • 131. Department of Oncology Annual Report 2006/2007 2) The value of Botox-A in the treatment of patients with radiation induced proctitis.(PI) 3) Anal Canal Carcinoma and expression of Epidermal Growth Factors. 4) A Phase II study testing the therapeutic value of Hydrogel Radio BioAquacare dressing in the prevention of radiation induced dermatitis for patients undergoing pelvic radiation with concurrent chemotherapy 5) Pre-operative high dose rate brachytherapy in preparation for sphincter preservation surgery for patients with advanced cancer of the lower rectum. 6) Three-D evaluation of Radiation dermatitis. 2. Research grants (new and ongoing) 1) NCIC grant #015127 starting July 2004. Pre-operative high dose rate brachytherapy in preparation for sphincter preservation surgery for patients with advanced cancer of the lower rectum. $250,000/July 1st 2004-July 1st 2006. 2) A phase III study to evaluate the value of Silver leaf dressing in preventing radiation dermatitis for patients undergoing chemotherapy and external radiation to the perineum (NCIC July 1st 2005-July 1st 2007; $128,000). 3) A Phase II study testing the value of Botox-A in the prevention of radiation induced proctitis ( 2006-2007) On going projects for grant submission 1) A multinational multicentric phase II study testing high dose rate endorectal brachytherapy as an alternative to external beam and chemotherapy for patients with resectable rectal cancer. 2) A phase III study to evaluate the value of Botox in patients with radiation induced protitis. 3) A validation study using 3 D imaging in the evaluation of radiation dermatitis. 131
  • 132. Department of Oncology Annual Report 2006/2007 3. Conference Organization 1) Member of the scientific committee and Chairman of the GI section. (12th International conference on optimal use in advanced radiotherapy in multimodality oncology. Rome, Italy, June 24-26th 2007) 4. Invited Presentations and Workshops (National and International) 1) High dose rate brachytherapy as a neoadjuvant modality for patients with resectable rectal cancer. International meeting on high dose rate brachytherapy for patients with rectal cancer. ( London, England April 3-4th 2006). 2) Evolution des techniques de radiothérapie dans le traitement des patients porteurs de cancer digestif bas. AROQ meeting (June 10-11 2006) Québec. 3) International meeting on High dose rate brachytherapy. A multinational study proposal on high dose rate brachytherapy for patients with resectable rectal cancer.(Clatterbridge, England; September 16-18th 2006) 4) High dose rate endorectal brachytherapy: a novel approach for patients with rectal cancer. Invited speaker JASTRO annual meeting, November 2006 (Sendai, Japan. November 23-25th 2006) 5) An objective scoring methodology for radiation induced dermatitis. Invited speaker, (Paris, France. Institut Curie, April 17th 2007). 6) Invited speaker . (12th International conference on optimal use in advanced radiotherapy in multimodality oncology. Rome, Italy, June 24-26th 2007). Therapeutic paradigms in the treatment of patients with curable rectal cancer.. 5. Peer-Reviewed Abstracts 1) Vuong T, Ducruet T, Kopek N, Portelance L, Bahoric B, Devic S. Conformal therapy as a means to improve treatment therapeutic index for patients with anal canal cancer. Lugano, third International conference on Translational Research and pre-clinical strategies in Radiation Oncology (March 12-15 2006). Radiother & Oncol 2006;78 [Suppl]:37,abstract #118. 2) Devic S, Jeuntgens S, Tomic N, Vuong T, Podgarsak E. Impact of absorption Spectoscopy on 2D Radiochromic film dosimetry. Radiother & Oncol March 2006;78[Suppl 1]:S78,abstract #223. 3) T.Vuong. R. Lisbona, G. Artho, K.Waschke, C. Richard, B. Stein, P. Charlebois, R.Lougnarath L.Portelance, C.Reinhold. A Prospective study to evaluate the value of Positron Emission Computerized Tomography (PET CT) in the primary management of patients with newly diagnosed rectal cancer. ESTRO 25 th annual meeting. Leipzig, Germany. October 8-12th 2006 Radiotherapy & Oncology Vol 81 suppl.1 oct 2006, S577 abstract # 195. 132
  • 133. Department of Oncology Annual Report 2006/2007 4) T. Vuong, L. Portelance, R. Ruo, T.Alcindor, F. Cury, B. Stein, P. Charlebois, R. Dalfen, S. Meterissian, M.Wexler. A dose escalation phase II study using Intensity Modulated radiation Therapy (IMRT) to deliver 60 Gy in 25 fractions with 5- Fluorouracil chemotherapy for patients with T4 recto sigmoid cancer. Annual meeting of ASTRO 2006. Philadelphia, November 5-9th 2006. Int J Radiat Oncol Biol 2006;66 [Suppl 1]:S270:abstract #2107. 6. Hospital Activities 1) MUHC Lower GI tumor board chairman 7. Involvement in continuing education activities Nouveaux paradigmes dans le traitement du cancer du rectum ( Journee scientifique des medecins et chirurgiens de la rive Sud, Montreal, Mars 21 2007). Jian Hui Wu 1. Summary of New and Ongoing Research Ongoing major projects 1) To design and synthesize chemical compounds as novel androgen receptor antagonists and EGFR tyrosine kinase inhibitors. 2) To develop novel algorithm to dissect, analyze and compare the binding pockets of drug targets. Ongoing collaborative research projects in Canada In collaboration with Dr Gerald Batist, project no. 1 is to identify small-molecule modulators of Nrf-2, Keap1 and Cul3 interactions as potential cancer prevention agents, where the project no. 2 is to identify novel human γ-glutamylcysteine synthetase inhibitors. In collaboration with Dr Moulay Alaoui-Jamali, the project is to identify small-molecule inhibitors of focal adhesion kinase. In collaboration with Dr Jacques Galipeau, my role is to predict the three-dimensional structural models for a series of novel proteins and correlate the models with the new found functions. Ongoing international activities. In collaboration with Dr. Liangnian Song, Georgetown University, Washington, DC, the project is to identify chemical compounds that bind ligand-binding domain of androgen receptor and induce/enhance recruitment of co-repressors. 133
  • 134. Department of Oncology Annual Report 2006/2007 In collaboration with Dr Qingwen Shi, Hebei Medical University and Dr. Jiang Tao, China Ocean Univeristy, the project is to mine traditional Chinese medicinal herbs for novel chemical compounds as anticancer agents. 2. Research grants (new and ongoing) Active Grants Project title: Chemical modulators that inhibit inappropriate activation of androgen receptor: towards novel AR antagonists against hormone-refractory prostate cancer Source: CIHR Dollars Awarded: $321,891 in total Dates of Approved Project: January 1, 2005 through March 31, 2008 Name of P.I.: Jian Hui Wu Co-applicant: Weimin Miao The major goal of this project is to develop novel antagonists of androgen receptor and its pathogenic mutants as potential anti-prostate cancer agents. Project title: Structure-based optimization of SARS-CoV main proteinase inhibitors and identification of small molecule entry inhibitors of SARS-CoV Source: CIHR SARS Small Molecule Pilot Project Grants Initiative Grant Number: #DOS-75171; Dollars Awarded: $150,000 in total Dates of Approved Project: April 1, 2005 through March 31, 2007 Name of P.I.: Jian Hui Wu The major goal of this project is to discover small molecules as anti-SARS therapeutic agents. Project title: Combination of multiple compounds as potential therapeutics against ovarian cancer: Mining of traditional Chinese medicine. Source: Award funded jointly by FRSQ and Nature Science Foundation of China. Dollars Awarded: $9300. Dates of Approved Project: April 1, 2007 through March 30, 2008. Name of P.I.: Jian Hui Wu Co-applicant: Dr. Qingwen Shi, Heibei Medical University, China. The major goal of this project is to investigate the extract of herba Scutellaria barbatae, a traditional Chinese medicinal herb used for the treatment of ovarian cancer. 134
  • 135. Department of Oncology Annual Report 2006/2007 Project title: Regulation of glutathione and related enzymes: dissection of the Nrf2- master regulator and generation of novel potential chemopreventive molecules Source: CIHR Dollars Awarded: $326,000 in total Dates of Approved Project: from 04/2006 to 03/2009 Name of P.I.: Gerald Batist Name of co-applicant: Jian Hui Wu The major goal of this project is to investigate the regulation of Nrf-2, and develop novel small molecules to induce phase II detoxifying enzymes by targeting Nrf- 2/Cul3 interface. 3. Research Training: undergraduate students, graduate students, postdocs/fellows a) Dr. Bing Liu, Postdoctoral fellow, 2005-present. b) Dr. Jinming Zhou, Postdoctoral fellow, 2006-present. 4. Scientific Reviews: Editorial Boards and Journal Reviews External reviewer for a) J Med Chem; b) Human mutation. 5. Invited Presentations and Workshops (National and International) a) Wu, J.H. “Computational Biology and virtual screening: investigation of the impact of point mutations on the sensitivity to gefitinib and identification of novel γ-GCS inhibitors” Department of Biochemistry, McGill University, Jan 19, 2006. b) Jian Hui Wu, “Investigating androgen receptor antagonism by structural analyses, molecular dynamics simulations and support vector machines”. The AACR Annual Meeting, April 14-18, 2007, Los Angels, CA, USA. 6. Peer-Reviewed Abstracts 1) Wu, J. H. & Liu, B. “Investigating androgen receptor antagonism by structural analyses, molecular dynamics simulations and support vector machines”. In: Am Ass. Cancer Res. Annual Meeting: Proceedings; 2007 Apr 14-18; Los Angeles, CA. Philadelphia (PA): AACR; 2007. Abstract #4426. 135
  • 136. Department of Oncology Annual Report 2006/2007 7. Involvement in continuing education activities Course Design and Teaching Workshop, Teaching and Learning Services, McGill University, May 10, 11 and May 14-16, 2007. Maria Zannis-Hadjopoulos 1. Summary of New and Ongoing Research With Dr. Edward Bradley, Institut du Cancer de Montréal, Université de Montréal; project on ‘Genome-wide mapping of asynchronous replication in cancer cells’. With Dr. Haian Fu, Emory University, and Dr. Lene Rasmussen, University of Copenhagen; projects on “Involvement of hExoI in mammalian DNA replication”. 2. Research grants (new and ongoing) PI: Maria Zannis-Hadjopoulos 1) Canadian Institutes of Health Research, 2004-2007, Research Grant for the "Characterization of mammalian origins of DNA replication and their interacting proteins". $135,881 2) National Cancer Institute of Canada, 2005-2008, Research Grant for “Differentially active human origins of DNA replication in tumor versus normal cells’ $116,868, PI: Maria Zannis-Hadjopoulos with Drs. Edward Bradley and Mark Basik (co- applicants) Canderel Innovative Research Award, May 2007-May 2008, pilot Research Grant distributed through the McGill Cancer Centre for ‘Genome-wide mapping of asynchronous replication in cancer cells’.$15,000 3. Research Training: undergraduate students, graduate students, postdocs/fellows Undergraduate students Wanda Marini BIOC-491B (2006) Albe Man Kid Chan BIOC-491B (2006, 2007) Vincent Lavallée (BIOC-491B (2007) Colin Bell BIOC-491B (2007) Chafik Safi BIOC-491B (2007) 136
  • 137. Department of Oncology Annual Report 2006/2007 Graduate students Domenic DiPaola (Biochemistry, 2002-present); Wafaa Yahyaoui (Experimental Medicine, 2003-present) Emmanouil Rampakakis (Biochemistry, 2004-present) Postdoctoral Fellow Dr. Constandina Arvanitis 4. Scientific Reviews: Editorial Boards and Journal Reviews Member, Editorial Board, International Society for Gene Therapy and Molecular Biology Journal Reviews Journal of Biological Chemistry Journal of Cellular Biochemistry Journal of Cell Science Genomics Trends in Biochemical Sciences (TIBS) Nucleic Acids Research BMC Molecular Biology Genome Biology Genome Research Trends in Biochemical Sciences 5. Research Advisory Work for National and International Organizations External Reviewer, European Science Foundation Evaluator of grant applications submitted to the Greek Ministry of Research and Technology (PENED) Member, Reviewing Board, Greek Ministry of National Education, Directorate of European Community Support Framework Member, Reviewing Board, European Science Foundation 137
  • 138. Department of Oncology Annual Report 2006/2007 6. Invited Presentations and Workshops (National and International) 2nd Gordon Research Conference on “BIOLOGY OF 14-3-3 PROTEINS”, Queen’s College, Oxford, UK, August 27 - September 1, 2006 7. Peer-Reviewed Abstracts Yahyaoui, W. and Zannis-Hadjopoulos, M. Analysis of the mechanism of 14-3-3 involvement in the initiation of DNA replication. 2nd Gordon Research Conference on the "Biology of 14-3-3 Proteins, Oxford, UK, August 27-September 1, 2006. Zannis-Hadjopoulos, M. The cruciform binding activity of 14-3-3 as a regulator of DNA replication. 2nd Gordon Research Conference on the "Biology of 14-3-3 Proteins, Oxford, UK, August 27-September 1, 2006. 8. McGill Committees Member (elected), McGill University Senate Member (elected), MAUT Council, McGill University 138
  • 139. Dept. of Oncology Appendix I: Honours, Awards and Prizes June 1, 2006-May 31, 2007 Appendix I: Honours Awards and Prizes Paul Allison Howard Katz Award for Excellence in Teaching (May, 2007): $1000 awarded to an individual at the Faculty of Dentistry, McGill University Dawn Anderson Recipient of the Inaugural Hingston Grant for Development of Medical Leadership. Nicole Beauchemin Faculty of Medicine “Faculty Honour List for Educational Excellence” 2007 William Foulkes 2007-2011: Fonds de la recherche en Santé du Québec : Chercheur National Eduardo Franco “Ambassadeur de Montréal”, prize by the Montreal Congress Centre, May 2007. Phil Gold Establishment of the Phil Gold Chair in Medicine (November 2006) Philip Gordon Cited in Marquis Who’s Who in the World 2006 23rd Edition Named to Faculty Honour List for Educational Excellence in recognition of contributions to teaching in the McGill Faculty of Medicine June 14, 2007 Walter Gotlieb June 2006: Canadian Foundation for Women's Health Grant I-1
  • 140. Dept. of Oncology Appendix I: Honours, Awards and Prizes June 1, 2006-May 31, 2007 Stephen Liben Service Award – Commander Palliative Care Presentation. Nov 2006 The Military & Hospitaller Order of St. Lazarus First Prize - Royal Society of Medicine Book Awards. Oct 2006, Oxford Textbook of Palliative Care for Children (Goldman, Hain, Liben eds). Carmen Loiselle Guest of honour at the McGill University School of Nursing 2007 Graduation Ball, Omni Hotel, Montreal. April, 27, 2007. Voted "the most significant teacher" by the BNI graduating students. Ervin Podgorsak Coolidge Award, American Association of Physicists in Medicine (AAPM), July 31, 2006. The Coolidge Award is the highest honor presented during the annual AAPM meeting to a medical physicist who has exhibited a distinguished career in medical physics in three areas: research, teaching and service and who has exerted a significant impact on the practice of medical physics. The organization gives one such award per year. Since 1974 three awards went to Canada: two to the University of Toronto (H. Johns 1976 and J.R. Cunningham 1988) and now one to McGill (2006). Elected Fellow, American College of Medical Physics (ACMP) 2007 Stephane Richard 2006 Prix d'excellence en recherche, Conseil des gouverneurs de l'Hôpital general juif 2007-2012 Chercheur Nationaux, FRSQ Marc Tischkowitz FRSQ Chercheur-bousier clinicien Junior 1 (commences July 2007) Te Vuong 1. RVH centennial Research Grant Award: 2006. ($10,000) 2. Howard W Pillow memorial Research Award. October 2006. ($7,000) 3. CIHR Investigator salary Award 2006-2010 ($70 000 X 5) I-2
  • 141. Dept. of Oncology Appendix II: Publications January-December 2006 Appendix II: Publications Articles in peer-reviewed journals Yasmeen, A., Bismar, T., and Al Moustafa A-E. 2006. ErbB receptors and epithelial- cadherin-catenin complex in human carcinomas. Future Oncology, 2: 765-781. Hernandez M, Shao Q, Yang XJ, Luh SP, Kandouz M, Batist G, Laird DW, Alaoui- Jamali MA. A histone deacetylation-dependent mechanism for transcriptional repression of the gap junction gene cx43 in prostate cancer cells. Prostate. 2006 Aug 1;66(11):1151- 61. Vilela LD*, Nicolau B*, Mahmud S, Edgar L, Hier M, Black M, Franco EL & Allison PJ. (2006) A comparison of psychosocial outcomes in head and neck cancer patients receiving a coping strategies intervention and control subjects receiving no intervention. Journal of Otolaryngology. 35(2):88-96 Cesaire R, Oliere S, Sharif-Askari E, Loignon M, Lezin A, Olindo S, Panelatti G, Kazanji M, Aloyz R, Panasci L, Bell JC, Hiscott J. Oncolytic activity of vesicular stomatitis virus in primary adult T-cell leukemia.Oncogene. 2006 Jan 19;25(3):349-58. Salvucci O, Bouchard A, Baccarelli A, Deschenes J, Sauter G, Simon R, Bianchi R, Basik M. The role of CXCR4 receptor expression in breast cancer : a large tissue microarray study. Breast Cancer Research & Treatment, 2006 Jun;97(3):275-83, Dec 2005 epub. Batist G, Harris L, Azarnia N, Lee LW, Daza-Ramirez P. Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis. Anticancer Drugs. 2006 Jun;17(5):587-95. Mes-Masson AM, Champoux L, Hebert J, Batist G, Lesperance B. The reseau de recherche sur le cancer: favoring a multi-disciplinary approach. Bull Cancer. 2006 Sep 1;93(9):831-4. French. CEACAM1 modulates vascular remodeling in vitro and in vivo. A.K. Horst, W.D. Ito, J. Dabelstein, U. Schumacher, H. Sander, C. Turbide, J. Brummer, T. Meinertz, N. Beauchemin* and C. Wagener*. J. Clin. Investig. 116(6):1596-1605, (2006). *contributed equally to the work. A novel role for the protein tyrosine phosphatase SHP-1 as a negative regulator of insulin-mediated glucose metabolism and insulin clearance. M.J. Dubois, K. Dombrowski, H.J. Kim, S. Bergeron, M. Perreault, R. Faure, M. Olivier, N. Beauchemin, G. I. Schulman, K.A. Siminovitch, J.K. Kim and A. Marette. Nat. Med. 12(5), 549-56. (2006). II-1
  • 142. Dept. of Oncology Appendix II: Publications January-December 2006 Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) contributes to progression of colon tumors. N. Leung, C. Turbide, V. Marcus, S. Jothy and N. Beauchemin. Oncogene, 25, 5527-5536 (2006). Binda, O., J.-S. Roy, and P. E. Branton. 2006. RBP1 Family Proteins Exhibit SUMOylation-Dependent Transcriptional Repression and Induce Cell Growth Inhibition Reminiscent of Senescence. Mol. Cell. Biol. 2006 26: 1917-1931 Belzile, J-P, Choudhury, SA, Cournoyer, D, and Chow, TYK. Targeting DNA Repair Proteins: A Promising Avenue for Cancer Gene Therapy. Current Gene Therapy 6(1):111-123, 2006. Mohammad Amin Kerachian, Edward J Harvey, Denis Cournoyer, Terry Y.K. Chow, Chantal Seguin. Avascular Necrosis of the Femoral Head: Vascular hypotheses. 2006. Endothelium 13:237-244. Lee V, Cohen SR, Edgar L, Laizner AM, Gagnon A. Meaning-making and Psychological Adjustment to cancer: development of an intervention and pilot results. Oncology Nursing Forum, 2006; 33 (2): 291-302. Lee V, Cohen SR, Edgar L, Laizner AM, Gagnon AJ. Meaning-making intervention during breast or colorectal cancer treatment improves self-esteem, optimism, and self- efficacy. Social Science & Medicine, 2006; 62(12) 3133-3145. Williams A, Crooks VA, Stajduhar KI, Allan D, Cohen SR. Canada’s Compassionate Care Benefit: Views of family caregivers in chronic illness. International Journal of Palliative Nursing, 2006; 12 (9) 438-45. Cohen SR, Leis AM, Kuhl D, Charbonneau C, Ritvo P, Ashbury FD. QOLLTI-F: measuring family carer quality of life. Palliative Medicine, 2006; 20: 755-767. Cohen V, Agulnik JS, Jarry J, Batist G, Small D, Kreisman H, Tejada A, Miller WH Jr, Chong G. Evaluation of Denaturing High Performance Liquid Chromatography as a Rapid Detection Method for Identification of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer. Cancer, 107:2858-2865, 2006. Cury FLB, Souhami L, Rajan R, Tanguay S, Gagnon B, Duclos M, Shenouda G, Faria SL, Marc D, Freeman CR. Intermittent androgen ablation in patients with biochemical failure after pelvic radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 64:842-848, 2006. Cury FBL, Souhami L. Phase II trial of intermittent androgen ablation for biochemical failure after radiotherapy for localized prostate cancer. Am J Hematol Oncol 5:434-438, 2006. Cury FL, Shenouda G, Souhami L, Duclos M, Faria SL, David M, Verhaegen F, Corns R, Falco T. Ultrasound-Based Image Guided Radiotherapy for Prostate Cancer- Comparison of Cross-Modality and Intramodality Methods for Daily Localization During II-2
  • 143. Dept. of Oncology Appendix II: Publications January-December 2006 External Beam Radiotherapy.Int J Radiat Oncol Biol Phys. 2006 Oct 20; [Epub ahead of print] Faria SL, Souhami L, Portelance L, Duclos M, Vuong T, Small D, Freeman CR. Absence of toxicity with hypofractionated 3-dimensional radiation therapy for inoperable, early stage non-small cell lung cancer. Radiat Oncol. 1:42, 2006. Faria SL, Mahmud S, Souhami L, David M, Duclos M, Shenouda G, Makis W, Freeman CR. No immediate treatment after biochemical failure in patients with prostate cancer treated by external beam radiotherapy. Urology 67:142-146, 2006. Faria SL, Mahmud S, Wakil G, Negrete, S, Souhami L, David M, Duclos M, Shenouda G, Freeman CR. Is there a detrimental effect of waiting for radiotherapy for patients with localized prostate cancer? Am J Clin Oncol 29:463-467, 2006. Chen MJ, Faria SL, Souhami L, Niazi TM, Duclos M, Guerra J. Tratamento do cancer de pequenas celulas de pulmao – doenca limitada: resultados de uma unica instituicao. Radiol Bras 39:39-43, 2006. Soravia C, Delozier CD, Dobbie Z, Berthod CR, Arrigoni E, Brundler MA, Blouin JL, Foulkes WD, Hutter P. Double frameshift mutations in APC and MSH2 in the same individual. Int J Colorectal Dis, 21 (1): 79-83, 2006. Barker KT, Foulkes WD, Schwartz CE, Labadie C, Monsell F, Houlston RS, Harper J. Is the E133K allele of VG5Q associated with Klippel-Trenaunay and other overgrowth syndromes? J Med Genet, 43(7): 613-614, 2006. Nkondjock A, Ghadirian P, Kotsopoulos J, Lubinski J, Lynch H, Kim-Sing C, Horsman D, Rosen B, Isaacs C, Weber B, Foulkes WD, Ainsworth P, Tung N, Eisen A, Friedman E, Eng C, Sun P, Narod SA. Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers. Int J Cancer, 118 (1): 103-7, 2006. McVety S, Li L, Gordon PH, Chong G, Foulkes WD. Disruption of an exon splicing enhancer in exon 3 of MLH1 is the cause of HNPCC in a Quebec family. J Med Genet 2006:43:153-6. Minoo P, Baker K, Goswami R, Chong G, Foulkes WD, Ruszkiewicz A, Barker M, Buchanan D, Young J, Jass JR. Extensive DNA methylation in normal colorectal mucosa in hyperplastic polyposis. Gut, 55(10): 1467-1474, 2006. Rudkin TM, Hamel N, Galvez M, Hogervorst F, Gille JJ, Moller P, Apold J, Foulkes WD. The frequent BRCA1 mutation 1135insA has multiple origins: a haplotype study in different populations. BMC Med Genet. 7 (1): 15, 2006. McVety S, Li L, Thiffault I, Gordon PH, MacNamara E, Wong N, Australie K, Kasprzak L, Chong G, Foulkes WD. The value of multi-modal gene screening in HNPCC in Quebec: three mutations in mismatch repair genes that would have not been correctly identified by genomic DNA sequencing alone. Familial Cancer. 2006:5:21-28. Li L, McVety S, Younan R, Liang P, DuSart D, Gordon, PH, Hutter P, Hogervorst FBL, Chong G, Foulkes WD. Distinct Patterns of Germ-line Deletions in MLH1 and II-3
  • 144. Dept. of Oncology Appendix II: Publications January-December 2006 MSH2: The implication of Alu Repetitive Element in the Genetic Etiology of Lynch Syndrome (HNPCC) Hum. Mutat. 2006:27:388. Friedman E, Kotsopoulos J, Lubinski J, Lynch HT, Ghadirian P, Neuhausen SL, Isaacs C, Weber B, Foulkes WD, Moller P, Rosen B, Kim-Sing C, Gershoni-Baruch R, Ainsworth P, Daly M, Tung N, Eisen A, Olopade OI, Karlan B, Saal HM, Garber JE, Rennert G, Gilchrist D, Eng C, Offit K, Osborne M, Sun P, Narod SA; the Hereditary Breast Cancer Clinical Study Group. Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. Breast Cancer Res, 8(2):R15, 2006. Morel CF, Thomas MA, Cao H, O’Neil CH, Pickering JG, Foulkes WD, Hegele RA. A LMNA splicing mutation in two sisters with severe Dunnigan-type familial partial lipodystrophy (FPLD2). J.Clin.Endocrinol.Metab., 91(7): 2689-2695, 2006. Gronwald J, Tung N, Foulkes WD, Offit K, Gershoni R, Daly M, Kim-Sing C, Olsson H, Ainsworth P, Eisen A, Saal H, Friedman E, Olopade O, Osborne M, Weitzel J, Lynch H, Ghadirian P, Lubinski J, Sun P, Narod SA. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update. Int J Cancer, 118 (9); 2281-4, 2006. Narod SA, Lubinski J, Ghadirian P, Lynch HT, Moller P, Foulkes WD, Rosen B, Kim- Sing C, Isaacs C, Domcheck S, Sun P; for the Hereditary Breast Cancer Clinical Study Group. Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case control study. Lancet Oncol, 7(5): 402-406, 2006. Goswami RS, Minoo P, Baker K, Chong G, Foulkes WD, Jass JR. Hyperplastic polyposis and cancer of the colon with gastrinoma of the duodenum. Nat Clin Pract Oncol, 3 (5): 281-4, 2006. Foulkes WD. BRCA1 and BRCA2: Chemosensitivity, Treatment Outcomes and Prognosis. Fam Cancer, 5 (2): 135-142, 2006. Shinto E, Baker K, Tsuda H, Mochizuki H, Ueno H, Matsubara O, Foulkes WD, Jass JR. Tumor Buds Show Reduced Expression of Laminin-5 gamma 2 Chain in DNA Mismatch Repair Deficient Colorectal Cancer. Dis. Colon and Rectum., 49(8): 1193-1202, 2006. Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Friedman E, Foulkes WD, Kim-Sing C, Wagner T, Tung N, Couch F, Stoppa-Lyonnet D, Ainsworth P, Daly M, Pasini B, Gershoni-Baruch R, Eng C, Olopade OI, McLennan J, Karlan B, Weitzel J, Sun P, Narod SA, Hereditary Ovarian Cancer Clinical Study Group. Salpingo-oophorectomy and the risk of ovarian, fallopian tube and peritoneal cancers in women with BRCA1 or BRCA2 mutation. JAMA, 296 (2): 185-192, 2006. Baker K, Chong G, Foulkes WD, Jass JR. Transforming growth factor-pathway disruption and infiltration of colorectal cancers by intraepithelial lymphocytes. Histopathology, 49(4): 371-380, 2006. Oros, KK, Ghadirian P, Maugard CM, Perret C, Paredes Y, Mes-Masson AM, Foulkes WD, Provencher D, Tonin P. Application of BRCA1 and BRCA2 mutation carrier II-4
  • 145. Dept. of Oncology Appendix II: Publications January-December 2006 prediction models in breast and/or ovarian cancer families of French Canadian descent. Clin Genet, 70(4):320-329, 2006. Schaid DJ, McDonnell SK, Zarfas KE, Cunningham JM, Hebbring S, Thibodeau SN, Eeles RA, Easton DF, Foulkes WD, Simard J, Giles GG, Hopper JL, Mahle L, Moller P, Badzioch M, Bishop DT, Evans C, Edwards S, Meitz J, Bullock S, Hope Q, Guy M, Hsieh C-L, Halpern J, Balise RR, Oakley-Girvan I, Whittemore AS, Xu J, Dimitrov L, Chang B- L, Adams TS, Turner AR, Meyers DA, Friedrichsen DM, Deutsch K, Kolb S, Janer M, Hood L, Ostrander EA, Stanford JL, Ewing CM, Gielzak M, Isaacs SD, Walsh PC, Wiley KE, Isaacs WB, Lange EM, Ho LA, Beebe-Dimmer JL, Wood DP, Cooney KA, Seminara D, Ikonen T, Baffoe-Bonnie A, Fredriksson H, Matikainen MP, Tammela T LJ, Bailey- Wilson J, Schleutker J, Maier C, Herkommer K, Hoegel JJ, Vogel W, Paiss T, Wiklund F, Emanuelsson M, Stenman E, Jonsson B-A, Grönberg H, Camp NJ, Farnham J, Cannon- Albright LA, Catalona WJ, Suarez BK, Roehl KA. Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics. Human Genetics, 120(4):471-485, 2006. Vilela LD(§), Nicolau B, Mahmud S, Edgar L, Hier M, Black M, Franco EL, Allison P(*).Comparison of psychosocial outcomes in head and neck cancer patients receiving a coping strategies intervention and control subjects receiving no intervention. Journal of Otolaryngology 35: 88-96, 2006. Burchell AN(§),Richardson H, Mahmud SM, Trottier H, Tellier PP, Hanley J, Coutlée F, Franco EL(*). Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada. American Journal of Epidemiology 163:534-543, 2006. Mahmud SM (§*), Tanguay S, Bégin LR, Franco EL, Aprikian AG. Non-steroidal anti- inflammatory drug use and prostate cancer in a high-risk population. European Journal of Cancer Prevention 15: 158-164, 2006. Monsonego J(*), Pintos J, Semaille C, Beumont M, Dachez R, Zerat L, Bianchi A, Franco E. Human papillomavirus testing improves the accuracy of colposcopy in detection of cervical intraepithelial neoplasia. International Journal of Gynecological Cancer 16:591-598, 2006. Mayrand MH(§), Duarte-Franco E, Coutlée F, Rodrigues I, Walter SD, Ratnam S, Franco EL(*), for the CCCaST Study Group. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: Design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST). International Journal of Cancer 119:615-623, 2006. Goffin F, Mayrand MH, Gauthier P, Alobaid A, Lussier C, Provencher D, Drouin P, Franco EL, Coutlée F(*).High-risk human papillomavirus infection of the genital tract of women with a previous history or current high-grade vulvar intraepithelial neoplasia. Journal of Medical Virology 78:814-819, 2006. II-5
  • 146. Dept. of Oncology Appendix II: Publications January-December 2006 Harper DM(*), Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins DD, Schuind A, Clemens SAC, Dubin G. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18. Follow-up from a randomized controlled trial in young women. Lancet 367: 1247- 1255, 2006. Alotaibi L, Provost N, Gagnon S, Franco EL, Coutlée F(*). Diversity of cutaneous human papillomavirus types in individuals with and without skin lesion. Journal of Clinical Virology 36: 133-140, 2006. Coutlée F(*), Rouleau D, Petignat P, Ghattas G, Kornegay JR, Schlag P, Boyle S, Hankins C, Vézina S, Coté P, Macleod J, Voyer H, Forest P, Walmsley S, Franco E. Enhanced Detection and typing of Human Papillomavirus DNA in Anogenital Samples with PGMY primers and the Linear Array HPV Genotyping Test. Journal of Clinical Microbiology 44: 1998-2006, 2006. Sangwa-Lugoma G(§), Mahmud S, Nasr S, Liaras J, Kayembe P, Tozin R, Drouin P, Lorincz A, Ferenczy A, Franco EL(*). Visual inspection as a cervical cancer screening method in a primary health care setting in Africa. International Journal of Cancer 119: 1389-1395, 2006. Trottier H(§), Mahmud S, Costa MC, Sobrinho JP, Duarte-Franco E, Rohan TE, Ferenczy A, Villa LL, Franco EL(*). Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiology, Biomarkers and Prevention 15: 1274- 1280, 2006. Khouadri S, Villa LL, Gagnon S, Koushik A, Richardson H, Ferreira S, Tellier P, Simao J, Matlashewski G, Roger M, Franco EL, Coutlée F(*). Human papillomavirus type 33 polymorphisms and high-grade squamous intraepithelial lesions of the uterine cervix. Journal of Infectious Diseases 194: 886-894, 2006. Schlecht NF(§), Trevisan A, Baggio ML, Galan L, Duarte-Franco E, Greenberg MD, Rohan TE, Ferenczy A, Villa LL, Franco EL(*). Lack of agreement between cervicography and cytology and the effect of human papillomavirus infection and viral load. Journal of Lower Genital Tract Disease 10: 229-237, 2006. Siegel EM, Craft N, Duarte-Franco EF, Villa LL, Franco EL, Giuliano AR(*). Associations between serum carotenoids and tocopherols and type-specific HPV persistence: the Ludwig-McGill Cohort Study. International Journal of Cancer 120: 672– 680, 2006. Franco EL(*), Cuzick J, Hildesheim A, Sanjose S. Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 24S3: 171-177, 2006. Franco EL(*), Bosch FX, Cuzick J, Schiller J, Garnett G, Meheus A,. Knowledge gaps and priorities for research on prevention of HPV infection and cervical cancer. Vaccine 24S3: 242-249, 2006. II-6
  • 147. Dept. of Oncology Appendix II: Publications January-December 2006 Wright TC, Bosch FX, Franco EL, Cuzick J, Schiller J, Garnett G, Meheus A. HPV Vaccines and screening in the prevention of cervical cancer: Conclusions from a 2006 Workshop of International Experts. Vaccine 24S3: 251-261, 2006. Franco EL. Invited Commentary: Epidemiology as a tool to reveal inequalities in breast cancer care. Public Library of Science-Medicine 3(3): e48, 2006. Franco EL, Lau S. LSIL in young women: Inaction is not an option. Canadian Medical Association Journal 174: 813, 2006. Franco EL(*), Ferenczy A. Invited Commentary: Is human papillomavirus testing with cytological triage a more logical approach in cervical cancer screening? Lancet Oncology 7: 527-529, 2006. Franco EL, Mayrand MH, Trottier H. Cervical cancer prevention: Promises and perils in a changing landscape. Oncology Exchange 5: 9-13, 2006. Gagnon B, Laurin C, Mayo N, Hanley J.A., MacDonald N. Identification in Administrative Databases of Women dying of Breast Cancer. Journal of Clinical Oncology 27 (6):865-862 (2006). Kosseim M, Mayo N, Scott S, Hanley J, Brophy J, Gagnon B, Pilote L. Ranking Hospitals According to Acute Myocardial Infarction Mortality. Should transfers be included? Med Care 44 (7): 664-670 (2006). Galiatsatos P, Foulkes WD. Familial adenomatous polyposis. Am J Gastroenterol, 101 (2): 385-98, 2006. Galiatsatos P, Kasprzak L, Chong G, Jass JR, Foulkes WD. Multiple primary malignancies in a patient with situs ambiguous. Clin Genet, 69 (6): 528-531, 2006. Parker, W., Freeman, C.R. A simple technique for craniospinal radiotherapy in the supine position. Radiotherapy and Oncology 2006; 78:217-222 Carret AS, Tabori U, Crooks B, Hukin J, Odame I, Johnston DL, Keene DL, Freeman C, Bouffet E. On behalf of the Canadian Pediatric Brain Tumour Consortium. Outcome of secondary high-grade glioma in children previously treated for a malignant condition: A study of the Canadian Pediatric Brain Tumour Consortium. Radiotherapy and Oncology 2006; 81:33-38 John Stagg, Sandra Pommey, Nicoletta Eliopoulos and Jacques Galipeau. Interferon- - Stimulated Marrow Stromal Cells: A New Type of Non-Hematopoietic Antigen Presenting Cell. Blood. 2006 Mar 15;107:2570-2577. Diana E. Jaalouk, Milena Crosato, Pnina Brodt and Jacques Galipeau. Inhibition of Histone Deacetylation in Retroviral Packaging Cell Lines Markedly Improves the Production of Self-Inactivating Retroviral Vectors. Virology Journal 2006, 3:27 (7 April 2006). II-7
  • 148. Dept. of Oncology Appendix II: Publications January-December 2006 Tomas Jimenez, W. Paul Fox, Christian C.G. Naus, Jacques Galipeau, and Daniel J. Belliveau. Connexin Over-Expression Differentially Suppresses Glioma Growth and Contributes to the Bystander Effect Following HSV-Thymidine Kinase Gene Therapy. Cell Communication and Adhesion 2006 Jan-Apr;13(1):79-92. N. Eliopoulos, R.F. Gagnon, M. Francois, and J. Galipeau. Erythropoietin Delivery by Genetically-Engineered Bone Marrow Stromal Cells for Correction of Anemia in Mice with Chronic Renal Failure. Journal of the American Society of Nephrology 2006 Jun;17(6):1576-1584. Sandra Pommey and Jacques Galipeau. The use of Mesenchymal Stromal Cells in oncology and cell therapy. Bulletin du Cancer. Volume 93, Number 9, 901-7, September 2006 Mayya Meriane, Stéphanie Duhamel, Laurence Lejeune, Jacques Galipeau and Borhane Annabi. Cooperation of matrix metalloproteinases with the RhoA/ROCK and MEK1/ERK signalling pathways is required for the sphingosine-1-phosphate-induced mobilization of marrow-derived stromal cells. Stem Cells 2006;24;2557-2565 Diana E. Jaalouk, Laurence Lejeune, Clément Couture, and Jacques Galipeau. A Self- Inactivating Retrovector Incorporating the IL-2 Promoter for Activation-Induced Transgene Expression in Genetically Engineered T-Cells. Virol J. 2006 Nov 21;3(1):97 Herzog, B., Cardenas, J., Hall, R. K., Villena, J. A., Budge, P. J., Giguère, V, Granner, D. K. and Kralli, A. (2006) Estrogen-related receptor α is a repressor of PEPCK gene transcription. J. Biol. Chem. 281:99-106. Barry, J., Laganière, J. and Giguère, V. (2006) A single nucleotide in an estrogen related receptor α site can dictate mode of binding and PGC-1α activation of target promoters. Mol. Endocrinol. 20:302-310. Grégoire, S., Tremblay, A. M., Xiao, L., Yang, Q., Ma, K., Nie, J., Mao, Z., Wu, Z., Giguère, V. and Yang, X.-J. (2006) Control of MEF2 transcriptional activity by coordinated phosphorylation and sumoylation. J. Biol. Chem. 281:4423-4433. Blanchette, M., Bataille, A.R., Chen, X., Laganière, J. Lefebvre, C., Deblois, G., Giguère, V., Ferretti, V., Bergeron, D., Coulombe, B. and Robert. F. (2006) Genome- wide computational prediction of transcriptional regulatory modules reveals new insights into human gene expression. Genome Research 16:656-668. Laganière, J. and Giguère, V. (2006) Détermination du répertoire des gènes cibles et du mode d’action du récepteur de l’oestrogène par la génomique fonctionnelle. Bulletin du cancer 93:883-887. Liu, D.Y., Hinshelwood, M.M., Willy, P.J., Giguère, V. and Mendelson, C.R. (2006) Estrogen related receptor α enhances surfactant protein-A (SP-A) gene expression in fetal lung type II cells. Endocrinology 147:5187-5195. Lu, N.Z., Wardell. S.E., Burnstein, K.L., DeFranco, D., Fuller, P.J., Giguère, V., Hochberg, R.B., McKay, L., Renoir, J.M., Weigel, N.L., Wilson, E.M., McDonnell, D.P. and Cidlowski, J.A. (2006) International Union of Pharmacology. LXV. The II-8
  • 149. Dept. of Oncology Appendix II: Publications January-December 2006 pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacol. Rev. 58:782-797. Benoit, G., Cooney, A., Giguère, V., Ingraham, H., Lazar, M.A., Muscat, G.E.O., Perlmann, T., Renaud, J.P., Schwabe, J., Sladek, F., Tsai, M.J. and Laudet, V. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. Pharmacol. Rev. 58:798-836. Fraser SA, Deschênes J, Bloom C, Gordon PH. Ileocecal Hobnail angioendothelioma : Report of a case and review of the literature. Dis Colon Rectum 2006:49:276-9. Miller G, Gordon PH. Small Bowel Obstruction – Problems and Pitfalls in Clinical Assessment. Parkhurst Exchange 2006:14:64. Wiser A, Korach J, Gotlieb WH, Fridman E, Apter S, and Ben-Baruch G. Importance of accurate preoperative diagnosis in the management of aggressive angiomyxoma: report of three cases and review of the literature. Abdominal Imaging (2006) 31:383-6 Gotlieb WH, Bruchim I, Gu J, Shi Y, Camirand A, Blouin MJ, Pollak MN Insulin-like growth factor I receptor (IGF-IR) targeting in epithelial ovarian cancer. Gynecologic Oncology (2006) 100: 389-396. Gotlieb WH, Barchana M, Ben-Baruch G, Friedman E, Malignancies following bilateral salpingo-oophorectomy, Eur J Surg Oncol. (2006) 32:1231-4. Hirao, K, Natsuka, Y, Tamura, T, Wada, I, Morito, D, Natsuka, S, Romero, PA, Sleno, B, Tremblay, LO, Herscovics, A, Nagata, K, Hosokawa, N. EDEM3, a soluble EDEM homolog, enhances glycoprotein ERAD and mannose trimming. J. Biol. Chem. 2006, 281, 9650-9658. Suissa S, Hutchinson T, Brophy JM, Kezouh A. ACE-inhibitor use and the long-term risk of renal failure in diabetes. Kidney International 2006; 69:913-919. Schneider V, Lévesque LE, Zhang B, Hutchinson T, Brophy JM. The association of selective and conventional non-steroidal anti-inflammatory drugs with acute renal failure: a population based nested case-control analysis. American Journal of Epidemiology 2006; 164(9): 881-889. Loiselle, C. G., Lambert, S., & Cooke, A. (2006). The searching, processing, and sharing of breast cancer information by women diagnosed with the illness. Canadian Journal of Nursing Research (CJNR), 38(3), 82-104. Cyr, N., Mathieu, L., Dubois, S., & Loiselle, C. G. (2006). Évaluer les sites Internet sur la santé. Perspective Infirmière, 3(3), 44-45. Macdonald ME, Liben S, Cohen SR. Truth and consequences: Parental perspectives on autopsy after the death of a child. Pediatric Intensive Care Nursing, 2006; 7(1) 6-15. Swinton N, Chasen M, MacDonald N. Simple Nutritional Screening in Clinical Practice. Oncology Exchange 2006; 5(4):34-37. II-9
  • 150. Dept. of Oncology Appendix II: Publications January-December 2006 DeLima L, MacDonald N, Doyle D. IAHPC List of Essential Medicines for Palliative Care: summary of process for editors of pain and palliative care journals. Journal of Palliative Care 2006; 22(4):300-304. Mann KK, Davison K, Colombo M, Colosimo A, Diaz Z, Padovani AMS, Guo Qi, Scrivens PJ, Gao W, Mader S, Miller WH Jr. Antimony trioxide-induced apoptosis is dependent on JNK signaling. Toxicology Letters, 160:158-170, 2006. Matsushita H, Scaglioni PP, Bhaumik M, Rego EM,Cai LF, Majid SM, Miyachi H, Kakizuka A, Miller WH Jr, Pandolfi PP. In vivo analysis of the role of aberrant HDAC recruitment and RARα blockade in the pathogenesis of APL. J Exp Med, 203:821-828, 2006. Bernardini S, Muccetelli M, Noguera NI, Bellincampi L, Lunghi P, Bonati A, Mann, KK, Miller WH Jr, Federici G, Lo Coco F. Role of GSTP1-1 in mediating the effect of As2O3 in the acute promyelocytic leukemia cell line NB4. Ann Hematol 85:681-687, 2006. Sansregret, L., B. Goulet, B. Wilson, M. Santaguida., L. Leduy, J. Bertoglio and A. Nepveu. The CDP/Cux p110 Transcription Factor Accelerates Entry Into S Phase. Molecular & Cellular Biology 26:2441-2455. 2006. Goulet, B., M. Truscott, and A. Nepveu. A Novel Proteolytically Processed CDP/Cux Isoform of 90 kDa Is Generated by Cathepsin L. Biological Chemistry 387:1285-1293. 2006. Cadieux, C., S. Fournier, A. Peterson, C. Bédard, B. J. Bedell and A. Nepveu. Transgenic Mice Expressing the p75 CDP/Cux Isoform Develop a Myeloproliferative- Disease-Like Myeloid Leukemia. Cancer Research, 66: 9492-9501. 2006. Kwan, T., Liu, J., DuBow, M., Gros, P. and Pelletier, J. (2006). Comparative Genomic Analysis of 18 Pseudomonas aeruginosa Bacteriophages. J. Bact. 188, 1184-1187 Park, E.-H., Lee, J.M., and Pelletier, J. (2006). The Tie2 5’ Untranslated Region is Inhibitory to 5’ end-Mediated Translation Initiation. FEBS Letters. 580, 1309-1319. Petersen, C.P., Bordeleau, M.-E., Pelletier, J., and Sharp, P. (2006). Short RNAs repress translation after initiation in mammalian cells. Mol. Cell. 21, 533-542. Bordeleau, M.-E., Mori, A., Oberer, M., Lindqvist, L., Higa, T., Belsham, G., Wagner, G., Tanaka, J., and Pelletier, J. (2006). Small Molecule Interference of Eukaryotic Translation Initiation Factor 4A RNA Binding Inhibits Translation. Nat. Chem. Biol. 2, 213-220. Chard, L.S., Bordeleau, M.E., Pelletier, J., Tanaka, J., and Belsham, G.J. (2006) Hepatitis C virus-related internal ribosome entry sites are found in multiple genera of the family Picornaviridae. J. Gen. Virol. 87, 927-936. Robert, F., Gao, H.Q., Donia, M., Merrick, W.C., Hamann, M.T., and Pelletier, J. (2006). Chlorolissoclimides: New inhibitors of eukaryotic protein synthesis. RNA 12, 717-724. II-10
  • 151. Dept. of Oncology Appendix II: Publications January-December 2006 Malo, N., Hanley, J.A., Cerquozzi, S., Pelletier, J., and Nadon, R. (2006). Statistical practice in high-throughput screening data analysis. Nat. Biotech. 24, 167-175. McKay, G.A., Reddy, R., Arhin, F., Belley, A., Lehoux, D., Moeck, G., Sarmiento, I., Parr, T.R., Gros, P., Pelletier, J., and Far, A.R. (2006) Triaminotriazine DNA helicase inhibitors with antibacterial activity. Bioorg. & Med. Chem. Lett. 16, 1286-1290. Arhin, F., Belanger, O., Ciblat, S., Dehbi, M., Delorme, D., Dietrich, E., Dixit, D., Lafontaine, Y., Lehoux, D., Liu, J., McKay, G.A., Moeck, G., Reddy, R., Rose, Y., Srikumar, R., Tanaka, K.S.E., Williams, D.M., Gros, P., Pelletier, J., Parr, T.R., and Far, A.R. (2006) A new class of small molecule RNA polymerase inhibitors with activity against Rifampicin-resistant Staphylococcus aureus. Bioorg. & Med. Chem. Lett. 14, 5812-5832. Chaudhry, Y., Nayak, A., Bordeleau, M.E., Tanaka, J., Pelletier, J., Belsham, G.J., Roberts, L.O., and Goodfellow, I.G. (2006). Caliciviruses differ in their functional requirements for eIF4F components. J.Biol. Chem. 281, 25315-25325 Mazroui, R., Sukarieh, R., Bordeleau, M.E., Kaufman, R.J., Northcote, P., Tanaka, J., Gallouzi, and Pelletier, J. (2006). Inhibition of ribosome recruitment induces stress granule formation independent of eIF2α phosphorylation. Mol. Biol. Cell. 17, 4212- 4219. Wendel, H.-G., Malina, A., Zhao, Z., Zender, L., Kogan, S.C., Cordon-Cardo, C., Pelletier, J., and Lowe, S.W. (2006). Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. Cancer Res. 66, 7639-7646. Robert, F., Kapp, L.D., Khan, S.N., Acker, M.G., Kolitz, S., Kazemi, S., Kaufman, R.J., Merrick, W.C., Koromilas, A.E., Lorsch, J.R., and Pelletier, J. (2006). Initiation of protein synthesis by Hepatitis C virus is refractory to reduced eIF2•GTP•Met-tRNAiMet ternary complex availability. Mol. Biol. Cell. 17, 4632-4644. Belley, A., Callejo, M., Arhin, F., Dehbi, M., Fadhil, I., Liu, J., McKay, G., Srikumar, R., Bauda, P., Bergeron, D., Ha, N., DuBow, M., Gros, P., Pelletier, J., and Moeck, G. (2006) Competition of bacteriophage polypeptides with native replicase proteins for binding to the DNA sliding clamp reveals a novel mechanism for DNA replication arrest in Staphylococcus aureus. Mol. Microbiol. 62, 1132-1143. Spevak CC, Park EH, Geballe AP, Pelletier J, Sachs MS. (2006). Her-2 upstream open reading frame effects on the use of downstream initiation codons. Biochem Biophys Res Commun. 350, 834-841. Bordeleau ME, Cencic R, Lindqvist L, Oberer M, Northcote P, Wagner G, Pelletier J. (2006) RNA-mediated sequestration of the RNA helicase eIF4A by Pateamine A inhibits translation initiation. Chem Biol. 13, 1287-1295. M.D.C. Evans, Renée-Xaviere Larouche, M. Olivares, P. Léger, C.R. Freeman, E.B. Podgorsak, Total body irradiation with a re-conditioned cobalt teletherapy unit, J. Appl. Clin. Med. Phys. 7, 42-51 (2006). II-11
  • 152. Dept. of Oncology Appendix II: Publications January-December 2006 S. Devic, J.P. Seuntjens, W. Abdel-Rahman, M.D.C. Evans, M. Olivares, E.B. Podgorsak, Accurate skin dose measurements using radiochromic film in clinical applications, Med. Phys. 33, 1116-1124 (2006). W. Abdel-Rahman, J.P. Seuntjens, F. Verhaegen, E.B. Podgorsak, Radiation induced currents in parallel-plate ionization chambers: Measurement and Monte Carlo simulation for megavoltage photon and electron beams, Med. Phys. 33, 3094-3104 (2006). S. Devic, Y.Z. Wang, N. Tomic, E.B. Podgorsak, Sensitivity of linear CCD array based film scanners used for film dosimetry, Med. Phys. 33, 3993-3996 (2006). Diorio C, Berube S, Byrne C, Masse B, Hebert-Croteau N, Yaffe M, Cote G, Pollak M, Brisson J. Influence of Insulin-like Growth Factors on the Strength of the Relation of Vitamin D and Calcium Intakes to Mammographic Breast Density. Cancer Res. 66: 588- 597, 2006. Rollison DE, Newschaffer CJ, Tao Y, Pollak M, Helzlsouer KJ. Premenopausal levels of circulating insulin-like growth factor I and the risk of postmenopausal breast cancer. Int J Cancer. 118: 1279-84, 2006. Rousseau MC, Parent ME, Pollak MN, Siemiatycki J. Diabetes mellitus and cancer risk in a population-based case-controlstudy among men from Montreal, Canada. Int J Cancer. 118: 2105-2109, 2006. Wei EK, Ma J, Pollak MN, Rifai N, Fuchs CS, Hankinson SE, Giovannucci E. C- peptide, insulin-like growth factor binding protein-1, glycosylated hemoglobin, and the risk of distal colorectal adenoma in women. Cancer Epidemiol Biomarkers Prev. 15: 750- 5, 2006. Harris TG, Strickler HD, Yu H, Pollak MN, Monrad ES, Travin MI, Xue X, Rohan TE, Kaplan RC. Specimen processing time and measurement of total insulin-like growth factor-I (IGF-I), free IGF-I, and IGF binding protein-3 (IGFBP-3). Growth Horm IGF Res. 16: 86-92, 2006. Missmer SA, Spiegelman D, Bertone-Johnson ER, Barbieri RL, Pollak MN, Hankinson SE. Reproducibility of Plasma Steroid Hormones, Prolactin, and Insulin-like Growth Factor Levels among Premenopausal Women over a 2- to 3-Year Period. Cancer Epidemiol Biomarkers Prev. 15: 972-8, 2006. Schernhammer ES, Holly JM, Hunter DJ, Pollak MN, Hankinson SE. Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. Endocr Relat Cancer. 13: 583-592, 2006. Tseng PH, Weng SC, Wang YC, Weng JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE, Pollak M, Chen CS. Overcoming Trastuzumab Resistance in HER2- Overexpressing Breast Cancer Cells by Using a Novel Celecoxib-Derived PDK-1 Inhibitor. Mol Pharmacol. 70: 1534-41, 2006. II-12
  • 153. Dept. of Oncology Appendix II: Publications January-December 2006 Zakikhani M, Dowling R, Fantus GI, Sonenberg N, Pollak M. Metformin is an AMP- kinase dependent growth inhibitor for breast cancer cells. Cancer Research. 66: 10269- 73, 2006. Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW, Lippman SM, Platz EA, Pollak MN, Thompson IM, Kristal AR. Obesity, Diabetes, and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial. Epidemiol Biomarkers Prev. 15: 1977-83, 2006. Ahn J, Weinstein SJ, Snyder K, Pollak MN, Virtamo J, Albanes D. No association between serum insulin-like growth factor (IGF)-I, IGF-binding protein-3, and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 15: 2010-2, 2006. Tran CD, Diorio C, Berube S, Pollak M, Brisson J. Relation of insulin-like growth factor (IGF) I and IGF-binding protein 3 concentrations with intakes of fruit, vegetables, and antioxidants. Am J Clin Nutr. 84(6): 1518-26, 2006. Tremblay, G. and S. Richard (2006) mRNAs associated with the Sam68 RNA binding protein. RNA Biology 3:1-4. Roberge D, Souhami L, Olivier A, Leblanc R, Podgorsak E. Hypofractionated stereotactic radiotherapy for low grade glioma at McGill University: long-term follow- up. Tech Cancer Res Treat 5:18, 2006. Roberge D, Ruo R, Souhami L. Killing two birds with one stone: a dosimetric study of dual target radiosurgery using a single isocenter. Tech Cancer Res Treat 5:613-617, 2006. Shenouda G, Mehio A, Souhami L, Duclos M, Portelance L, Belenkov A, Chow T. Erythrpoietin receptor expression in biopsy specimens from patients with uterine cervix squamous cell carcinoma. Int J Gynecol Cancer 16:752-756, 2006. Fadlo R. Khuri, J. Jack Lee, Scott M. Lippman, Edward S. Kim, Jay S. Cooper, Steven E. Benner, Rodger Winn, Thomas F. Pajak, Brendell Williams, George Shenouda, Ian Hodson, Karen Fu, Dong M. Shin, Everett E.Vokes, Lei Feng, Helmuth Goepfert, Waun Ki Hong. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in Stage I and II head and neck cancer patients. J Natl Cancer Inst. 2006 Apr 5;98(7): 441-50. Gari A, Souhami L, Arseneau J, Stanimir G. Primary Malignant Mesodermal Ovarian Sarcomas. Int J Gynecol Cancer 16:106-9, 2006. Caircross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Mehta M, Curran W. Phase III trial of chemotherapy plus radiothjerapy compared to radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Threrapy Oncology Group trial 9402. J Clin Oncol 24:2707-2714, 2006. Cardinale R, Won M, Choucair A, Gillin M, Chakravarti A, Schultz C, Souhami L, Chen A, Pham H, Mehta M. A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023. Int J Radiat Oncol Biol Phys 65:1422-1428, 2006. II-13
  • 154. Dept. of Oncology Appendix II: Publications January-December 2006 Wong RK, Paul N, Ding K, Whitehead M, Brundage M, Fyles A, Wilke D, Nabid A, Fortin A, Wilson D, McKenzie M, Souhami L, Chabot P, Pater J. 5-Hydroxytryptamine- 3 Receptor Antagonist With or Without Short-Course Dexamethasone in the Prophylaxis of Radiation Induced Emesis: A Placebo-Controlled Randomized Trial of the National Cancer Institute of Canada Clinical Trials Group (SC19). J Clin Oncol 24:3458-64, 2006. Ezer H, Ricard N, Bouchard L, Souhami L, Saad F, Aprikian A, Taguchi Y. Adaptation of wives to prostate cancer following diagnosis and 3 months after treatment: A test of family adaptation theory. Int J Nurs Stud 43:827-838, 2006. Robin NH, Taylor CJ, McDonald-McGinn DM, Zackai EH, Bingham P, Collins KJ, Earl D, Gill D, Granata T, Guerrini R, Katz N, Kimonis V, Lin JP, Lynch DR, Mohammed SN, Massey RF, McDonald M, Rogers RC, Splitt M, Stevens CA, Tischkowitz MD, Stoodley N, Leventer RJ, Pilz DT, Dobyns WB. Polymicrogyria and deletion 22q11.2 syndrome: Window to the etiology of a common cortical malformation. Am J Med Genet A. 2006;140(22):2416-25 Vogt J, Ryan E, Tischkowitz MD, Reardon W, Brueton LA. The tale of a nail sign in chromosome 4q34 deletion syndrome. Clin Dysmorphol. 2006;15(3):127-132. Le Page C, Ouellet V, Madore J, Hudson TJ, Tonin PN, Provencher DM, Mes-Masson A-M. 2006. From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serum-based markers in epithelial ovarian cancer. Int J Cancer. 118:1750-8. Le Page C, Ouellet V, Madore J, Ren F, Hudson TJ, Tonin PN, Provencher D, Mes- Masson A-M. 2006. Gene profiling in primary cultures of ovarian epithelial cells identifies novel molecular classifiers of ovarian cancer. Br J Cancer. 94:436-445. Oros KK, Leblanc G, Arcand SL, Shen Z, Perret C, Mes-Masson A-M, Foulkes WD, Ghadiran P, Provencher D, Tonin PN. Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families. BMC Medical Genetics, 7: 23, 2006 Ouellet V, Guyot, M-C, Le Page,C, Filali-Mouhim A, Lussier C, Tonin PN, Provencher D, Mes-Masson A-M. 2006. Tissue array analysis of microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. Int J Cancer 119:599-607 Ouellet V, Le Page C, Guyot M-C, Lussier C, Provencher DM, Tonin PN, Mes-Masson A-M. 2006. The SET complex in serous epithelial ovarian cancer. Int J Cancer 119:2119- 26. Cody, N, Ouellet V, Manderson EN, Quinn M, Filali-Mouhim A, Tellis, P, Provencher D, Mes-Masson A-M, Chevrette M, Tonin PN. 2007. Transfer of chromosome 3 fragments identified candidate regions involved in growth suppression of a human ovarian cancer cell line monoallelic for chromosome 3p. Oncogene 26(4):618-32. Oros KK, Ghadirian P, Mes-Masson A-M, Foulkes WD, Provencher D, Tonin PN. 2006. Application of BRCA1/2 carrier prediction models to French Canadian breast and breast-ovarian cancer families. Clin Genet. 70:320-9. II-14
  • 155. Dept. of Oncology Appendix II: Publications January-December 2006 Xu W, Towers A, Li P, Collet JP. Traditional Chinese Medicine in Cancer Care: Perspectives and Experiences of Patients and Professionals in China ECC-2005-0074, European Journal of Cancer Care, online 22 May 2006 E. Poon, B.Reniers, S. Devic, T.Vuong, F. Verhaegen. Dosimetric characterization of a novel intracavitary mold applicator for 192Ir high dose rate endorectal brachytherapy treatment. Medical Physics .2006.33:4515-4526. Zlobec.I, T.Vuong, C.Compton.The predictive value of PAF-1 in rectal tumors treated with pre-operative high dose rate brachytherapy. Cancer. 2006; 106: 284-6. S.Devic, J.Seuntjens, W.Abdel-Rahman, M.Evans, M.Olivares, EB Podgorsak, T.Vuong, SoaresCG. Accurate skin dose measurements using radiochromic film in clinical applications. Am Assoc Phys Med. 2006.33: 116-1124. O.Ballivy, W. Parker, T.Vuong, G.Shenouda, H.Patrocinio. Impact of geometric uncertainties on the dose distribution during intensity-modulated radiotherapy (IMRT) of head and neck cancer: the need for planning target volume (PTV) and planning organ at risk volume (PRV). Current Oncology, Vol. 13, No. 3.108-115. 2006. Liu, B.; Bernard, B. & Wu, J.H. Impact of EGFR point mutations on the sensitivity to gefitinib: insight from comparative structural analyses and molecular dynamics simulations, PROTEINS: Structure, Function and Bioinformatics, 2006, 65:331-346. Callejo, M., Sibani, S., Di Paola, D., Price, G.B. and Zannis-Hadjopoulos, M. (2006). Identification and functional analysis of a human homologue of the monkey replication origin, ors8. J. Cell. Biochem., 99:1606-1615. Teer, J.K., Machida, Y., Labit, H., Novac, O., Hyrien, O., Mahreneike, K., Zannis- Hadjopoulos, M. and Dutta, (2006). A. Proliferating human cells hypomorphic for Orc2 and pre-RC formation have a defect in p53 activation and Cdk2 kinase activation. J. Biol. Chem., 281:6253 - 6260 Di Paola, D., Price, G.B. and Zannis-Hadjopoulos, M. (2006). Differentially active origins of DNA replication in tumor versus normal cells. Cancer Res., 66(10):5094-5103. Monographs Justine Farley, Normes en matière de soins palliatifs pédiatriques, Ministère de la Santé et des Services sociaux, Québec, 2006 (à titre de membre du groupe de travail) Bosch FX, Cuzick J, Schiller J, Garnett G, Meheus A, Franco E, Wright T (Co-Editors). HPV Vaccines and Screening in the Prevention of Cervical Cancer. Vaccine, Volume 24, Supplement 3, 31 August 2006, ISSN 0264-410X. Loiselle, C. G., Profetto-McGrath, J., Polit, D. F., & Beck, C.T. (2007). Canadian essentials of nursing research. Second Edition. New York: Lippincott. II-15
  • 156. Dept. of Oncology Appendix II: Publications January-December 2006 Reviews Aguilar-Mahecha A, Hassan S, Ferrario C, Basik M. Microarrays as validation strategies in clinical samples: tissue and protein microarrays. OMICS A Journal of Integrative Biology, 2006 Fall;10(3):311-26. Farley J, En fin de vie, hydrater ou ne pas hydrater?, Le Médecin du Québec 2006 Nov : 41(11) : 81-86 Tischkowitz MD, Foulkes WD. The basal phenotype of BRCA1-related breast cancer: past, present and future. Cell Cycle. 2006 May;5(9):963-7. Trottier H(§), Franco EL(*). The epidemiology of genital human papillomavirus infection. Vaccine 24: S1/4-15, 2006. Burchell AN(§), Winer RL, Sanjosé S, Franco EL. Epidemiology and transmission dynamics of genital human papillomavirus infection. Vaccine 24S3: 52-61, 2006. Trottier H(§), Franco EL. Human papillomavirus and cervical cancer: burden of illness and basis for prevention. American Journal of Managed Care 12: S462-472, 2006. Frazer IH(*), Cox JT, Mayeaux EJ, Franco EL, Moscicki AB, Palefsky J, Ferris D, Ferenczy A, Villa, L. Advances in prevention of cervical cancer and other human papillomavirus-related diseases. Pediatric Infectious Disease Journal 25: S65–S81, 2006. Tonin PN. 2006. Le spectre limité des mutations pathogéniques BRCA1 et BRCA2 dans le cancer du sein et le cancer du sein-ovaire dans les familles canadiennes-françaises, une population fondatrice du Québec, Canada [The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada]. Bulletin du Cancer 2006 93:841-6 [Invited review, for special issue to commemorate 100th anniversary of Société Française du Cancer en 2006] Books and Book Chapters Mohammad Amin Kerachian, Denis Cournoyer, Edward J. Harvey, Terry Chow, Chantal Séguin. Avascular necrosis of the Femoral Head : Vascular Hypotheses. Endothelium. In press. October 2006 Cohen SR. Quality of life assessment in palliative care. In: Textbook in Palliative Medicine, E. Bruera, I. Higginson, C. von Gunten, and C. Ripamonti eds. Hodder Arnold Limited, London, England. Distributed by Oxford University Press, New York, N.Y. (2006) pp. 349-55. Farmer, J-P., McNeely, P.D., Freeman, C.R. Brainstem gliomas. In Principles andPractice of Pediatric Neurosurgery. Ed. Albright, A.L. 2006. A practical guide to human cancer genetics, third edition: Hodgson SV, Foulkes WD, Eng C and Maher ER. Cambridge University Press, 2006. II-16
  • 157. Dept. of Oncology Appendix II: Publications January-December 2006 Burchell AN(§), Franco EL(*). Epidemiology of oncogenic and nononcogenic HPV types, and the evidence for differences in their sexual transmissibility. In: Monsonego J (ed.) Emerging issues on HPV infections: From science to practice. Karger AG, Basel, 2006, pp. 20-33, ISBN 3-8055-8120-3. Duarte-Franco E, Franco EL(*). Epidemiologia do cancer mamario e ginecologico. In: Abrao F (ed.) Tratado de oncologia genital e mamaria. 2a. Edição, Editora Revinter, Sao Paulo, 2006, pp. 1-25, ISBN 85-372-0005-0. Rohan TE, Henson D, Franco EL, Albores-Saavedra J. Cancer Precursors. In: Schottenfeld D, Fraumeni J (eds.) Cancer Epidemiology and Prevention, 3rd edition, Oxford University Press, 2006; pp. 21-46, ISBN-13: 978-0-19-514961-6 and ISBN-10: 0- 19-514961-0. Koushik A(§), Franco EL(*). Chapter 18: Epidemiology and the role of human papillomaviruses. In: Jordan JA, Singer A (eds.) The Cervix, 2nd Edition, Blackwell, Oxford, 2006, pp. 259-276, ISBN-13: 978-1-4051-3137-7, ISBN-10: 1-4051-3137-3. Spence A(§), Franco EL(*). Chapter 26: Screening for cervical cancer using HPV tests. In: Jordan JA, Singer A (eds.) The Cervix, 2nd Edition, Blackwell, Oxford, 2006, pp. 373-386, ISBN-13: 978-1-4051-3137-7, ISBN-10: 1-4051-3137-3. Gagnon B. Day Hospitals. Bruera E, Higginson I, Ripamonti C, von Gunten C. Eds. In: Textbook of Palliative Medicine. Hodder Arnold, pp. 285-293 (2006) Roberge D, Souhami L, Olivier A, Leblanc R, Podgorsak EB. Stereotactic radiosurgery/radiotherapy in the management of low grade gliomas. In: Brain Cancer Therapy and Surgical Interventions (Series: Horizons in Cancer Research). Yang AV (ed). Nova Publishers, pp 147-169, 2006. Liben S. Breathlessness in Children (2006). In :Dyspnoea in advanced disease; a guide to clinical management. S Booth & D Dudgeon (eds). Oxford University Press. The Oxford Textbook of Palliative Care for Children – Edited by Goldman A, Liben S, and Hain R. Oxford University Press, 2006 Alimentation/hydration. Chasen M and MacDonald N. In: ESMO Handbook of Advanced Cancer Care. Catane R, Cherny NI, Kloke M, Tanneberger S and Schrijvers D (eds). Oxford: Taylor & Francis 2006: 71-79. The Development of Palliative Care in Canada. MacDonald N. In: Palliative Medicine. Bruera E, Higginson I, Ripamonti C and von Gunten C. (eds). London: Hodder Arnold Publishers. 2006: 22-29. Quality end-of-Life Care. Singer PA, MacDonald N. Tulsky JA. In: Bioethics for Clinicians. Cambridge University Press. 2007. Accepted for publication. Pelletier, J. and Peltz, S.W. (2006). Therapeutic Opportunities in Translation. In “Translational Control in Biology and Medicine” (Matthews, M., Sonenberg, N., and Hershey, J.W.B.). II-17
  • 158. Dept. of Oncology Appendix II: Publications January-December 2006 Truscott, M. and A. Nepveu. Homeodomains Transcription Factors. Encyclopedic Reference of Genomics and Proteomics in Molecular Medicine. Springer-Verlag. http://encref.springer.de/genomics/ Lymphoedema Framework: Best Practice for the Management of Lymphoedema. International Consensus. London MEP Ltd, 2006. ISBN 0-9547669-4-6. Anna Towers was a member of the international advisory board that drafted these practice guidelines. Conference Proceedings The p75 neurotrophin receptor regulates activity-dependent axon competition by antagonizing TrkA-mediated Ras-Raf-MAPK signaling Singh K (Singh, K.), Kramer B (Kramer, B.), Lin D (Lin, D.), Aloyz R (Aloyz, R.), Kaplan D (Kaplan, D.), Miller F (Miller, F.) International Journal Of Developmental Neuroscience 24 (8): 578-579 Dec 2006 Inhibition of DNA repair vis-a-vis resistance in chronic lymphocytic leukemia Amrein L, Loignon M, Aloyz R, et al.. EJC Supplements 4 (12): 152-152 498 Nov 2006 Bouchard A, Mamo A, Basik M. High resolution array CGH in 12 colorectal cell lines reveals multiple novel areas of amplifications and deletions in both MSI and MSS colorectal cell lines. Proceedings AACR 2006 Annual Meeting abstract # 148. Hassan S, Salvucci O, Basik M . Stromal cell derived factor-1 polymorphism associated with earlier onset of metastasis in breast cancer. Proceedings AACR 2006 Annual Meeting, abstract # 298 Ferrario C, Hostetter G and Basik M. Expression of Neuropilin-1 and related proteins in breast cancer. Proceedings AACR 2006 Annual Meeting abstract # 5034. Aguilar-Mahecha A, Cantin C, Deneault JS, Nantel A, O’Connor M, Basik M. Development of Reverse Phase Protein Arrays for the Validation of Newly Discovered Biomarkers in Plasma or Serum. Presented at the Annual Meeting of the Human Proteome Organization (HUPO), Boston March 2006. Hassan S., Salvucci O, Baccarelli A, Basik M. Stromal cell derived factor (SDF)-1: predictive marker of distant metastasis and poorer survival in breast cancer. Clinical and Investigative Medicine Vol. 29 (4), Aug 2006: 268. Mamo A., Cavallone L., Ferrario C., Rancourt C. and Basik M. Genomic alterations as a guide to the discovery of novel therapeutic targets in breast cancer. Presented at the 25th Congress of the International Association for Breast Cancer Research, Montreal, September 2006. Cavallone L., Mamo A., Basik M. and Tonin P.An integrated genomics approach towards the identification of tumor suppressor gene candidates through nonsense- mediated mRNA decay inhibition of breast cancer cell lines. Presented at the 25th Congress of the International Association for Breast Cancer Research, Montreal, September 2006. II-18
  • 159. Dept. of Oncology Appendix II: Publications January-December 2006 Hassan S., Salvucci O, Baccarelli A, Basik M. Stromal cell derived factor (SDF)-1: predictive marker of distant metastasis and poorer survival in breast cancer. Presented at the 25th Congress of the International Association for Breast Cancer Research, Montreal, September 2006. Aguilar-Mahecha A, Cantin C, Deneault JS, Wu M, Huneau MC, O'Connor-McCourt M, Nantel A, Basik M. Optimization of reverse phase protein microarrays for blood biomarker validation . Presented at 5th Annual World Congress Human Proteome Organization, Long Beach, CA, Oct 2006 Choudhury, S.A., Asefa, B., Kauler, P., and Chow T.Y.-K. Evidences for overlapping function of TRM2/RNC1 and Exo1 in DNA double strand break repair in yeast Saccharomyces cerevisiae. Yeast Genetics and Molecular Biology Meeting. 2006. Sergio L Faria, Bosede Joshua, Horacio Patrocinio, Francois Deblois, Marie Duclos, Marc David, George Shenouda, Luis Souhami. Lack of correlation between recognized Dose-volume guidelines and late rectal toxicity after hypofractionated radiation therapy for prostate cancer. Poster Presentation at the ESTRO 2006, October 8-12th 2006, Leipzig, Germany. Filion, E., Parker, W., Freeman, C.R. Intensity modulated radiation therapy provides superior normal tissue sparing in the treatment of patients with retinoblastoma. Annual meeting of the International Paediatric Oncology Society (SIOP). Geneva. September 2006. Filion, E., Parker, W., Roberge, D., Freeman, C.R. IMRT for spinal irradiation in the treatment of pediatric medulloblastoma. American Society for Therapeutic Radiology and Oncology annual meeting. Philadelphia. November 2006. de Pokomandy A(§), Rouleau D, Ghattas G, Vézina S, Coté P, Macleod J, Allaire G, Franco EF, Coutlée F. HPV-16, 18, 31, 45 viral loads in anal intra-epithelial lesions in HIV-seropositive men. 15th Annual Canadian Conference on HIV/AIDS research, Ottawa, Canada, June 2006. Gagnon S, Hankins C, Pourreaux K, Franco E, The Canadian Women’s HIV Study Group, Coutlée F. Polymorphism of the capsid L1 gene is not a determinant of persistence of HPV-52 infection in HIV-seropositive women. 15th Annual Canadian Conference on HIV/AIDS research, Ottawa, Canada, June 2006. Mayrand MH(§), Mahmud SM, Franco EL, Hanley J. Design, ethical and statistical challenges when studying the performance of new screening tests for cervical cancer. 23rd International Biometric Conference, Montreal, Canada, July 2006. Burchell AN(§), Hanley J, Richardson H, Mahmud SM, Trottier H, Tellier PP, Coutlée F, Franco EL. Use of stochastic computer simulation and maximum likelihood methods to estimate sexual transmissibility of human papillomavirus infection. 23rd International Biometric Conference, Montreal, Canada, July 2006. II-19
  • 160. Dept. of Oncology Appendix II: Publications January-December 2006 Trottier H(§), Schaffer A, Koushik A, Duarte-Franco E, Coutlée F, Pollak M, Franco EL. Insulin-like growth factor-I and risk of high-grade cervical intraepithelial neoplasia. 23rd International Papillomavirus Conference, Prague, Czech Republic, September 2006. Trottier H(§), Mahmud S, Prado J, Rohan TE, Villa LL, Franco EL. Duration of type- specific HPV infection: Results from the Ludwig-McGill cohort study. 23rd International Papillomavirus Conference, Prague, Czech Republic, September 2006. Kohli M, Ferko N, Martin A, Franco EL, Jenkins D, Gallivan S, Sherlaw-Johnson C, Drummond M. Estimating the long-term impact of a prophylactic human papillomavirus (HPV) 16/18 vaccine on the burden of cervical disease in the UK. 23rd International Papillomavirus Conference, Prague, Czech Republic, September 2006. Trevisan A, Schlecht NF, Ferreira S, Sichero L, Ferenczy A, Duarte-Franco E, Franco EL, Villa LL. Correlation between viral load measured by real-time and low-stringency PCR testing of cervical specimens. 23rd International Papillomavirus Conference, Prague, Czech Republic, September 2006. Sichero L, Ferreira S, Trottier H, Ferenczy A, Franco EL, Villa LL. High grade cervical lesions are caused preferentially by non-European variants of HPVs 16 and 18. 23rd International Papillomavirus Conference, Prague, Czech Republic, September 2006. Sénécal M, Maunsell E, Ferenczy A, Franco EL, Ratnam S, Coutlée F, Palefsky JM, Foucart S, Brisson M, Mansi JA. Psychosocial impact of cervical screening and condyloma: an epidemiological study (pisces). 23rd International Papillomavirus Conference, Prague, Czech Republic, September 2006. Mayrand MH(§), Duarte-Franco E, Rodrigues I, Walter SD, Coutlée F , Ratnam S, Franco EL. Comparison of Pap and hpv testing strategies for screening high-grade cervical cancer precursors: Results from the Canadian Cervical Cancer Screening Trial (CCCaST). 23rd International Papillomavirus Conference, Prague, Czech Republic, September 2006. De Pokomandy A(§), Rouleau D, Ghattas G, Vézina S, Côté P, MacLeod J, Allaire G, Fontaine J, Trépanier JM, Franco EL, Coutlée F. Human Papillomavirus 16, 18, 31, 45 viral loads and grade of anal intraepithelial neoplasia in HIV-infected men. 23rd International Papillomavirus Conference, Prague, Czech Republic, September 2006. Tomita LY(§), Carneiro LC, Villa LL, Franco EL, Cardoso MA. Serum micronutrients in relation to human papillomavirus infection in Brazilian women: Preliminary results. 1st World Congress of Public Health Nutrition, Barcelona, Spain, September 2006. Tomita LY(§), D´Almeida V, Longatto-Filho A, Villa LL, Franco EL, Cardoso MA. Higher homocysteine and lower serum levels of alpha-tocopherol are risk factors for cervical dysplasia in women living in São Paulo, Brazil. Frontiers in Cancer Prevention Research Conference, American Association for Cancer Research, Boston, USA, November, 2006. II-20
  • 161. Dept. of Oncology Appendix II: Publications January-December 2006 Mahmud S, Turner D, Franco E, Aprikian A. Meta-analysis of the effects of aspirin, NSAID and acetaminophen use on prostate cancer risk. Poster presentation. Canadian Society of Epidemiology and Biostatistics. Calgary, Canada, May 2007. I Bruchim, M.N. Pollak, Y Shi, S Lau, W.H. Gotlieb, In vivo antitumor activity of oral NVP-AEW541, an IGF-I receptor kinase inhibitor, Society of Gynecologic Oncology Meeting, Palm Springs March 2006 AM Mes-Masson, D. Provencher, W. Gotlieb, C. Rancourt, D. Bachvarov , B. Têtu. The Réseau de recherche sur le cancer (RRCancer) of the Fonds de la recherche en santé du Québec (FRSQ): A consortium of multiple ovarian cancer banking hubs Vancouver May 2006. I Bruchim, M.N. Pollak, Y Shi, S Lau, W.H. Gotlieb In vivo antitumor activity of oral NVP-AEW541, an IGF-I receptor kinase inhibitor, Society of Obstetrics and Gynecology of Canada, Vancouver June 2006 Lobsanov, YD, Yoshida, T, Desmet, T, Nerinckx, W, Herscovics, A, Howell, P.L. Possible mechanism of regulation of activity in Class I α1,2-mannosidases : structure of a fungal a1,2-mannosidase in complex with a substrate analog. XXIIIrd International Carbohydrate Symposium. Whistler, Canada 2006. Rodionov, D, Romero, PA and Herscovics, A. Production of recombinant yeast mannosyltransferase complex M-Pol I. Society for Glycobiology, Los Angeles 2006. Dawood S, Vogelesang L, Bismar TA, Mulder D, Sirois C, and Hirsh V: Pilot Prospective Exploratory Study about Predictive Values for NSCLC Patient Compliance with Adjuvant Chemotherapy After Complete Resection. Annals of Oncology Vol. 17 (Supplement 9): ix 236, 2006. Major P, Hirsh V, Lipton A, Cook RJ, Langer C, and Shirina N: Zoledronic Acid May Improve Survival in Lung Cancer Patients With High Baseline Bone Marker Levels. Annals of Oncology Vol. 17 (Supplement 9): ix 221, 2006. Matczak E, Hirsh V, Lipton A, Cook RJ, Langer C, Hei YJ, and Major P: Effects of Zoledronic Acid on Survival in Patients with Lung Cancer and High Baseline N- Telopeptide (NTX) levels: Stratified by Baseline Bone Alkaline Phosphatase (BALP). Journal of Clinical Oncology Vol. 24, No. 18S, 2006. Berruti A, Dogliotti L, Tampellini M, Lipton A, Hirsh V, Saad F, Liati P, Shirina N, and Cook R: Effect of Zoledronic Acid Treatment Based on Serum Parathyroid Hormone Levels in Patients with Malignant Bone Disease. Journal of Clinical Oncology Vol. 24, No. 18S, 2006. Hirsh V, Duclos M, Souhami L, Del Vecchio P, Ofiara L, Faria S, Ayoub JP, Charpentier D, Portelance L, and Soulieres D: A Phase II Trial with Carboplatin/Gemcitabine Induction Chemotherapy Followed by Radiotherapy II-21
  • 162. Dept. of Oncology Appendix II: Publications January-December 2006 Concomitantly with Paclitaxel/Gemcitabine in Stage III Non Small Cell Lung Cancer (NSCLC). Journal of Clinical Oncology Vol. 24, No. 18S, 2006. Liben S. Understanding what families want and what children need; pediatric palliative care research brings us closer. Chair: Pediatric Day Seminar: 16th International Congress On Care of the Terminally Ill. Sept 2006 Montreal Loiselle, C. G. (2006). PORT- A Canadian exemplar of high quality, cutting-edge transdisciplinary research training in psychosocial oncology. 8th World Congress of Psycho-Oncology. Multidisciplinary Psychosocial Oncology: Dialogue and Interaction. International Psycho-Oncology Society (IPOS). Venice, Italy, October 18-21, 2006. Psycho-Oncology, 15(Suppl. 2), S148. Loiselle, C. G., Dubois, S., & Edgar, L. (2006). The role of interactive health communication (IHC) in softening the blow of a cancer diagnosis and guiding the use of health care services: Are women and men reacting to IHC differently? 8th World Congress of Psycho-Oncology. Multidisciplinary Psychosocial Oncology: Dialogue and Interaction. International Psycho-Oncology Society (IPOS). Venice, Italy, October 18-21, 2006. Psycho-Oncology, 15(Suppl. 2), S310. Lambert, S., Dubois, S., & Loiselle, G. C. (2006). Focus groups with individuals diagnosed with cancer: Guidelines from specific experience. 8th World Congress of Psycho-Oncology. Multidisciplinary Psychosocial Oncology: Dialogue and Interaction. International Psycho-Oncology Society (IPOS). Venice, Italy, October 18-21, 2006. Psycho-Oncology, 15(Suppl. 2), S299. A. Sarfehnia, K. Jabbari, J.P. Seuntjens, E.B. Podgorsak, High contrast imaging using orthogonal bremsstrahlung beams: An experimental study of radiation quality, Proceedings of the 52-nd Annual Scientific Meeting of the Canadian Organization of Medical Physicists (COMP), Saskatoon, Saskatchewan; 31 May – 2 June, 2006; pp. 170- 172. M.D.C. Evans, M. Olivares, J.P. Seuntjens, W. Parker, S. Devic, E. Poli, C. Freeman, E.B. Podgorsak, A rotational total skin electron irradiation technique using a linear accelerator with a commercially available high dose rate total body electron mode, Proceedings of the 52-nd Annual Scientific Meeting of the Canadian Organization of Medical Physicists (COMP), Saskatoon, Saskatchewan; 31 May – 2 June, 2006; pp. 261- 264. M. E. Ramos-Poli, W. Parker, E.B. Podgorsak, L. Campos, Influence of planning target volume definition on skin dose for head and neck patients treated with inverse planned IMRT, Proceedings of the World Congress on Medical Physics and Biomedical Engineering, COEX Seoul, Korea, August 27 – September 1, 2006; pp. 1803-1805. W. Parker, M. Esmeralda Poli, H. Patrocinio, L. Souhami, G. Shenouda, L. Lucente Campos, E. Podgorsak. An Assessment of Inter-Fraction Prostate Motion Based On 10,327 Pre-Treatment Ultrasound Localizations for 387 Prostate Cancer Patients II-22
  • 163. Dept. of Oncology Appendix II: Publications January-December 2006 Treated With Conformal 3D External Beam Radiation Therapy (EBRT). Poster Presentation at the ESTRO 2006, October 8-12th 2006 , Leipzig, Germany. G Shenouda, D Roberge, P Kavan, T Muanza, C Lambert, R Leblanc, R Del Maestro, MC Guiot, L. Souhami. A Novel Approach using Accelerated Hypo- fractionation-IMRT (AH-IMRT) and Temozolomide (TMZ) in patients with Glioblastoma Multiforme (GBM). Oral Presentation at the 12th Biennial Canadian Neuro-Oncology Conference 2006, Winnipeg, Canada, May 26-28, 2006. G Shenouda, D Roberge, P Kavan, T Muanza, C Lambert, R Leblanc, R Del Maestro, MC Guiot, L. Souhami. A Novel Approach using Accelerated Hypo- fractionation-IMRT (AH-IMRT) and Temozolomide (TMZ) in patients with Glioblastoma Multiforme (GBM). Oral Presentation at the CARO 2006 Annual Scientific Meeting, Calgary, Alberta, Sept.13-16, 2006. Huang, F, Chauvin P, Mehio A, Muanza T, Shenouda G. Erythropoietin receptor expression in human squamous cell carcinoma of the tongue-molecular consideration for radiation oncologist. Poster Presentation at the CARO 2006 Annual Scientific Meeting, Calgary, Alberta, September 13-16, 2006. G. Shenouda, F. DeBlois, A. Alexander, H. Patrocinio, R. Ruo, J. Chankowski. The use of the BrainLAB relocatable stereotactic frame for irradiation of choroidal melanoma: design and treatment accuracy study. Oral Presentation at the ESTRO 2006, October 8- 12th 2006, Leipzig, Germany. II-23
  • 164. Dept. of Oncology Appendix III: Consulting Activities June 1, 2006-May 31, 2007 Appendix III: Consulting Activities Name of Faculty Private Public Sector Other (explain) Total Member Sector (number of days) (number of days) (number of days) Ala-Eddin Al Moustafa 0 0 0 0 Paul Allison 0 0 0 0 Raquel Aloyz 0 0 0 0 Dawn Anderson 0 0 0 0 Mark Basik 0 0 0 0 Gerald Batist 0 0 0 0 Nicole Beauchemin 0 0 0 0 Philip Branton 2 20 150 days 172 (CIHR SD) Terry Chow 0 0 0 0 S. Robin Cohen 0 0 0 0 Justine Farley 0 0 0 0 William Foulkes 0 0 0 0 Eduardo Franco 5 10 0 15 Carolyn Freeman 0 0 0 0 Bruno Gagnon 4 0 0 4 Jacques Galipeau 0 0 0 0 Vincent Giguère 2 0 0 2 Philip Gordon 0 0 0 0 Walter Gotlieb 2.5 0 0 2.5 Annette Herscovics 0 0 0 0 Vera Hirsch 11 0 0 11 Thomas Hutchinson 0 0 0 0 Stephen Liben 0 0 0 0 Carmen Loiselle 0 0 0 0 Mary Ellen MacDonald 0 0 0 0 Neil MacDonald 0 0 0 0 Wilson Miller 0 0 0 0 Alain Nepveu 0 0 0 0 Jerry Pelletier 30 0 0 30 Ervin Podgorsak 0 45 hours/year 45 hours/year teaching radiotherapy physics Michael Pollak 0 0 0 0 Stephane Richard 0 0 0 0 Luis Souhami 0 0 0 0 Marc Tischkowitz 0 5 0 5 III-1
  • 165. Dept. of Oncology Appendix III: Consulting Activities June 1, 2006-May 31, 2007 Name of Faculty Private Public Sector Other (explain) Total Member Sector (number of days) (number of days) (number of days) Patricia Tonin 0 0 0 0 Anna Towers 0 0 0 0 Antonio Vigano 0 0 0 0 Te Vuong 0 0 0 0 Jian Hui Wu 0 0 0 0 Maria Zannis-Hadjopoulos 2 0 0 2 Philip Branton GeminX Advanced Cancer Therapeutics (Montreal) Consultant and member of the Research Advisory Board , etc. Eduardo Franco GSK, GenProbe, Innovus, Merck-Frosst, Roche Molecular Systems, NCIC, NIH, CIHR; Several hours reviewing documents, participating in committees or conference calls; Scattered throughout the year; Expert consultation on the topics of my research. Bruno Gagnon Continuing Medical Education program entitled “The Next Step in Pain Management”, is being sponsored through an educational grant from Paladin Labs. 2 days, February – April, 2007, Participation in developing a teaching module on Methadone. Methylnaltrexone Dinner Discussions, Wyeth Pharmaceuticals, A Division of Wyeth Canada. Toronto, April 2, 2007, 2 days, April, 2007, Participation in discussions involving Methylnaltrexone. Vincent Giguère Wyeth-Ayerst, private sector. Seminar presentation and discussion of research data with staff. A single 2-day meeting. Walter Gotlieb Abraxis Advisory board: 1 day June 2006: Evaluation of Abraxane Ipsos Reid: 2 hours December 2006: Research on Human Papillomavirus Sanofi Aventis, Private Sector: 1 day in February 2007: coordinating investigator for study on VEGF-TRAP in recurrent ovarian cancer. III-2
  • 166. Dept. of Oncology Appendix III: Consulting Activities June 1, 2006-May 31, 2007 Vera Hirsch Advisory Boards • 3 days (Amgen, Nov. 2006) • 2 days (Roche, May 2007) • 1 day (Eli Lilly, Dec. 2006) • 2 days (Eli Lilly, Nov. 2006) • 1 day (Astrazeneca, Nov. 2006) • 1 day (Astrazeneca, Sept. 2006) • 1 day (Abraxis, Oct. 2006) Jerry Pelletier Scientific Consultant for Targanta Therapeutics, Time spent: 30 days Maria Zannis-Hadjopoulos Replicor Inc: 2 days, 1 day per 6 mos, Advisory III-3
  • 167. Dept. of Oncology Appendix I: Honours, Awards and Prizes June 1, 2006-May 31, 2007 Appendix I: Honours Awards and Prizes Paul Allison Howard Katz Award for Excellence in Teaching (May, 2007): $1000 awarded to an individual at the Faculty of Dentistry, McGill University Dawn Anderson Recipient of the Inaugural Hingston Grant for Development of Medical Leadership. Nicole Beauchemin Faculty of Medicine “Faculty Honour List for Educational Excellence” 2007 William Foulkes 2007-2011: Fonds de la recherche en Santé du Québec : Chercheur National Eduardo Franco “Ambassadeur de Montréal”, prize by the Montreal Congress Centre, May 2007. Phil Gold Establishment of the Phil Gold Chair in Medicine (November 2006) Philip Gordon Cited in Marquis Who’s Who in the World 2006 23rd Edition Named to Faculty Honour List for Educational Excellence in recognition of contributions to teaching in the McGill Faculty of Medicine June 14, 2007 Walter Gotlieb June 2006: Canadian Foundation for Women's Health Grant I-1
  • 168. Dept. of Oncology Appendix I: Honours, Awards and Prizes June 1, 2006-May 31, 2007 Stephen Liben Service Award – Commander Palliative Care Presentation. Nov 2006 The Military & Hospitaller Order of St. Lazarus First Prize - Royal Society of Medicine Book Awards. Oct 2006, Oxford Textbook of Palliative Care for Children (Goldman, Hain, Liben eds). Carmen Loiselle Guest of honour at the McGill University School of Nursing 2007 Graduation Ball, Omni Hotel, Montreal. April, 27, 2007. Voted "the most significant teacher" by the BNI graduating students. Ervin Podgorsak Coolidge Award, American Association of Physicists in Medicine (AAPM), July 31, 2006. The Coolidge Award is the highest honor presented during the annual AAPM meeting to a medical physicist who has exhibited a distinguished career in medical physics in three areas: research, teaching and service and who has exerted a significant impact on the practice of medical physics. The organization gives one such award per year. Since 1974 three awards went to Canada: two to the University of Toronto (H. Johns 1976 and J.R. Cunningham 1988) and now one to McGill (2006). Elected Fellow, American College of Medical Physics (ACMP) 2007 Stephane Richard 2006 Prix d'excellence en recherche, Conseil des gouverneurs de l'Hôpital general juif 2007-2012 Chercheur Nationaux, FRSQ Marc Tischkowitz FRSQ Chercheur-bousier clinicien Junior 1 (commences July 2007) Te Vuong 1. RVH centennial Research Grant Award: 2006. ($10,000) 2. Howard W Pillow memorial Research Award. October 2006. ($7,000) 3. CIHR Investigator salary Award 2006-2010 ($70 000 X 5) I-2
  • 169. Dept. of Oncology Appendix II: Publications January-December 2006 Appendix II: Publications Articles in peer-reviewed journals Yasmeen, A., Bismar, T., and Al Moustafa A-E. 2006. ErbB receptors and epithelial- cadherin-catenin complex in human carcinomas. Future Oncology, 2: 765-781. Hernandez M, Shao Q, Yang XJ, Luh SP, Kandouz M, Batist G, Laird DW, Alaoui- Jamali MA. A histone deacetylation-dependent mechanism for transcriptional repression of the gap junction gene cx43 in prostate cancer cells. Prostate. 2006 Aug 1;66(11):1151- 61. Vilela LD*, Nicolau B*, Mahmud S, Edgar L, Hier M, Black M, Franco EL & Allison PJ. (2006) A comparison of psychosocial outcomes in head and neck cancer patients receiving a coping strategies intervention and control subjects receiving no intervention. Journal of Otolaryngology. 35(2):88-96 Cesaire R, Oliere S, Sharif-Askari E, Loignon M, Lezin A, Olindo S, Panelatti G, Kazanji M, Aloyz R, Panasci L, Bell JC, Hiscott J. Oncolytic activity of vesicular stomatitis virus in primary adult T-cell leukemia.Oncogene. 2006 Jan 19;25(3):349-58. Salvucci O, Bouchard A, Baccarelli A, Deschenes J, Sauter G, Simon R, Bianchi R, Basik M. The role of CXCR4 receptor expression in breast cancer : a large tissue microarray study. Breast Cancer Research & Treatment, 2006 Jun;97(3):275-83, Dec 2005 epub. Batist G, Harris L, Azarnia N, Lee LW, Daza-Ramirez P. Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis. Anticancer Drugs. 2006 Jun;17(5):587-95. Mes-Masson AM, Champoux L, Hebert J, Batist G, Lesperance B. The reseau de recherche sur le cancer: favoring a multi-disciplinary approach. Bull Cancer. 2006 Sep 1;93(9):831-4. French. CEACAM1 modulates vascular remodeling in vitro and in vivo. A.K. Horst, W.D. Ito, J. Dabelstein, U. Schumacher, H. Sander, C. Turbide, J. Brummer, T. Meinertz, N. Beauchemin* and C. Wagener*. J. Clin. Investig. 116(6):1596-1605, (2006). *contributed equally to the work. A novel role for the protein tyrosine phosphatase SHP-1 as a negative regulator of insulin-mediated glucose metabolism and insulin clearance. M.J. Dubois, K. Dombrowski, H.J. Kim, S. Bergeron, M. Perreault, R. Faure, M. Olivier, N. Beauchemin, G. I. Schulman, K.A. Siminovitch, J.K. Kim and A. Marette. Nat. Med. 12(5), 549-56. (2006). II-1
  • 170. Dept. of Oncology Appendix II: Publications January-December 2006 Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) contributes to progression of colon tumors. N. Leung, C. Turbide, V. Marcus, S. Jothy and N. Beauchemin. Oncogene, 25, 5527-5536 (2006). Binda, O., J.-S. Roy, and P. E. Branton. 2006. RBP1 Family Proteins Exhibit SUMOylation-Dependent Transcriptional Repression and Induce Cell Growth Inhibition Reminiscent of Senescence. Mol. Cell. Biol. 2006 26: 1917-1931 Belzile, J-P, Choudhury, SA, Cournoyer, D, and Chow, TYK. Targeting DNA Repair Proteins: A Promising Avenue for Cancer Gene Therapy. Current Gene Therapy 6(1):111-123, 2006. Mohammad Amin Kerachian, Edward J Harvey, Denis Cournoyer, Terry Y.K. Chow, Chantal Seguin. Avascular Necrosis of the Femoral Head: Vascular hypotheses. 2006. Endothelium 13:237-244. Lee V, Cohen SR, Edgar L, Laizner AM, Gagnon A. Meaning-making and Psychological Adjustment to cancer: development of an intervention and pilot results. Oncology Nursing Forum, 2006; 33 (2): 291-302. Lee V, Cohen SR, Edgar L, Laizner AM, Gagnon AJ. Meaning-making intervention during breast or colorectal cancer treatment improves self-esteem, optimism, and self- efficacy. Social Science & Medicine, 2006; 62(12) 3133-3145. Williams A, Crooks VA, Stajduhar KI, Allan D, Cohen SR. Canada’s Compassionate Care Benefit: Views of family caregivers in chronic illness. International Journal of Palliative Nursing, 2006; 12 (9) 438-45. Cohen SR, Leis AM, Kuhl D, Charbonneau C, Ritvo P, Ashbury FD. QOLLTI-F: measuring family carer quality of life. Palliative Medicine, 2006; 20: 755-767. Cohen V, Agulnik JS, Jarry J, Batist G, Small D, Kreisman H, Tejada A, Miller WH Jr, Chong G. Evaluation of Denaturing High Performance Liquid Chromatography as a Rapid Detection Method for Identification of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer. Cancer, 107:2858-2865, 2006. Cury FLB, Souhami L, Rajan R, Tanguay S, Gagnon B, Duclos M, Shenouda G, Faria SL, Marc D, Freeman CR. Intermittent androgen ablation in patients with biochemical failure after pelvic radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 64:842-848, 2006. Cury FBL, Souhami L. Phase II trial of intermittent androgen ablation for biochemical failure after radiotherapy for localized prostate cancer. Am J Hematol Oncol 5:434-438, 2006. Cury FL, Shenouda G, Souhami L, Duclos M, Faria SL, David M, Verhaegen F, Corns R, Falco T. Ultrasound-Based Image Guided Radiotherapy for Prostate Cancer- Comparison of Cross-Modality and Intramodality Methods for Daily Localization During II-2
  • 171. Dept. of Oncology Appendix II: Publications January-December 2006 External Beam Radiotherapy.Int J Radiat Oncol Biol Phys. 2006 Oct 20; [Epub ahead of print] Faria SL, Souhami L, Portelance L, Duclos M, Vuong T, Small D, Freeman CR. Absence of toxicity with hypofractionated 3-dimensional radiation therapy for inoperable, early stage non-small cell lung cancer. Radiat Oncol. 1:42, 2006. Faria SL, Mahmud S, Souhami L, David M, Duclos M, Shenouda G, Makis W, Freeman CR. No immediate treatment after biochemical failure in patients with prostate cancer treated by external beam radiotherapy. Urology 67:142-146, 2006. Faria SL, Mahmud S, Wakil G, Negrete, S, Souhami L, David M, Duclos M, Shenouda G, Freeman CR. Is there a detrimental effect of waiting for radiotherapy for patients with localized prostate cancer? Am J Clin Oncol 29:463-467, 2006. Chen MJ, Faria SL, Souhami L, Niazi TM, Duclos M, Guerra J. Tratamento do cancer de pequenas celulas de pulmao – doenca limitada: resultados de uma unica instituicao. Radiol Bras 39:39-43, 2006. Soravia C, Delozier CD, Dobbie Z, Berthod CR, Arrigoni E, Brundler MA, Blouin JL, Foulkes WD, Hutter P. Double frameshift mutations in APC and MSH2 in the same individual. Int J Colorectal Dis, 21 (1): 79-83, 2006. Barker KT, Foulkes WD, Schwartz CE, Labadie C, Monsell F, Houlston RS, Harper J. Is the E133K allele of VG5Q associated with Klippel-Trenaunay and other overgrowth syndromes? J Med Genet, 43(7): 613-614, 2006. Nkondjock A, Ghadirian P, Kotsopoulos J, Lubinski J, Lynch H, Kim-Sing C, Horsman D, Rosen B, Isaacs C, Weber B, Foulkes WD, Ainsworth P, Tung N, Eisen A, Friedman E, Eng C, Sun P, Narod SA. Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers. Int J Cancer, 118 (1): 103-7, 2006. McVety S, Li L, Gordon PH, Chong G, Foulkes WD. Disruption of an exon splicing enhancer in exon 3 of MLH1 is the cause of HNPCC in a Quebec family. J Med Genet 2006:43:153-6. Minoo P, Baker K, Goswami R, Chong G, Foulkes WD, Ruszkiewicz A, Barker M, Buchanan D, Young J, Jass JR. Extensive DNA methylation in normal colorectal mucosa in hyperplastic polyposis. Gut, 55(10): 1467-1474, 2006. Rudkin TM, Hamel N, Galvez M, Hogervorst F, Gille JJ, Moller P, Apold J, Foulkes WD. The frequent BRCA1 mutation 1135insA has multiple origins: a haplotype study in different populations. BMC Med Genet. 7 (1): 15, 2006. McVety S, Li L, Thiffault I, Gordon PH, MacNamara E, Wong N, Australie K, Kasprzak L, Chong G, Foulkes WD. The value of multi-modal gene screening in HNPCC in Quebec: three mutations in mismatch repair genes that would have not been correctly identified by genomic DNA sequencing alone. Familial Cancer. 2006:5:21-28. Li L, McVety S, Younan R, Liang P, DuSart D, Gordon, PH, Hutter P, Hogervorst FBL, Chong G, Foulkes WD. Distinct Patterns of Germ-line Deletions in MLH1 and II-3
  • 172. Dept. of Oncology Appendix II: Publications January-December 2006 MSH2: The implication of Alu Repetitive Element in the Genetic Etiology of Lynch Syndrome (HNPCC) Hum. Mutat. 2006:27:388. Friedman E, Kotsopoulos J, Lubinski J, Lynch HT, Ghadirian P, Neuhausen SL, Isaacs C, Weber B, Foulkes WD, Moller P, Rosen B, Kim-Sing C, Gershoni-Baruch R, Ainsworth P, Daly M, Tung N, Eisen A, Olopade OI, Karlan B, Saal HM, Garber JE, Rennert G, Gilchrist D, Eng C, Offit K, Osborne M, Sun P, Narod SA; the Hereditary Breast Cancer Clinical Study Group. Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. Breast Cancer Res, 8(2):R15, 2006. Morel CF, Thomas MA, Cao H, O’Neil CH, Pickering JG, Foulkes WD, Hegele RA. A LMNA splicing mutation in two sisters with severe Dunnigan-type familial partial lipodystrophy (FPLD2). J.Clin.Endocrinol.Metab., 91(7): 2689-2695, 2006. Gronwald J, Tung N, Foulkes WD, Offit K, Gershoni R, Daly M, Kim-Sing C, Olsson H, Ainsworth P, Eisen A, Saal H, Friedman E, Olopade O, Osborne M, Weitzel J, Lynch H, Ghadirian P, Lubinski J, Sun P, Narod SA. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update. Int J Cancer, 118 (9); 2281-4, 2006. Narod SA, Lubinski J, Ghadirian P, Lynch HT, Moller P, Foulkes WD, Rosen B, Kim- Sing C, Isaacs C, Domcheck S, Sun P; for the Hereditary Breast Cancer Clinical Study Group. Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case control study. Lancet Oncol, 7(5): 402-406, 2006. Goswami RS, Minoo P, Baker K, Chong G, Foulkes WD, Jass JR. Hyperplastic polyposis and cancer of the colon with gastrinoma of the duodenum. Nat Clin Pract Oncol, 3 (5): 281-4, 2006. Foulkes WD. BRCA1 and BRCA2: Chemosensitivity, Treatment Outcomes and Prognosis. Fam Cancer, 5 (2): 135-142, 2006. Shinto E, Baker K, Tsuda H, Mochizuki H, Ueno H, Matsubara O, Foulkes WD, Jass JR. Tumor Buds Show Reduced Expression of Laminin-5 gamma 2 Chain in DNA Mismatch Repair Deficient Colorectal Cancer. Dis. Colon and Rectum., 49(8): 1193-1202, 2006. Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Friedman E, Foulkes WD, Kim-Sing C, Wagner T, Tung N, Couch F, Stoppa-Lyonnet D, Ainsworth P, Daly M, Pasini B, Gershoni-Baruch R, Eng C, Olopade OI, McLennan J, Karlan B, Weitzel J, Sun P, Narod SA, Hereditary Ovarian Cancer Clinical Study Group. Salpingo-oophorectomy and the risk of ovarian, fallopian tube and peritoneal cancers in women with BRCA1 or BRCA2 mutation. JAMA, 296 (2): 185-192, 2006. Baker K, Chong G, Foulkes WD, Jass JR. Transforming growth factor-pathway disruption and infiltration of colorectal cancers by intraepithelial lymphocytes. Histopathology, 49(4): 371-380, 2006. Oros, KK, Ghadirian P, Maugard CM, Perret C, Paredes Y, Mes-Masson AM, Foulkes WD, Provencher D, Tonin P. Application of BRCA1 and BRCA2 mutation carrier II-4
  • 173. Dept. of Oncology Appendix II: Publications January-December 2006 prediction models in breast and/or ovarian cancer families of French Canadian descent. Clin Genet, 70(4):320-329, 2006. Schaid DJ, McDonnell SK, Zarfas KE, Cunningham JM, Hebbring S, Thibodeau SN, Eeles RA, Easton DF, Foulkes WD, Simard J, Giles GG, Hopper JL, Mahle L, Moller P, Badzioch M, Bishop DT, Evans C, Edwards S, Meitz J, Bullock S, Hope Q, Guy M, Hsieh C-L, Halpern J, Balise RR, Oakley-Girvan I, Whittemore AS, Xu J, Dimitrov L, Chang B- L, Adams TS, Turner AR, Meyers DA, Friedrichsen DM, Deutsch K, Kolb S, Janer M, Hood L, Ostrander EA, Stanford JL, Ewing CM, Gielzak M, Isaacs SD, Walsh PC, Wiley KE, Isaacs WB, Lange EM, Ho LA, Beebe-Dimmer JL, Wood DP, Cooney KA, Seminara D, Ikonen T, Baffoe-Bonnie A, Fredriksson H, Matikainen MP, Tammela T LJ, Bailey- Wilson J, Schleutker J, Maier C, Herkommer K, Hoegel JJ, Vogel W, Paiss T, Wiklund F, Emanuelsson M, Stenman E, Jonsson B-A, Grönberg H, Camp NJ, Farnham J, Cannon- Albright LA, Catalona WJ, Suarez BK, Roehl KA. Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics. Human Genetics, 120(4):471-485, 2006. Vilela LD(§), Nicolau B, Mahmud S, Edgar L, Hier M, Black M, Franco EL, Allison P(*).Comparison of psychosocial outcomes in head and neck cancer patients receiving a coping strategies intervention and control subjects receiving no intervention. Journal of Otolaryngology 35: 88-96, 2006. Burchell AN(§),Richardson H, Mahmud SM, Trottier H, Tellier PP, Hanley J, Coutlée F, Franco EL(*). Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada. American Journal of Epidemiology 163:534-543, 2006. Mahmud SM (§*), Tanguay S, Bégin LR, Franco EL, Aprikian AG. Non-steroidal anti- inflammatory drug use and prostate cancer in a high-risk population. European Journal of Cancer Prevention 15: 158-164, 2006. Monsonego J(*), Pintos J, Semaille C, Beumont M, Dachez R, Zerat L, Bianchi A, Franco E. Human papillomavirus testing improves the accuracy of colposcopy in detection of cervical intraepithelial neoplasia. International Journal of Gynecological Cancer 16:591-598, 2006. Mayrand MH(§), Duarte-Franco E, Coutlée F, Rodrigues I, Walter SD, Ratnam S, Franco EL(*), for the CCCaST Study Group. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: Design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST). International Journal of Cancer 119:615-623, 2006. Goffin F, Mayrand MH, Gauthier P, Alobaid A, Lussier C, Provencher D, Drouin P, Franco EL, Coutlée F(*).High-risk human papillomavirus infection of the genital tract of women with a previous history or current high-grade vulvar intraepithelial neoplasia. Journal of Medical Virology 78:814-819, 2006. II-5
  • 174. Dept. of Oncology Appendix II: Publications January-December 2006 Harper DM(*), Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins DD, Schuind A, Clemens SAC, Dubin G. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18. Follow-up from a randomized controlled trial in young women. Lancet 367: 1247- 1255, 2006. Alotaibi L, Provost N, Gagnon S, Franco EL, Coutlée F(*). Diversity of cutaneous human papillomavirus types in individuals with and without skin lesion. Journal of Clinical Virology 36: 133-140, 2006. Coutlée F(*), Rouleau D, Petignat P, Ghattas G, Kornegay JR, Schlag P, Boyle S, Hankins C, Vézina S, Coté P, Macleod J, Voyer H, Forest P, Walmsley S, Franco E. Enhanced Detection and typing of Human Papillomavirus DNA in Anogenital Samples with PGMY primers and the Linear Array HPV Genotyping Test. Journal of Clinical Microbiology 44: 1998-2006, 2006. Sangwa-Lugoma G(§), Mahmud S, Nasr S, Liaras J, Kayembe P, Tozin R, Drouin P, Lorincz A, Ferenczy A, Franco EL(*). Visual inspection as a cervical cancer screening method in a primary health care setting in Africa. International Journal of Cancer 119: 1389-1395, 2006. Trottier H(§), Mahmud S, Costa MC, Sobrinho JP, Duarte-Franco E, Rohan TE, Ferenczy A, Villa LL, Franco EL(*). Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiology, Biomarkers and Prevention 15: 1274- 1280, 2006. Khouadri S, Villa LL, Gagnon S, Koushik A, Richardson H, Ferreira S, Tellier P, Simao J, Matlashewski G, Roger M, Franco EL, Coutlée F(*). Human papillomavirus type 33 polymorphisms and high-grade squamous intraepithelial lesions of the uterine cervix. Journal of Infectious Diseases 194: 886-894, 2006. Schlecht NF(§), Trevisan A, Baggio ML, Galan L, Duarte-Franco E, Greenberg MD, Rohan TE, Ferenczy A, Villa LL, Franco EL(*). Lack of agreement between cervicography and cytology and the effect of human papillomavirus infection and viral load. Journal of Lower Genital Tract Disease 10: 229-237, 2006. Siegel EM, Craft N, Duarte-Franco EF, Villa LL, Franco EL, Giuliano AR(*). Associations between serum carotenoids and tocopherols and type-specific HPV persistence: the Ludwig-McGill Cohort Study. International Journal of Cancer 120: 672– 680, 2006. Franco EL(*), Cuzick J, Hildesheim A, Sanjose S. Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 24S3: 171-177, 2006. Franco EL(*), Bosch FX, Cuzick J, Schiller J, Garnett G, Meheus A,. Knowledge gaps and priorities for research on prevention of HPV infection and cervical cancer. Vaccine 24S3: 242-249, 2006. II-6
  • 175. Dept. of Oncology Appendix II: Publications January-December 2006 Wright TC, Bosch FX, Franco EL, Cuzick J, Schiller J, Garnett G, Meheus A. HPV Vaccines and screening in the prevention of cervical cancer: Conclusions from a 2006 Workshop of International Experts. Vaccine 24S3: 251-261, 2006. Franco EL. Invited Commentary: Epidemiology as a tool to reveal inequalities in breast cancer care. Public Library of Science-Medicine 3(3): e48, 2006. Franco EL, Lau S. LSIL in young women: Inaction is not an option. Canadian Medical Association Journal 174: 813, 2006. Franco EL(*), Ferenczy A. Invited Commentary: Is human papillomavirus testing with cytological triage a more logical approach in cervical cancer screening? Lancet Oncology 7: 527-529, 2006. Franco EL, Mayrand MH, Trottier H. Cervical cancer prevention: Promises and perils in a changing landscape. Oncology Exchange 5: 9-13, 2006. Gagnon B, Laurin C, Mayo N, Hanley J.A., MacDonald N. Identification in Administrative Databases of Women dying of Breast Cancer. Journal of Clinical Oncology 27 (6):865-862 (2006). Kosseim M, Mayo N, Scott S, Hanley J, Brophy J, Gagnon B, Pilote L. Ranking Hospitals According to Acute Myocardial Infarction Mortality. Should transfers be included? Med Care 44 (7): 664-670 (2006). Galiatsatos P, Foulkes WD. Familial adenomatous polyposis. Am J Gastroenterol, 101 (2): 385-98, 2006. Galiatsatos P, Kasprzak L, Chong G, Jass JR, Foulkes WD. Multiple primary malignancies in a patient with situs ambiguous. Clin Genet, 69 (6): 528-531, 2006. Parker, W., Freeman, C.R. A simple technique for craniospinal radiotherapy in the supine position. Radiotherapy and Oncology 2006; 78:217-222 Carret AS, Tabori U, Crooks B, Hukin J, Odame I, Johnston DL, Keene DL, Freeman C, Bouffet E. On behalf of the Canadian Pediatric Brain Tumour Consortium. Outcome of secondary high-grade glioma in children previously treated for a malignant condition: A study of the Canadian Pediatric Brain Tumour Consortium. Radiotherapy and Oncology 2006; 81:33-38 John Stagg, Sandra Pommey, Nicoletta Eliopoulos and Jacques Galipeau. Interferon- - Stimulated Marrow Stromal Cells: A New Type of Non-Hematopoietic Antigen Presenting Cell. Blood. 2006 Mar 15;107:2570-2577. Diana E. Jaalouk, Milena Crosato, Pnina Brodt and Jacques Galipeau. Inhibition of Histone Deacetylation in Retroviral Packaging Cell Lines Markedly Improves the Production of Self-Inactivating Retroviral Vectors. Virology Journal 2006, 3:27 (7 April 2006). II-7
  • 176. Dept. of Oncology Appendix II: Publications January-December 2006 Tomas Jimenez, W. Paul Fox, Christian C.G. Naus, Jacques Galipeau, and Daniel J. Belliveau. Connexin Over-Expression Differentially Suppresses Glioma Growth and Contributes to the Bystander Effect Following HSV-Thymidine Kinase Gene Therapy. Cell Communication and Adhesion 2006 Jan-Apr;13(1):79-92. N. Eliopoulos, R.F. Gagnon, M. Francois, and J. Galipeau. Erythropoietin Delivery by Genetically-Engineered Bone Marrow Stromal Cells for Correction of Anemia in Mice with Chronic Renal Failure. Journal of the American Society of Nephrology 2006 Jun;17(6):1576-1584. Sandra Pommey and Jacques Galipeau. The use of Mesenchymal Stromal Cells in oncology and cell therapy. Bulletin du Cancer. Volume 93, Number 9, 901-7, September 2006 Mayya Meriane, Stéphanie Duhamel, Laurence Lejeune, Jacques Galipeau and Borhane Annabi. Cooperation of matrix metalloproteinases with the RhoA/ROCK and MEK1/ERK signalling pathways is required for the sphingosine-1-phosphate-induced mobilization of marrow-derived stromal cells. Stem Cells 2006;24;2557-2565 Diana E. Jaalouk, Laurence Lejeune, Clément Couture, and Jacques Galipeau. A Self- Inactivating Retrovector Incorporating the IL-2 Promoter for Activation-Induced Transgene Expression in Genetically Engineered T-Cells. Virol J. 2006 Nov 21;3(1):97 Herzog, B., Cardenas, J., Hall, R. K., Villena, J. A., Budge, P. J., Giguère, V, Granner, D. K. and Kralli, A. (2006) Estrogen-related receptor α is a repressor of PEPCK gene transcription. J. Biol. Chem. 281:99-106. Barry, J., Laganière, J. and Giguère, V. (2006) A single nucleotide in an estrogen related receptor α site can dictate mode of binding and PGC-1α activation of target promoters. Mol. Endocrinol. 20:302-310. Grégoire, S., Tremblay, A. M., Xiao, L., Yang, Q., Ma, K., Nie, J., Mao, Z., Wu, Z., Giguère, V. and Yang, X.-J. (2006) Control of MEF2 transcriptional activity by coordinated phosphorylation and sumoylation. J. Biol. Chem. 281:4423-4433. Blanchette, M., Bataille, A.R., Chen, X., Laganière, J. Lefebvre, C., Deblois, G., Giguère, V., Ferretti, V., Bergeron, D., Coulombe, B. and Robert. F. (2006) Genome- wide computational prediction of transcriptional regulatory modules reveals new insights into human gene expression. Genome Research 16:656-668. Laganière, J. and Giguère, V. (2006) Détermination du répertoire des gènes cibles et du mode d’action du récepteur de l’oestrogène par la génomique fonctionnelle. Bulletin du cancer 93:883-887. Liu, D.Y., Hinshelwood, M.M., Willy, P.J., Giguère, V. and Mendelson, C.R. (2006) Estrogen related receptor α enhances surfactant protein-A (SP-A) gene expression in fetal lung type II cells. Endocrinology 147:5187-5195. Lu, N.Z., Wardell. S.E., Burnstein, K.L., DeFranco, D., Fuller, P.J., Giguère, V., Hochberg, R.B., McKay, L., Renoir, J.M., Weigel, N.L., Wilson, E.M., McDonnell, D.P. and Cidlowski, J.A. (2006) International Union of Pharmacology. LXV. The II-8
  • 177. Dept. of Oncology Appendix II: Publications January-December 2006 pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacol. Rev. 58:782-797. Benoit, G., Cooney, A., Giguère, V., Ingraham, H., Lazar, M.A., Muscat, G.E.O., Perlmann, T., Renaud, J.P., Schwabe, J., Sladek, F., Tsai, M.J. and Laudet, V. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. Pharmacol. Rev. 58:798-836. Fraser SA, Deschênes J, Bloom C, Gordon PH. Ileocecal Hobnail angioendothelioma : Report of a case and review of the literature. Dis Colon Rectum 2006:49:276-9. Miller G, Gordon PH. Small Bowel Obstruction – Problems and Pitfalls in Clinical Assessment. Parkhurst Exchange 2006:14:64. Wiser A, Korach J, Gotlieb WH, Fridman E, Apter S, and Ben-Baruch G. Importance of accurate preoperative diagnosis in the management of aggressive angiomyxoma: report of three cases and review of the literature. Abdominal Imaging (2006) 31:383-6 Gotlieb WH, Bruchim I, Gu J, Shi Y, Camirand A, Blouin MJ, Pollak MN Insulin-like growth factor I receptor (IGF-IR) targeting in epithelial ovarian cancer. Gynecologic Oncology (2006) 100: 389-396. Gotlieb WH, Barchana M, Ben-Baruch G, Friedman E, Malignancies following bilateral salpingo-oophorectomy, Eur J Surg Oncol. (2006) 32:1231-4. Hirao, K, Natsuka, Y, Tamura, T, Wada, I, Morito, D, Natsuka, S, Romero, PA, Sleno, B, Tremblay, LO, Herscovics, A, Nagata, K, Hosokawa, N. EDEM3, a soluble EDEM homolog, enhances glycoprotein ERAD and mannose trimming. J. Biol. Chem. 2006, 281, 9650-9658. Suissa S, Hutchinson T, Brophy JM, Kezouh A. ACE-inhibitor use and the long-term risk of renal failure in diabetes. Kidney International 2006; 69:913-919. Schneider V, Lévesque LE, Zhang B, Hutchinson T, Brophy JM. The association of selective and conventional non-steroidal anti-inflammatory drugs with acute renal failure: a population based nested case-control analysis. American Journal of Epidemiology 2006; 164(9): 881-889. Loiselle, C. G., Lambert, S., & Cooke, A. (2006). The searching, processing, and sharing of breast cancer information by women diagnosed with the illness. Canadian Journal of Nursing Research (CJNR), 38(3), 82-104. Cyr, N., Mathieu, L., Dubois, S., & Loiselle, C. G. (2006). Évaluer les sites Internet sur la santé. Perspective Infirmière, 3(3), 44-45. Macdonald ME, Liben S, Cohen SR. Truth and consequences: Parental perspectives on autopsy after the death of a child. Pediatric Intensive Care Nursing, 2006; 7(1) 6-15. Swinton N, Chasen M, MacDonald N. Simple Nutritional Screening in Clinical Practice. Oncology Exchange 2006; 5(4):34-37. II-9
  • 178. Dept. of Oncology Appendix II: Publications January-December 2006 DeLima L, MacDonald N, Doyle D. IAHPC List of Essential Medicines for Palliative Care: summary of process for editors of pain and palliative care journals. Journal of Palliative Care 2006; 22(4):300-304. Mann KK, Davison K, Colombo M, Colosimo A, Diaz Z, Padovani AMS, Guo Qi, Scrivens PJ, Gao W, Mader S, Miller WH Jr. Antimony trioxide-induced apoptosis is dependent on JNK signaling. Toxicology Letters, 160:158-170, 2006. Matsushita H, Scaglioni PP, Bhaumik M, Rego EM,Cai LF, Majid SM, Miyachi H, Kakizuka A, Miller WH Jr, Pandolfi PP. In vivo analysis of the role of aberrant HDAC recruitment and RARα blockade in the pathogenesis of APL. J Exp Med, 203:821-828, 2006. Bernardini S, Muccetelli M, Noguera NI, Bellincampi L, Lunghi P, Bonati A, Mann, KK, Miller WH Jr, Federici G, Lo Coco F. Role of GSTP1-1 in mediating the effect of As2O3 in the acute promyelocytic leukemia cell line NB4. Ann Hematol 85:681-687, 2006. Sansregret, L., B. Goulet, B. Wilson, M. Santaguida., L. Leduy, J. Bertoglio and A. Nepveu. The CDP/Cux p110 Transcription Factor Accelerates Entry Into S Phase. Molecular & Cellular Biology 26:2441-2455. 2006. Goulet, B., M. Truscott, and A. Nepveu. A Novel Proteolytically Processed CDP/Cux Isoform of 90 kDa Is Generated by Cathepsin L. Biological Chemistry 387:1285-1293. 2006. Cadieux, C., S. Fournier, A. Peterson, C. Bédard, B. J. Bedell and A. Nepveu. Transgenic Mice Expressing the p75 CDP/Cux Isoform Develop a Myeloproliferative- Disease-Like Myeloid Leukemia. Cancer Research, 66: 9492-9501. 2006. Kwan, T., Liu, J., DuBow, M., Gros, P. and Pelletier, J. (2006). Comparative Genomic Analysis of 18 Pseudomonas aeruginosa Bacteriophages. J. Bact. 188, 1184-1187 Park, E.-H., Lee, J.M., and Pelletier, J. (2006). The Tie2 5’ Untranslated Region is Inhibitory to 5’ end-Mediated Translation Initiation. FEBS Letters. 580, 1309-1319. Petersen, C.P., Bordeleau, M.-E., Pelletier, J., and Sharp, P. (2006). Short RNAs repress translation after initiation in mammalian cells. Mol. Cell. 21, 533-542. Bordeleau, M.-E., Mori, A., Oberer, M., Lindqvist, L., Higa, T., Belsham, G., Wagner, G., Tanaka, J., and Pelletier, J. (2006). Small Molecule Interference of Eukaryotic Translation Initiation Factor 4A RNA Binding Inhibits Translation. Nat. Chem. Biol. 2, 213-220. Chard, L.S., Bordeleau, M.E., Pelletier, J., Tanaka, J., and Belsham, G.J. (2006) Hepatitis C virus-related internal ribosome entry sites are found in multiple genera of the family Picornaviridae. J. Gen. Virol. 87, 927-936. Robert, F., Gao, H.Q., Donia, M., Merrick, W.C., Hamann, M.T., and Pelletier, J. (2006). Chlorolissoclimides: New inhibitors of eukaryotic protein synthesis. RNA 12, 717-724. II-10
  • 179. Dept. of Oncology Appendix II: Publications January-December 2006 Malo, N., Hanley, J.A., Cerquozzi, S., Pelletier, J., and Nadon, R. (2006). Statistical practice in high-throughput screening data analysis. Nat. Biotech. 24, 167-175. McKay, G.A., Reddy, R., Arhin, F., Belley, A., Lehoux, D., Moeck, G., Sarmiento, I., Parr, T.R., Gros, P., Pelletier, J., and Far, A.R. (2006) Triaminotriazine DNA helicase inhibitors with antibacterial activity. Bioorg. & Med. Chem. Lett. 16, 1286-1290. Arhin, F., Belanger, O., Ciblat, S., Dehbi, M., Delorme, D., Dietrich, E., Dixit, D., Lafontaine, Y., Lehoux, D., Liu, J., McKay, G.A., Moeck, G., Reddy, R., Rose, Y., Srikumar, R., Tanaka, K.S.E., Williams, D.M., Gros, P., Pelletier, J., Parr, T.R., and Far, A.R. (2006) A new class of small molecule RNA polymerase inhibitors with activity against Rifampicin-resistant Staphylococcus aureus. Bioorg. & Med. Chem. Lett. 14, 5812-5832. Chaudhry, Y., Nayak, A., Bordeleau, M.E., Tanaka, J., Pelletier, J., Belsham, G.J., Roberts, L.O., and Goodfellow, I.G. (2006). Caliciviruses differ in their functional requirements for eIF4F components. J.Biol. Chem. 281, 25315-25325 Mazroui, R., Sukarieh, R., Bordeleau, M.E., Kaufman, R.J., Northcote, P., Tanaka, J., Gallouzi, and Pelletier, J. (2006). Inhibition of ribosome recruitment induces stress granule formation independent of eIF2α phosphorylation. Mol. Biol. Cell. 17, 4212- 4219. Wendel, H.-G., Malina, A., Zhao, Z., Zender, L., Kogan, S.C., Cordon-Cardo, C., Pelletier, J., and Lowe, S.W. (2006). Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. Cancer Res. 66, 7639-7646. Robert, F., Kapp, L.D., Khan, S.N., Acker, M.G., Kolitz, S., Kazemi, S., Kaufman, R.J., Merrick, W.C., Koromilas, A.E., Lorsch, J.R., and Pelletier, J. (2006). Initiation of protein synthesis by Hepatitis C virus is refractory to reduced eIF2•GTP•Met-tRNAiMet ternary complex availability. Mol. Biol. Cell. 17, 4632-4644. Belley, A., Callejo, M., Arhin, F., Dehbi, M., Fadhil, I., Liu, J., McKay, G., Srikumar, R., Bauda, P., Bergeron, D., Ha, N., DuBow, M., Gros, P., Pelletier, J., and Moeck, G. (2006) Competition of bacteriophage polypeptides with native replicase proteins for binding to the DNA sliding clamp reveals a novel mechanism for DNA replication arrest in Staphylococcus aureus. Mol. Microbiol. 62, 1132-1143. Spevak CC, Park EH, Geballe AP, Pelletier J, Sachs MS. (2006). Her-2 upstream open reading frame effects on the use of downstream initiation codons. Biochem Biophys Res Commun. 350, 834-841. Bordeleau ME, Cencic R, Lindqvist L, Oberer M, Northcote P, Wagner G, Pelletier J. (2006) RNA-mediated sequestration of the RNA helicase eIF4A by Pateamine A inhibits translation initiation. Chem Biol. 13, 1287-1295. M.D.C. Evans, Renée-Xaviere Larouche, M. Olivares, P. Léger, C.R. Freeman, E.B. Podgorsak, Total body irradiation with a re-conditioned cobalt teletherapy unit, J. Appl. Clin. Med. Phys. 7, 42-51 (2006). II-11
  • 180. Dept. of Oncology Appendix II: Publications January-December 2006 S. Devic, J.P. Seuntjens, W. Abdel-Rahman, M.D.C. Evans, M. Olivares, E.B. Podgorsak, Accurate skin dose measurements using radiochromic film in clinical applications, Med. Phys. 33, 1116-1124 (2006). W. Abdel-Rahman, J.P. Seuntjens, F. Verhaegen, E.B. Podgorsak, Radiation induced currents in parallel-plate ionization chambers: Measurement and Monte Carlo simulation for megavoltage photon and electron beams, Med. Phys. 33, 3094-3104 (2006). S. Devic, Y.Z. Wang, N. Tomic, E.B. Podgorsak, Sensitivity of linear CCD array based film scanners used for film dosimetry, Med. Phys. 33, 3993-3996 (2006). Diorio C, Berube S, Byrne C, Masse B, Hebert-Croteau N, Yaffe M, Cote G, Pollak M, Brisson J. Influence of Insulin-like Growth Factors on the Strength of the Relation of Vitamin D and Calcium Intakes to Mammographic Breast Density. Cancer Res. 66: 588- 597, 2006. Rollison DE, Newschaffer CJ, Tao Y, Pollak M, Helzlsouer KJ. Premenopausal levels of circulating insulin-like growth factor I and the risk of postmenopausal breast cancer. Int J Cancer. 118: 1279-84, 2006. Rousseau MC, Parent ME, Pollak MN, Siemiatycki J. Diabetes mellitus and cancer risk in a population-based case-controlstudy among men from Montreal, Canada. Int J Cancer. 118: 2105-2109, 2006. Wei EK, Ma J, Pollak MN, Rifai N, Fuchs CS, Hankinson SE, Giovannucci E. C- peptide, insulin-like growth factor binding protein-1, glycosylated hemoglobin, and the risk of distal colorectal adenoma in women. Cancer Epidemiol Biomarkers Prev. 15: 750- 5, 2006. Harris TG, Strickler HD, Yu H, Pollak MN, Monrad ES, Travin MI, Xue X, Rohan TE, Kaplan RC. Specimen processing time and measurement of total insulin-like growth factor-I (IGF-I), free IGF-I, and IGF binding protein-3 (IGFBP-3). Growth Horm IGF Res. 16: 86-92, 2006. Missmer SA, Spiegelman D, Bertone-Johnson ER, Barbieri RL, Pollak MN, Hankinson SE. Reproducibility of Plasma Steroid Hormones, Prolactin, and Insulin-like Growth Factor Levels among Premenopausal Women over a 2- to 3-Year Period. Cancer Epidemiol Biomarkers Prev. 15: 972-8, 2006. Schernhammer ES, Holly JM, Hunter DJ, Pollak MN, Hankinson SE. Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. Endocr Relat Cancer. 13: 583-592, 2006. Tseng PH, Weng SC, Wang YC, Weng JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE, Pollak M, Chen CS. Overcoming Trastuzumab Resistance in HER2- Overexpressing Breast Cancer Cells by Using a Novel Celecoxib-Derived PDK-1 Inhibitor. Mol Pharmacol. 70: 1534-41, 2006. II-12
  • 181. Dept. of Oncology Appendix II: Publications January-December 2006 Zakikhani M, Dowling R, Fantus GI, Sonenberg N, Pollak M. Metformin is an AMP- kinase dependent growth inhibitor for breast cancer cells. Cancer Research. 66: 10269- 73, 2006. Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW, Lippman SM, Platz EA, Pollak MN, Thompson IM, Kristal AR. Obesity, Diabetes, and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial. Epidemiol Biomarkers Prev. 15: 1977-83, 2006. Ahn J, Weinstein SJ, Snyder K, Pollak MN, Virtamo J, Albanes D. No association between serum insulin-like growth factor (IGF)-I, IGF-binding protein-3, and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 15: 2010-2, 2006. Tran CD, Diorio C, Berube S, Pollak M, Brisson J. Relation of insulin-like growth factor (IGF) I and IGF-binding protein 3 concentrations with intakes of fruit, vegetables, and antioxidants. Am J Clin Nutr. 84(6): 1518-26, 2006. Tremblay, G. and S. Richard (2006) mRNAs associated with the Sam68 RNA binding protein. RNA Biology 3:1-4. Roberge D, Souhami L, Olivier A, Leblanc R, Podgorsak E. Hypofractionated stereotactic radiotherapy for low grade glioma at McGill University: long-term follow- up. Tech Cancer Res Treat 5:18, 2006. Roberge D, Ruo R, Souhami L. Killing two birds with one stone: a dosimetric study of dual target radiosurgery using a single isocenter. Tech Cancer Res Treat 5:613-617, 2006. Shenouda G, Mehio A, Souhami L, Duclos M, Portelance L, Belenkov A, Chow T. Erythrpoietin receptor expression in biopsy specimens from patients with uterine cervix squamous cell carcinoma. Int J Gynecol Cancer 16:752-756, 2006. Fadlo R. Khuri, J. Jack Lee, Scott M. Lippman, Edward S. Kim, Jay S. Cooper, Steven E. Benner, Rodger Winn, Thomas F. Pajak, Brendell Williams, George Shenouda, Ian Hodson, Karen Fu, Dong M. Shin, Everett E.Vokes, Lei Feng, Helmuth Goepfert, Waun Ki Hong. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in Stage I and II head and neck cancer patients. J Natl Cancer Inst. 2006 Apr 5;98(7): 441-50. Gari A, Souhami L, Arseneau J, Stanimir G. Primary Malignant Mesodermal Ovarian Sarcomas. Int J Gynecol Cancer 16:106-9, 2006. Caircross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Mehta M, Curran W. Phase III trial of chemotherapy plus radiothjerapy compared to radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Threrapy Oncology Group trial 9402. J Clin Oncol 24:2707-2714, 2006. Cardinale R, Won M, Choucair A, Gillin M, Chakravarti A, Schultz C, Souhami L, Chen A, Pham H, Mehta M. A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023. Int J Radiat Oncol Biol Phys 65:1422-1428, 2006. II-13
  • 182. Dept. of Oncology Appendix II: Publications January-December 2006 Wong RK, Paul N, Ding K, Whitehead M, Brundage M, Fyles A, Wilke D, Nabid A, Fortin A, Wilson D, McKenzie M, Souhami L, Chabot P, Pater J. 5-Hydroxytryptamine- 3 Receptor Antagonist With or Without Short-Course Dexamethasone in the Prophylaxis of Radiation Induced Emesis: A Placebo-Controlled Randomized Trial of the National Cancer Institute of Canada Clinical Trials Group (SC19). J Clin Oncol 24:3458-64, 2006. Ezer H, Ricard N, Bouchard L, Souhami L, Saad F, Aprikian A, Taguchi Y. Adaptation of wives to prostate cancer following diagnosis and 3 months after treatment: A test of family adaptation theory. Int J Nurs Stud 43:827-838, 2006. Robin NH, Taylor CJ, McDonald-McGinn DM, Zackai EH, Bingham P, Collins KJ, Earl D, Gill D, Granata T, Guerrini R, Katz N, Kimonis V, Lin JP, Lynch DR, Mohammed SN, Massey RF, McDonald M, Rogers RC, Splitt M, Stevens CA, Tischkowitz MD, Stoodley N, Leventer RJ, Pilz DT, Dobyns WB. Polymicrogyria and deletion 22q11.2 syndrome: Window to the etiology of a common cortical malformation. Am J Med Genet A. 2006;140(22):2416-25 Vogt J, Ryan E, Tischkowitz MD, Reardon W, Brueton LA. The tale of a nail sign in chromosome 4q34 deletion syndrome. Clin Dysmorphol. 2006;15(3):127-132. Le Page C, Ouellet V, Madore J, Hudson TJ, Tonin PN, Provencher DM, Mes-Masson A-M. 2006. From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serum-based markers in epithelial ovarian cancer. Int J Cancer. 118:1750-8. Le Page C, Ouellet V, Madore J, Ren F, Hudson TJ, Tonin PN, Provencher D, Mes- Masson A-M. 2006. Gene profiling in primary cultures of ovarian epithelial cells identifies novel molecular classifiers of ovarian cancer. Br J Cancer. 94:436-445. Oros KK, Leblanc G, Arcand SL, Shen Z, Perret C, Mes-Masson A-M, Foulkes WD, Ghadiran P, Provencher D, Tonin PN. Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families. BMC Medical Genetics, 7: 23, 2006 Ouellet V, Guyot, M-C, Le Page,C, Filali-Mouhim A, Lussier C, Tonin PN, Provencher D, Mes-Masson A-M. 2006. Tissue array analysis of microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. Int J Cancer 119:599-607 Ouellet V, Le Page C, Guyot M-C, Lussier C, Provencher DM, Tonin PN, Mes-Masson A-M. 2006. The SET complex in serous epithelial ovarian cancer. Int J Cancer 119:2119- 26. Cody, N, Ouellet V, Manderson EN, Quinn M, Filali-Mouhim A, Tellis, P, Provencher D, Mes-Masson A-M, Chevrette M, Tonin PN. 2007. Transfer of chromosome 3 fragments identified candidate regions involved in growth suppression of a human ovarian cancer cell line monoallelic for chromosome 3p. Oncogene 26(4):618-32. Oros KK, Ghadirian P, Mes-Masson A-M, Foulkes WD, Provencher D, Tonin PN. 2006. Application of BRCA1/2 carrier prediction models to French Canadian breast and breast-ovarian cancer families. Clin Genet. 70:320-9. II-14
  • 183. Dept. of Oncology Appendix II: Publications January-December 2006 Xu W, Towers A, Li P, Collet JP. Traditional Chinese Medicine in Cancer Care: Perspectives and Experiences of Patients and Professionals in China ECC-2005-0074, European Journal of Cancer Care, online 22 May 2006 E. Poon, B.Reniers, S. Devic, T.Vuong, F. Verhaegen. Dosimetric characterization of a novel intracavitary mold applicator for 192Ir high dose rate endorectal brachytherapy treatment. Medical Physics .2006.33:4515-4526. Zlobec.I, T.Vuong, C.Compton.The predictive value of PAF-1 in rectal tumors treated with pre-operative high dose rate brachytherapy. Cancer. 2006; 106: 284-6. S.Devic, J.Seuntjens, W.Abdel-Rahman, M.Evans, M.Olivares, EB Podgorsak, T.Vuong, SoaresCG. Accurate skin dose measurements using radiochromic film in clinical applications. Am Assoc Phys Med. 2006.33: 116-1124. O.Ballivy, W. Parker, T.Vuong, G.Shenouda, H.Patrocinio. Impact of geometric uncertainties on the dose distribution during intensity-modulated radiotherapy (IMRT) of head and neck cancer: the need for planning target volume (PTV) and planning organ at risk volume (PRV). Current Oncology, Vol. 13, No. 3.108-115. 2006. Liu, B.; Bernard, B. & Wu, J.H. Impact of EGFR point mutations on the sensitivity to gefitinib: insight from comparative structural analyses and molecular dynamics simulations, PROTEINS: Structure, Function and Bioinformatics, 2006, 65:331-346. Callejo, M., Sibani, S., Di Paola, D., Price, G.B. and Zannis-Hadjopoulos, M. (2006). Identification and functional analysis of a human homologue of the monkey replication origin, ors8. J. Cell. Biochem., 99:1606-1615. Teer, J.K., Machida, Y., Labit, H., Novac, O., Hyrien, O., Mahreneike, K., Zannis- Hadjopoulos, M. and Dutta, (2006). A. Proliferating human cells hypomorphic for Orc2 and pre-RC formation have a defect in p53 activation and Cdk2 kinase activation. J. Biol. Chem., 281:6253 - 6260 Di Paola, D., Price, G.B. and Zannis-Hadjopoulos, M. (2006). Differentially active origins of DNA replication in tumor versus normal cells. Cancer Res., 66(10):5094-5103. Monographs Justine Farley, Normes en matière de soins palliatifs pédiatriques, Ministère de la Santé et des Services sociaux, Québec, 2006 (à titre de membre du groupe de travail) Bosch FX, Cuzick J, Schiller J, Garnett G, Meheus A, Franco E, Wright T (Co-Editors). HPV Vaccines and Screening in the Prevention of Cervical Cancer. Vaccine, Volume 24, Supplement 3, 31 August 2006, ISSN 0264-410X. Loiselle, C. G., Profetto-McGrath, J., Polit, D. F., & Beck, C.T. (2007). Canadian essentials of nursing research. Second Edition. New York: Lippincott. II-15
  • 184. Dept. of Oncology Appendix II: Publications January-December 2006 Reviews Aguilar-Mahecha A, Hassan S, Ferrario C, Basik M. Microarrays as validation strategies in clinical samples: tissue and protein microarrays. OMICS A Journal of Integrative Biology, 2006 Fall;10(3):311-26. Farley J, En fin de vie, hydrater ou ne pas hydrater?, Le Médecin du Québec 2006 Nov : 41(11) : 81-86 Tischkowitz MD, Foulkes WD. The basal phenotype of BRCA1-related breast cancer: past, present and future. Cell Cycle. 2006 May;5(9):963-7. Trottier H(§), Franco EL(*). The epidemiology of genital human papillomavirus infection. Vaccine 24: S1/4-15, 2006. Burchell AN(§), Winer RL, Sanjosé S, Franco EL. Epidemiology and transmission dynamics of genital human papillomavirus infection. Vaccine 24S3: 52-61, 2006. Trottier H(§), Franco EL. Human papillomavirus and cervical cancer: burden of illness and basis for prevention. American Journal of Managed Care 12: S462-472, 2006. Frazer IH(*), Cox JT, Mayeaux EJ, Franco EL, Moscicki AB, Palefsky J, Ferris D, Ferenczy A, Villa, L. Advances in prevention of cervical cancer and other human papillomavirus-related diseases. Pediatric Infectious Disease Journal 25: S65–S81, 2006. Tonin PN. 2006. Le spectre limité des mutations pathogéniques BRCA1 et BRCA2 dans le cancer du sein et le cancer du sein-ovaire dans les familles canadiennes-françaises, une population fondatrice du Québec, Canada [The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada]. Bulletin du Cancer 2006 93:841-6 [Invited review, for special issue to commemorate 100th anniversary of Société Française du Cancer en 2006] Books and Book Chapters Mohammad Amin Kerachian, Denis Cournoyer, Edward J. Harvey, Terry Chow, Chantal Séguin. Avascular necrosis of the Femoral Head : Vascular Hypotheses. Endothelium. In press. October 2006 Cohen SR. Quality of life assessment in palliative care. In: Textbook in Palliative Medicine, E. Bruera, I. Higginson, C. von Gunten, and C. Ripamonti eds. Hodder Arnold Limited, London, England. Distributed by Oxford University Press, New York, N.Y. (2006) pp. 349-55. Farmer, J-P., McNeely, P.D., Freeman, C.R. Brainstem gliomas. In Principles andPractice of Pediatric Neurosurgery. Ed. Albright, A.L. 2006. A practical guide to human cancer genetics, third edition: Hodgson SV, Foulkes WD, Eng C and Maher ER. Cambridge University Press, 2006. II-16
  • 185. Dept. of Oncology Appendix II: Publications January-December 2006 Burchell AN(§), Franco EL(*). Epidemiology of oncogenic and nononcogenic HPV types, and the evidence for differences in their sexual transmissibility. In: Monsonego J (ed.) Emerging issues on HPV infections: From science to practice. Karger AG, Basel, 2006, pp. 20-33, ISBN 3-8055-8120-3. Duarte-Franco E, Franco EL(*). Epidemiologia do cancer mamario e ginecologico. In: Abrao F (ed.) Tratado de oncologia genital e mamaria. 2a. Edição, Editora Revinter, Sao Paulo, 2006, pp. 1-25, ISBN 85-372-0005-0. Rohan TE, Henson D, Franco EL, Albores-Saavedra J. Cancer Precursors. In: Schottenfeld D, Fraumeni J (eds.) Cancer Epidemiology and Prevention, 3rd edition, Oxford University Press, 2006; pp. 21-46, ISBN-13: 978-0-19-514961-6 and ISBN-10: 0- 19-514961-0. Koushik A(§), Franco EL(*). Chapter 18: Epidemiology and the role of human papillomaviruses. In: Jordan JA, Singer A (eds.) The Cervix, 2nd Edition, Blackwell, Oxford, 2006, pp. 259-276, ISBN-13: 978-1-4051-3137-7, ISBN-10: 1-4051-3137-3. Spence A(§), Franco EL(*). Chapter 26: Screening for cervical cancer using HPV tests. In: Jordan JA, Singer A (eds.) The Cervix, 2nd Edition, Blackwell, Oxford, 2006, pp. 373-386, ISBN-13: 978-1-4051-3137-7, ISBN-10: 1-4051-3137-3. Gagnon B. Day Hospitals. Bruera E, Higginson I, Ripamonti C, von Gunten C. Eds. In: Textbook of Palliative Medicine. Hodder Arnold, pp. 285-293 (2006) Roberge D, Souhami L, Olivier A, Leblanc R, Podgorsak EB. Stereotactic radiosurgery/radiotherapy in the management of low grade gliomas. In: Brain Cancer Therapy and Surgical Interventions (Series: Horizons in Cancer Research). Yang AV (ed). Nova Publishers, pp 147-169, 2006. Liben S. Breathlessness in Children (2006). In :Dyspnoea in advanced disease; a guide to clinical management. S Booth & D Dudgeon (eds). Oxford University Press. The Oxford Textbook of Palliative Care for Children – Edited by Goldman A, Liben S, and Hain R. Oxford University Press, 2006 Alimentation/hydration. Chasen M and MacDonald N. In: ESMO Handbook of Advanced Cancer Care. Catane R, Cherny NI, Kloke M, Tanneberger S and Schrijvers D (eds). Oxford: Taylor & Francis 2006: 71-79. The Development of Palliative Care in Canada. MacDonald N. In: Palliative Medicine. Bruera E, Higginson I, Ripamonti C and von Gunten C. (eds). London: Hodder Arnold Publishers. 2006: 22-29. Quality end-of-Life Care. Singer PA, MacDonald N. Tulsky JA. In: Bioethics for Clinicians. Cambridge University Press. 2007. Accepted for publication. Pelletier, J. and Peltz, S.W. (2006). Therapeutic Opportunities in Translation. In “Translational Control in Biology and Medicine” (Matthews, M., Sonenberg, N., and Hershey, J.W.B.). II-17
  • 186. Dept. of Oncology Appendix II: Publications January-December 2006 Truscott, M. and A. Nepveu. Homeodomains Transcription Factors. Encyclopedic Reference of Genomics and Proteomics in Molecular Medicine. Springer-Verlag. http://encref.springer.de/genomics/ Lymphoedema Framework: Best Practice for the Management of Lymphoedema. International Consensus. London MEP Ltd, 2006. ISBN 0-9547669-4-6. Anna Towers was a member of the international advisory board that drafted these practice guidelines. Conference Proceedings The p75 neurotrophin receptor regulates activity-dependent axon competition by antagonizing TrkA-mediated Ras-Raf-MAPK signaling Singh K (Singh, K.), Kramer B (Kramer, B.), Lin D (Lin, D.), Aloyz R (Aloyz, R.), Kaplan D (Kaplan, D.), Miller F (Miller, F.) International Journal Of Developmental Neuroscience 24 (8): 578-579 Dec 2006 Inhibition of DNA repair vis-a-vis resistance in chronic lymphocytic leukemia Amrein L, Loignon M, Aloyz R, et al.. EJC Supplements 4 (12): 152-152 498 Nov 2006 Bouchard A, Mamo A, Basik M. High resolution array CGH in 12 colorectal cell lines reveals multiple novel areas of amplifications and deletions in both MSI and MSS colorectal cell lines. Proceedings AACR 2006 Annual Meeting abstract # 148. Hassan S, Salvucci O, Basik M . Stromal cell derived factor-1 polymorphism associated with earlier onset of metastasis in breast cancer. Proceedings AACR 2006 Annual Meeting, abstract # 298 Ferrario C, Hostetter G and Basik M. Expression of Neuropilin-1 and related proteins in breast cancer. Proceedings AACR 2006 Annual Meeting abstract # 5034. Aguilar-Mahecha A, Cantin C, Deneault JS, Nantel A, O’Connor M, Basik M. Development of Reverse Phase Protein Arrays for the Validation of Newly Discovered Biomarkers in Plasma or Serum. Presented at the Annual Meeting of the Human Proteome Organization (HUPO), Boston March 2006. Hassan S., Salvucci O, Baccarelli A, Basik M. Stromal cell derived factor (SDF)-1: predictive marker of distant metastasis and poorer survival in breast cancer. Clinical and Investigative Medicine Vol. 29 (4), Aug 2006: 268. Mamo A., Cavallone L., Ferrario C., Rancourt C. and Basik M. Genomic alterations as a guide to the discovery of novel therapeutic targets in breast cancer. Presented at the 25th Congress of the International Association for Breast Cancer Research, Montreal, September 2006. Cavallone L., Mamo A., Basik M. and Tonin P.An integrated genomics approach towards the identification of tumor suppressor gene candidates through nonsense- mediated mRNA decay inhibition of breast cancer cell lines. Presented at the 25th Congress of the International Association for Breast Cancer Research, Montreal, September 2006. II-18
  • 187. Dept. of Oncology Appendix II: Publications January-December 2006 Hassan S., Salvucci O, Baccarelli A, Basik M. Stromal cell derived factor (SDF)-1: predictive marker of distant metastasis and poorer survival in breast cancer. Presented at the 25th Congress of the International Association for Breast Cancer Research, Montreal, September 2006. Aguilar-Mahecha A, Cantin C, Deneault JS, Wu M, Huneau MC, O'Connor-McCourt M, Nantel A, Basik M. Optimization of reverse phase protein microarrays for blood biomarker validation . Presented at 5th Annual World Congress Human Proteome Organization, Long Beach, CA, Oct 2006 Choudhury, S.A., Asefa, B., Kauler, P., and Chow T.Y.-K. Evidences for overlapping function of TRM2/RNC1 and Exo1 in DNA double strand break repair in yeast Saccharomyces cerevisiae. Yeast Genetics and Molecular Biology Meeting. 2006. Sergio L Faria, Bosede Joshua, Horacio Patrocinio, Francois Deblois, Marie Duclos, Marc David, George Shenouda, Luis Souhami. Lack of correlation between recognized Dose-volume guidelines and late rectal toxicity after hypofractionated radiation therapy for prostate cancer. Poster Presentation at the ESTRO 2006, October 8-12th 2006, Leipzig, Germany. Filion, E., Parker, W., Freeman, C.R. Intensity modulated radiation therapy provides superior normal tissue sparing in the treatment of patients with retinoblastoma. Annual meeting of the International Paediatric Oncology Society (SIOP). Geneva. September 2006. Filion, E., Parker, W., Roberge, D., Freeman, C.R. IMRT for spinal irradiation in the treatment of pediatric medulloblastoma. American Society for Therapeutic Radiology and Oncology annual meeting. Philadelphia. November 2006. de Pokomandy A(§), Rouleau D, Ghattas G, Vézina S, Coté P, Macleod J, Allaire G, Franco EF, Coutlée F. HPV-16, 18, 31, 45 viral loads in anal intra-epithelial lesions in HIV-seropositive men. 15th Annual Canadian Conference on HIV/AIDS research, Ottawa, Canada, June 2006. Gagnon S, Hankins C, Pourreaux K, Franco E, The Canadian Women’s HIV Study Group, Coutlée F. Polymorphism of the capsid L1 gene is not a determinant of persistence of HPV-52 infection in HIV-seropositive women. 15th Annual Canadian Conference on HIV/AIDS research, Ottawa, Canada, June 2006. Mayrand MH(§), Mahmud SM, Franco EL, Hanley J. Design, ethical and statistical challenges when studying the performance of new screening tests for cervical cancer. 23rd International Biometric Conference, Montreal, Canada, July 2006. Burchell AN(§), Hanley J, Richardson H, Mahmud SM, Trottier H, Tellier PP, Coutlée F, Franco EL. Use of stochastic computer simulation and maximum likelihood methods to estimate sexual transmissibility of human papillomavirus infection. 23rd International Biometric Conference, Montreal, Canada, July 2006. II-19
  • 188. Dept. of Oncology Appendix II: Publications January-December 2006 Trottier H(§), Schaffer A, Koushik A, Duarte-Franco E, Coutlée F, Pollak M, Franco EL. Insulin-like growth factor-I and risk of high-grade cervical intraepithelial neoplasia. 23rd International Papillomavirus Conference, Prague, Czech Republic, September 2006. Trottier H(§), Mahmud S, Prado J, Rohan TE, Villa LL, Franco EL. Duration of type- specific HPV infection: Results from the Ludwig-McGill cohort study. 23rd International Papillomavirus Conference, Prague, Czech Republic, September 2006. Kohli M, Ferko N, Martin A, Franco EL, Jenkins D, Gallivan S, Sherlaw-Johnson C, Drummond M. Estimating the long-term impact of a prophylactic human papillomavirus (HPV) 16/18 vaccine on the burden of cervical disease in the UK. 23rd International Papillomavirus Conference, Prague, Czech Republic, September 2006. Trevisan A, Schlecht NF, Ferreira S, Sichero L, Ferenczy A, Duarte-Franco E, Franco EL, Villa LL. Correlation between viral load measured by real-time and low-stringency PCR testing of cervical specimens. 23rd International Papillomavirus Conference, Prague, Czech Republic, September 2006. Sichero L, Ferreira S, Trottier H, Ferenczy A, Franco EL, Villa LL. High grade cervical lesions are caused preferentially by non-European variants of HPVs 16 and 18. 23rd International Papillomavirus Conference, Prague, Czech Republic, September 2006. Sénécal M, Maunsell E, Ferenczy A, Franco EL, Ratnam S, Coutlée F, Palefsky JM, Foucart S, Brisson M, Mansi JA. Psychosocial impact of cervical screening and condyloma: an epidemiological study (pisces). 23rd International Papillomavirus Conference, Prague, Czech Republic, September 2006. Mayrand MH(§), Duarte-Franco E, Rodrigues I, Walter SD, Coutlée F , Ratnam S, Franco EL. Comparison of Pap and hpv testing strategies for screening high-grade cervical cancer precursors: Results from the Canadian Cervical Cancer Screening Trial (CCCaST). 23rd International Papillomavirus Conference, Prague, Czech Republic, September 2006. De Pokomandy A(§), Rouleau D, Ghattas G, Vézina S, Côté P, MacLeod J, Allaire G, Fontaine J, Trépanier JM, Franco EL, Coutlée F. Human Papillomavirus 16, 18, 31, 45 viral loads and grade of anal intraepithelial neoplasia in HIV-infected men. 23rd International Papillomavirus Conference, Prague, Czech Republic, September 2006. Tomita LY(§), Carneiro LC, Villa LL, Franco EL, Cardoso MA. Serum micronutrients in relation to human papillomavirus infection in Brazilian women: Preliminary results. 1st World Congress of Public Health Nutrition, Barcelona, Spain, September 2006. Tomita LY(§), D´Almeida V, Longatto-Filho A, Villa LL, Franco EL, Cardoso MA. Higher homocysteine and lower serum levels of alpha-tocopherol are risk factors for cervical dysplasia in women living in São Paulo, Brazil. Frontiers in Cancer Prevention Research Conference, American Association for Cancer Research, Boston, USA, November, 2006. II-20
  • 189. Dept. of Oncology Appendix II: Publications January-December 2006 Mahmud S, Turner D, Franco E, Aprikian A. Meta-analysis of the effects of aspirin, NSAID and acetaminophen use on prostate cancer risk. Poster presentation. Canadian Society of Epidemiology and Biostatistics. Calgary, Canada, May 2007. I Bruchim, M.N. Pollak, Y Shi, S Lau, W.H. Gotlieb, In vivo antitumor activity of oral NVP-AEW541, an IGF-I receptor kinase inhibitor, Society of Gynecologic Oncology Meeting, Palm Springs March 2006 AM Mes-Masson, D. Provencher, W. Gotlieb, C. Rancourt, D. Bachvarov , B. Têtu. The Réseau de recherche sur le cancer (RRCancer) of the Fonds de la recherche en santé du Québec (FRSQ): A consortium of multiple ovarian cancer banking hubs Vancouver May 2006. I Bruchim, M.N. Pollak, Y Shi, S Lau, W.H. Gotlieb In vivo antitumor activity of oral NVP-AEW541, an IGF-I receptor kinase inhibitor, Society of Obstetrics and Gynecology of Canada, Vancouver June 2006 Lobsanov, YD, Yoshida, T, Desmet, T, Nerinckx, W, Herscovics, A, Howell, P.L. Possible mechanism of regulation of activity in Class I α1,2-mannosidases : structure of a fungal a1,2-mannosidase in complex with a substrate analog. XXIIIrd International Carbohydrate Symposium. Whistler, Canada 2006. Rodionov, D, Romero, PA and Herscovics, A. Production of recombinant yeast mannosyltransferase complex M-Pol I. Society for Glycobiology, Los Angeles 2006. Dawood S, Vogelesang L, Bismar TA, Mulder D, Sirois C, and Hirsh V: Pilot Prospective Exploratory Study about Predictive Values for NSCLC Patient Compliance with Adjuvant Chemotherapy After Complete Resection. Annals of Oncology Vol. 17 (Supplement 9): ix 236, 2006. Major P, Hirsh V, Lipton A, Cook RJ, Langer C, and Shirina N: Zoledronic Acid May Improve Survival in Lung Cancer Patients With High Baseline Bone Marker Levels. Annals of Oncology Vol. 17 (Supplement 9): ix 221, 2006. Matczak E, Hirsh V, Lipton A, Cook RJ, Langer C, Hei YJ, and Major P: Effects of Zoledronic Acid on Survival in Patients with Lung Cancer and High Baseline N- Telopeptide (NTX) levels: Stratified by Baseline Bone Alkaline Phosphatase (BALP). Journal of Clinical Oncology Vol. 24, No. 18S, 2006. Berruti A, Dogliotti L, Tampellini M, Lipton A, Hirsh V, Saad F, Liati P, Shirina N, and Cook R: Effect of Zoledronic Acid Treatment Based on Serum Parathyroid Hormone Levels in Patients with Malignant Bone Disease. Journal of Clinical Oncology Vol. 24, No. 18S, 2006. Hirsh V, Duclos M, Souhami L, Del Vecchio P, Ofiara L, Faria S, Ayoub JP, Charpentier D, Portelance L, and Soulieres D: A Phase II Trial with Carboplatin/Gemcitabine Induction Chemotherapy Followed by Radiotherapy II-21
  • 190. Dept. of Oncology Appendix II: Publications January-December 2006 Concomitantly with Paclitaxel/Gemcitabine in Stage III Non Small Cell Lung Cancer (NSCLC). Journal of Clinical Oncology Vol. 24, No. 18S, 2006. Liben S. Understanding what families want and what children need; pediatric palliative care research brings us closer. Chair: Pediatric Day Seminar: 16th International Congress On Care of the Terminally Ill. Sept 2006 Montreal Loiselle, C. G. (2006). PORT- A Canadian exemplar of high quality, cutting-edge transdisciplinary research training in psychosocial oncology. 8th World Congress of Psycho-Oncology. Multidisciplinary Psychosocial Oncology: Dialogue and Interaction. International Psycho-Oncology Society (IPOS). Venice, Italy, October 18-21, 2006. Psycho-Oncology, 15(Suppl. 2), S148. Loiselle, C. G., Dubois, S., & Edgar, L. (2006). The role of interactive health communication (IHC) in softening the blow of a cancer diagnosis and guiding the use of health care services: Are women and men reacting to IHC differently? 8th World Congress of Psycho-Oncology. Multidisciplinary Psychosocial Oncology: Dialogue and Interaction. International Psycho-Oncology Society (IPOS). Venice, Italy, October 18-21, 2006. Psycho-Oncology, 15(Suppl. 2), S310. Lambert, S., Dubois, S., & Loiselle, G. C. (2006). Focus groups with individuals diagnosed with cancer: Guidelines from specific experience. 8th World Congress of Psycho-Oncology. Multidisciplinary Psychosocial Oncology: Dialogue and Interaction. International Psycho-Oncology Society (IPOS). Venice, Italy, October 18-21, 2006. Psycho-Oncology, 15(Suppl. 2), S299. A. Sarfehnia, K. Jabbari, J.P. Seuntjens, E.B. Podgorsak, High contrast imaging using orthogonal bremsstrahlung beams: An experimental study of radiation quality, Proceedings of the 52-nd Annual Scientific Meeting of the Canadian Organization of Medical Physicists (COMP), Saskatoon, Saskatchewan; 31 May – 2 June, 2006; pp. 170- 172. M.D.C. Evans, M. Olivares, J.P. Seuntjens, W. Parker, S. Devic, E. Poli, C. Freeman, E.B. Podgorsak, A rotational total skin electron irradiation technique using a linear accelerator with a commercially available high dose rate total body electron mode, Proceedings of the 52-nd Annual Scientific Meeting of the Canadian Organization of Medical Physicists (COMP), Saskatoon, Saskatchewan; 31 May – 2 June, 2006; pp. 261- 264. M. E. Ramos-Poli, W. Parker, E.B. Podgorsak, L. Campos, Influence of planning target volume definition on skin dose for head and neck patients treated with inverse planned IMRT, Proceedings of the World Congress on Medical Physics and Biomedical Engineering, COEX Seoul, Korea, August 27 – September 1, 2006; pp. 1803-1805. W. Parker, M. Esmeralda Poli, H. Patrocinio, L. Souhami, G. Shenouda, L. Lucente Campos, E. Podgorsak. An Assessment of Inter-Fraction Prostate Motion Based On 10,327 Pre-Treatment Ultrasound Localizations for 387 Prostate Cancer Patients II-22
  • 191. Dept. of Oncology Appendix II: Publications January-December 2006 Treated With Conformal 3D External Beam Radiation Therapy (EBRT). Poster Presentation at the ESTRO 2006, October 8-12th 2006 , Leipzig, Germany. G Shenouda, D Roberge, P Kavan, T Muanza, C Lambert, R Leblanc, R Del Maestro, MC Guiot, L. Souhami. A Novel Approach using Accelerated Hypo- fractionation-IMRT (AH-IMRT) and Temozolomide (TMZ) in patients with Glioblastoma Multiforme (GBM). Oral Presentation at the 12th Biennial Canadian Neuro-Oncology Conference 2006, Winnipeg, Canada, May 26-28, 2006. G Shenouda, D Roberge, P Kavan, T Muanza, C Lambert, R Leblanc, R Del Maestro, MC Guiot, L. Souhami. A Novel Approach using Accelerated Hypo- fractionation-IMRT (AH-IMRT) and Temozolomide (TMZ) in patients with Glioblastoma Multiforme (GBM). Oral Presentation at the CARO 2006 Annual Scientific Meeting, Calgary, Alberta, Sept.13-16, 2006. Huang, F, Chauvin P, Mehio A, Muanza T, Shenouda G. Erythropoietin receptor expression in human squamous cell carcinoma of the tongue-molecular consideration for radiation oncologist. Poster Presentation at the CARO 2006 Annual Scientific Meeting, Calgary, Alberta, September 13-16, 2006. G. Shenouda, F. DeBlois, A. Alexander, H. Patrocinio, R. Ruo, J. Chankowski. The use of the BrainLAB relocatable stereotactic frame for irradiation of choroidal melanoma: design and treatment accuracy study. Oral Presentation at the ESTRO 2006, October 8- 12th 2006, Leipzig, Germany. II-23